

ISPH-0664WO

-122-

PATENT

Example 15

Antisense inhibition of human apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

5 In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human apolipoprotein B RNA, using published sequence (GenBank accession number NM_000384, incorporated herein as SEQ ID NO: 3). The oligonucleotides are shown in Table 1.

10 "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of

15 ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine

20 residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

25

Table 1

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
147780	5'UTR	3	1	CCGCAGGTCCCGGTGGGAAT	40	17
147781	5'UTR	3	21	ACCGAGAAGGGCACTCAGCC	35	18
147782	5'UTR	3	71	GCCTCGGCCTCGCGCCCTG	67	19

ISPH-0664WO

-123-

PATENT

147783	Start Codon	3	114	TCCATCGCCAGCTGCGGTGG	N.D.	20
147784	Coding	3	151	CAGCGCCAGCAGCGCCAGCA	70	21
147785	Coding	3	181	GCCCCCAGCAGCAGCAGCA	29	22
147786	Coding	3	321	CTTGAATCAGCAGTCCCAGG	34	23
147787	Coding	3	451	CTTCAGCAAGGCTTTGCCCT	N.D.	24
147788	Coding	3	716	TTTCTGTTGCCACATTGCCC	95	25
147789	Coding	3	911	GGAAGAGGTGTTGCTCCTTG	24	26
147790	Coding	3	951	TGTGCTACCATCCCATACTT	33	27
147791	Coding	3	1041	TCAATGCGAGGCCCATCTT	N.D.	28
147792	Coding	3	1231	GGACACCTCAATCAGCTGTG	26	29
147793	Coding	3	1361	TCAGGGCCACCAGGTAGGTG	N.D.	30
147794	Coding	3	1561	GTAATCTTCATCCCCAGTGC	47	31
147795	Coding	3	1611	TGCTCCATGGTTTGGCCCAT	N.D.	32
147796	Coding	3	1791	GCAGCCAGTCGCTTATCTCC	8	33
147797	Coding	3	2331	GTATAGCCAAAGTGGTCCAC	N.D.	34
147798	Coding	3	2496	CCCAGGAGCTGGAGGTCATG	N.D.	35
147799	Coding	3	2573	TTGAGCCCTTCCTGATGACC	N.D.	36
147800	Coding	3	2811	ATCTGGACCCCACTCCTAGC	N.D.	37
147801	Coding	3	2842	CAGACCCGACTCGTGGAAGA	38	38
147802	Coding	3	3367	GCCCTCAGTAGATTTCATCAT	N.D.	39
147803	Coding	3	3611	GCCATGCCACCCTCTTGGA	N.D.	40
147804	Coding	3	3791	AACCCACGTGCCGAAAGTC	N.D.	41
147805	Coding	3	3841	ACTCCAGATGCCTTCTGAA	N.D.	42
147806	Coding	3	4281	ATGTGGTAACGAGCCCGAAG	100	43
147807	Coding	3	4391	GGCGTAGAGACCCATCACAT	25	44
147808	Coding	3	4641	GTGTTAGGATCCCTCTGACA	N.D.	45
147809	Coding	3	5241	CCCAGTGATAGCTCTGTGAG	60	46
147810	Coding	3	5355	ATTTTCAGCATATGAGCCCAT	0	47
147811	Coding	3	5691	CCCTGAACCTTAGCAACAGT	N.D.	48
147812	Coding	3	5742	GCTGAAGCCAGCCAGCGAT	N.D.	49
147813	Coding	3	5891	ACAGCTGCCCAGTATGTTCT	N.D.	50
147814	Coding	3	7087	CCCAATAAGATTTATAACAA	34	51
147815	Coding	3	7731	TGGCCTACCAGAGACAGGTA	45	52
147816	Coding	3	7841	TCATACGTTTAGCCCAATCT	100	53
147817	Coding	3	7901	GCATGGTCCCAAGGATGGTC	0	54
147818	Coding	3	8491	AGTGATGGAAGCTGCGATAC	30	55
147819	Coding	3	9181	ATGAGCATCATGCCTCCAG	N.D.	56
147820	Coding	3	9931	GAACACATAGCCGAATGCCG	100	57
147821	Coding	3	10263	GTGGTGCCCTCTAATTTGTA	N.D.	58
147822	Coding	3	10631	CCCAGAAAGAACCGAACCC	N.D.	59
147823	Coding	3	10712	TGCCCTGCAGCTTCACTGAA	19	60
147824	Coding	3	11170	GAAATCCCATAGCTCTTGT	N.D.	61
147825	Coding	3	12301	AGAAGCTGCCTCTTCTTCCC	72	62
147826	Coding	3	12401	TCAGGGTGAGCCCTGTGTGT	80	63
147827	Coding	3	12471	CTAATGGCCCTTGATAAAC	13	64
147828	Coding	3	12621	ACGTTATCCTTGAGTCCCTG	12	65
147829	Coding	3	12741	TATATCCAGGTTTCCCCGG	64	66
147830	Coding	3	12801	ACCTGGGACAGTACCGTCCC	N.D.	67
147831	3'UTR	3	13921	CTGCCTACTGCAAGGCTGGC	0	68
147832	3'UTR	3	13991	AGAGACCTTCCGAGCCCTGG	N.D.	69
147833	3'UTR	3	14101	ATGATACACAATAAAGACTC	25	70

ISPH-0664WO

-124-

PATENT

As shown in Table 1, SEQ ID NOS 17, 18, 19, 21, 23, 25, 27, 31, 38, 43, 46, 51, 52, 53, 55, 57, 62, 63 and 66 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention. As apolipoprotein B exists in two forms in mammals (ApoB-48 and ApoB-100) which are colinear at the amino terminus, antisense oligonucleotides targeting nucleotides 1-6530 hybridize to both forms, while those targeting nucleotides 6531-14121 are specific to the long form of apolipoprotein B.

Example 16

Antisense inhibition of human apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap-Dose Response Study.

In accordance with the present invention, a subset of the antisense oligonucleotides in Example 15 were further investigated in dose-response studies. Treatment doses were 50, 150 and 250 nM. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments and are shown in Table 2.

Table 2

Inhibition of human apolipoprotein B mRNA levels by
chimeric phosphorothioate oligonucleotides having 2'-MOE
wings and a deoxy gap

ISIS #	Percent Inhibition		
	50 nM	150 nM	250 nM
147788	54	63	72
147806	23	45	28
147816	25	81	65
147820	10	0	73

Example 17

Antisense inhibition of mouse apolipoprotein B expression
by chimeric phosphorothioate oligonucleotides having 2'-MOE
wings and a deoxy gap

In accordance with the present invention, a series of
oligonucleotides were designed to target different regions
of the mouse apolipoprotein B RNA, using published sequence
(GenBank accession number M35186, incorporated herein as
SEQ ID NO: 10). The oligonucleotides are shown in Table 3.

"Target site" indicates the first (5'-most) nucleotide
number on the particular target sequence to which the
oligonucleotide binds. All compounds in Table 3 are
chimeric oligonucleotides ("gapmers") 20 nucleotides in
length, composed of a central "gap" region consisting of
ten 2'-deoxynucleotides, which is flanked on both sides (5'
and 3' directions) by five-nucleotide "wings". The wings
are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The
internucleoside (backbone) linkages are phosphorothioate
(P=S) throughout the oligonucleotide. All cytidine
residues are 5-methylcytidines. The compounds were
analyzed for their effect on mouse apolipoprotein B mRNA
levels in primary hepatocytes by quantitative real-time PCR
as described in other examples herein. Data are averages

ISPH-0664WO

-126-

PATENT

from two experiments. If present, "N.D." indicates "no data".

Table 3

5 Inhibition of mouse apolipoprotein B mRNA levels by
chimeric phosphorothioate oligonucleotides having 2'-MOE
wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
147475	Coding	10	13	ATTGTATGTGAGAGGTGAGG	79	71
147476	Coding	10	66	GAGGAGATTGGATCTTAAGG	13	72
147477	Coding	10	171	CTTCAAATTGGGACTCTCCT	N.D	73
147478	Coding	10	211	TCCAGGAATTGAGCTTGTC	78	74
147479	Coding	10	238	TTCAGGACTGGAGGATGAGG	N.D	75
147480	Coding	10	291	TCTCACCCCTCATGCTCCATT	54	76
147481	Coding	10	421	TGACTGTCAAGGGTGAGCTG	24	77
147482	Coding	10	461	GTCCAGCCTAGGAACACTCA	59	78
147483	Coding	10	531	ATGTCAATGCCACATGTCCA	N.D	79
147484	Coding	10	581	TTCATCCGAGAAGTTGGGAC	49	80
147485	Coding	10	601	ATTTGGGACGAATGTATGCC	64	81
147486	Coding	10	711	AGTTGAGGAAGCCAGATTCA	N.D	82
147487	Coding	10	964	TTCCCAGTCAGCTTTAGTGG	73	83
147488	Coding	10	1023	AGCTTGCTTGTGGGCACGG	72	84
147489	Coding	10	1111	CCTATACTGGCTTCTATGTT	5	85
147490	Coding	10	1191	TGAACCTCCGTGTAAGGCAAG	N.D	86
147491	Coding	10	1216	GAGAAATCCTTCAGTAAGGG	71	87
147492	Coding	10	1323	CAATGGAATGCTTGTCACCTG	68	88
147493	Coding	10	1441	GCTTCATTATAGGAGGTGGT	41	89
147494	Coding	10	1531	ACAACCTGGGATAGTGTAGCC	84	90
147495	Coding	10	1631	GTTAGGACCAGGGATTGTGA	0	91
147496	Coding	10	1691	ACCATGGAAGAACTGGCAACT	19	92
147497	Coding	10	1721	TGGGAGGAAAACTTGAATA	N.D	93
147498	Coding	10	1861	TGGGCAACGATATCTGATTG	0	94
147499	Coding	10	1901	CTGCAGGGCGTCAGTGACAA	29	95
147500	Coding	10	1932	GCATCAGACGTGATGTTCCC	N.D	96
147501	Coding	10	2021	CTTGTTAAACTAATGGTGC	18	97
147502	Coding	10	2071	ATGGGAGCATGGAGTTGGC	16	98
147503	Coding	10	2141	AATGGATGATGAAACAGTGG	26	99
147504	Coding	10	2201	ATCAATGCCTCCTGTTCAG	N.D	100
147505	Coding	10	2231	GGAAGTGAGACTTTCTAAGC	76	101
147506	Coding	10	2281	AGGAAGGAACTCTTGATATT	58	102
147507	Coding	10	2321	ATTGGCTTCATTGGCAACAC	81	103
147759	Coding	10	1	AGGTGAGGAAGTTGGAATTC	19	104
147760	Coding	10	121	TTGTTCCCTGAAGTTGTAC	N.D	105
147761	Coding	10	251	GTTTCATGGATTCTTCAGGA	45	106
147762	Coding	10	281	ATGCTCCATTCTCACATGCT	46	107
147763	Coding	10	338	TGCGACTGTGTCTGATTTC	34	108
147764	Coding	10	541	GTCCCTGAAGATGTCAATGC	97	109
147765	Coding	10	561	AGGCCCAAGTTCCATGACCC	59	110
147766	Coding	10	761	GGAGCCCACGTGCTGAGATT	59	111

ISPH-0664WO

-127-

PATENT

147767	Coding	10	801	CGTCCTTGAGCAGTGCCCGA	5	112
147768	Coding	10	1224	CCCATATGGAGAAATCCTTC	24	113
147769	Coding	10	1581	CATGCCTGGAAGCCAGTGTC	89	114
147770	Coding	10	1741	GTGTTGAATCCCTTGAAATC	67	115
147771	Coding	10	1781	GGTAAAGTTGCCCATGGCTG	68	116
147772	Coding	10	1841	GTTATAAAGTCCAGCATTGG	78	117
147773	Coding	10	1931	CATCAGACGTGATGTTCCCT	85	118
147774	Coding	10	1956	TGGCTAGTTTCAATCCCCTT	84	119
147775	Coding	10	2002	CTGTCATGACTGCCCTTTAC	52	120
147776	Coding	10	2091	GCTTGAAGTTTCATTGAGAAT	92	121
147777	Coding	10	2291	TTCCTGAGAAAGGAAGGAAC	N.D	122
147778	Coding	10	2331	TCAGATATACATTGGCTTCA	14	123

As shown in Table 3, SEQ ID Nos 71, 74, 76, 78, 81, 83, 84, 87, 88, 90, 101, 102, 103, 109, 111, 111, 114, 115, 116, 117, 118, 119, 120 and 121 demonstrated at least 50% inhibition of mouse apolipoprotein B expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

Example 18

Antisense inhibition mouse apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap- Dose Response Study

In accordance with the present invention, a subset of the antisense oligonucleotides in Example 17 were further investigated in dose-response studies. Treatment doses were 50, 150 and 300 nM. The compounds were analyzed for their effect on mouse apolipoprotein B mRNA levels in primary hepatocytes cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments and are shown in Table 4.

Table 4

Inhibition of mouse apolipoprotein B mRNA levels by
chimeric phosphorothioate oligonucleotides having 2'-MOE
wings and a deoxy gap

ISIS #	Percent Inhibition		
	50 nM	150 nM	300 nM
147483	56	88	89
147764	48	84	90
147769	3	14	28
147776	0	17	44

5

Example 19**Western blot analysis of apolipoprotein B protein levels**

Western blot analysis (immunoblot analysis) was
carried out using standard methods. Cells were harvested
10 16-20 h after oligonucleotide treatment, washed once with
PBS, suspended in Laemmli buffer (100 ul/well), boiled for
5 minutes and loaded on a 16% SDS-PAGE gel. Gels were run
for 1.5 hours at 150 V, and transferred to membrane for
western blotting. Appropriate primary antibody directed to
15 apolipoprotein B was used, with a radiolabelled or
fluorescently labeled secondary antibody directed against
the primary antibody species. Bands were visualized using
a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

20 **Example 20**

**Effects of antisense inhibition of apolipoprotein B (ISIS
147764) in C57BL/6 mice: Lean animals vs. High Fat Fed
animals.**

C57BL/6 mice, a strain reported to be susceptible to
25 hyperlipidemia-induced atherosclerotic plaque formation
were used in the following studies to evaluate antisense
oligonucleotides as potential lipid lowering compounds in
lean versus high fat fed mice.

Male C57BL/6 mice were divided into two matched groups; (1) wild-type control animals (lean animals) and (2) animals receiving a high fat diet (60% kcal fat). Control animals received saline treatment and were maintained on a normal rodent diet. After overnight fasting, mice from each group were dosed intraperitoneally every three days with saline or 50 mg/kg ISIS 147764 (SEQ ID No: 109) for six weeks. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver, cholesterol and triglyceride levels, liver enzyme levels and serum glucose levels.

The results of the comparative studies are shown in Table 5.

Table 5

Effects of ISIS 147764 treatment on apolipoprotein B mRNA, cholesterol, lipid, triglyceride, liver enzyme and glucose levels in lean and high fat mice.

Treatment Group	Percent Change								
	Lipoproteins						Liver Enzymes		
	mRNA	CHOL	VLDL	LDL	HDL	TRIG	AST	ALT	GLUC
Lean-control	-73	-63	No change	-64	-44	-34	Slight decrease	No change	No change
High Fat Group	-87	-67	No change	-87	-65	No change	Slight decrease	Slight increase	-28

It is evident from these data that treatment with ISIS 147764 lowered cholesterol as well as LDL and HDL lipoproteins and serum glucose in both lean and high fat mice and that the effects demonstrated are, in fact, due to the inhibition of apolipoprotein B expression as supported by the decrease in mRNA levels. No significant changes in liver enzyme levels were observed, indicating that the

ISPH-0664WO

-130-

PATENT

antisense oligonucleotide was not toxic to either treatment group.

Example 21

5 Effects of antisense inhibition of apolipoprotein B (ISIS 147764) on High Fat Fed Mice; 6 Week Timecourse Study

In accordance with the present invention, a 6-week timecourse study was performed to further investigate the effects of ISIS 147764 on lipid and glucose metabolism in
10 high fat fed mice.

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of treatment with the antisense oligonucleotide, ISIS 147764. Control animals received saline treatment (50
15 mg/kg). A subset of animals received a daily oral dose (20 mg/kg) atorvastatin calcium (Lipitor®, Pfizer Inc.). All mice, except atorvastatin-treated animals, were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID
20 No: 109) or saline (50 mg/kg) for six weeks. Serum cholesterol and lipoproteins were analyzed at 0, 2 and 6 week interim timepoints. At study termination, animals were sacrificed 48 hours after the final injections and evaluated for levels of target mRNA levels in liver,
25 cholesterol, lipoprotein, triglyceride, liver enzyme (AST and ALT) and serum glucose levels as well as body, liver, spleen and fat pad weights.

Example 22

30 Effects of antisense inhibition of apolipoprotein B (ISIS 147764) in high fat fed mice- mRNA expression in liver

ISPH-0664WO

-131-

PATENT

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on mRNA expression. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks. At study termination, animals were sacrificed 48 hours after the final injections and evaluated for levels of target mRNA levels in liver. ISIS 147764 showed a dose-response effect, reducing mRNA levels by 15, 75 and 88% at doses of 5, 25 and 50 mg/kg, respectively.

Example 23

15 Effects of antisense inhibition of apolipoprotein B (ISIS 147764) on serum cholesterol and triglyceride levels

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on serum cholesterol and triglyceride levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

25 Serum cholesterol levels were measured at 0, 2 and 6 weeks and this data is shown in Table 6. Values in the table are expressed as percent inhibition and are normalized to the saline control.

In addition to serum cholesterol, at study termination, animals were sacrificed 48 hours after the final injections and evaluated for triglyceride levels.

ISPH-0664WO

-132-

PATENT

Mice treated with ISIS 147764 showed a reduction in both serum cholesterol (240 mg/dL for control animals and 225, 125 and 110 mg/dL for doses of 5, 25, and 50 mg/kg, respectively) and triglycerides (115 mg/dL for control animals and 125, 150 and 85 mg/dL for doses of 5, 25, and 50 mg/kg, respectively) to normal levels by study end. These data were also compared to the effects of atorvastatin calcium at an oral dose of 20 mg/kg which showed only a minimal decrease in serum cholesterol of 20 percent at study termination.

Table 6

Percent Inhibition of mouse apolipoprotein B cholesterol levels by ISIS 147764

time	Percent Inhibition			
	Saline	5 mg/kg	25 mg/kg	50 mg/kg
0 weeks	0	0	0	0
2 weeks	0	5	12	20
6 weeks	0	10	45	55

Example 24

Effects of antisense inhibition of apolipoprotein B (ISIS 147764) on lipoprotein levels

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on lipoprotein (VLDL, LDL and HDL) levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

Lipoprotein levels were measured at 0, 2 and 6 weeks and this data is shown in Table 7. Values in the table are expressed as percent inhibition and are normalized to the

ISPH-0664WO

-133-

PATENT

saline control. Negative values indicate an observed increase in lipoprotein levels.

These data were also compared to the effects of atorvastatin calcium at a daily oral dose of 20 mg/kg at 0, 2 and 6 weeks.

These data demonstrate that at a dose of 50 mg/kg, ISIS 147764 is capable of lowering all categories of serum lipoproteins investigated to a greater extent than atorvastatin.

10

Table 7

Percent Inhibition of mouse apolipoprotein B lipoprotein levels by ISIS 147764 as compared to atorvastatin

Lipoprotein	Time (weeks)	Percent Inhibition				
		Dose				atorvastatin (20 mg/kg)
		Saline	5 mg/kg	25 mg/kg	50 mg/kg	
VLDL	0	0	0	0	0	0
	2	0	25	30	40	15
	6	0	10	-30	15	-5
LDL	0	0	0	0	0	0
	2	0	-30	10	40	10
	6	0	-10	55	90	-10
HDL	0	0	0	0	0	0
	2	0	5	10	10	15
	6	0	10	45	50	20

15 **Example 25**

Effects of antisense inhibition of apolipoprotein B (ISIS 147764) on serum AST and ALT levels

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on liver enzyme (AST and ALT) levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50

20

ISPH-0664WO

-134-

PATENT

mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

AST and ALT levels were measured at 6 weeks and this data is shown in Table 8. Values in the table are expressed as IU/L. Increased levels of the liver enzymes ALT and AST indicate toxicity and liver damage.

Mice treated with ISIS 147764 showed no significant change in AST levels over the duration of the study compared to saline controls (105, 70 and 80 IU/L for doses of 5, 25 and 50 mg/kg, respectively compared to 65 IU/L for saline control). Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had AST levels of 85 IU/L.

ALT levels were increased by all treatments over the duration of the study compared to saline controls (50, 70 and 100 IU/L for doses of 5, 25 and 50 mg/kg, respectively compared to 25 IU/L for saline control). Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had AST levels of 40 IU/L.

Example 26

Effects of antisense inhibition of apolipoprotein B (ISIS 147764) on serum glucose levels

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on serum glucose levels. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

At study termination, animals were sacrificed 48 hours after the final injections and evaluated for serum glucose levels. ISIS 147764 showed a dose-response effect, reducing

ISPH-0664WO

-135-

PATENT

serum glucose levels to 225, 190 and 180 mg/dL at doses of 5, 25 and 50 mg/kg, respectively compared to the saline control of 300 mg/dL. Mice treated with atorvastatin at a daily oral dose of 20 mg/kg had serum glucose levels of 215 mg/dL. These data demonstrate that ISIS 147764 is capable of reducing serum glucose levels in high fat fed mice.

Example 27

Effects of antisense inhibition of apolipoprotein B (ISIS 147764) on body, spleen, liver and fat pad weight

Male C57BL/6 mice (n=8) receiving a high fat diet (60% kcal fat) were evaluated over the course of 6 weeks for the effects of ISIS 147764 on body, spleen, liver and fat pad weight. Control animals received saline treatment (50 mg/kg). Mice were dosed intraperitoneally every three days (twice a week), after fasting overnight, with 5, 25, 50 mg/kg ISIS 147764 (SEQ ID No: 109) or saline (50 mg/kg) for six weeks.

At study termination, animals were sacrificed 48 hours after the final injections and body, spleen, liver and fat pad weights were measured. These data are shown in Table 8. Values are expressed as percent change in body weight or organ weight compared to the saline-treated control animals. Data from mice treated with atorvastatin at a daily dose of 20 mg/kg are also shown in the table. Negative values indicated a decrease in weight.

Table 8

Effects of antisense inhibition of mouse apolipoprotein B on body and organ weight

ISPH-0664WO

-136-

PATENT

	Percent Change			
	Dose			Atorvastatin 20 mg/kg
	5 mg/kg	25 mg/kg	50 mg/kg	
Total Body Wt.	5	5	-4	1
Spleen	10	10	46	10
Liver	18	70	80	15
Fat	10	6	-47	7

These data show a decrease in fat over the dosage range of ISIS 147764 counterbalanced by an increase in both spleen and liver weight with increased dose to give an overall decrease in total body weight.

Example 28

Effects of antisense inhibition of apolipoprotein B (ISIS 147764) in B6.129P-ApoE^{tm1Unc} knockout mice: Lean animals vs.

10 High Fat Fed animals.

B6.129P-ApoE^{tm1Unc} knockout mice (herein referred to as ApoE knockout mice) obtained from The Jackson Laboratory (Bar Harbor, ME), are homozygous for the ApoE^{tm1Unc} mutation and show a marked increase in total plasma cholesterol levels that are unaffected by age or sex. These animals present with fatty streaks in the proximal aorta at 3 months of age. These lesions increase with age and progress to lesions with less lipid but more elongated cells, typical of a more advanced stage of pre-atherosclerotic lesion.

The mutation in these mice resides in the apolipoprotein E (ApoE) gene. The primary role of the ApoE protein is to transport cholesterol and triglycerides throughout the body. It stabilizes lipoprotein structure, binds to the low density lipoprotein receptor (LDLR) and related proteins, and is present in a subclass of HDLs, providing them the ability to bind to LDLR. ApoE is

ISPH-0664WO

-137-

PATENT

expressed most abundantly in the liver and brain. Female B6.129P-Apoetm1Unc knockout mice (ApoE knockout mice) were used in the following studies to evaluate antisense oligonucleotides as potential lipid lowering compounds.

5 Female ApoE knockout mice ranged in age from 5 to 7 weeks and were placed on a normal diet for 2 weeks before study initiation. ApoE knockout mice were then fed *ad libitum* a 60% fat diet, with 0.15% added cholesterol to induce dyslipidemia and obesity. Control animals were
10 maintained on a high-fat diet with no added cholesterol. After overnight fasting, mice from each group were dosed intraperitoneally every three days with saline, 50 mg/kg of a control antisense oligonucleotide (ISIS 29837 TCGATCTCCTTTTATGCCCG; SEQ ID NO. 124) or 5, 25 or 50 mg/kg
15 ISIS 147764 (SEQ ID No: 109) for six weeks.

The control oligonucleotide is a chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3'
20 directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines.

25 At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver by RT-PCR methods verified by Northern Blot analysis, glucose levels, cholesterol and lipid levels by HPLC separation methods and triglyceride
30 and liver enzyme levels (performed by LabCorp Preclinical Services; San Diego, CA). Data from ApoE knockout mice

ISPH-0664WO

-138-

PATENT

treated with atorvastatin at a daily dose of 20 mg/kg are also shown in the table for comparison.

The results of the comparative studies are shown in Table 9. Data are normalized to saline controls.

5

Table 9

10 Effects of ISIS 147764 treatment on apolipoprotein B mRNA, cholesterol, glucose, lipid, triglyceride and liver enzyme levels in ApoE knockout mice.

		Percent Inhibition				
		Dose				
		Control	5 mg/kg	25 mg/kg	50 mg/kg	atorvastatin (20 mg/kg)
mRNA		0	2	42	70	10
Glucose	Glucose Levels (mg/dL)					
		225	195	209	191	162
Cholesterol	Cholesterol Levels (mg/dL)					
		1750	1630	1750	1490	938
Lipoprotein	Lipoprotein Levels (mg/dL)					
	HDL	51	49	62	61	42
	LDL	525	475	500	325	250
	VLDL	1190	1111	1194	1113	653
Liver Enzymes	Liver Enzyme Levels (IU/L)					
	AST	55	50	60	85	75
	ALT	56	48	59	87	76

15 It is evident from these data that treatment with ISIS 147764 lowered glucose and cholesterol as well as all lipoproteins investigated (HDL, LDL and VLDL) in ApoE knockout mice. Further, these decreases correlated with a decrease in both protein and RNA levels of apolipoprotein B, demonstrating an antisense mechanism of action. No

ISPH-0664WO

-139-

PATENT

significant changes in liver enzyme levels were observed, indicating that the antisense oligonucleotide was not toxic to either treatment group.

5

10 Example 29

Antisense inhibition of human apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap: Additional Oligonucleotides

In accordance with the present invention, another series of oligonucleotides were designed to target different regions of the human apolipoprotein B RNA, using published sequence (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3). The oligonucleotides are shown in Table 10.

20

Table 10.

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
270985	5'UTR	3	199	TTCTCTTCGGCCCTGGCGC	75	124
270986	coding	3	299	CTCCACTGGAAGCTCTCAGCC	0	125
270987	exon: exon junction	3	359	CCTCCAGCTCAACCTTGCAG	0	126
270988	coding	3	429	GGGTTGAAGCCATACACCTC	6	127
270989	exon: exon junction	3	509	CCAGCTTGAGCTCATACTG	64	128
270990	coding	3	584	CCCTCTTGATGTTTCAGGATG	42	129

ISPH-0664WO

-140-

PATENT

270991	coding	3	669	GAGCAGTTTCCATACACGGT	21	130
270992	coding	3	699	CCCTTCCTCGTCTTGACGGT	8	131
270993	coding	3	756	TTGAAGCGATCACACTGCCC	69	132
270994	coding	3	799	GCCTTTGATGAGAGCAAGTG	51	133
270995	coding	3	869	TCCTCTTAGCGTCCAGTGTG	40	134
270996	coding	3	1179	CCTCTCAGCTCAGTAACCAG	0	135
270997	coding	3	1279	GCACTGAGGCTGTCCACACT	24	136
270998	coding	3	1419	CGCTGATCCCTCGCCATGTT	1	137
270999	coding	3	1459	GTTGACCGCGTGGCTCAGCG	76	138
271000	coding	3	1499	GCAGCTCCTGGGTCCCTGTA	22	139
271001	coding	3	1859	CCCATGGTAGAATTTGGACA	53	140
271002	exon: exon junction	3	2179	AATCTCGATGAGGTCAGCTG	48	141
271003	coding	3	2299	GACACCATCAGGAACCTTGAC	46	142
271004	coding	3	2459	GCTCCTCTCCCAAGATGCGG	10	143
271005	coding	3	2518	GGCACCATCAGAAGCAGCT	32	144
271006	coding	3	2789	AGTCCGGAATGATGATGCCC	42	145
271007	coding	3	2919	CTGAGCAGCTTGACTGGTCT	26	146
271008	coding	3	3100	CCCGGTCAGCGGATAGTAGG	37	147
271010	exon: exon junction	3	3449	TGTCACAACTTAGGTGGCCC	57	148
271011	coding	3	3919	GTCTGGCAATCCCATGTTCT	51	149
271012	coding	3	4089	CCCACAGACTTGAAGTGGAG	55	150
271013	coding	3	4579	GAACTGCCCATCAATCTTGA	19	151
271014	coding	3	5146	CCCAGAGAGGCCAAGCTCTG	54	152
271015	coding	3	5189	TGTGTTCCCTGAAGCGGCCA	43	153
271016	coding	3	5269	ACCCAGAATCATGGCCTGAT	19	154
271017	coding	3	6049	GGTGCTGTCTGCTCAGCTG	30	155
271018	coding	3	6520	ATGTGAACTTGTCTCTCCC	44	156
271019	coding	3	6639	TATGTCTGCAGTTGAGATAG	15	157
271020	coding	3	6859	TTGAATCCAGGATGCAGTAC	35	158
271021	coding	3	7459	GAGTCTCTGAGTCACCTCAC	38	159
271022	coding	3	7819	GATAGAATATTGCTCTGCAA	100	160
271023	coding	3	7861	CCCTTGCTCTACCAATGCTT	44	161
271025	coding	3	8449	TCCATTCCCTATGTCAGCAT	16	162
271026	coding	3	8589	GACTCCTTCAGAGCCAGCGG	39	163
271027	coding	3	8629	CCCATGCTCCGTTCTCAGGT	26	164
271028	coding	3	8829	CGCAGGTCAGCCTGACTAGA	98	165
271030	coding	3	9119	CAGTTAGAACACTGTGGCCC	52	166
271031	coding	3	10159	CAGTGTGATGACACTTGATT	49	167
271032	coding	3	10301	CTGTGGCTAACTTCAATCCC	22	168
271033	coding	3	10349	CAGTACTGTTATGACTACCC	34	169
271034	coding	3	10699	CACTGAAGACCGTGTGCTCT	35	170
271035	coding	3	10811	TCGTACTGTGCTCCAGAGG	23	171
271036	coding	3	10839	AAGAGGCCCTCTAGCTGTAA	95	172
271037	coding	3	11039	AAGACCCAGAATGAATCCGG	23	173
271038	coding	3	11779	GTCTACCTCAAAGCGTGCAG	29	174
271039	coding	3	11939	TAGAGGCTAACGTACCATCT	4	175
271041	coding	3	12149	CCATATCCATGCCACGGTG	37	176

ISPH-0664WO

-141-

PATENT

271042	coding	3	12265	AGTTTCCTCATCAGATTCCC	57	177
271043	coding	3	12380	CCCAGTGGTACTTGTGACA	68	178
271044	coding	3	12526	CCCAGTGGTGCCACTGGCTG	22	179
271045	coding	3	12579	GTCAACAGTTCCTGGTACAG	19	180
271046	coding	3	12749	CCCTAGTGTATATCCCAGGT	61	181
271048	coding	3	13009	CTGAAGATTACGTAGCACCT	7	182
271049	coding	3	13299	GTCCAGCCAACATACTTGG	54	183
271050	coding	3	13779	CCTGGAGCAAGCTTCATGTA	42	184
281586	exon: exon junction	3	229	TGGACAGACCAGGCTGACAT	80	185
281587	coding	3	269	ATGTGTACTTCCGAGGTGC	77	186
281588	coding	3	389	TCTTCAGGATGAAGCTGCAG	80	187
281589	coding	3	449	TCAGCAAGGCTTTGCCCTCA	90	188
281590	coding	3	529	CTGCTTCCCTTCTGGAATGG	84	189
281591	coding	3	709	TGCCACATTGCCCTTCCTCG	90	190
281592	coding	3	829	GCTGATCAGAGTTGACAAGG	56	191
281593	coding	3	849	TACTGACAGGACTGGCTGCT	93	192
281594	coding	3	889	GATGGCTTCTGCCACATGCT	74	193
281595	coding	3	1059	GATGTGGATTGTTGGTCTCTC	76	194
281596	coding	3	1199	TGACTGCTTCATCACTGAGG	77	195
281597	coding	3	1349	GGTAGGTGACCACATCTATC	36	196
281598	coding	3	1390	TCGCAGCTGCTGTGCTGAGG	70	197
281599	exon: exon junction	3	1589	TTCCAATGACCCGCAGAATC	74	198
281600	coding	3	1678	GATCATCAGTGATGGCTTTG	52	199
281601	coding	3	1699	AGCCTGGATGGCAGCTTTCT	83	200
281602	coding	3	1749	GTCTGAAGAAGAACCTCCTG	84	201
281603	coding	3	1829	TATCTGCCTGTGAAGGACTC	82	202
281604	coding	3	1919	CTGAGTTCAAGATATTGGCA	78	203
281605	exon: exon junction	3	2189	CTTCCAAGCCAATCTCGATG	82	204
281606	coding	3	2649	TGCAACTGTAATCCAGCTCC	86	205
281607	exon: exon junction	3	2729	CCAGTTCAGCCTGCATGTTG	84	206
281608	coding	3	2949	GTAGAGACCAAATGTAATGT	62	207
281609	coding	3	3059	CGTTGGAGTAAGCGCCTGAG	70	208
281610	exon: exon junction	3	3118	CAGCTCTAATCTGGTGTCCC	69	209
281611	coding	3	3189	CTGTCCTCTCTCTGGAGCTC	93	210
281612	coding	3	3289	CAAGGTCATACTCTGCCGAT	83	211
281613	coding	3	3488	GTATGGAAATAACACCCTTG	70	212
281614	coding	3	3579	TAAGCTGTAGCAGATGAGTC	63	213
281615	coding	3	4039	TAGATCTCTGGAGGATTGTC	81	214
281616	coding	3	4180	GTCTAGAACACCCAGGAGAG	66	215
281617	coding	3	4299	ACCACAGAGTCAGCCTTCAT	89	216
281618	coding	3	4511	AAGCAGACATCTGTGGTCCC	90	217
281619	coding	3	4660	CTCTCCATTGAGCCGGCCAG	96	218

ISPH-0664WO

-142-

PATENT

281620	coding	3	4919	CCTGATATTCAGAACGCAGC	89	219
281621	coding	3	5009	CAGTGCCTAAGATGTCAGCA	53	220
281622	coding	3	5109	AGCACCAGGAGACTACACTT	88	221
281623	coding	3	5212	CCCATCCAGACTGAATTTTG	59	222
281624	coding	3	5562	GGTTCTAGCCGTAGTTTCCC	75	223
281625	coding	3	5589	AGGTTACCAGCCACATGCAG	94	224
281626	coding	3	5839	ATGTGCATCGATGGTCATGG	88	225
281627	coding	3	5869	CCAGAGAGCGAGTTTCCCAT	82	226
281628	coding	3	5979	CTAGACACGAGATGATGACT	81	227
281629	coding	3	6099	TCCAAGTCCTGGCTGTATTC	83	228
281630	coding	3	6144	CGTCCAGTAAGCTCCACGCC	82	229
281631	coding	3	6249	TCAACGGCATCTCTCATCTC	88	230
281632	coding	3	6759	TGATAGTGCTCATCAAGACT	75	231
281633	coding	3	6889	GATTCTGATTGGTACTTAG	73	232
281634	coding	3	7149	CTCTCGATTAACATCATGGAC	81	233
281635	coding	3	7549	ATACACTGCAACTGTGGCCT	89	234
281636	coding	3	7779	GCAAGAGTCCACCAATCAGA	68	235
281637	coding	3	7929	AGAGCCTGAAGACTGACTTC	74	236
281638	coding	3	8929	TCCCTCATCTGAGAATCTGG	66	237
281640	coding	3	10240	CAGTGCATCAATGACAGATG	87	238
281641	coding	3	10619	CCGAACCCCTTGACATCTCCT	72	239
281642	coding	3	10659	GCCTCACTAGCAATAGTTCC	59	240
281643	coding	3	10899	GACATTTGCCATGGAGAGAG	61	241
281644	coding	3	11209	CTGTCTCCTACCAATGCTGG	26	242
281645	exon: exon junction	3	11979	TCTGCACTGAAGTCACGGTG	78	243
281646	coding	3	12249	TCCCGGACCCTCAACTCAGT	76	244
281648	3'UTR	3	13958	GCAGGTCCAGTTCATATGTG	81	245
281649	3'UTR	3	14008	GCCATCCTTCTGAGTTCAGA	76	246
301012	exon: exon junction	3	3249	GCCTCAGTCTGCTTCGCACC	87	247
301013	5'UTR	3	3	CCCCGCAGGTCCCGGTGGGA	82	248
301014	5'UTR	3	6	CAGCCCCGCAGGTCCCGGTG	88	249
301015	5'UTR	3	23	CAACCGAGAAGGGCACTCAG	53	250
301016	5'UTR	3	35	CCTCAGCGGCAGCAACCGAG	62	251
301017	5'UTR	3	36	TCCTCAGCGGCAGCAACCGA	47	252
301018	5'UTR	3	37	CTCCTCAGCGGCAGCAACCG	45	253
301019	5'UTR	3	39	GGCTCCTCAGCGGCAGCAAC	70	254
301020	5'UTR	3	43	GGCGGGCTCCTCAGCGGCAG	85	255
301021	5'UTR	3	116	GGTCCATCGCCAGCTGCGGT	89	256
301022	Start Codon	3	120	GGCGGGTCCATCGCCAGCTG	69	257
301023	Stop Codon	3	13800	TAGAGGATGATAGTAAGTTC	69	258
301024	3'UTR	3	13824	AAATGAAGATTCTTTTAAA	5	259
301025	3'UTR	3	13854	TATGTGAAAGTTCAATTGGA	76	260
301026	3'UTR	3	13882	ATATAGGCAGTTTGAATTTT	57	261
301027	3'UTR	3	13903	GCTCACTGTATGGTTTATC	89	262
301028	3'UTR	3	13904	GGCTCACTGTATGGTTTAT	93	263
301029	3'UTR	3	13908	GGCTGGCTCACTGTATGGTT	90	264

ISPH-0664WO

-143-

PATENT

301030	3'UTR	3	13909	AGGCTGGCTCACTGTATGGT	90	265
301031	3'UTR	3	13910	AAGGCTGGCTCACTGTATGG	90	266
301032	3'UTR	3	13917	CTACTGCAAGGCTGGCTCAC	63	267
301033	3'UTR	3	13922	ACTGCCTACTGCAAGGCTGG	77	268
301034	3'UTR	3	13934	TGCTTATAGTCTACTGCCTA	88	269
301035	3'UTR	3	13937	TTCTGCTTATAGTCTACTGC	82	270
301036	3'UTR	3	13964	TTTGGTGCAGGTCCAGTTCA	88	271
301037	3'UTR	3	13968	CAGCTTTGGTGCAGGTCCAG	90	272
301038	3'UTR	3	13970	GCCAGCTTTGGTGCAGGTCC	86	273
301039	3'UTR	3	13974	TGGTGCCAGCTTTGGTGCAG	73	274
301040	3'UTR	3	13978	GCCCTGGTGCCAGCTTTGGT	74	275
301041	3'UTR	3	13997	GAGTTCAGAGACCTTCCGAG	85	276
301042	3'UTR	3	14012	AAATGCCATCCTTCTGAGTT	81	277
301043	3'UTR	3	14014	AAAAATGCCATCCTTCTGAG	81	278
301044	3'UTR	3	14049	AAAATAACTCAGATCCTGAT	76	279
301045	3'UTR	3	14052	AGCAAAATAACTCAGATCCT	90	280
301046	3'UTR	3	14057	AGTTTAGCAAAATAACTCAG	80	281
301047	3'UTR	3	14064	TCCCCCAAGTTTAGCAAAAT	56	282
301048	3'UTR	3	14071	TTCTCTCTCCCCCAAGTTTA	67	283
301217	3'UTR	3	14087	AGACTCCATTTATTTGTTCC	81	284

Example 30**Antisense inhibition of apolipoprotein B - Gene walk**

In accordance with the present invention, a "gene walk" was conducted in which another series of oligonucleotides was designed to target the regions of the human apolipoprotein B RNA (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3) which are near the target site of SEQ ID Nos 224 or 247. The oligonucleotides are shown in Table 11. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 10 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate

ISPH-0664WO

-144-

PATENT

(P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 11

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Gene walk

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nM	% INHIB 50 nM	SEQ ID NO
308589	exon: exon junction	3	3230	CTTCTGCTTGAGTTACAAAC	94	20	285
308590	exon: exon junction	3	3232	ACCTTCTGCTTGAGTTACAA	98	26	286
308591	exon: exon junction	3	3234	GCACCTTCTGCTTGAGTTAC	92	76	287
308592	exon: exon junction	3	3236	TCGCACCTTCTGCTTGAGTT	96	49	288
308593	exon: exon junction	3	3238	CTTCGCACCTTCTGCTTGAG	80	41	289
308594	exon: exon junction	3	3240	TGCTTCGCACCTTCTGCTTG	88	57	290
308595	exon: exon junction	3	3242	TCTGCTTCGCACCTTCTGCT	82	60	291
308596	exon: exon junction	3	3244	AGTCTGCTTCGCACCTTCTG	94	81	292
308597	exon: exon junction	3	3246	TCAGTCTGCTTCGCACCTTC	91	66	293
308598	exon: exon junction	3	3248	CCTCAGTCTGCTTCGCACCT	85	59	294
308599	exon: exon junction	3	3250	AGCCTCAGTCTGCTTCGCAC	94	79	295

ISPH-0664WO

-145-

PATENT

308600	coding	3	3252	GTAGCCTCAGTCTGCTTCGC	89	72	296
308601	coding	3	3254	TGGTAGCCTCAGTCTGCTTC	91	63	297
308602	coding	3	3256	CATGGTAGCCTCAGTCTGCT	92	83	298
308603	coding	3	3258	GTCATGGTAGCCTCAGTCTG	97	56	299
308604	coding	3	3260	ATGTCATGGTAGCCTCAGTC	90	73	300
308605	coding	3	3262	GAATGTCATGGTAGCCTCAG	81	50	301
308606	coding	3	3264	TTGAATGTCATGGTAGCCTC	97	54	302
308607	coding	3	3266	ATTGAATGTCATGGTAGCC	77	9	303
308608	coding	3	3268	ATATTGAATGTCATGGTAG	85	70	304
308609	coding	3	5582	CAGCCACATGCAGCTTCAGG	96	78	305
308610	coding	3	5584	ACCAGCCACATGCAGCTTCA	90	40	306
308611	coding	3	5586	TTACCAGCCACATGCAGCTT	95	59	307
308612	coding	3	5588	GGTTACCAGCCACATGCAGC	90	75	308
308613	coding	3	5590	TAGGTTACCAGCCACATGCA	87	43	309
308614	coding	3	5592	TTTAGGTTACCAGCCACATG	92	74	310
308615	coding	3	5594	CTTTTAGGTTACCAGCCACA	85	45	311
308616	coding	3	5596	TCCTTTTAGGTTACCAGCCA	81	39	312
308617	coding	3	5598	GCTCCTTTTAGGTTACCAGC	87	77	313
308618	coding	3	5600	AGGCTCCTTTTAGGTTACCA	77	61	314
308619	coding	3	5602	GTAGGCTCCTTTTAGGTTAC	74	69	315
308620	coding	3	5604	TGGTAGGCTCCTTTTAGGTT	88	69	316
308621	coding	3	5606	TTTGGTAGGCTCCTTTTAGG	91	56	317

As shown in Tables 10 and 11, SEQ ID Nos 124, 128,
129, 132, 133, 134, 138, 140, 141, 142, 144, 145, 147, 148,
149, 150, 152, 153, 155, 156, 158, 159, 160, 161, 163, 165,
5 166, 167, 169, 170, 172, 176, 177, 178, 181, 183, 184, 185,
186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197,
198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209,
210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221,
222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233,
10 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 246,
247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258,
260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271,
272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283,
284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295,
15 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307,
308, 309, 310, 311, 312, 313, 314, 315, 316, and 317
demonstrated at least 30% inhibition of human

ISPH-0664WO

-146-

PATENT

apolipoprotein B expression in this assay and are therefore preferred. More preferred are SEQ ID Nos 224, 247, and 262. The target regions to which these preferred sequences are complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Tables 10 and 11. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

Example 31

Antisense inhibition of human apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap: Targeting GenBank Accession number M14162.1

In accordance with the present invention, another series of oligonucleotides were designed to target different regions of the human apolipoprotein B RNA, using published sequence (GenBank accession number M14162.1, incorporated herein as SEQ ID NO: 318). The oligonucleotides are shown in Table 12. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 12 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are

ISPH-0664WO

-147-

PATENT

composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

10

Table 12

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
271009	coding	318	3121	GCCTCAGTCTGCTTCGCGCC	75	319
271024	coding	318	8031	GCTCACTGTTTCAGCATCTGG	27	320
271029	coding	318	8792	TGAGAATCTGGGCGAGGCC	N.D.	321
271040	coding	318	11880	GTCCTTCATATTGCCATCT	0	322
271047	coding	318	12651	CCTCCCTCATGAACATAGTG	32	323
281639	coding	318	9851	GACGTCAGAACCTATGATGG	38	324
281647	coding	318	12561	TGAGTGAGTCAATCAGCTTC	73	325

15 **Example 32**

Antisense Inhibition of human apolipoprotein B - Gene walk targeting GenBank Accession number M14162.1

In accordance with the present invention, a "gene walk" was conducted in which another series of oligonucleotides were designed to target the regions of the human apolipoprotein B RNA (GenBank accession number M14162.1, incorporated herein as SEQ ID NO: 318) which are near the target site of SEQ ID NO: 319. The oligonucleotides are shown in Table 13. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide

ISPH-0664WO

-148-

PATENT

binds. All compounds in Table 12 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 13

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nM	% INHIB 50 nM	SEQ ID NO
308622	coding	318	3104	GCCTTCTGCTTGAGTTACAA	87	25	326
308623	coding	318	3106	GCGCCTTCTGCTTGAGTTAC	71	62	327
308624	coding	318	3108	TCGCGCCTTCTGCTTGAGTT	89	69	328
308625	coding	318	3110	CTTCGCGCCTTCTGCTTGAG	83	64	329
308626	coding	318	3116	AGTCTGCTTCGCGCCTTCTG	94	38	330
308627	coding	318	3118	TCAGTCTGCTTCGCGCCTTC	89	67	331
308628	coding	318	3120	CCTCAGTCTGCTTCGCGCCT	92	61	332
308629	coding	318	3122	AGCCTCAGTCTGCTTCGCGC	95	77	333

As shown in Tables 12 and 13, SEQ ID Nos 319, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, and 333 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. More preferred is SEQ ID NO: 319. The target regions to which these preferred sequences are

ISPH-0664WO

-149-

PATENT

complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Tables 12 and 13. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

Example 33

Antisense inhibition of human apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Targeting the Genomic sequence

In accordance with the present invention, another series of oligonucleotides were designed to target different regions of the human apolipoprotein B RNA, using published sequence (the complement of nucleotides 39835 to 83279 of the sequence with GenBank accession number NT_022227.9, representing a genomic sequence, incorporated herein as SEQ ID NO: 334). The oligonucleotides are shown in Table 14. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 14 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine

ISPH-0664WO

-150-

PATENT

residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 14

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301049	intron: exon junction	334	904	TCTGTAAGACAGGAGAAAGA	41	335
301050	intron: exon junction	334	913	ATTTCCTCTTCTGTAAGACA	22	336
301051	exon: intron junction	334	952	GATGCCTTACTTGGACAGAC	27	337
301052	intron	334	1945	AGAAATAGCTCTCCCAAGGA	13	338
301053	intron: exon junction	334	1988	GTCGCATCTTCTAACGTGGG	45	339
301054	exon: intron junction	334	2104	TCCTCCATACCTTGCAGTTG	0	340
301055	intron	334	2722	TGGCTCATGTCTACCATATT	49	341
301056	intron	334	2791	CAGTTGAAATGCAGCTAATG	35	342
301057	intron	334	3045	TGCAGACTAGGAGTGAAAGT	30	343
301058	intron	334	3117	AGGAGGATGTCCTTTTATTG	27	344
301059	intron	334	3290	ATCAGAGCACCAAAGGGAAT	12	345
301060	intron: exon junction	334	3381	CCAGCTCAACCTGAGAATTC	17	346
301061	exon: intron junction	334	3527	CATGACTTACCTGGACATGG	52	347
301062	intron	334	3566	CCTCAGCGGACACACACACA	21	348
301063	intron	334	3603	GTCACATCCGTGCCTGGTGC	41	349
301064	intron	334	3864	CAGTGCCTCTGGGACCCAC	60	350
301065	intron	334	3990	AGCTGCAGTGGCCGATCAGC	50	351
301066	intron	334	4251	GACCTCCCCAGCCACGTGGA	61	352
301067	intron	334	4853	TCTGATCACCATACATTACA	45	353

ISPH-0664WO

-151-

PATENT

301068	intron	334	5023	ATTTCCCACTGGGTACTCTC	44	354
301069	intron	334	5055	GGCTGAAGCCCATGCTGACT	44	355
301070	intron	334	5091	GTTGGACAGTCATTCTTTTG	38	356
301071	intron	334	5096	CACTTGTTGGACAGTCATTC	48	357
301072	intron	334	5301	ATTTTAAATTACAGTAGATA	43	358
301073	intron	334	5780	CTGTTCTCCACCCATATCAG	37	359
301074	intron: exon junction	334	6353	GAGCTCATACCTGTCCCAGA	75	360
301075	intron	334	6534	TTCAAGGGCCACTGCTATCA	52	361
301076	intron	334	6641	CCAGTATTTACGCCAATCC	36	362
301077	intron	334	6661	GGCAGGAGGAACCTCGGGCA	55	363
301078	intron	334	6721	TTTAAAAATTAGACCCAACC	22	364
301079	intron	334	6727	TGACTGTTTTAAAAATTAGAC	20	365
301080	intron	334	6788	CCCAGCAAACACAGGTGAAG	25	366
301081	intron	334	7059	GAGTGTGGTCTTGCTAGTGC	46	367
301082	intron	334	7066	CTATGCAGAGTGTGGTCTTG	41	368
301083	intron	334	7189	AGAAGATGCAACCACATGTA	29	369
301084	intron: exon junction	334	7209	ACACGGTATCCTATGGAGGA	49	370
301085	exon: intron junction	334	7365	TGGGACTTACCATGCCTTTG	11	371
301086	intron	334	7702	GGTTTTGCTGCCCTACATCC	30	372
301087	intron	334	7736	ACAAGGAGTCCTTGTGCAGA	40	373
301088	intron	334	8006	ATGTTCACTGAGACAGGCTG	41	374
301089	intron	334	8215	GAAGGTCCATGGTTCATCTG	0	375
301090	intron	334	8239	ATTAGACTGGAAGCATCCTG	39	376
301091	intron	334	8738	GAGATTGGAGACGAGCATTT	35	377
301092	exon: intron junction	334	8881	CATGACCTACTTGTAGGAGA	22	378
301093	intron	334	9208	TGGATTTGGATACACAAGTT	42	379
301094	intron	334	9244	ACTCAATATATATTCATTGA	22	380
301095	intron	334	9545	CAAGGAAGCACACCATGTCA	38	381
301096	intron: exon junction	334	9563	ATACTTATTCTGGTAACCA	24	382
301097	intron	334	9770	GGTAGCCAGAACACCAGTGT	50	383
301098	intron	334	9776	ACTAGAGGTAGCCAGAACAC	34	384
301099	intron	334	10149	ACCACCTGACATCACAGGTT	24	385
301100	intron	334	10341	TACTGTGACCTATGCCAGGA	55	386
301101	intron	334	10467	GGAGGTGCTACTGTTGACAT	42	387
301102	intron	334	10522	TCCAGACTTGTCTGAGTCTA	47	388
301103	intron	334	10547	TCTAAGAGGTAGAGCTAAAG	7	389
301104	intron	334	10587	CCAGAGATGAGCAACTTAGG	38	390
301105	intron	334	10675	GGCCATGTAAATTGCTCATC	7	391
301106	intron	334	10831	AAAGAACTATCCTGTATTC	12	392
301107	intron: exon junction	334	10946	TTCTTAGTACCTGGAAGATG	23	393

ISPH-0664WO

-152-

PATENT

301108	exon: intron junction	334	11166	CATTAGATACCTGGACACCT	29	394
301109	intron	334	11337	GTTTCATGGAACCTCAGCGCA	44	395
301110	intron	334	11457	CTGGAGAGCACCTGCAATAG	35	396
301111	intron	334	11521	TGAAGGGTAGAGAAATCATA	9	397
301112	exon: intron junction	334	12111	GGAAACTCACTTGTGACCG	25	398
301113	intron	334	12155	AGGTGCAAGATGTTCTCTG	46	399
301114	intron	334	12162	TGCACAGAGGTGCAAGATGT	16	400
301115	intron	334	12221	CACAAGAGTAAGGAGCAGAG	39	401
301116	intron	334	12987	GATGGATGGTGAGAAATTAC	33	402
301117	intron	334	13025	TAGACAATTGAGACTCAGAA	39	403
301118	intron	334	13057	ATGTGCACACAAGGACATAG	33	404
301119	intron	334	13634	ACATACAAATGGCAATAGGC	33	405
301120	intron	334	13673	TAGGCAAAGGACATGAATAG	30	406
301121	coding	334	14448	TTATGATAGCTACAGAATAA	29	407
301122	exon: intron junction	334	14567	CTGAGATTACCCGCAGAATC	32	408
301123	intron	334	14587	GATGTATGTCATATAAAAGA	26	409
301124	intron: exon junction	334	14680	TTTCCAATGACCTGCATTGA	48	410
301125	intron	334	15444	AGGGATGGTCAATCTGGTAG	57	411
301126	intron	334	15562	GGCTAATAAATAGGGTAGTT	22	412
301127	intron	334	15757	TCCTAGAGCACTATCAAGTA	41	413
301128	intron: exon junction	334	15926	CCTCCTGGTCCTGCAGTCAA	56	414
301129	intron	334	16245	CATTTGCACAAGTGTGTT	35	415
301130	intron	334	16363	CTGACACACCATGTTATTAT	10	416
301131	intron: exon junction	334	16399	CTTTTTCAGACTAGATAAGA	0	417
301132	exon: intron junction	334	16637	TCACACTTACCTCGATGAGG	29	418
301133	intron	334	17471	AAGAAAATGGCATCAGGTTT	13	419
301134	intron: exon junction	334	17500	CCAAGCCAATCTGAGAAAGA	25	420
301135	exon: intron junction	334	17677	AAATACACACCTGCTCATGT	20	421
301136	exon: intron junction	334	17683	CTTCACAAATACACACCTGC	20	422
301137	intron	334	18519	AGTGGAAGTTTGGTCTCATT	41	423
301138	intron	334	18532	TTGCTAGCTTCAAAGTGGA	44	424
301139	intron	334	18586	TCAAGAATAAGCTCCAGATC	41	425
301140	intron	334	18697	GCATACAAGTCACATGAGGT	34	426

ISPH-0664WO

-153-

PATENT

301141	intron	334	18969	TACAAGGTGTTTCTTAAGAA	38	427
301142	intron	334	19250	ATGCAGCCAGGATGGGCCTA	54	428
301143	intron: exon junction	334	19340	TTACCATATCCTGAGAGTTT	55	429
301144	intron	334	19802	GCAAAGGTAGAGGAAGGTAT	32	430
301145	intron	334	19813	AAGGACCTTCAGCAAAGGTA	36	431
301146	intron	334	20253	CATAGGAGTACATTTATATA	23	432
301147	intron	334	20398	ATTATGATAAAATCAATTTT	19	433
301148	intron	334	20567	AGAAATTTCACTAGATAGAT	31	434
301149	intron	334	20647	AGCATATTTTGATGAGCTGA	44	435
301150	intron	334	20660	GAAAGGAAGGACTAGCATAT	39	436
301151	intron: exon junction	334	20772	CCTCTCCAATCTGTAGACCC	28	437
301152	intron	334	21316	CTGGATAACTCAGACCTTTG	40	438
301153	intron	334	21407	AGTCAGAAAACAACCTATTC	11	439
301154	intron: exon junction	334	21422	CAGCCTGCATCTATAAGTCA	31	440
301155	exon: intron junction	334	21634	AAAGAATTACCCTCCACTGA	33	441
301156	intron	334	21664	TCTTTCAAACCTGGCTAGGCA	39	442
301157	intron	334	21700	GCCTGGCAAAATTCTGCAGG	37	443
301158	intron	334	22032	CTACCTCAAATCAATATGTT	28	444
301159	intron	334	22048	TGCTTTACCTACCTAGCTAC	36	445
301160	intron	334	22551	ACCTTGTTGTTCTCACTCAA	49	446
301161	intron	334	22694	ATGCATTCCCTGACTAGCAC	34	447
301162	intron	334	22866	CATCTCTGAGCCCCCTTACCA	24	448
301163	intron	334	22903	GCTGGGCATGCTCTCTCCCC	51	449
301164	intron	334	22912	GCTTTGCGAGCTGGGCATGC	55	450
301165	intron	334	23137	ACTCCTTTCTATACCTGGCT	47	451
301166	intron	334	23170	ATTCTGCCTCTTAGAAAAGTT	38	452
301167	intron	334	23402	CCAAGCCTCTTTACTGGGCT	29	453
301168	intron	334	23882	CACTCATGACCAGACTAAGA	35	454
301169	intron	334	23911	ACCTCCCAGAAGCCTTCCAT	22	455
301170	intron	334	24184	TTCATATGAAATCTCCTACT	40	456
301171	intron	334	24425	TATTTAATTTACTGAGAAAC	7	457
301172	intron: exon junction	334	24559	TAATGTGTTGCTGGTGAAGA	35	458
301173	exon: intron junction	334	24742	CATCTCTAACCTGGTGTCCC	21	459
301174	intron	334	24800	GTGCCATGCTAGGTGGCCAT	37	460
301175	intron	334	24957	AGCAAATTGGGATCTGTGCT	29	461
301176	intron	334	24991	TCTGGAGGCTCAGAAACATG	57	462
301177	intron	334	25067	TGAAGACAGGGAGCCACCTA	40	463
301178	intron	334	25152	AGGATTCCTCAAGACTTTGGA	38	464
301179	intron: exon	334	25351	CAGCTCTAATCTAAAGACAT	22	465

ISPH-0664WO

-154-

PATENT

	junction					
301180	exon: intron junction	334	25473	GAATACTCACCTTCTGCTTG	6	466
301181	intron	334	26047	ATCTCTCTGTCCCTCATCTTC	28	467
301182	intron	334	26749	CCAACTCCCCCTTTCTTTGT	37	468
301183	intron	334	26841	TCTGGGCCAGGAAGACACGA	68	469
301184	intron	334	27210	TATTGTGTGCTGGGCACTGC	52	470
301185	intron: exon junction	334	27815	TGCTTCGCACCTGGACGAGT	51	471
301186	exon: intron junction	334	28026	CCTTCTTTACCTTAGGTGGC	37	472
301187	intron	334	28145	GCTCTCTCTGCCACTCTGAT	47	473
301188	intron	334	28769	AACTTCTAAAGCCAACATTC	27	474
301189	intron: exon junction	334	28919	TGTGTCACTATGGTAAA	63	475
301190	exon: intron junction	334	29095	AGACACATACCATAATGCCA	22	476
301191	intron: exon junction	334	29204	TTCTCTTCATCTGAAAATAC	21	477
301192	intron	334	29440	TGAGGATGTAATTAGCACTT	27	478
301193	intron: exon junction	334	29871	AGCTCATTGCCTACAAAATG	31	479
301194	intron	334	30181	GTTCTCATGTTTACTAATGC	40	480
301195	intron	334	30465	GAATTGAGACAACTTGATTT	26	481
301196	intron: exon junction	334	30931	CCGGCCATCGCTGAAATGAA	54	482
301197	exon: intron junction	334	31305	CATAGCTCACCTTGCACATT	28	483
301198	intron	334	31325	CGGTGCACCCTTTACCTGAG	28	484
301199	intron: exon junction	334	31813	TCTCCAGATCCTAACATAAA	19	485
301200	intron	334	39562	TTGAATGACACTAGATTTTC	37	486
301201	intron	334	39591	AAAATCCATTTTCTTTAAAG	12	487
301202	intron	334	39654	CAGCTCACACTTATTTTAAA	7	488
301203	intron: exon junction	334	39789	GTTCCCAAACTGTATAGGA	36	489
301204	exon: intron junction	334	39904	AGCTCCATACTGAAGTCCTT	37	490
301205	intron	334	39916	CAATTCAATAAAAGCTCCAT	31	491
301206	intron	334	39938	GTTTTCAAAAGGTATAAGGT	28	492
301207	intron: exon	334	40012	TTCCCATTCCTGAAAGCAG	13	493

ISPH-0664WO

-155-

PATENT

	junction					
301208	exon: intron junction	334	40196	TGGTATTTACCTGAGGGCTG	21	494
301209	intron	334	40412	ATAAATAATAGTGCTGATGG	39	495
301210	intron	334	40483	CTATGGCTGAGCTTGCCTAT	33	496
301211	intron	334	40505	CTCTCTGAAAAATATACCCT	17	497
301212	intron	334	40576	TTGATGTATCTCATCTAGCA	41	498
301213	intron	334	40658	TAGAACCATGTTTGGTCTTC	35	499
301214	intron	334	40935	TTCTCTTTATCACATGCCC	29	500
301215	intron	334	41066	TATAGTACACTAAACTTCA	1	501
301216	intron: exon junction	334	41130	CTGGAGAGGACTAAACAGAG	49	502

As shown in Table 14, SEQ ID Nos 335, 339, 341, 342, 343, 347, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 367, 368, 370, 372, 373, 374, 376, 377, 379, 381, 383, 384, 386, 387, 388, 390, 395, 396, 399, 401, 402, 403, 404, 405, 406, 408, 410, 411, 413, 414, 415, 423, 424, 425, 426, 427, 428, 429, 430, 431, 434, 435, 436, 438, 440, 441, 442, 443, 445, 446, 447, 449, 450, 451, 452, 454, 456, 458, 460, 462, 463, 464, 468, 469, 470, 471, 472, 473, 475, 479, 480, 482, 486, 489, 490, 491, 495, 496, 498, 499, and 502 demonstrated at least 30% inhibition of human apolipoprotein B expression in this assay and are therefore preferred. The target regions to which these preferred sequences are complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 14. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide

ISPH-0664WO

-156-

PATENT

binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

Example 34

- 5 Antisense inhibition of human apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Targeting GenBank accession number AI249040.1

10 In accordance with the present invention, another series of oligonucleotides were designed to target different regions of the human apolipoprotein B RNA, using published sequence (the complement of the sequence with GenBank accession number AI249040.1, incorporated herein as SEQ ID NO: 503). The oligonucleotides are shown in Table

15 15. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 15 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of

20 ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine

25 residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in HepG2 cells by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

30

Table 15

Inhibition of human apolipoprotein B mRNA levels by

ISPH-0664WO

-157-

PATENT

chimeric phosphorothioate oligonucleotides having 2'-MOE
wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
301218	3'UTR	503	484	ACATTTTATCAATGCCCTCG	23	504
301219	3'UTR	503	490	GCCAGAACATTTTATCAATG	35	505
301220	3'UTR	503	504	AGAGGTTTTGCTGTGCCAGA	51	506
301221	3'UTR	503	506	CTAGAGGTTTTGCTGTGCCA	61	507
301222	3'UTR	503	507	TCTAGAGGTTTTGCTGTGCC	14	508
301223	3'UTR	503	522	AATCACACTATGTGTCTAG	26	509
301224	3'UTR	503	523	AAATCACACTATGTGTCTA	33	510
301225	3'UTR	503	524	TAAATCACACTATGTGTCT	3	511
301226	3'UTR	503	526	CTTAAATCACACTATGTGTT	39	512
301227	3'UTR	503	536	TATTCTGTTACTTAAATCAC	23	513

As shown in Table 15, SEQ ID Nos 505, 506, 507, 510,
5 and 512 demonstrated at least 30% inhibition of human
apolipoprotein B expression in this assay and are therefore
preferred. The target regions to which these preferred
sequences are complementary are herein referred to as
"preferred target segments" and are therefore preferred for
10 targeting by compounds of the present invention. These
preferred target segments are shown in Table 18. The
sequences represent the reverse complement of the preferred
antisense compounds shown in Table 15. "Target site"
indicates the first (5'-most) nucleotide number on the
15 particular target nucleic acid to which the oligonucleotide
binds. Also shown in Table 18 is the species in which each
of the preferred target segments was found.

Example 35

20 Antisense inhibition of human apolipoprotein B expression
by chimeric phosphorothioate oligonucleotides having 2'-MOE
wings and a deoxy gap - Variation in position of the gap

In accordance with the present invention, a series of
antisense compounds were designed to target different

ISPH-0664WO

-158-

PATENT

regions of the human apolipoprotein B RNA, using published sequences (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3). The compounds are shown in Table 16. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the compound binds. All compounds in Table 13 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length. The "gap" region consists of 2'-deoxynucleotides, which is flanked on one or both sides (5' and 3' directions) by "wings" composed of 2'-methoxyethyl (2'-MOE)nucleotides. The number of 2'-MOE nucleotides on either side of the gap varies such that the total number of 2'-MOE nucleotides always equals 10 and the total length of the chimeric oligonucleotide is 20 nucleotides. The exact structure of each oligonucleotide is designated in Table 16 as the "gap structure" and the 2'-deoxynucleotides are in bold type. A designation of 8-10-2, for instance, indicates that the first (5'-most) 8 nucleotides and the last (3'-most) 2 nucleotides are 2'-MOE nucleotides and the 10 nucleotides in the gap are 2'-deoxynucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments in which HepG2 cells were treated with the antisense oligonucleotides of the present invention at a dose of 50 nM and 150 nM. If present, "N.D." indicates "no data".

30

Table 16

Inhibition of human apolipoprotein B mRNA levels by

chimeric phosphorothioate oligonucleotides having 2'-MOE
wings and a variable deoxy gap

ISIS #	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nM	% INHIB 50 nM	gap structure	SEQ ID NO
308631	3	5589	AGGTTACCAGCCACATGCAG	94	74	0-10-10	224
308632	3	3249	GCCTCAGTCTGCTTCGCACC	97	41	0-10-10	247
308634	3	5589	AGGTTACCAGCCACATGCAG	67	45	10-10-0	224
308635	3	3249	GCCTCAGTCTGCTTCGCACC	93	69	10-10-0	247
308637	3	5589	AGGTTACCAGCCACATGCAG	95	79	1-10-9	224
308638	3	3249	GCCTCAGTCTGCTTCGCACC	94	91	1-10-9	247
308640	3	5589	AGGTTACCAGCCACATGCAG	96	76	2-10-8	224
308641	3	3249	GCCTCAGTCTGCTTCGCACC	89	77	2-10-8	247
308643	3	5589	AGGTTACCAGCCACATGCAG	96	56	3-10-7	224
308644	3	3249	GCCTCAGTCTGCTTCGCACC	93	71	3-10-7	247
308646	3	5589	AGGTTACCAGCCACATGCAG	76	50	4-10-6	224
308647	3	3249	GCCTCAGTCTGCTTCGCACC	86	53	4-10-6	247
308649	3	5589	AGGTTACCAGCCACATGCAG	91	68	6-10-4	224
308650	3	3249	GCCTCAGTCTGCTTCGCACC	94	74	6-10-4	247
308652	3	5589	AGGTTACCAGCCACATGCAG	95	73	7-10-3	224
308653	3	3249	GCCTCAGTCTGCTTCGCACC	89	73	7-10-3	247
308655	3	5589	AGGTTACCAGCCACATGCAG	83	84	8-10-2	224
308656	3	3249	GCCTCAGTCTGCTTCGCACC	97	37	8-10-2	247
308658	3	5589	AGGTTACCAGCCACATGCAG	78	86	9-10-1	224
308659	3	3249	GCCTCAGTCTGCTTCGCACC	93	70	9-10-1	247
308660	3	3254	TGGTAGCCTCAGTCTGCTTC	92	72	2-10-8	514
308662	3	3254	TGGTAGCCTCAGTCTGCTTC	83	76	8-10-2	514

As shown in Table 16, SEQ ID Nos 224, 247, and 514

5 demonstrated at least 30% inhibition of human
apolipoprotein B expression in this assay at both doses.
These data suggest that the oligonucleotides are effective
with a number of variations in the gap placement. The
target regions to which these preferred sequences are
10 complementary are herein referred to as "preferred target
segments" and are therefore preferred for targeting by
compounds of the present invention. These preferred target
segments are shown in Table 18. The sequences represent
the reverse complement of the preferred antisense compounds
15 shown in Table 16. "Target site" indicates the first (5'-

ISPH-0664WO

-160-

PATENT

most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

5

Example 36

Antisense inhibition of human apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Variation in position of the gap of
10 **SEQ ID Nos: 319 and 515**

In accordance with the present invention, a series of antisense compounds were designed based on SEQ ID Nos 319 and 515, with variations in the gap structure. The compounds are shown in Table 17. "Target site" indicates
15 the first (5'-most) nucleotide number on the particular target sequence to which the compound binds. All compounds in Table 17 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length. The "gap" region consists of 2'-deoxynucleotides, which is flanked on one or both sides (5' and 3' directions) by "wings" composed of 2'-methoxyethyl
20 (2'-MOE)nucleotides. The number of 2'-MOE nucleotides on either side of the gap varies such that the total number of 2'-MOE nucleotides always equals 10 and the total length of the chimeric oligonucleotide is 20 nucleotides. The exact
25 structure of each oligonucleotide is designated in Table 17 as the "gap structure" and the 2'-deoxynucleotides are in bold type. A designation of 8~10~2, for instance, indicates that the first (5'-most) 8 nucleotides and the last (3'-most) 2 nucleotides are 2'-MOE nucleotides and the
30 10 nucleotides in the gap are 2'-deoxynucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine

ISPH-0664WO

-161-

PATENT

residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein C-III mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments in which HepG2 cells were treated with the antisense oligonucleotides of the present invention at a dose of 50 nM and 150 nM. If present, "N.D." indicates "no data".

Table 17

Inhibition of human apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a variable deoxy gap

ISIS #	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB 150 nM	% INHIB 50 nM	gap structure	SEQ ID NO
308630	318	3121	GCCTCAGTCTGCTTCGCGCC	89	69	0~10~10	319
308633	318	3121	GCCTCAGTCTGCTTCGCGCC	83	66	10~10~0	319
308636	318	3121	GCCTCAGTCTGCTTCGCGCC	91	81	1~10~9	319
308639	318	3121	GCCTCAGTCTGCTTCGCGCC	94	86	2~10~8	319
308642	318	3121	GCCTCAGTCTGCTTCGCGCC	95	85	3~10~7	319
308645	318	3121	GCCTCAGTCTGCTTCGCGCC	98	57	4~10~6	319
308648	318	3121	GCCTCAGTCTGCTTCGCGCC	89	78	6~10~4	319
308651	318	3121	GCCTCAGTCTGCTTCGCGCC	88	87	7~10~3	319
308654	318	3121	GCCTCAGTCTGCTTCGCGCC	90	81	8~10~2	319
308657	318	3121	GCCTCAGTCTGCTTCGCGCC	78	61	9~10~1	319
308661	318	3116	AGTCTGCTTCGCGCCTTCTG	91	70	2~10~8	515
308663	318	3116	AGTCTGCTTCGCGCCTTCTG	84	44	8~10~2	515

As shown in Table 17, SEQ ID Nos 319 and 515 demonstrated at least 44% inhibition of human apolipoprotein B expression in this assay for either dose. These data suggest that the compounds are effective with a number of variations in gap placement. The target regions to which these preferred sequences are complementary are herein referred to as "preferred target segments" and are therefore preferred for targeting by compounds of the

ISPH-0664WO

-162-

PATENT

present invention. These preferred target segments are shown in Table 18. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 17. "Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 18 is the species in which each of the preferred target segments was found.

Table 18

Sequence and position of preferred target segments identified in apolipoprotein B.

SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID NO	ACTIVE IN	SEQ ID NO
187342	3	199	GCGCCAGGGCCGAAGAGGAA	124	<i>H. sapiens</i>	516
187346	3	509	CAGGTATGAGCTCAAGCTGG	128	<i>H. sapiens</i>	517
187347	3	584	CATCCTGAACATCAAGAGGG	129	<i>H. sapiens</i>	518
187350	3	756	GGGCAGTGTGATCGCTTCAA	132	<i>H. sapiens</i>	519
187351	3	799	CACCTTGCTCTCATCAAAGGC	133	<i>H. sapiens</i>	520
187352	3	869	CACACTGGACGCTAAGAGGA	134	<i>H. sapiens</i>	521
187356	3	1459	CGCTGAGCCACGCGGTCAAC	138	<i>H. sapiens</i>	522
187358	3	1859	TGTCCAAATTCTACCATGGG	140	<i>H. sapiens</i>	523
187359	3	2179	CAGCTGACCTCATCGAGATT	141	<i>H. sapiens</i>	524
187360	3	2299	GTCAAGTTCCTGATGGTGTC	142	<i>H. sapiens</i>	525
187362	3	2518	AGCTGCTTCTGATGGGTGCC	144	<i>H. sapiens</i>	526
187363	3	2789	GGGCATCATCATTCGGGACT	145	<i>H. sapiens</i>	527
187365	3	3100	CCTACTATCCGCTGACCGGG	147	<i>H. sapiens</i>	528
187367	3	3449	GGGCCACCTAAGTTGTGACA	148	<i>H. sapiens</i>	529
187368	3	3919	AGAACATGGGATTGCCAGAC	149	<i>H. sapiens</i>	530
187369	3	4089	CTCCACTTCAAGTCTGTGGG	150	<i>H. sapiens</i>	531
187371	3	5146	CAGAGCTTGGCCTCTCTGGG	152	<i>H. sapiens</i>	532
187372	3	5189	TGGCCGCTTCAGGGAACACA	153	<i>H. sapiens</i>	533
187374	3	6049	CAGCTGAGCAGACAGGCACC	155	<i>H. sapiens</i>	534
187375	3	6520	GGGAGAGACAAGTTTCACAT	156	<i>H. sapiens</i>	535
187377	3	6859	GTACTGCATCCTGGATTCAA	158	<i>H. sapiens</i>	536
187378	3	7459	GTGAGGTGACTCAGAGACTC	159	<i>H. sapiens</i>	537
187379	3	7819	TTGCAGAGCAATATTCTATC	160	<i>H. sapiens</i>	538
187380	3	7861	AAGCATTGGTAGAGCAAGGG	161	<i>H. sapiens</i>	539
187383	3	8589	CCGCTGGCTCTGAAGGAGTC	163	<i>H. sapiens</i>	540
187385	3	8829	TCTAGTCAGGCTGACCTGCG	165	<i>H. sapiens</i>	541
187387	3	9119	GGGCCACAGTGTCTAACTG	166	<i>H. sapiens</i>	542

ISPH-0664WO

-163-

PATENT

187388	3	10159	AATCAAGTGTCTCATCAGCTG	167	<i>H. sapiens</i>	543
187390	3	10349	GGGTAGTCATAACAGTACTG	169	<i>H. sapiens</i>	544
187391	3	10699	AGAGCACACGGTCTTCAGTG	170	<i>H. sapiens</i>	545
187393	3	10839	TTACAGCTAGAGGGCTCTT	172	<i>H. sapiens</i>	546
187398	3	12149	CACCGTGGGCATGGATATGG	176	<i>H. sapiens</i>	547
187399	3	12265	GGGAATCTGATGAGGAACT	177	<i>H. sapiens</i>	548
187400	3	12380	TGTCAACAAGTACCACTGGG	178	<i>H. sapiens</i>	549
187403	3	12749	ACCTGGGATATACACTAGGG	181	<i>H. sapiens</i>	550
187406	3	13299	CCAAGTATAGTTGGCTGGAC	183	<i>H. sapiens</i>	551
187407	3	13779	TACATGAAGCTTGCTCCAGG	184	<i>H. sapiens</i>	552
197724	3	229	ATGTCAGCCTGGTCTGTCCA	185	<i>H. sapiens</i>	553
197725	3	269	GCACCTCCGGAAGTACACAT	186	<i>H. sapiens</i>	554
197726	3	389	CTGCAGCTTCATCCTGAAGA	187	<i>H. sapiens</i>	555
197727	3	449	TGAGGGCAAAGCCTTGCTGA	188	<i>H. sapiens</i>	556
197728	3	529	CCATTCCAGAAGGGAAGCAG	189	<i>H. sapiens</i>	557
197729	3	709	CGAGGAAGGGCAATGTGGCA	190	<i>H. sapiens</i>	558
197730	3	829	CCTTGTCAACTCTGATCAGC	191	<i>H. sapiens</i>	559
197731	3	849	AGCAGCCAGTCCTGTCTAGTA	192	<i>H. sapiens</i>	560
197732	3	889	AGCATGTGGCAGAAGCCATC	193	<i>H. sapiens</i>	561
197733	3	1059	GAGAGCACCAATCCACATC	194	<i>H. sapiens</i>	562
197734	3	1199	CCTCAGTGATGAAGCAGTCA	195	<i>H. sapiens</i>	563
197735	3	1349	GATAGATGTGGTCACCTACC	196	<i>H. sapiens</i>	564
197736	3	1390	CCTCAGCACAGCAGTGCAG	197	<i>H. sapiens</i>	565
197737	3	1589	GATTCTGCGGGTCATTGGAA	198	<i>H. sapiens</i>	566
197738	3	1678	CAAAGCCATCACTGATGATC	199	<i>H. sapiens</i>	567
197739	3	1699	AGAAAGCTGCCATCCAGGCT	200	<i>H. sapiens</i>	568
197740	3	1749	CAGGAGGTTCTTCTTCAGAC	201	<i>H. sapiens</i>	569
197741	3	1829	GAGTCCTTCACAGGCAGATA	202	<i>H. sapiens</i>	570
197742	3	1919	TGCCAATATCTTGAAGTCAG	203	<i>H. sapiens</i>	571
197743	3	2189	CATCGAGATTGGCTTGGAAG	204	<i>H. sapiens</i>	572
197744	3	2649	GGAGCTGGATTACAGTTGCA	205	<i>H. sapiens</i>	573
197745	3	2729	CAACATGCAGGCTGAAGTGG	206	<i>H. sapiens</i>	574
197746	3	2949	ACATTACATTTGGTCTCTAC	207	<i>H. sapiens</i>	575
197747	3	3059	CTCAGGCGCTTACTCCAACG	208	<i>H. sapiens</i>	576
197748	3	3118	GGGACACCAGATTAGAGCTG	209	<i>H. sapiens</i>	577
197749	3	3189	GAGCTCCAGAGAGAGGACAG	210	<i>H. sapiens</i>	578
197750	3	3289	ATCGGCAGAGTATGACCTTG	211	<i>H. sapiens</i>	579
197751	3	3488	CAAGGGTGTTATTTCCATAC	212	<i>H. sapiens</i>	580
197752	3	3579	GACTCATCTGCTACAGCTTA	213	<i>H. sapiens</i>	581
197753	3	4039	GCAAATCCTCCAGAGATCTA	214	<i>H. sapiens</i>	582
197754	3	4180	CTCTCCTGGGTGTTCTAGAC	215	<i>H. sapiens</i>	583
197755	3	4299	ATGAAGGCTGACTCTGTGGT	216	<i>H. sapiens</i>	584
197756	3	4511	GGGACCACAGATGTCTGCTT	217	<i>H. sapiens</i>	585
197757	3	4660	CTGGCCGGCTCAATGGAGAG	218	<i>H. sapiens</i>	586
197758	3	4919	GCTGCGTTCTGAATATCAGG	219	<i>H. sapiens</i>	587
197759	3	5009	TGCTGACATCTTAGGCACTG	220	<i>H. sapiens</i>	588
197760	3	5109	AAGTGATGCTCCTGGTGCT	221	<i>H. sapiens</i>	589
197761	3	5212	CAAAATTCAGTCTGGATGGG	222	<i>H. sapiens</i>	590

ISPH-0664WO

-164-

PATENT

197762	3	5562	GGGAAACTACGGCTAGAACC	223	<i>H. sapiens</i>	591
197763	3	5589	CTGCATGTGGCTGGTAACCT	224	<i>H. sapiens</i>	592
197764	3	5839	CCATGACCATCGATGCACAT	225	<i>H. sapiens</i>	593
197765	3	5869	ATGGGAAACTCGCTCTCTGG	226	<i>H. sapiens</i>	594
197766	3	5979	AGTCATCATCTCGTGTCTAG	227	<i>H. sapiens</i>	595
197767	3	6099	GAATACAGCCAGGACTTGGA	228	<i>H. sapiens</i>	596
197768	3	6144	GGCGTGAGCTTACTGGACG	229	<i>H. sapiens</i>	597
197769	3	6249	GAGATGAGAGATGCCGTTGA	230	<i>H. sapiens</i>	598
197770	3	6759	AGTCTTGATGAGCACTATCA	231	<i>H. sapiens</i>	599
197771	3	6889	CTAAGTACCAAATCAGAATC	232	<i>H. sapiens</i>	600
197772	3	7149	GTCCATGAGTTAATCGAGAG	233	<i>H. sapiens</i>	601
197773	3	7549	AGGCCACAGTTGCAGTGTAT	234	<i>H. sapiens</i>	602
197774	3	7779	TCTGATTGGTGGACTCTTGC	235	<i>H. sapiens</i>	603
197775	3	7929	GAAGTCAGTCTTCAGGCTCT	236	<i>H. sapiens</i>	604
197776	3	8929	CCAGATTCTCAGATGAGGGA	237	<i>H. sapiens</i>	605
197778	3	10240	CATCTGTCTTATGATGCACTG	238	<i>H. sapiens</i>	606
197779	3	10619	AGGAGATGTCAAGGGTTTCGG	239	<i>H. sapiens</i>	607
197780	3	10659	GGAAGTATTGCTAGTGAGGC	240	<i>H. sapiens</i>	608
197781	3	10899	CTCTCTCCATGGCAAATGTC	241	<i>H. sapiens</i>	609
197783	3	11979	CACCGTGACTTCAGTGCAGA	243	<i>H. sapiens</i>	610
197784	3	12249	ACTGAGTTGAGGGTCCGGGA	244	<i>H. sapiens</i>	611
197786	3	13958	CACATATGAAGTGGACCTGC	245	<i>H. sapiens</i>	612
197787	3	14008	TCTGAAGTCAAGGATGGC	246	<i>H. sapiens</i>	613
216825	3	3249	GGTGCGAAGCAGACTGAGGC	247	<i>H. sapiens</i>	614
216826	3	3	TCCCACCGGGACCTGCGGGG	248	<i>H. sapiens</i>	615
216827	3	6	CACCGGGACCTGCGGGGCTG	249	<i>H. sapiens</i>	616
216828	3	23	CTGAGTGCCCTTCTCGGTTG	250	<i>H. sapiens</i>	617
216829	3	35	CTCGGTTGCTGCCGCTGAGG	251	<i>H. sapiens</i>	618
216830	3	36	TCGGTTGCTGCCGCTGAGGA	252	<i>H. sapiens</i>	619
216831	3	37	CGGTTGCTGCCGCTGAGGAG	253	<i>H. sapiens</i>	620
216832	3	39	GTTGCTGCCGCTGAGGAGCC	254	<i>H. sapiens</i>	621
216833	3	43	CTGCCGCTGAGGAGCCCGCC	255	<i>H. sapiens</i>	622
216834	3	116	ACCGCAGCTGGCGATGGACC	256	<i>H. sapiens</i>	623
216835	3	120	CAGCTGGCGATGGACCCGCC	257	<i>H. sapiens</i>	624
216836	3	13800	GAAGTACTATCATCCTCTA	258	<i>H. sapiens</i>	625
216838	3	13854	TCCAATTGAAGTTTCACATA	260	<i>H. sapiens</i>	626
216839	3	13882	AAAATTCAAAGTGCCTATAT	261	<i>H. sapiens</i>	627
216840	3	13903	GATAAAACCATACAGTGAGC	262	<i>H. sapiens</i>	628
216841	3	13904	ATAAAACCATACAGTGAGCC	263	<i>H. sapiens</i>	629
216842	3	13908	AACCATACAGTGAGCCAGCC	264	<i>H. sapiens</i>	630
216843	3	13909	ACCATACAGTGAGCCAGCCT	265	<i>H. sapiens</i>	631
216844	3	13910	CCATACAGTGAGCCAGCCTT	266	<i>H. sapiens</i>	632
216845	3	13917	GTGAGCCAGCCTTGAGTAG	267	<i>H. sapiens</i>	633
216846	3	13922	CCAGCCTTGAGTAGGAGT	268	<i>H. sapiens</i>	634
216847	3	13934	TAGGCAGTAGACTATAAGCA	269	<i>H. sapiens</i>	635
216848	3	13937	GCAGTAGACTATAAGCAGAA	270	<i>H. sapiens</i>	636
216849	3	13964	TGAAGTGGACCTGCACCAAA	271	<i>H. sapiens</i>	637
216850	3	13968	CTGGACCTGCACCAAAGCTG	272	<i>H. sapiens</i>	638

ISPH-0664WO

-165-

PATENT

216851	3	13970	GGACCTGCACCAAAGCTGGC	273	<i>H. sapiens</i>	639
216852	3	13974	CTGCACCAAAGCTGGCACCA	274	<i>H. sapiens</i>	640
216853	3	13978	ACCAAAGCTGGCACCAGGGC	275	<i>H. sapiens</i>	641
216854	3	13997	CTCGGAAGGTCTCTGAATC	276	<i>H. sapiens</i>	642
216855	3	14012	AACTCAGAAGGATGGCATT	277	<i>H. sapiens</i>	643
216856	3	14014	CTCAGAAGGATGGCATT	278	<i>H. sapiens</i>	644
216857	3	14049	ATCAGGATCTGAGTTAT	279	<i>H. sapiens</i>	645
216858	3	14052	AGGATCTGAGTTATTTGCT	280	<i>H. sapiens</i>	646
216859	3	14057	CTGAGTTATTTTGCTAACT	281	<i>H. sapiens</i>	647
216860	3	14064	ATTTTGCTAACTTGGGGGA	282	<i>H. sapiens</i>	648
216861	3	14071	TAAACTTGGGGGAGGAGGAA	283	<i>H. sapiens</i>	649
217030	3	14087	GGAACAAATAAATGGAGTCT	284	<i>H. sapiens</i>	650
224316	3	3230	GTTTGTAACCTCAAGCAGAAG	285	<i>H. sapiens</i>	651
224317	3	3232	TTGTAACCTCAAGCAGAAGGT	286	<i>H. sapiens</i>	652
224318	3	3234	GTAACCTCAAGCAGAAGGTGC	287	<i>H. sapiens</i>	653
224319	3	3236	AACTCAAGCAGAAGGTGCGA	288	<i>H. sapiens</i>	654
224320	3	3238	CTCAAGCAGAAGGTGCGAAG	289	<i>H. sapiens</i>	655
224321	3	3240	CAAGCAGAAGGTGCGAAGCA	290	<i>H. sapiens</i>	656
224322	3	3242	AGCAGAAGGTGCGAAGCAGA	291	<i>H. sapiens</i>	657
224323	3	3244	CAGAAGGTGCGAAGCAGACT	292	<i>H. sapiens</i>	658
224324	3	3246	GAAGGTGCGAAGCAGACTGA	293	<i>H. sapiens</i>	659
224325	3	3248	AGGTGCGAAGCAGACTGAGG	294	<i>H. sapiens</i>	660
224326	3	3250	GTGCGAAGCAGACTGAGGCT	295	<i>H. sapiens</i>	661
224327	3	3252	GCGAAGCAGACTGAGGCTAC	296	<i>H. sapiens</i>	662
224328	3	3254	GAAGCAGACTGAGGCTACCA	297	<i>H. sapiens</i>	663
224329	3	3256	AGCAGACTGAGGCTACCATG	298	<i>H. sapiens</i>	664
224330	3	3258	CAGACTGAGGCTACCATGAC	299	<i>H. sapiens</i>	665
224331	3	3260	GAAGTGAAGCTGACATGACAT	300	<i>H. sapiens</i>	666
224332	3	3262	CTGAGGCTACCATGACATTC	301	<i>H. sapiens</i>	667
224333	3	3264	GAGGCTACCATGACATTCAA	302	<i>H. sapiens</i>	668
224334	3	3266	GGCTACCATGACATTCAAAT	303	<i>H. sapiens</i>	669
224335	3	3268	CTACCATGACATTCAAATAT	304	<i>H. sapiens</i>	670
224336	3	5582	CCTGAAGCTGCATGTGGCTG	305	<i>H. sapiens</i>	671
224337	3	5584	TGAAGCTGCATGTGGCTGGT	306	<i>H. sapiens</i>	672
224338	3	5586	AAGCTGCATGTGGCTGGTAA	307	<i>H. sapiens</i>	673
224339	3	5588	GCTGCATGTGGCTGGTAAACC	308	<i>H. sapiens</i>	674
224340	3	5590	TGCATGTGGCTGGTAAACCTA	309	<i>H. sapiens</i>	675
224341	3	5592	CATGTGGCTGGTAAACCTAAA	310	<i>H. sapiens</i>	676
224342	3	5594	TGTGGCTGGTAAACCTAAAAG	311	<i>H. sapiens</i>	677
224343	3	5596	TGGCTGGTAAACCTAAAAGGA	312	<i>H. sapiens</i>	678
224344	3	5598	GCTGGTAAACCTAAAAGGAGC	313	<i>H. sapiens</i>	679
224345	3	5600	TGGTAAACCTAAAAGGAGCCT	314	<i>H. sapiens</i>	680
224346	3	5602	GTAACCTAAAAGGAGCCTAC	315	<i>H. sapiens</i>	681
224347	3	5604	AACCTAAAAGGAGCCTACCA	316	<i>H. sapiens</i>	682
224348	3	5606	CCTAAAAGGAGCCTACCAAA	317	<i>H. sapiens</i>	683
187366	318	3121	GGCGCGAAGCAGACTGAGGC	319	<i>H. sapiens</i>	684
187404	318	12651	CACTATGTTTCATGAGGGAGG	323	<i>H. sapiens</i>	685
197777	318	9851	CCATCATAGGTTCTGACGTC	324	<i>H. sapiens</i>	686

ISPH-0664WO

-166-

PATENT

197785	318	12561	GAAGCTGATTGACTCACTCA	325	<i>H. sapiens</i>	687
224349	318	3104	TTGTAACCAAGCAGAAGGC	326	<i>H. sapiens</i>	688
224350	318	3106	GTAACCAAGCAGAAGGCGC	327	<i>H. sapiens</i>	689
224351	318	3108	AACTCAAGCAGAAGGCGCGA	328	<i>H. sapiens</i>	690
224352	318	3110	CTCAAGCAGAAGGCGCGAAG	329	<i>H. sapiens</i>	691
224353	318	3116	CAGAAGGCGCGAAGCAGACT	330	<i>H. sapiens</i>	692
224354	318	3118	GAAGGCGCGAAGCAGACTGA	331	<i>H. sapiens</i>	693
224355	318	3120	AGGCGCGAAGCAGACTGAGG	332	<i>H. sapiens</i>	694
224356	318	3122	GCGCGAAGCAGACTGAGGCT	333	<i>H. sapiens</i>	695
224328	3	3254	GAAGCAGACTGAGGCTACCA	514	<i>H. sapiens</i>	696
224353	318	3116	CAGAAGGCGCGAAGCAGACT	515	<i>H. sapiens</i>	697
216862	334	904	TCTTTCTCCTGTCTTACAGA	335	<i>H. sapiens</i>	698
216866	334	1988	CCCACGTTAGAAGATGCGAC	339	<i>H. sapiens</i>	699
216868	334	2722	AATATGGTAGACATGAGCCA	341	<i>H. sapiens</i>	700
216869	334	2791	CATTAGCTGCATTTCAACTG	342	<i>H. sapiens</i>	701
216870	334	3045	ACTTTCACTCCTAGTCTGCA	343	<i>H. sapiens</i>	702
216874	334	3527	CCATGTCCAGGTAAGTCATG	347	<i>H. sapiens</i>	703
216876	334	3603	GCACCAGGCACGGATGTGAC	349	<i>H. sapiens</i>	704
216877	334	3864	GTGGGGTCCCAGAGGCACTG	350	<i>H. sapiens</i>	705
216878	334	3990	GCTGATCGGCCACTGCAGCT	351	<i>H. sapiens</i>	706
216879	334	4251	TCCACGTGGCTGGGGAGGTC	352	<i>H. sapiens</i>	707
216880	334	4853	TGTAATGTATGGTGATCAGA	353	<i>H. sapiens</i>	708
216881	334	5023	GAGAGTACCCAGTGGGAAAT	354	<i>H. sapiens</i>	709
216882	334	5055	AGTCAGCATGGGCTTCAGCC	355	<i>H. sapiens</i>	710
216883	334	5091	CAAAAGAATGACTGTCCAAC	356	<i>H. sapiens</i>	711
216884	334	5096	GAATGACTGTCCAACAAGTG	357	<i>H. sapiens</i>	712
216885	334	5301	TATCTACTGTAATTTAAAAT	358	<i>H. sapiens</i>	713
216886	334	5780	CTGATATGGGTGGAGAACAG	359	<i>H. sapiens</i>	714
216887	334	6353	TCTGGGACAGGTATGAGCTC	360	<i>H. sapiens</i>	715
216888	334	6534	TGATAGCAGTGGCCCTTGAA	361	<i>H. sapiens</i>	716
216889	334	6641	GGATTGGCGTGAAATACTGG	362	<i>H. sapiens</i>	717
216890	334	6661	TGCCCAGGTTCCCTCCTGCC	363	<i>H. sapiens</i>	718
216894	334	7059	GCACTAGCAAGACCACACTC	367	<i>H. sapiens</i>	719
216895	334	7066	CAAGACCACACTCTGCATAG	368	<i>H. sapiens</i>	720
216897	334	7209	TCCTCCATAGGATACCGTGT	370	<i>H. sapiens</i>	721
216899	334	7702	GGATGTAGGGCAGCAAAACC	372	<i>H. sapiens</i>	722
216900	334	7736	TCTGCACAAGGACTCCTTGT	373	<i>H. sapiens</i>	723
216901	334	8006	CAGCCTGTCTCAGTGAACAT	374	<i>H. sapiens</i>	724
216903	334	8239	CAGGATGCTTCCAGTCTAAT	376	<i>H. sapiens</i>	725
216904	334	8738	AAATGCTCGTCTCCAATCTC	377	<i>H. sapiens</i>	726
216906	334	9208	AACTGTGTATCCAAATCCA	379	<i>H. sapiens</i>	727
216908	334	9545	TGACATGGTGTGCTTCCTTG	381	<i>H. sapiens</i>	728
216910	334	9770	ACACTGGTGTCTGGCTACC	383	<i>H. sapiens</i>	729
216911	334	9776	GTGTTCTGGCTACCTCTAGT	384	<i>H. sapiens</i>	730
216913	334	10341	TCCTGGCATAGGTCACAGTA	386	<i>H. sapiens</i>	731
216914	334	10467	ATGTCAACAGTAGCACCTCC	387	<i>H. sapiens</i>	732
216915	334	10522	TAGACTCAGACAAGTCTGGA	388	<i>H. sapiens</i>	733
216917	334	10587	CCTAAGTTGCTCATCTCTGG	390	<i>H. sapiens</i>	734

ISPH-0664WO

-167-

PATENT

216922	334	11337	TGCGCTGAGTTCCATGAAAC	395	<i>H. sapiens</i>	735
216923	334	11457	CTATTGCAGGTGCTCTCCAG	396	<i>H. sapiens</i>	736
216926	334	12155	CAGAGGAACATCTTGCACCT	399	<i>H. sapiens</i>	737
216928	334	12221	CTCTGCTCCTTACTCTTGTG	401	<i>H. sapiens</i>	738
216929	334	12987	GTAATTTCTCACCATCCATC	402	<i>H. sapiens</i>	739
216930	334	13025	TTCTGAGTCTCAATTGTCTA	403	<i>H. sapiens</i>	740
216931	334	13057	CTATGTCCTTGTGTGCACAT	404	<i>H. sapiens</i>	741
216932	334	13634	GCCTATTGCCATTTGTATGT	405	<i>H. sapiens</i>	742
216933	334	13673	CTATTCATGTCCTTTGCCTA	406	<i>H. sapiens</i>	743
216935	334	14567	GATTCCTGCGGGTAATCTCAG	408	<i>H. sapiens</i>	744
216937	334	14680	TCAATGCAGGTCAATTGAAA	410	<i>H. sapiens</i>	745
216938	334	15444	CTACCAGATTGACCATCCCT	411	<i>H. sapiens</i>	746
216940	334	15757	TACTTGATAGTGTCTTAGGA	413	<i>H. sapiens</i>	747
216941	334	15926	TTGACTGCAGGACCAGGAGG	414	<i>H. sapiens</i>	748
216942	334	16245	AACAAACACTTGTGCAAATG	415	<i>H. sapiens</i>	749
216950	334	18519	AATGAGACCAACTTCCACT	423	<i>H. sapiens</i>	750
216951	334	18532	TTCCACTTTGAAGCTAGCAA	424	<i>H. sapiens</i>	751
216952	334	18586	GATCTGGAGCTTATTCTTGA	425	<i>H. sapiens</i>	752
216953	334	18697	ACCTCATGTGACTTGTATGC	426	<i>H. sapiens</i>	753
216954	334	18969	TTCTTAAGAAACACCTTGTA	427	<i>H. sapiens</i>	754
216955	334	19250	TAGGCCCATCCTGGCTGCAT	428	<i>H. sapiens</i>	755
216956	334	19340	AAACTCTCAGGATATGGTAA	429	<i>H. sapiens</i>	756
216957	334	19802	ATACCTTCCTCTACCTTTGC	430	<i>H. sapiens</i>	757
216958	334	19813	TACCTTTGCTGAAGGTCCTT	431	<i>H. sapiens</i>	758
216961	334	20567	ATCTATCTAGTGAAATTTCT	434	<i>H. sapiens</i>	759
216962	334	20647	TCAGCTCATCAAATATGCT	435	<i>H. sapiens</i>	760
216963	334	20660	ATATGCTAGTCCTTCCTTTC	436	<i>H. sapiens</i>	761
216965	334	21316	CAAAGGTCTGAGTTATCCAG	438	<i>H. sapiens</i>	762
216967	334	21422	TGACTTATAGATGCAGGCTG	440	<i>H. sapiens</i>	763
216968	334	21634	TCAGTGGAGGGTAATTCTTT	441	<i>H. sapiens</i>	764
216969	334	21664	TGCCTAGCCAGTTTGAAAGA	442	<i>H. sapiens</i>	765
216970	334	21700	CCTGCAGAATTTTGCCAGGC	443	<i>H. sapiens</i>	766
216972	334	22048	GTAGCTAGGTAGGTAAAGCA	445	<i>H. sapiens</i>	767
216973	334	22551	TTGAGTGAGACACACAAGGT	446	<i>H. sapiens</i>	768
216974	334	22694	GTGCTAGTCAGGGAATGCAT	447	<i>H. sapiens</i>	769
216976	334	22903	GGGGAGAGAGCATGCCCAGC	449	<i>H. sapiens</i>	770
216977	334	22912	GCATGCCAGCTGCGAAAGC	450	<i>H. sapiens</i>	771
216978	334	23137	AGCCAGGTATAGAAAGGAGT	451	<i>H. sapiens</i>	772
216979	334	23170	AACTTTCTAAGAGGCAGAAT	452	<i>H. sapiens</i>	773
216981	334	23882	TCTTAGTCTGGTCATGAGTG	454	<i>H. sapiens</i>	774
216983	334	24184	AGTAGGAGATTTTCATATGAA	456	<i>H. sapiens</i>	775
216985	334	24559	TCTTCACCAGCAACACATTA	458	<i>H. sapiens</i>	776
216987	334	24800	ATGGCCACCTAGCATGGCAC	460	<i>H. sapiens</i>	777
216989	334	24991	CATGTTTCTGAGCCTCCAGA	462	<i>H. sapiens</i>	778
216990	334	25067	TAGGTGGCTCCCTGTCTTCA	463	<i>H. sapiens</i>	779
216991	334	25152	TCCAAAGTCTTGGGAATCCT	464	<i>H. sapiens</i>	780
216995	334	26749	ACAAAGAAAGGGGAGTTGG	468	<i>H. sapiens</i>	781
216996	334	26841	TCGTGTCTTCCTGGCCCAGA	469	<i>H. sapiens</i>	782

ISPH-0664WO

-168-

PATENT

216997	334	27210	GCAGTGCCCGACACACAATA	470	<i>H. sapiens</i>	783
216998	334	27815	ACTCGTCCAGGTGCGAAGCA	471	<i>H. sapiens</i>	784
216999	334	28026	GCCACCTAAGGTAAAGAAGG	472	<i>H. sapiens</i>	785
217000	334	28145	ATCAGAGTGGCAGAGAGAGC	473	<i>H. sapiens</i>	786
217002	334	28919	TTTACCATAGTTGTGACACA	475	<i>H. sapiens</i>	787
217006	334	29871	CATTTTGTAGGCAATGAGCT	479	<i>H. sapiens</i>	788
217007	334	30181	GCATTAGTAAACATGAGAAC	480	<i>H. sapiens</i>	789
217009	334	30931	TTCATTTTCAGCGATGGCCGG	482	<i>H. sapiens</i>	790
217013	334	39562	GAAAATCTAGTGTTCATTCAA	486	<i>H. sapiens</i>	791
217016	334	39789	TCCTATACAGTTTGGGAAC	489	<i>H. sapiens</i>	792
217017	334	39904	AAGGACTTCAGTATGGAGCT	490	<i>H. sapiens</i>	793
217018	334	39916	ATGGAGCTTTTATTGAATTG	491	<i>H. sapiens</i>	794
217022	334	40412	CCATCAGCACTATTATTTAT	495	<i>H. sapiens</i>	795
217023	334	40483	ATAGGCAAGCTCAGCCATAG	496	<i>H. sapiens</i>	796
217025	334	40576	TGCTAGATGAGATACATCAA	498	<i>H. sapiens</i>	797
217026	334	40658	GAAGACCAAACATGGTTCTA	499	<i>H. sapiens</i>	798
217029	334	41130	CTCTGTTTAGTCCTCTCCAG	502	<i>H. sapiens</i>	799
217032	503	490	CATTGATAAAATGTTCTGGC	505	<i>H. sapiens</i>	800
217033	503	504	TCTGGCACAGCAAAACCTCT	506	<i>H. sapiens</i>	801
217034	503	506	TGGCACAGCAAAACCTCTAG	507	<i>H. sapiens</i>	802
217037	503	523	TAGAACACATAGTGTGATTT	510	<i>H. sapiens</i>	803
217039	503	526	AACACATAGTGTGATTTAAG	512	<i>H. sapiens</i>	804

As these "preferred target segments" have been found by experimentation to be open to, and accessible for, hybridization with the antisense compounds of the present invention, one of skill in the art will recognize or be able to ascertain, using no more than routine experimentation, further embodiments of the invention that encompass other compounds that specifically hybridize to these preferred target segments and consequently inhibit the expression of apolipoprotein B.

According to the present invention, antisense compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other short oligomeric compounds which hybridize to at least a portion of the target nucleic acid.

ISPH-0664WO

-169-

PATENT

Example 37

Antisense inhibition of human apolipoprotein B expression -
dose response of selected oligonucleotides

In accordance with the present invention, 12
5 oligonucleotides described in Examples 29 and 31 were
further investigated in a dose response study. The control
oligonucleotides used in this study were ISIS 18076 (SEQ ID
NO: 805) and ISIS 13650 (SEQ ID NO: 806).

All compounds in this study, including the controls,
10 were chimeric oligonucleotides ("gapmers") 20 nucleotides
in length, composed of a central "gap" region consisting of
ten 2'-deoxynucleotides, which is flanked on both sides (5'
and 3' directions) by five-nucleotide "wings". The wings
are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The
15 internucleoside (backbone) linkages are phosphorothioate
(P=S) throughout the oligonucleotides. All cytidine
residues are 5-methylcytidines.

In the dose-response experiment, with mRNA levels as
the endpoint, HepG2 cells were treated with the antisense
20 oligonucleotides or the control oligonucleotides at doses
of 37, 75, 150, and 300 nM oligonucleotide. Data were
obtained by real-time quantitative PCR as described in
other examples herein and are averaged from two experiments
with mRNA levels in the treatment groups being normalized
25 to an untreated control group. The data are shown in Table
19.

Table 19

Inhibition of apolipoprotein B mRNA levels by chimeric
30 phosphorothioate oligonucleotides having 2'-MOE wings and a
deoxy gap - Dose Response

Dose

	37 nM	75 nM	150 nM	300 nM	
ISIS #	% inhibition				SEQ ID NO
271009	82	91	94	96	319
281625	62	76	84	94	224
301014	75	90	96	98	249
301027	80	90	95	96	262
301028	70	79	85	92	263
301029	54	67	79	85	264
301030	64	75	87	92	265
301031	61	82	92	96	266
301034	73	87	93	97	269
301036	67	83	92	95	271
301037	73	85	89	96	272
301045	77	86	94	98	280

Example 38**Antisense inhibition of human apolipoprotein B expression -
dose response - Lower dose range**

5 In accordance with the present invention, seven
oligonucleotides described in Examples 29, 31, 35, and 36
were further investigated in a dose response study. The
control oligonucleotides used in this study were ISIS 18076
(SEQ ID NO: 805), ISIS 13650 (SEQ ID NO: 806), and ISIS
10 129695 (SEQ ID NO: 807).

All compounds in this study, including the controls,
were chimeric oligonucleotides ("gapmers") 20 nucleotides
in length, composed of a central "gap" region consisting of
ten 2'-deoxynucleotides, which is flanked on both sides (5'
15 and 3' directions) by five-nucleotide "wings". The wings
are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The
internucleoside (backbone) linkages are phosphorothioate
(P=S) throughout the oligonucleotides. All cytidine
residues are 5-methylcytidines.

20 In the dose-response experiment, with mRNA levels as
the endpoint, HepG2 cells were treated with the antisense
oligonucleotides or the control oligonucleotides at doses

ISPH-0664WO

-171-

PATENT

of 12.5, 37, 75, 150, and 300 nM oligonucleotide. Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments with mRNA levels in the treatment groups being normalized to an untreated control group. The data are shown in Table 20.

Table 20

Inhibition of apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap - Dose Response

	Dose					
	12.5 nM	37 nM	75 nM	150 nM	300 nM	
ISIS #	% inhibition					SEQ ID #
271009	67	86	92	94	95	319
281625	44	66	83	85	94	224
301012	63	79	90	92	95	247
308638	42	73	91	96	97	247
308642	59	84	91	97	98	319
308651	57	76	84	90	88	319
308658	29	61	73	78	90	224

Example 39

RNA Synthesis

In general, RNA synthesis chemistry is based on the selective incorporation of various protecting groups at strategic intermediary reactions. Although one of ordinary skill in the art will understand the use of protecting groups in organic synthesis, a useful class of protecting groups includes silyl ethers. In particular bulky silyl ethers are used to protect the 5'-hydroxyl in combination with an acid-labile orthoester protecting group on the 2'-hydroxyl. This set of protecting groups is then used with standard solid-phase synthesis technology. It is important

ISPH-0664WO

-172-

PATENT

to lastly remove the acid labile orthoester protecting group after all other synthetic steps. Moreover, the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2' hydroxyl.

Following this procedure for the sequential protection of the 5'-hydroxyl in combination with protection of the 2'-hydroxyl by protecting groups that are differentially removed and are differentially chemically labile, RNA oligonucleotides were synthesized.

RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3'- to 5'- direction) to a solid support-bound oligonucleotide. The first nucleoside at the 3'-end of the chain is covalently attached to a solid support. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5'-end of the first nucleoside. The support is washed and any unreacted 5'-hydroxyl groups are capped with acetic anhydride to yield 5'-acetyl moieties. The linkage is then oxidized to the more stable and ultimately desired P(V) linkage. At the end of the nucleotide addition cycle, the 5'-silyl group is cleaved with fluoride. The cycle is repeated for each subsequent nucleotide.

Following synthesis, the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate trihydrate (S_2Na_2) in DMF. The deprotection solution is washed from the solid support-bound oligonucleotide using water. The support is then treated with 40% methylamine in water for 10 minutes at 55 °C. This releases the RNA oligonucleotides into solution, deprotects the exocyclic

ISPH-0664WO

-173-

PATENT

amines, and modifies the 2'- groups. The oligonucleotides can be analyzed by anion exchange HPLC at this stage.

The 2'-orthoester groups are the last protecting groups to be removed. The ethylene glycol monoacetate orthoester protecting group developed by Dharmacon Research, Inc. (Lafayette, CO), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions of nucleoside phosphoramidite synthesis and oligonucleotide synthesis. However, after oligonucleotide synthesis the oligonucleotide is treated with methylamine which not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters. The resulting 2-ethyl-hydroxyl substituents on the orthoester are less electron withdrawing than the acetylated precursor. As a result, the modified orthoester becomes more labile to acid-catalyzed hydrolysis. Specifically, the rate of cleavage is approximately 10 times faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous conditions compatible with the final RNA oligonucleotide product.

Additionally, methods of RNA synthesis are well known in the art (Scaringe, S. A. Ph.D. Thesis, University of Colorado, 1996; Scaringe, S. A., et al., *J. Am. Chem. Soc.*, 1998, 120, 11820-11821; Matteucci, M. D. and Caruthers, M. H. *J. Am. Chem. Soc.*, 1981, 103, 3185-3191; Beaucage, S. L. and Caruthers, M. H. *Tetrahedron Lett.*, 1981, 22, 1859-1862; Dahl, B. J., et al., *Acta Chem. Scand.*, 1990, 44, 639-641; Reddy, M. P., et al., *Tetrahedron Lett.*, 1994, 25,

ISPH-0664WO

-174-

PATENT

4311-4314; Wincott, F. et al., *Nucleic Acids Res.*, 1995, 23, 2677-2684; Griffin, B. E., et al., *Tetrahedron*, 1967, 23, 2301-2313; Griffin, B. E., et al., *Tetrahedron*, 1967, 23, 2315-2331).

5 RNA antisense compounds (RNA oligonucleotides) of the present invention can be synthesized by the methods herein or purchased from Dharmacon Research, Inc (Lafayette, CO). Once synthesized, complementary RNA antisense compounds can then be annealed by methods known in the art to form double
10 stranded (duplexed) antisense compounds. For example, duplexes can be formed by combining 30 μ l of each of the complementary strands of RNA oligonucleotides (50 uM RNA oligonucleotide solution) and 15 μ l of 5X annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM
15 magnesium acetate) followed by heating for 1 minute at 90°C, then 1 hour at 37°C. The resulting duplexed antisense compounds can be used in kits, assays, screens, or other methods to investigate the role of a target nucleic acid.

20 Example 40

Design and screening of duplexed antisense compounds targeting apolipoprotein B

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of
25 the present invention and their complements can be designed to target apolipoprotein B. The nucleobase sequence of the antisense strand of the duplex comprises at least a portion of an oligonucleotide in Table 1. The ends of the strands may be modified by the addition of one or more natural or
30 modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and may also contain

ISPH-0664WO

-175-

PATENT

modifications or additions to either terminus. For example, in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini.

5 For example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGGACCG and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

10 cgagaggcggacgggaccgTT Antisense Strand
 |||||
 TTgctctccgcctgccctggc Complement

RNA strands of the duplex can be synthesized by methods disclosed herein or purchased from Dharmacon Research Inc., (Lafayette, CO). Once synthesized, the complementary strands are annealed. The single strands are aliquoted and diluted to a concentration of 50 uM. Once diluted, 30 uL of each strand is combined with 15uL of a 5X solution of annealing buffer. The final concentration of said buffer is 100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, and 2mM magnesium acetate. The final volume is 75 uL. This solution is incubated for 1 minute at 90°C and then centrifuged for 15 seconds. The tube is allowed to sit for 1 hour at 37°C at which time the dsRNA duplexes are used in experimentation. The final concentration of the dsRNA duplex is 20 uM. This solution can be stored frozen (-20°C) and freeze-thawed up to 5 times.

Once prepared, the duplexed antisense compounds are evaluated for their ability to modulate apolipoprotein B expression.

When cells reached 80% confluency, they are treated with duplexed antisense compounds of the invention. For cells grown in 96-well plates, wells are washed once with

ISPH-0664WO

-176-

PATENT

200 μ L OPTI-MEM-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM-1 containing 12 μ g/mL LIPOFECTIN (Gibco BRL) and the desired duplex antisense compound at a final concentration of 200 nM. After 5 hours of treatment, the medium is replaced with fresh medium. Cells are harvested 16 hours after treatment, at which time RNA is isolated and target reduction measured by RT-PCR.

Example 41

10 Design of phenotypic assays and *in vivo* studies for the use of apolipoprotein B inhibitors

Phenotypic assays

Once apolipoprotein B inhibitors have been identified by the methods disclosed herein, the compounds are further investigated in one or more phenotypic assays, each having measurable endpoints predictive of efficacy in the treatment of a particular disease state or condition. Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of apolipoprotein B in health and disease. Representative phenotypic assays, which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival (Molecular Probes, Eugene, OR; PerkinElmer, Boston, MA), protein-based assays including enzymatic assays (Panvera, LLC, Madison, WI; BD Biosciences, Franklin Lakes, NJ; Oncogene Research Products, San Diego, CA), cell regulation, signal transduction, inflammation, oxidative processes and apoptosis (Assay Designs Inc., Ann Arbor, MI), triglyceride accumulation (Sigma-Aldrich, St. Louis, MO), angiogenesis assays, tube formation assays, cytokine and hormone assays

ISPH-0664WO

-177-

PATENT

and metabolic assays (Chemicon International Inc., Temecula, CA; Amersham Biosciences, Piscataway, NJ).

5 In one non-limiting example, cells determined to be appropriate for a particular phenotypic assay (i.e., MCF-7 cells selected for breast cancer studies; adipocytes for obesity studies) are treated with apolipoprotein B inhibitors identified from the *in vitro* studies as well as control compounds at optimal concentrations which are determined by the methods described above. At the end of
10 the treatment period, treated and untreated cells are analyzed by one or more methods specific for the assay to determine phenotypic outcomes and endpoints.

Phenotypic endpoints include changes in cell morphology over time or treatment dose as well as changes
15 in levels of cellular components such as proteins, lipids, nucleic acids, hormones, saccharides or metals. Measurements of cellular status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest.

20 Analysis of the genotype of the cell (measurement of the expression of one or more of the genes of the cell) after treatment is also used as an indicator of the efficacy or potency of the apolipoprotein B inhibitors. Hallmark genes, or those genes suspected to be associated
25 with a specific disease state, condition, or phenotype, are measured in both treated and untreated cells.

In vivo studies

The individual subjects of the *in vivo* studies
30 described herein are warm-blooded vertebrate animals, which includes humans.

ISPH-0664WO

-178-

PATENT

The clinical trial is subjected to rigorous controls to ensure that individuals are not unnecessarily put at risk and that they are fully informed about their role in the study.

5 To account for the psychological effects of receiving treatments, volunteers are randomly given placebo or apolipoprotein B inhibitor. Furthermore, to prevent the doctors from being biased in treatments, they are not informed as to whether the medication they are
10 administering is a apolipoprotein B inhibitor or a placebo. Using this randomization approach, each volunteer has the same chance of being given either the new treatment or the placebo.

Volunteers receive either the apolipoprotein B
15 inhibitor or placebo for eight week period with biological parameters associated with the indicated disease state or condition being measured at the beginning (baseline measurements before any treatment), end (after the final treatment), and at regular intervals during the study
20 period. Such measurements include the levels of nucleic acid molecules encoding apolipoprotein B or apolipoprotein B protein levels in body fluids, tissues or organs compared to pre-treatment levels. Other measurements include, but are not limited to, indices of the disease state or
25 condition being treated, body weight, blood pressure, serum titers of pharmacologic indicators of disease or toxicity as well as ADME (absorption, distribution, metabolism and excretion) measurements.

Information recorded for each patient includes age
30 (years), gender, height (cm), family history of disease state or condition (yes/no), motivation rating

ISPH-0664WO

-179-

PATENT

(some/moderate/great) and number and type of previous treatment regimens for the indicated disease or condition.

Volunteers taking part in this study are healthy adults (age 18 to 65 years) and roughly an equal number of males and females participate in the study. Volunteers with certain characteristics are equally distributed for placebo and apolipoprotein B inhibitor treatment. In general, the volunteers treated with placebo have little or no response to treatment, whereas the volunteers treated with the apolipoprotein B inhibitor show positive trends in their disease state or condition index at the conclusion of the study.

Example 42

Antisense inhibition of rabbit apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of rabbit apolipoprotein B, using published sequences (GenBank accession number X07480.1, incorporated herein as SEQ ID NO: 808, GenBank accession number M17780.1, incorporated herein as SEQ ID NO: 809, and a sequence was derived using previously described primers (Tanaka, *Journ. Biol. Chem.*, 1993, 268, 12713-12718) representing an mRNA of the rabbit apolipoprotein B, incorporated herein as SEQ ID NO: 810). The oligonucleotides are shown in Table 21.

"Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 21 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of

ISPH-0664WO

-180-

PATENT

ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human apolipoprotein B mRNA levels in primary rabbit hepatocytes by quantitative real-time PCR as described in other examples herein. For rabbit apolipoprotein B the PCR primers were:

forward primer: AAGCACCCCAATGTCACC (SEQ ID NO: 811)
reverse primer: GGGATGGCAGAGCCAATGTA (SEQ ID NO: 812) and
the PCR probe was: FAM- TCCTGGATTCAAGCTTCTATGTGCCTTCA - TAMRA (SEQ ID NO: 813) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. Data are averages from two experiments. If present, "N.D." indicates "no data".

20

Table 21

Inhibition of rabbit apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
233149	808	1	TGCTTGGAGAAGGTAAGATC	0	814
233150	810	1	GCGTTGTCTCCGATGTTCTG	20	815
233151	809	13	TAATCATTAAGTTGCTGTGG	20	816
233152	808	22	TCAGCACGTAGCAATGCATT	0	817
233153	808	31	GCCTGATACTCAGCACGTAG	0	818
233154	809	31	CAATTGAATGTACTCAGATA	18	819
233155	808	51	ACCTCAGTGACTTGTAATCA	47	820
233156	809	51	CACTGGAAACTTGTCTCTCC	23	821
233157	809	71	AGTAGTTAGTTTCTCCTTGG	0	822
233159	808	121	TCAGTGCCCAAGATGTCAGC	0	823
233160	810	121	ATTGGAATAATGTATCCAGG	81	824
233161	809	130	TTGGCATTATCCAATGCAGT	28	825

ISPH-0664WO

-181-

PATENT

233162	808	151	GTTGCCTTGTGAGCAGCAGT	0	826
233163	810	151	ATTGTGAGTGGAGATACTTC	80	827
233164	809	171	CATATGTCTGAAGTTGAGAC	8	828
233165	808	181	GTAGATACTCCATTTTGGCC	0	829
233166	810	181	GGATCACATGACTGAATGCT	82	830
233167	808	201	TCAAGCTGGTTGTTGCACTG	28	831
233168	808	211	GGACTGTACCTCAAGCTGGT	0	832
233169	808	231	GCTCATTCTCCAGCATCAGG	14	833
233170	809	251	TTGATCTATAATACTAGCTA	23	834
233172	810	282	ATGGAAGACTGGCAGCTCTA	86	835
233173	808	301	TTGTGTTTCCTTGAAGCGGCC	3	836
233174	809	301	TGTGCACGGATATGATAACG	21	837
233175	810	306	GACCTTGAGTAGATTCCTGG	90	838
233176	810	321	GAAATCTGGAAGAGAGACCT	62	839
233177	808	331	GTAGCTTTCCTCATCTAGGCT	0	840
233178	808	346	GATAACTCTGTGAGGGTAGC	0	841
233179	810	371	ATGTTGCCCATGGCTGGAAT	65	842
233180	809	381	AAGATGCAGTACTACTTCCA	13	843
233181	808	382	GCACCCAGAATCATGGCCTG	0	844
233182	809	411	CTTGATACTTGGTATCCACA	59	845
233183	810	411	CAGTGTAATGATCGTTGATT	88	846
233184	810	431	TAAAGTCCAGCATTGGTATT	69	847
233185	810	451	CAACAATGTCTGATTGGTTA	73	848
233186	810	473	GAAGAGGAAGAAAGGATATG	60	849
233187	810	481	TGACAGATGAAGAGGAAGAA	66	850
233188	810	500	TTGTACTGTAGTGCATCAAT	74	851
233189	809	511	GCCTCAATCTGTTGTTTCAG	46	852
233190	810	520	ACTTGAGCGTGCCCTCTAAT	69	853
233191	809	561	GAAATGGAATTGTAGTTCTC	31	854

Example 43

Antisense inhibition of rabbit apolipoprotein B expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap-Dose Response Study

In accordance with the present invention, a subset of the antisense oligonucleotides in Example 42 was further investigated in dose-response studies. Treatment doses were 10, 50, 150 and 300 nM. ISIS 233160 (SEQ ID NO: 824),
 10 ISIS 233166 (SEQ ID NO: 830), ISIS 233172 (SEQ ID NO: 835), ISIS 233175 (SEQ ID NO: 838), and ISIS 233183 (SEQ ID NO: 846) were analyzed for their effect on rabbit apolipoprotein B mRNA levels in primary rabbit hepatocytes

ISPH-0664WO

-182-

PATENT

by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments and are shown in Table 22.

5

Table 22

Inhibition of rabbit apolipoprotein B mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	Percent Inhibition			
	300 nM	150 nM	50 nM	10 nM
233160	80	74	67	33
233166	73	79	81	66
233172	84	81	76	60
233175	93	90	85	67
233183	80	81	71	30

10 **Example 44**

Effects of antisense inhibition of apolipoprotein B in LDLr^{-/-} mice - Dose Response

LDL receptor-deficient mice (LDLr^{-/-} mice), a strain that cannot edit the apolipoprotein B mRNA and therefore
15 synthesize exclusively apolipoprotein B-100, have markedly elevated LDL cholesterol and apolipoprotein B-100 levels and develop extensive atherosclerosis.

LDLr^{-/-} mice, purchased from Taconic (Germantown, NY) were used to evaluate antisense oligonucleotides for
20 their potential to lower apolipoprotein B mRNA or protein levels, as well as phenotypic endpoints associated with apolipoprotein B. LDLr^{-/-} mice were separated into groups of males and females. LDLr^{-/-} mice were dosed intraperitoneally twice a week for six weeks with either
25 10, 25, or 50 mg/kg of ISIS 147764 (SEQ ID NO: 109) or ISIS 270906 (SEQ ID NO: 856) which is a 4 base mismatch of ISIS 147764, or with saline, or 20 mg/kg of Atorvastatin. At

ISPH-0664WO

-183-

PATENT

study termination animals were sacrificed and evaluated for several phenotypic markers.

ISIS 147764 was able to lower cholesterol, triglycerides, and mRNA levels in a dose-dependent manner in both male and female mice while the 4-base mismatch ISIS 270906 was not able to do this. The results of the study are summarized in Table 23.

Table 23

Effects of ISIS 147764 treatment in male and female LDLr-/- mice on apolipoprotein B mRNA, liver enzyme, cholesterol, and triglyceride levels.

ISIS No.	Dose	Liver Enzymes IU/L		Lipoproteins mg/dL				mRNA %
	mg/kg	AST	ALT	CHOL	HDL	LDL	TRIG	control
Males								
Saline		68.4	26.6	279.2	125.4	134.7	170.6	100.0
147764	10	57.6	29.8	314.2	150.0	134.7	198.6	61.7
	25	112.6	78.8	185.0	110.6	66.2	104.2	30.7
	50	163.6	156.8	165.6	107.8	51.2	113.4	16.6
270906	50	167.4	348.0	941.0	244.2	541.9	844.8	N.D.
Atorvastatin	20	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	110.9
Females								
Saline		65.0	23.4	265.8	105.8	154.9	121.4	100.0
147764	10	82.0	27.2	269.6	121.0	127.8	140.8	64.2
	25	61.4	32.2	175.8	99.5	68.9	100.4	41.3
	50	134.6	120.4	138.2	92.2	45.9	98.0	18.5
270906	50	96.0	88.6	564.6	200.0	310.0	240.4	N.D.
Atorvastatin	20	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.	109.0

Example 45

Effects of antisense inhibition of apolipoprotein B in Cynomolgus monkeys

Cynomolgus monkeys fed an atherogenic diet develop atherosclerosis with many similarities to atherosclerosis of human beings. Female Cynomolgus macaques share several similarities in lipoproteins and the cardiovascular system with humans. In addition to these characteristics, there

ISPH-0664WO

-184-

PATENT

are similarities in reproductive biology. The Cynomolgus female has a 28-day menstrual cycle like that of women. Plasma hormone concentrations have been measured throughout the Cynomolgus menstrual cycle, and the duration of the follicular and luteal phases, as well as plasma estradiol and progesterone concentrations across the cycle, are also remarkably similar to those in women.

Cynomolgus monkeys (male or female) can be used to evaluate antisense oligonucleotides for their potential to lower apolipoprotein B mRNA or protein levels, as well as phenotypic endpoints associated with apolipoprotein B including, but not limited to cardiovascular indicators, atherosclerosis, lipid diseases, obesity, and plaque formation. One study could include normal and induced hypercholesterolemic monkeys fed diets that are normal or high in lipid and cholesterol. Cynomolgus monkeys can be dosed in a variety of regimens, one being subcutaneously with 10-20 mg/kg of the oligomeric compound for 1-2 months. Parameters that may be observed during the test period could include: total plasma cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, arterial wall cholesterol content, and coronary intimal thickening.

Example 46

Sequencing of Cynomolgus monkey (*Macaca fascicularis*) apolipoprotein B preferred target segment

In accordance with the present invention, a portion of the cynomolgus monkey apolipoprotein B mRNA not available in the art, was amplified. Positions 2920 to 3420 of the human apolipoprotein B mRNA sequence (GenBank accession number NM_000384.1, incorporated herein as SEQ ID NO: 3) contain the preferred target segment to which ISIS 301012

ISPH-0664WO

-185-

PATENT

hybridizes and the corresponding segment of cynomolgus monkey apolipoprotein B mRNA was amplified and sequenced. The site to which ISIS 301012 hybridizes in the human apolipoprotein B was amplified by placing primers at 5' position 2920 and 3' position 3420. The cynomolgus monkey hepatocytes were purchased from In Vitro Technologies (Gaithersburg, MD). The 500 bp fragments were produced using human and cynomolgus monkey 1° hepatocyte cDNA and were produced by reverse transcription of purified total RNA followed by 40 rounds of PCR amplification. Following gel purification of the human and cynomolgus amplicons, the forward and reverse sequencing reactions of each product were performed by Retrogen (Invitrogen kit was used to create the single-stranded cDNA and provided reagents for Amplitaq PCR reaction). This cynomolgus monkey sequence is incorporated herein as SEQ ID NO: 855 and is 96% identical to positions 2920 to 3420 of the human apolipoprotein B mRNA.

20 Example 47

Effects of antisense inhibition of human apolipoprotein B gene (ISIS 281625 and 301012) in C57BL/6NTac-TgN(APOB100) transgenic mice

C57BL/6NTac-TgN(APOB100) transgenic mice have the human apolipoprotein B gene "knocked-in". These mice express high levels of human apolipoprotein B100 resulting in mice with elevated serum levels of LDL cholesterol. These mice are useful in identifying and evaluating compounds to reduce elevated levels of LDL cholesterol and the risk of atherosclerosis. When fed a high fat cholesterol diet, these mice develop significant foam cell accumulation underlying the endothelium and within the

media, and have significantly more complex atherosclerotic lesions than control animals.

C57BL/6NTac-TgN(APOB100) mice were divided into two groups - one group receiving oligonucleotide treatment and control animals receiving saline treatment. After overnight fasting, mice were dosed intraperitoneally twice a week with saline or 25 mg/kg ISIS 281625 (SEQ ID No: 224) or ISIS 301012 (SEQ ID No: 247) for eight weeks. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver, cholesterol and triglyceride levels, and liver enzyme levels. In addition, the endogenous mouse apolipoprotein B levels in liver were measured to evaluate any effects of these antisense oligonucleotides targeted to the human apolipoprotein B.

Upon treatment with either ISIS 281625 or ISIS 301012, the AST and ALT levels were increased, yet did not exceed normal levels (~300 IU/L). Cholesterol levels were slightly increased relative to saline treatment, while triglyceride levels were slightly decreased. Treatment with either of these oligonucleotides targeted to the human apolipoprotein B which is expressed in these mice markedly decreased the mRNA levels of the human apolipoprotein, while the levels of the endogenous mouse apolipoprotein B were unaffected, indicating that these oligonucleotides exhibit specificity for the human apolipoprotein B. The results of the comparative studies are shown in Table 24.

Table 24

Effects of ISIS 281625 and 301012 treatment in mice on apolipoprotein B mRNA, liver enzyme, cholesterol, and triglyceride levels.

	SALINE	ISIS No.	
		281625	301012
Liver Enzymes IU/L			
AST	70.3	265.8	208.4
ALT	32.8	363.8	137.4
Lipoproteins mg/dL			
CHOL	109.5	152.0	145.1
HDL	67.3	84.6	98.6
LDL	30.2	49.8	36.6
TRIG	194.5	171.1	157.8
mRNA % control			
human mRNA	100.0	45.2	23.7
mouse mRNA	100.0	111.0	94.6

Example 48

Effects of antisense inhibition of apolipoprotein B (ISIS 233172, 233175, 281625, 301012, and 301027) in C57BL/6 mice

- 5 C57BL/6 mice, a strain reported to be susceptible to hyperlipidemia-induced atherosclerotic plaque formation were used in the following studies to evaluate the toxicity in mice of several antisense oligonucleotides targeted to human or rabbit apolipoprotein B.
- 10 C57BL/6 mice were divided into two groups - one group receiving oligonucleotide treatment and control animals receiving saline treatment. After overnight fasting, mice were dosed intraperitoneally twice a week with saline or 25 mg/kg of one of several oligonucleotides for two weeks.
- 15 The antisense oligonucleotides used in the present study were ISIS 233172 (SEQ ID NO: 835) and ISIS 233175 (SEQ ID NO: 838), both targeted to rabbit apolipoprotein B, and ISIS 281625 (SEQ ID NO: 224), ISIS 301012 (SEQ ID NO: 247), and ISIS 301027 (SEQ ID NO: 262), targeted to human
- 20 apolipoprotein B. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for liver enzyme levels, body weight, liver weight, and spleen weight.

The levels of liver enzymes in mice were decreased relative to saline treatment for three of the antisense oligonucleotide. However, the rabbit oligonucleotide ISIS 233175 and the human oligonucleotide ISIS 301027 both elicited drastically increased levels of these liver enzymes, indicating toxicity. For all of the oligonucleotides tested, the change in weight of body, liver, and spleen were minor. The results of the comparative studies are shown in Table 25.

Table 25

Effects of antisense oligonucleotides targeted to human or rabbit apolipoprotein B on mouse apolipoprotein B mRNA, liver enzyme, cholesterol, and triglyceride levels.

		ISIS No.					
		SALINE	233172	233175	281625	301012	301027
Liver Enzymes							
AST	IU/L	104.5	94.3	346.7	89.5	50.6	455.3
ALT	IU/L	39.5	43.3	230.2	36.2	21.2	221.3
Weight							
BODY		21.2	21.3	21.5	20.9	21.3	21.2
LIVER		1.1	1.3	1.4	1.2	1.1	1.3
SPLEEN		0.1	0.1	0.1	0.1	0.1	0.1

Example 49

Time course evaluation of oligonucleotide at two different doses

C57BL/6 mice, a strain reported to be susceptible to hyperlipidemia-induced atherosclerotic plaque formation were used in the following studies to evaluate the toxicity in mice of several antisense oligonucleotides targeted to human apolipoprotein B.

Female C57BL/6 mice were divided into two groups - one group receiving oligonucleotide treatment and control

ISPH-0664WO

-189-

PATENT

animals receiving saline treatment. After overnight fasting, mice were dosed intraperitoneally twice a week with saline or 25 mg/kg or 50 mg/kg of ISIS 281625 (SEQ ID NO: 224), ISIS 301012 (SEQ ID NO: 247), or ISIS 301027 (SEQ ID NO: 262). After 2 weeks, a blood sample was taken from the tail of the mice and evaluated for liver enzyme. After 4 weeks, and study termination, animals were sacrificed and evaluated for liver enzyme levels.

For ISIS 281625 and ISIS 301012, AST and ALT levels remained close to those of saline at either dose after 2 weeks. After 4 weeks, AST and ALT levels showed a moderate increase over saline treated animals for the lower dose, but a large increase at the higher dose. ISIS 301027, administered at either dose, showed a small increase in AST and ALT levels after 2 weeks and a huge increase in AST and ALT levels after 4 weeks. The results of the studies are summarized in Table 26.

Table 26

AST and ALT levels in mice treated with ISIS 281625, 301012, or 301027 after 2 and 4 weeks

		AST (IU/L)		ALT (IU/L)	
		2 weeks	4 weeks	2 weeks	4 weeks
SALINE		49.6	63.2	22.4	25.2
ISIS No.	Dose (mg/kg)				
281625	25	40.8	75	21.2	31.8
	50	44.4	152.4	30.8	210.4
301012	25	37.2	89.8	22.4	24.8
	50	38.4	107.4	23.2	29.2
301027	25	55.4	537.6	27.2	311.2
	50	64	1884	34.8	1194

Example 50

Effects of antisense inhibition of apolipoprotein B (ISIS

ISPH-0664WO

-190-

PATENT

147483 and 147764) in ob/ob mice

Ob/ob mice receiving a high fat, high cholesterol diet (60% kcal fat supplemented with 0.15% cholesterol) were treated with one of several oligonucleotides to evaluate their effect on apolipoprotein B-related phenotypic endpoints in ob/ob mice. After overnight fasting, mice from each group were dosed intraperitoneally twice a week with 50 mg/kg of ISIS 147483 (SEQ ID NO: 79), or 147764 (SEQ ID NO: 109), or the controls ISIS 116847 (SEQ ID NO: 857), or 141923 (SEQ ID NO: 858), or saline for six weeks. At study termination and forty eight hours after the final injections, animals were sacrificed and evaluated for target mRNA levels in liver, cholesterol and triglyceride levels, liver enzyme levels, serum glucose levels, and PTEN levels.

ISIS 147483 and 147764 were both able to lower apolipoprotein B mRNA levels, as well as glucose, cholesterol, and triglyceride levels. The results of the comparative studies are shown in Table 27.

Table 27

Effects of ISIS 147483 and 147764 treatment in ob/ob mice on apolipoprotein B mRNA, cholesterol, lipid, triglyceride, liver enzyme, glucose, and PTEN levels.

		ISIS No.				
		SALINE	116847	141923	147483	147764
Glucose mg/dL		269.6	135.5	328.5	213.2	209.2
Liver Enzymes						
IU/L	AST	422.3	343.2	329.3	790.2	406.5
	ALT	884.3	607.5	701.7	941.7	835.0
Lipoproteins						
mg/dL	CHOL	431.9	287.5	646.3	250.0	286.3
	TRIG	128.6	196.5	196.5	99.8	101.2
mRNA % control						
	ApoB	100.0	77.0	100.0	25.2	43.1
	PTEN	100.0	20.0	113.6	143.2	115.3

What is claimed is:

1. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding apolipoprotein B, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOS: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854.
2. A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding apolipoprotein B, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOS: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854, said active site being a region in said nucleic acid wherein binding of said compound to said site significantly inhibits apolipoprotein B expression as compared to a control.
3. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with said nucleic acid and inhibits expression of apolipoprotein B, wherein the apolipoprotein B is encoded by a polynucleotide selected from the group consisting of: (a) SEQ ID NO: 3 and (b) a naturally occurring variant apolipoprotein B-encoding

ISPH-0664WO

-192-

PATENT

polynucleotide that hybridizes to the complement of the polynucleotide of (a) under stringent conditions, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854.

4. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with said nucleic acid and inhibits expression of apolipoprotein B, wherein the apolipoprotein B is encoded by a polynucleotide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 17, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854.

5. A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with an active site in said nucleic acid and inhibits expression of apolipoprotein B, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854, said active site being a region in said nucleic acid wherein binding of said compound to said site

significantly inhibits apolipoprotein B expression as compared to a control.

6. An oligonucleotide mimetic compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with said nucleic acid and inhibits expression of apolipoprotein B, said compound comprising at least 8 contiguous nucleobases of any one of SEQ ID NOs: 127-134, 136, 138-174, 176-317, 319-321, 323-333, 335-339, 341-374, 376-416, 418-500, 502-510, 512-804, 815, 816, 819-821, 824, 825, 827, 828, 830, 831, 833-835, 837-839, 842, 843, and 845-854.

7. The compound of any one of claims 1-6 targeted to a nucleic acid molecule encoding apolipoprotein B, wherein said compound specifically hybridizes with and inhibits expression of the long form of apolipoprotein B, ApoB-100.

8. The compound of any one of claims 1-7, wherein said compound specifically hybridizes with said nucleic acid and inhibits expression of mRNA encoding apolipoprotein B by at least 5% in 80% confluent HepG2 cells in culture at an optimum concentration.

9. The compound of claim 8 wherein the compound inhibits expression of mRNA encoding apolipoprotein B by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, or at least 50%.

10. The compound of any one of claims 1-9 which is an antisense oligonucleotide.

ISPH-0664WO

-194-

PATENT

11. The compound of any one of claims 1-10 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 224.

12. The compound of any one of claims 1-10 wherein the antisense oligonucleotide hybridizes with a region complementary to SEQ ID NO: 224.

13. The compound of any one of claims 1-10 comprising SEQ ID NO: 224.

14. The compound of any one of claims 1-10 consisting essentially of SEQ ID NO: 224.

15. The compound of any one of claims 1-10 consisting of SEQ ID NO: 224.

16. The compound of any one of claims 1-10 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 247.

17. The compound of any one of claims 1-10 wherein the antisense oligonucleotide hybridizes with a region complementary to SEQ ID NO: 247.

18. The compound of any one of claims 1-10 comprising SEQ ID NO: 247.

19. The compound of any one of claims 1-10 consisting essentially of SEQ ID NO: 247.

20. The compound of any one of claims 1-10 consisting of SEQ ID NO: 247.

21. The compound of any one of claims 1-10 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 319.

22. The compound of any one of claims 1-10 wherein the antisense oligonucleotide hybridizes with a region complementary to SEQ ID NO: 319.

23. The compound of any one of claims 1-10 comprising SEQ ID NO: 319.

24. The compound of any one of claims 1-10 consisting essentially of SEQ ID NO: 319.

25. The compound of any one of claims 1-10 consisting of SEQ ID NO: 319.

26. The compound of any one of claims 1-25 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

27. The compound of claim 26 wherein the modified internucleoside linkage is a phosphorothioate linkage.

28. The compound of any one of claims 1-27 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

29. The compound of claim 28 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

30. The compound of any one of claims 1-29 wherein the

antisense oligonucleotide comprises at least one modified nucleobase.

31. The compound of claim 30 wherein the modified nucleobase is a 5-methylcytosine.

32. The compound of any one of claims 1-31 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

33. A composition comprising the compound of any one of claims 1-32 and a pharmaceutically acceptable carrier or diluent.

34. The composition of claim 33 further comprising a colloidal dispersion system.

35. The composition of claim 33 or 34 wherein the compound is an antisense oligonucleotide.

36. A method of inhibiting the expression of apolipoprotein B in cells or tissues comprising contacting said cells or tissues with the compound of any one of claims 1-32 so that expression of apolipoprotein B is inhibited.

37. A method of treating an animal having a disease or condition associated with apolipoprotein B comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claims 1-32 so that expression of apolipoprotein B is inhibited.

38. The method of claim 37 wherein the condition is associated with abnormal lipid metabolism.

39. The method of claim 37 wherein the condition is associated with abnormal cholesterol metabolism.

40. The method of claim 37 wherein the condition is atherosclerosis.

41. The method of claim 37 wherein the condition is an abnormal metabolic condition.

42. The method of claim 41 wherein the abnormal metabolic condition is hyperlipidemia.

43. The method of claim 37 wherein the disease is diabetes.

44. The method of claim 43 wherein the diabetes is Type 2 diabetes.

45. The method of claim 37 wherein the condition is obesity.

46. The method of claim 37 wherein the disease is cardiovascular disease.

47. A method of modulating glucose levels in an animal comprising administering to said animal the compound of claims 1-32.

48. The method of claim 47 wherein the animal is a human.

49. The method of claim 47 wherein the glucose levels are plasma glucose levels.

50. The method of claim 47 wherein the glucose levels are serum glucose levels.

51. The method of claim 47 wherein the animal is a diabetic animal.

52. A method of preventing or delaying the onset of a disease or condition associated with apolipoprotein B in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claims 1-32.

53. The method of claim 52 wherein the animal is a human.

54. The method of claim 52 wherein the condition is an abnormal metabolic condition.

55. The method of claim 52 wherein the abnormal metabolic condition is hyperlipidemia.

56. The method of claim 52 wherein the disease is diabetes.

57. The method of claim 56 wherein the diabetes is Type 2 diabetes.

58. The method of claim 52 wherein the condition is obesity.

59. The method of claim 52 wherein the condition is atherosclerosis.

60. The method of claim 52 wherein the condition involves abnormal lipid metabolism.

61. The method of claim 52 wherein the condition involves abnormal cholesterol metabolism.

62. A method of preventing or delaying the onset of an increase in glucose levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claims 1-32.

63. The method of claim 62 wherein the animal is a human.

64. The method of claim 62 wherein the glucose levels are serum glucose levels.

65. The method of claim 62 wherein the glucose levels are plasma glucose levels.

66. A method of modulating serum cholesterol levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claims 1-32.

67. The method of claim 66 wherein the animal is a human.

68. A method of modulating lipoprotein levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claims 1-32.

69. The method of claim 69 wherein the animal is a human.

70. The method of claim 68 wherein the lipoprotein is VLDL.

71. The method of claim 68 wherein the lipoprotein is HDL.

72. The method of claim 68 wherein the lipoprotein is LDL.

73. A method of modulating serum triglyceride levels in an animal comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claims 1-32.

74. The method of claim 73 wherein the animal is a human.

75. The compound of any one of claims 1-32, wherein said compound specifically hybridizes with and inhibits the expression of a nucleic acid molecule encoding an alternatively spliced form of apolipoprotein B.

76. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of a disease or condition associated with apolipoprotein B expression.

77. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of a condition associated with abnormal lipid metabolism.

78. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of a condition associated with abnormal cholesterol metabolism.

79. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of atherosclerosis.

80. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of hyperlipidemia.

81. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of diabetes.

82. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of Type 2 diabetes.

83. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of obesity.

84. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the treatment of cardiovascular disease.

85. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for preventing or delaying the onset of increased glucose levels.

86. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for preventing or delaying the onset of increased serum glucose levels.

87. Use of a compound of any one of claims 1-32 for the

manufacture of a medicament for preventing or delaying the onset of increased plasma glucose levels.

88. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the modulation of serum cholesterol levels.

89. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the modulation of serum lipoprotein levels.

90. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the modulation of serum VLDL levels.

91. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the modulation of serum HDL levels.

92. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the modulation of serum LDL levels.

93. Use of a compound of any one of claims 1-32 for the manufacture of a medicament for the modulation of serum triglyceride levels.

SEQUENCE LISTING

<110> Rosanne M. Crooke
Mark J. Graham

<120> ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION

<130> 30566/39327

<160> 858

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctcttcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

atgcattctg cccccaagga

20

<210> 3

<211> 14121

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (129) .. (13820)

<400> 3

atccccaccg ggacctgagg ggctgagtg ccttctcggt tgctgccgct gaggagcccg 60

cccagccagc cagggccgag aggccgaggg cagggccgag cccaggagcc gcccaccgc 120

agctggcg atg gac ccg ccg agg ccc gcg ctg ctg gcg ctg ctg gcg ctg 170

Met Asp Pro Pro Arg Pro Ala Leu Leu Ala Leu Leu Ala Leu

1

5

10

cct gcg ctg ctg ctg ctg ctg gcg ggc gcc agg gcc gaa gag gaa 218

Pro Ala Leu Leu Leu Leu Leu Ala Gly Ala Arg Ala Glu Glu Glu

15

20

25

30

atg ctg gaa aat gtc agc ctg gtc tgt cca aaa gat gcg acc cga ttc 266

Met Leu Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala Thr Arg Phe

35

40

45

aag cac ctc cgg aag tac aca tac aac tat gag gct gag agt tcc agt 314

Lys His Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu Ser Ser Ser

50

55

60

gga gtc cct ggg act gct gat tca aga agt gcc acc agg atc aac tgc Gly Val Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg Ile Asn Cys 65 70 75	362
aag gtt gag ctg gag gtt ccc cag ctc tgc agc ttc atc ctg aag acc Lys Val Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile Leu Lys Thr 80 85 90	410
agc cag tgc acc ctg aaa gag gtg tat ggc ttc aac cct gag ggc aaa Ser Gln Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro Glu Gly Lys 95 100 105 110	458
gcc ttg ctg aag aaa acc aag aac tct gag gag ttt gct gca gcc atg Ala Leu Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala Ala Ala Met 115 120 125	506
tcc agg tat gag ctc aag ctg gcc att cca gaa ggg aag cag gtt ttc Ser Arg Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys Gln Val Phe 130 135 140	554
ctt tac ccg gag aaa gat gaa cct act tac atc ctg aac atc aag agg Leu Tyr Pro Glu Lys Asp Glu Pro Thr Tyr Ile Leu Asn Ile Lys Arg 145 150 155	602
ggc atc att tct gcc ctc ctg gtt ccc cca gag aca gaa gaa gcc aag Gly Ile Ile Ser Ala Leu Leu Val Pro Pro Glu Thr Glu Glu Ala Lys 160 165 170	650
caa gtg ttg ttt ctg gat acc gtg tat gga aac tgc tcc act cac ttt Gln Val Leu Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser Thr His Phe 175 180 185 190	698
acc gtc aag acg agg aag ggc aat gtg gca aca gaa ata tcc act gaa Thr Val Lys Thr Arg Lys Gly Asn Val Ala Thr Glu Ile Ser Thr Glu 195 200 205	746
aga gac ctg ggg cag tgt gat cgc ttc aag ccc atc cgc aca ggc atc Arg Asp Leu Gly Gln Cys Asp Arg Phe Lys Pro Ile Arg Thr Gly Ile 210 215 220	794
agc cca ctt gct ctc atc aaa ggc atg acc cgc ccc ttg tca act ctg Ser Pro Leu Ala Leu Ile Lys Gly Met Thr Arg Pro Leu Ser Thr Leu 225 230 235	842
atc agc agc agc cag tcc tgt cag tac aca ctg gac gct aag agg aag Ile Ser Ser Ser Gln Ser Cys Gln Tyr Thr Leu Asp Ala Lys Arg Lys 240 245 250	890
cat gtg gca gaa gcc atc tgc aag gag caa cac ctc ttc ctg cct ttc His Val Ala Glu Ala Ile Cys Lys Glu Gln His Leu Phe Leu Pro Phe 255 260 265 270	938
tcc tac aac aat aag tat ggg atg gta gca caa gtg aca cag act ttg Ser Tyr Asn Asn Lys Tyr Gly Met Val Ala Gln Val Thr Gln Thr Leu 275 280 285	986
aaa ctt gaa gac aca cca aag atc aac agc cgc ttc ttt ggt gaa ggt Lys Leu Glu Asp Thr Pro Lys Ile Asn Ser Arg Phe Phe Gly Glu Gly 290 295 300	1034

act aag aag atg ggc ctc gca ttt gag agc acc aaa tcc aca tca cct	1082
Thr Lys Lys Met Gly Leu Ala Phe Glu Ser Thr Lys Ser Thr Ser Pro	
305 310 315	
cca aag cag gcc gaa gct gtt ttg aag act ctc cag gaa ctg aaa aaa	1130
Pro Lys Gln Ala Glu Ala Val Leu Lys Thr Leu Gln Glu Leu Lys Lys	
320 325 330	
cta acc atc tct gag caa aat atc cag aga gct aat ctc ttc aat aag	1178
Leu Thr Ile Ser Glu Gln Asn Ile Gln Arg Ala Asn Leu Phe Asn Lys	
335 340 345 350	
ctg gtt act gag ctg aga ggc ctc agt gat gaa gca gtc aca tct ctc	1226
Leu Val Thr Glu Leu Arg Gly Leu Ser Asp Glu Ala Val Thr Ser Leu	
355 360 365	
ttg cca cag ctg att gag gtg tcc agc ccc atc act tta caa gcc ttg	1274
Leu Pro Gln Leu Ile Glu Val Ser Ser Pro Ile Thr Leu Gln Ala Leu	
370 375 380	
gtt cag tgt gga cag cct cag tgc tcc act cac atc ctc cag tgg ctg	1322
Val Gln Cys Gly Gln Pro Gln Cys Ser Thr His Ile Leu Gln Trp Leu	
385 390 395	
aaa cgt gtg cat gcc aac ccc ctt ctg ata gat gtg gtc acc tac ctg	1370
Lys Arg Val His Ala Asn Pro Leu Leu Ile Asp Val Val Thr Tyr Leu	
400 405 410	
gtg gcc ctg atc ccc gag ccc tca gca cag cag ctg cga gag atc ttc	1418
Val Ala Leu Ile Pro Glu Pro Ser Ala Gln Gln Leu Arg Glu Ile Phe	
415 420 425 430	
aac atg gcg agg gat cag cgc agc cga gcc acc ttg tat gcg ctg agc	1466
Asn Met Ala Arg Asp Gln Arg Ser Arg Ala Thr Leu Tyr Ala Leu Ser	
435 440 445	
cac gcg gtc aac aac tat cat aag aca aac cct aca ggg acc cag gag	1514
His Ala Val Asn Asn Tyr His Lys Thr Asn Pro Thr Gly Thr Gln Glu	
450 455 460	
ctg ctg gac att gct aat tac ctg atg gaa cag att caa gat gac tgc	1562
Leu Leu Asp Ile Ala Asn Tyr Leu Met Glu Gln Ile Gln Asp Asp Cys	
465 470 475	
act ggg gat gaa gat tac acc tat ttg att ctg cgg gtc att gga aat	1610
Thr Gly Asp Glu Asp Tyr Thr Tyr Leu Ile Leu Arg Val Ile Gly Asn	
480 485 490	
atg ggc caa acc atg gag cag tta act cca gaa ctc aag tct tca atc	1658
Met Gly Gln Thr Met Glu Gln Leu Thr Pro Glu Leu Lys Ser Ser Ile	
495 500 505 510	
ctc aaa tgt gtc caa agt aca aag cca tca ctg atg atc cag aaa gct	1706
Leu Lys Cys Val Gln Ser Thr Lys Pro Ser Leu Met Ile Gln Lys Ala	
515 520 525	
gcc atc cag gct ctg cgg aaa atg gag cct aaa gac aag gac cag gag	1754
Ala Ile Gln Ala Leu Arg Lys Met Glu Pro Lys Asp Lys Asp Gln Glu	
530 535 540	
gtt ctt ctt cag act ttc ctt gat gat gct tct ccg gga gat aag cga	1802
Val Leu Leu Gln Thr Phe Leu Asp Asp Ala Ser Pro Gly Asp Lys Arg	
545 550 555	

ctg gct gcc tat ctt atg ttg atg agg agt cct tca cag gca gat att	1850
Leu Ala Ala Tyr Leu Met Leu Met Arg Ser Pro Ser Gln Ala Asp Ile	
560 565 570	
aac aaa att gtc caa att cta cca tgg gaa cag aat gag caa gtg aag	1898
Asn Lys Ile Val Gln Ile Leu Pro Trp Glu Gln Asn Glu Gln Val Lys	
575 580 585 590	
aac ttt gtg gct tcc cat att gcc aat atc ttg aac tca gaa gaa ttg	1946
Asn Phe Val Ala Ser His Ile Ala Asn Ile Leu Asn Ser Glu Glu Leu	
595 600 605	
gat atc caa gat ctg aaa aag tta gtg aaa gaa gct ctg aaa gaa tct	1994
Asp Ile Gln Asp Leu Lys Lys Leu Val Lys Glu Ala Leu Lys Glu Ser	
610 615 620	
caa ctt cca act gtc atg gac ttc aga aaa ttc tct cgg aac tat caa	2042
Gln Leu Pro Thr Val Met Asp Phe Arg Lys Phe Ser Arg Asn Tyr Gln	
625 630 635	
ctc tac aaa tct gtt tct ctt cca tca ctt gac cca gcc tca gcc aaa	2090
Leu Tyr Lys Ser Val Ser Leu Pro Ser Leu Asp Pro Ala Ser Ala Lys	
640 645 650	
ata gaa ggg aat ctt ata ttt gat cca aat aac tac ctt cct aaa gaa	2138
Ile Glu Gly Asn Leu Ile Phe Asp Pro Asn Asn Tyr Leu Pro Lys Glu	
655 660 665 670	
agc atg ctg aaa act acc ctc act gcc ttt gga ttt gct tca gct gac	2186
Ser Met Leu Lys Thr Thr Leu Thr Ala Phe Gly Phe Ala Ser Ala Asp	
675 680 685	
ctc atc gag att ggc ttg gaa gga aaa ggc ttt gag cca aca ttg gaa	2234
Leu Ile Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro Thr Leu Glu	
690 695 700	
gct ctt ttt ggg aag caa gga ttt ttc cca gac agt gtc aac aaa gct	2282
Ala Leu Phe Gly Lys Gln Gly Phe Phe Pro Asp Ser Val Asn Lys Ala	
705 710 715	
ttg tac tgg gtt aat ggt caa gtt cct gat ggt gtc tct aag gtc tta	2330
Leu Tyr Trp Val Asn Gly Gln Val Pro Asp Gly Val Ser Lys Val Leu	
720 725 730	
gtg gac cac ttt ggc tat acc aaa gat gat aaa cat gag cag gat atg	2378
Val Asp His Phe Gly Tyr Thr Lys Asp Asp Lys His Glu Gln Asp Met	
735 740 745 750	
gta aat gga ata atg ctc agt gtt gag aag ctg att aaa gat ttg aaa	2426
Val Asn Gly Ile Met Leu Ser Val Glu Lys Leu Ile Lys Asp Leu Lys	
755 760 765	
tcc aaa gaa gtc ccg gaa gcc aga gcc tac ctc cgc atc ttg gga gag	2474
Ser Lys Glu Val Pro Glu Ala Arg Ala Tyr Leu Arg Ile Leu Gly Glu	
770 775 780	
gag ctt ggt ttt gcc agt ctc cat gac ctc cag ctc ctg gga aag ctg	2522
Glu Leu Gly Phe Ala Ser Leu His Asp Leu Gln Leu Leu Gly Lys Leu	
785 790 795	

ctt ctg atg ggt gcc cgc act ctg cag ggg atc ccc cag atg att gga	2570
Leu Leu Met Gly Ala Arg Thr Leu Gln Gly Ile Pro Gln Met Ile Gly	
800 805 810	
gag gtc atc agg aag ggc tca aag aat gac ttt ttt ctt cac tac atc	2618
Glu Val Ile Arg Lys Gly Ser Lys Asn Asp Phe Phe Leu His Tyr Ile	
815 820 825 830	
ttc atg gag aat gcc ttt gaa ctc ccc act gga gct gga tta cag ttg	2666
Phe Met Glu Asn Ala Phe Glu Leu Pro Thr Gly Ala Gly Leu Gln Leu	
835 840 845	
caa ata tct tca tct gga gtc att gct ccc gga gcc aag gct gga gta	2714
Gln Ile Ser Ser Ser Gly Val Ile Ala Pro Gly Ala Lys Ala Gly Val	
850 855 860	
aaa ctg gaa gta gcc aac atg cag gct gaa ctg gtg gca aaa ccc tcc	2762
Lys Leu Glu Val Ala Asn Met Gln Ala Glu Leu Val Ala Lys Pro Ser	
865 870 875	
gtg tct gtg gag ttt gtg aca aat atg ggc atc atc att ccg gac ttc	2810
Val Ser Val Glu Phe Val Thr Asn Met Gly Ile Ile Ile Pro Asp Phe	
880 885 890	
gct agg agt ggg gtc cag atg aac acc aac ttc ttc cac gag tcc ggt	2858
Ala Arg Ser Gly Val Gln Met Asn Thr Asn Phe Phe His Glu Ser Gly	
895 900 905 910	
ctg gag gct cat gtt gcc cta aaa gct ggg aag ctg aag ttt atc att	2906
Leu Glu Ala His Val Ala Leu Lys Ala Gly Lys Leu Lys Phe Ile Ile	
915 920 925	
cct tcc cca aag aga cca gtc aag ctg ctc agt gga ggc aac aca tta	2954
Pro Ser Pro Lys Arg Pro Val Lys Leu Leu Ser Gly Gly Asn Thr Leu	
930 935 940	
cat ttg gtc tct acc acc aaa acg gag gtg atc cca cct ctc att gag	3002
His Leu Val Ser Thr Thr Lys Thr Glu Val Ile Pro Pro Leu Ile Glu	
945 950 955	
aac agg cag tcc tgg tca gtt tgc aag caa gtc ttt cct ggc ctg aat	3050
Asn Arg Gln Ser Trp Ser Val Cys Lys Gln Val Phe Pro Gly Leu Asn	
960 965 970	
tac tgc acc tca ggc gct tac tcc aac gcc agc tcc aca gac tcc gcc	3098
Tyr Cys Thr Ser Gly Ala Tyr Ser Asn Ala Ser Ser Thr Asp Ser Ala	
975 980 985 990	
tcc tac tat ccg ctg acc ggg gac acc aga tta gag ctg gaa ctg agg	3146
Ser Tyr Tyr Pro Leu Thr Gly Asp Thr Arg Leu Glu Leu Glu Leu Arg	
995 1000 1005	
cct aca gga gag att gag cag tat tct gtc agc gca acc tat gag ctc	3194
Pro Thr Gly Glu Ile Glu Gln Tyr Ser Val Ser Ala Thr Tyr Glu Leu	
1010 1015 1020	
cag aga gag gac aga gcc ttg gtg gat acc ctg aag ttt gta act caa	3242
Gln Arg Glu Asp Arg Ala Leu Val Asp Thr Leu Lys Phe Val Thr Gln	
1025 1030 1035	
gca gaa ggt gcg aag cag act gag gct acc atg aca ttc aaa tat aat	3290
Ala Glu Gly Ala Lys Gln Thr Glu Ala Thr Met Thr Phe Lys Tyr Asn	
1040 1045 1050	

cgg cag agt atg acc ttg tcc agt gaa gtc caa att ccg gat ttt gat	3338
Arg Gln Ser Met Thr Leu Ser Ser Glu Val Gln Ile Pro Asp Phe Asp	
1055 1060 1065 1070	
ggt gac ctc gga aca atc ctc aga gtt aat gat gaa tct act gag ggc	3386
Val Asp Leu Gly Thr Ile Leu Arg Val Asn Asp Glu Ser Thr Glu Gly	
1075 1080 1085	
aaa acg tct tac aga ctc acc ctg gac att cag aac aag aaa att act	3434
Lys Thr Ser Tyr Arg Leu Thr Leu Asp Ile Gln Asn Lys Lys Ile Thr	
1090 1095 1100	
gag gtc gcc ctc atg ggc cac cta agt tgt gac aca aag gaa gaa aga	3482
Glu Val Ala Leu Met Gly His Leu Ser Cys Asp Thr Lys Glu Glu Arg	
1105 1110 1115	
aaa atc aag ggt gtt att tcc ata ccc cgt ttg caa gca gaa gcc aga	3530
Lys Ile Lys Gly Val Ile Ser Ile Pro Arg Leu Gln Ala Glu Ala Arg	
1120 1125 1130	
agt gag atc ctc gcc cac tgg tgg cct gcc aaa ctg ctt ctc caa atg	3578
Ser Glu Ile Leu Ala His Trp Ser Pro Ala Lys Leu Leu Leu Gln Met	
1135 1140 1145 1150	
gac tca tct gct aca gct tat ggc tcc aca gtt tcc aag agg gtg gca	3626
Asp Ser Ser Ala Thr Ala Tyr Gly Ser Thr Val Ser Lys Arg Val Ala	
1155 1160 1165	
tgg cat tat gat gaa gag aag att gaa ttt gaa tgg aac aca ggc acc	3674
Trp His Tyr Asp Glu Glu Lys Ile Glu Phe Glu Trp Asn Thr Gly Thr	
1170 1175 1180	
aat gta gat acc aaa aaa atg act tcc aat ttc cct gtg gat ctc tcc	3722
Asn Val Asp Thr Lys Lys Met Thr Ser Asn Phe Pro Val Asp Leu Ser	
1185 1190 1195	
gat tat cct aag agc ttg cat atg tat gct aat aga ctc ctg gat cac	3770
Asp Tyr Pro Lys Ser Leu His Met Tyr Ala Asn Arg Leu Leu Asp His	
1200 1205 1210	
aga gtc cct gaa aca gac atg act ttc cgg cac gtg ggt tcc aaa tta	3818
Arg Val Pro Glu Thr Asp Met Thr Phe Arg His Val Gly Ser Lys Leu	
1215 1220 1225 1230	
ata gtt gca atg agc tca tgg ctt cag aag gca tct ggg agt ctt cct	3866
Ile Val Ala Met Ser Ser Trp Leu Gln Lys Ala Ser Gly Ser Leu Pro	
1235 1240 1245	
tat acc cag act ttg caa gac cac ctc aat agc ctg aag gag ttc aac	3914
Tyr Thr Gln Thr Leu Gln Asp His Leu Asn Ser Leu Lys Glu Phe Asn	
1250 1255 1260	
ctc cag aac atg gga ttg cca gac ttc cac atc cca gaa aac ctc ttc	3962
Leu Gln Asn Met Gly Leu Pro Asp Phe His Ile Pro Glu Asn Leu Phe	
1265 1270 1275	
tta aaa agc gat ggc cgg gtc aaa tat acc ttg aac aag aac agt ttg	4010
Leu Lys Ser Asp Gly Arg Val Lys Tyr Thr Leu Asn Lys Asn Ser Leu	
1280 1285 1290	

aaa att gag att cct ttg cct ttt ggt ggc aaa tcc tcc aga gat cta	4058
Lys Ile Glu Ile Pro Leu Pro Phe Gly Gly Lys Ser Ser Arg Asp Leu	
1295 1300 1305 1310	
aag atg tta gag act gtt agg aca cca gcc ctc cac ttc aag tct gtg	4106
Lys Met Leu Glu Thr Val Arg Thr Pro Ala Leu His Phe Lys Ser Val	
1315 1320 1325	
gga ttc cat ctg cca tct cga gag ttc caa gtc cct act ttt acc att	4154
Gly Phe His Leu Pro Ser Arg Glu Phe Gln Val Pro Thr Phe Thr Ile	
1330 1335 1340	
ccc aag ttg tat caa ctg caa gtg cct ctc ctg ggt gtt cta gac ctc	4202
Pro Lys Leu Tyr Gln Leu Gln Val Pro Leu Leu Gly Val Leu Asp Leu	
1345 1350 1355	
tcc acg aat gtc tac agc aac ttg tac aac tgg tcc gcc tcc tac agt	4250
Ser Thr Asn Val Tyr Ser Asn Leu Tyr Asn Trp Ser Ala Ser Tyr Ser	
1360 1365 1370	
ggt ggc aac acc agc aca gac cat ttc agc ctt cgg gct cgt tac cac	4298
Gly Gly Asn Thr Ser Thr Asp His Phe Ser Leu Arg Ala Arg Tyr His	
1375 1380 1385 1390	
atg aag gct gac tct gtg gtt gac ctg ctt tcc tac aat gtg caa gga	4346
Met Lys Ala Asp Ser Val Val Asp Leu Leu Ser Tyr Asn Val Gln Gly	
1395 1400 1405	
tct gga gaa aca aca tat gac cac aag aat acg ttc aca cta tca tgt	4394
Ser Gly Glu Thr Tyr Asp His Lys Asn Thr Phe Thr Leu Ser Cys	
1410 1415 1420	
gat ggg tct cta cgc cac aaa ttt cta gat tcg aat atc aaa ttc agt	4442
Asp Gly Ser Leu Arg His Lys Phe Leu Asp Ser Asn Ile Lys Phe Ser	
1425 1430 1435	
cat gta gaa aaa ctt gga aac aac cca gtc tca aaa ggt tta cta ata	4490
His Val Glu Lys Leu Gly Asn Asn Pro Val Ser Lys Gly Leu Leu Ile	
1440 1445 1450	
ttc gat gca tct agt tcc tgg gga cca cag atg tct gct tca gtt cat	4538
Phe Asp Ala Ser Ser Ser Trp Gly Pro Gln Met Ser Ala Ser Val His	
1455 1460 1465 1470	
ttg gac tcc aaa aag aaa cag cat ttg ttt gtc aaa gaa gtc aag att	4586
Leu Asp Ser Lys Lys Lys Gln His Leu Phe Val Lys Glu Val Lys Ile	
1475 1480 1485	
gat ggg cag ttc aga gtc tct tcg ttc tat gct aaa ggc aca tat ggc	4634
Asp Gly Gln Phe Arg Val Ser Ser Phe Tyr Ala Lys Gly Thr Tyr Gly	
1490 1495 1500	
ctg tct tgt cag agg gat cct aac act ggc cgg ctc aat gga gag tcc	4682
Leu Ser Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn Gly Glu Ser	
1505 1510 1515	
aac ctg agg ttt aac tcc tcc tac ctc caa ggc acc aac cag ata aca	4730
Asn Leu Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr Asn Gln Ile Thr	
1520 1525 1530	
gga aga tat gaa gat gga acc ctc tcc ctc acc tcc acc tct gat ctg	4778

-8-

1775	1780	1785	1790	
tat tct ctg gta act act tta aac agt gac ctg aaa tac aat gct ctg				5546
Tyr Ser Leu Val Thr Thr Leu Asn Ser Asp Leu Lys Tyr Asn Ala Leu				
	1795	1800	1805	
gat ctc acc aac aat ggg aaa cta cgg cta gaa ccc ctg aag ctg cat				5594
Asp Leu Thr Asn Asn Gly Lys Leu Arg Leu Glu Pro Leu Lys Leu His				
	1810	1815	1820	
gtg gct ggt aac cta aaa gga gcc tac caa aat aat gaa ata aaa cac				5642
Val Ala Gly Asn Leu Lys Gly Ala Tyr Gln Asn Asn Glu Ile Lys His				
	1825	1830	1835	
atc tat gcc atc tct tct gct gcc tta tca gca agc tat aaa gca gac				5690
Ile Tyr Ala Ile Ser Ser Ala Ala Leu Ser Ala Ser Tyr Lys Ala Asp				
	1840	1845	1850	
act gtt gct aag gtt cag ggt gtg gag ttt agc cat cgg ctc aac aca				5738
Thr Val Ala Lys Val Gln Gly Val Glu Phe Ser His Arg Leu Asn Thr				
	1855	1860	1865	1870
gac atc gct ggg ctg gct tca gcc att gac atg agc aca aac tat aat				5786
Asp Ile Ala Gly Leu Ala Ser Ala Ile Asp Met Ser Thr Asn Tyr Asn				
	1875	1880	1885	
tca gac tca ctg cat ttc agc aat gtc ttc cgt tct gta atg gcc ccg				5834
Ser Asp Ser Leu His Phe Ser Asn Val Phe Arg Ser Val Met Ala Pro				
	1890	1895	1900	
ttt acc atg acc atc gat gca cat aca aat ggc aat ggg aaa ctc gct				5882
Phe Thr Met Thr Ile Asp Ala His Thr Asn Gly Asn Gly Lys Leu Ala				
	1905	1910	1915	
ctc tgg gga gaa cat act ggg cag ctg tat agc aaa ttc ctg ttg aaa				5930
Leu Trp Gly Glu His Thr Gly Gln Leu Tyr Ser Lys Phe Leu Leu Lys				
	1920	1925	1930	
gca gaa cct ctg gca ttt act ttc tct cat gat tac aaa ggc tcc aca				5978
Ala Glu Pro Leu Ala Phe Thr Phe Ser His Asp Tyr Lys Gly Ser Thr				
	1935	1940	1945	1950
agt cat cat ctc gtg tct agg aaa agc atc agt gca gct ctt gaa cac				6026
Ser His His Leu Val Ser Arg Lys Ser Ile Ser Ala Ala Leu Glu His				
	1955	1960	1965	
aaa gtc agt gcc ctg ctt act cca gct gag cag aca ggc acc tgg aaa				6074
Lys Val Ser Ala Leu Leu Thr Pro Ala Glu Gln Thr Gly Thr Trp Lys				
	1970	1975	1980	
ctc aag acc caa ttt aac aac aat gaa tac agc cag gac ttg gat gct				6122
Leu Lys Thr Gln Phe Asn Asn Asn Glu Tyr Ser Gln Asp Leu Asp Ala				
	1985	1990	1995	
tac aac act aaa gat aaa att ggc gtg gag ctt act gga cga act ctg				6170
Tyr Asn Thr Lys Asp Lys Ile Gly Val Glu Leu Thr Gly Arg Thr Leu				
	2000	2005	2010	
gct gac cta act cta cta gac tcc cca att aaa gtg cca ctt tta ctc				6218
Ala Asp Leu Thr Leu Leu Asp Ser Pro Ile Lys Val Pro Leu Leu Leu				
	2015	2020	2025	2030
agt gag ccc atc aat atc att gat gct tta gag atg aga gat gcc gtt				6266

Ser Glu Pro Ile	Asn Ile Ile Asp Ala Leu Glu Met Arg Asp Ala Val	
2035	2040	2045
gag aag ccc caa gaa ttt aca att gtt gct ttt gta aag tat gat aaa 6314		
Glu Lys Pro	Gln Glu Phe Thr Ile Val Ala Phe Val Lys Tyr Asp Lys	
2050	2055	2060
aac caa gat gtt cac tcc att aac ctc cca ttt ttt gag acc ttg caa 6362		
Asn Gln Asp	Val His Ser Ile Asn Leu Pro Phe Phe Glu Thr Leu Gln	
2065	2070	2075
gaa tat ttt gag agg aat cga caa acc att ata gtt gta gtg gaa aac 6410		
Glu Tyr Phe	Glu Arg Asn Arg Gln Thr Ile Ile Val Val Val Glu Asn	
2080	2085	2090
gta cag aga aac ctg aag cac atc aat att gat caa ttt gta aga aaa 6458		
Val Gln Arg	Asn Leu Lys His Ile Asn Ile Asp Gln Phe Val Arg Lys	
2095	2100	2105
tac aga gca gcc ctg gga aaa ctc cca cag caa gct aat gat tat ctg 6506		
Tyr Arg Ala	Ala Leu Gly Lys Leu Pro Gln Gln Ala Asn Asp Tyr Leu	
2115	2120	2125
aat tca ttc aat tgg gag aga caa gtt tca cat gcc aag gag aaa ctg 6554		
Asn Ser Phe	Asn Trp Glu Arg Gln Val Ser His Ala Lys Glu Lys Leu	
2130	2135	2140
act gct ctc aca aaa aag tat aga att aca gaa aat gat ata caa att 6602		
Thr Ala Leu	Thr Lys Lys Tyr Arg Ile Thr Glu Asn Asp Ile Gln Ile	
2145	2150	2155
gca tta gat gat gcc aaa atc aac ttt aat gaa aaa cta tct caa ctg 6650		
Ala Leu Asp	Asp Ala Lys Ile Asn Phe Asn Glu Lys Leu Ser Gln Leu	
2160	2165	2170
cag aca tat atg ata caa ttt gat cag tat att aaa gat agt tat gat 6698		
Gln Thr Tyr	Met Ile Gln Phe Asp Gln Tyr Ile Lys Asp Ser Tyr Asp	
2175	2180	2185
tta cat gat ttg aaa ata gct att gct aat att att gat gaa atc att 6746		
Leu His Asp	Leu Lys Ile Ala Ile Ala Asn Ile Ile Asp Glu Ile Ile	
2195	2200	2205
gaa aaa tta aaa agt ctt gat gag cac tat cat atc cgt gta aat tta 6794		
Glu Lys Leu	Lys Ser Leu Asp Glu His Tyr His Ile Arg Val Asn Leu	
2210	2215	2220
gta aaa aca atc cat gat cta cat ttg ttt att gaa aat att gat ttt 6842		
Val Lys Thr	Ile His Asp Leu His Leu Phe Ile Glu Asn Ile Asp Phe	
2225	2230	2235
aac aaa agt gga agt agt act gca tcc tgg att caa aat gtg gat act 6890		
Asn Lys Ser	Gly Ser Ser Thr Ala Ser Trp Ile Gln Asn Val Asp Thr	
2240	2245	2250
aag tac caa atc aga atc cag ata caa gaa aaa ctg cag cag ctt aag 6938		
Lys Tyr Gln	Ile Arg Ile Gln Ile Gln Glu Lys Leu Gln Gln Leu Lys	
2255	2260	2265
aga cac ata cag aat ata gac atc cag cac cta gct gga aag tta aaa 6986		
Arg His Ile	Gln Asn Ile Asp Ile Gln His Leu Ala Gly Lys Leu Lys	
2275	2280	2285

caa cac att gag gct att gat gtt aga gtg ctt tta gat caa ttg gga Gln His Ile Glu Ala Ile Asp Val Arg Val Leu Leu Asp Gln Leu Gly 2290 2295 2300	7034
act aca att tca ttt gaa aga ata aat gat gtt ctt gag cat gtc aaa Thr Thr Ile Ser Phe Glu Arg Ile Asn Asp Val Leu Glu His Val Lys 2305 2310 2315	7082
cac ttt gtt ata aat ctt att ggg gat ttt gaa gta gct gag aaa atc His Phe Val Ile Asn Leu Ile Gly Asp Phe Glu Val Ala Glu Lys Ile 2320 2325 2330	7130
aat gcc ttc aga gcc aaa gtc cat gag tta atc gag agg tat gaa gta Asn Ala Phe Arg Ala Lys Val His Glu Leu Ile Glu Arg Tyr Glu Val 2335 2340 2345 2350	7178
gac caa caa atc cag gtt tta atg gat aaa tta gta gag ttg acc cac Asp Gln Gln Ile Gln Val Leu Met Asp Lys Leu Val Glu Leu Thr His 2355 2360 2365	7226
caa tac aag ttg aag gag act att cag aag cta agc aat gtc cta caa Gln Tyr Lys Leu Lys Glu Thr Ile Gln Lys Leu Ser Asn Val Leu Gln 2370 2375 2380	7274
caa gtt aag ata aaa gat tac ttt gag aaa ttg gtt gga ttt att gat Gln Val Lys Ile Lys Asp Tyr Phe Glu Lys Leu Val Gly Phe Ile Asp 2385 2390 2395	7322
gat gct gtg aag aag ctt aat gaa tta tct ttt aaa aca ttc att gaa Asp Ala Val Lys Lys Leu Asn Glu Leu Ser Phe Lys Thr Phe Ile Glu 2400 2405 2410	7370
gat gtt aac aaa ttc ctt gac atg ttg ata aag aaa tta aag tca ttt Asp Val Asn Lys Phe Leu Asp Met Leu Ile Lys Lys Leu Lys Ser Phe 2415 2420 2425 2430	7418
gat tac cac cag ttt gta gat gaa acc aat gac aaa atc cgt gag gtg Asp Tyr His Gln Phe Val Asp Glu Thr Asn Asp Lys Ile Arg Glu Val 2435 2440 2445	7466
act cag aga ctc aat ggt gaa att cag gct ctg gaa cta cca caa aaa Thr Gln Arg Leu Asn Gly Glu Ile Gln Ala Leu Glu Leu Pro Gln Lys 2450 2455 2460	7514
gct gaa gca tta aaa ctg ttt tta gag gaa acc aag gcc aca gtt gca Ala Glu Ala Leu Lys Leu Phe Leu Glu Glu Thr Lys Ala Thr Val Ala 2465 2470 2475	7562
gtg tat ctg gaa agc cta cag gac acc aaa ata acc tta atc atc aat Val Tyr Leu Glu Ser Leu Gln Asp Thr Lys Ile Thr Leu Ile Ile Asn 2480 2485 2490	7610
tgg tta cag gag gct tta agt tca gca tct ttg gct cac atg aag gcc Trp Leu Gln Glu Ala Leu Ser Ser Ala Ser Leu Ala His Met Lys Ala 2495 2500 2505 2510	7658
aaa ttc cga gag act cta gaa gat aca cga gac cga atg tat caa atg Lys Phe Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr Gln Met 2515 2520 2525	7706
gac att cag cag gaa ctt caa cga tac ctg tct ctg gta ggc cag gtt	7754

Asp Ile Gln Gln Glu Leu Gln Arg Tyr Leu Ser Leu Val Gly Gln Val	
2530 2535 2540	
tat agc aca ctt gtc acc tac att tct gat tgg tgg act ctt gct gct	7802
Tyr Ser Thr Leu Val Thr Tyr Ile Ser Asp Trp Trp Thr Leu Ala Ala	
2545 2550 2555	
aag aac ctt act gac ttt gca gag caa tat tct atc caa gat tgg gct	7850
Lys Asn Leu Thr Asp Phe Ala Glu Gln Tyr Ser Ile Gln Asp Trp Ala	
2560 2565 2570	
aaa cgt atg aaa gca ttg gta gag caa ggg ttc act gtt cct gaa atc	7898
Lys Arg Met Lys Ala Leu Val Glu Gln Gly Phe Thr Val Pro Glu Ile	
2575 2580 2585 2590	
aag acc atc ctt ggg acc atg cct gcc ttt gaa gtc agt ctt cag gct	7946
Lys Thr Ile Leu Gly Thr Met Pro Ala Phe Glu Val Ser Leu Gln Ala	
2595 2600 2605	
ctt cag aaa gct acc ttc cag aca cct gat ttt ata gtc ccc cta aca	7994
Leu Gln Lys Ala Thr Phe Gln Thr Pro Asp Phe Ile Val Pro Leu Thr	
2610 2615 2620	
gat ttg agg att cca tca gtt cag ata aac ttc aaa gac tta aaa aat	8042
Asp Leu Arg Ile Pro Ser Val Gln Ile Asn Phe Lys Asp Leu Lys Asn	
2625 2630 2635	
ata aaa atc cca tcc agg ttt tcc aca cca gaa ttt acc atc ctt aac	8090
Ile Lys Ile Pro Ser Arg Phe Ser Thr Pro Glu Phe Thr Ile Leu Asn	
2640 2645 2650	
acc ttc cac att cct tcc ttt aca att gac ttt gtc gaa atg aaa gta	8138
Thr Phe His Ile Pro Ser Phe Thr Ile Asp Phe Val Glu Met Lys Val	
2655 2660 2665 2670	
aag atc atc aga acc att gac cag atg cag aac agt gag ctg cag tgg	8186
Lys Ile Ile Arg Thr Ile Asp Gln Met Gln Asn Ser Glu Leu Gln Trp	
2675 2680 2685	
ccc gtt cca gat ata tat ctc agg gat ctg aag gtg gag gac att cct	8234
Pro Val Pro Asp Ile Tyr Leu Arg Asp Leu Lys Val Glu Asp Ile Pro	
2690 2695 2700	
cta gcg aga atc acc ctg cca gac ttc cgt tta cca gaa atc gca att	8282
Leu Ala Arg Ile Thr Leu Pro Asp Phe Arg Leu Pro Glu Ile Ala Ile	
2705 2710 2715	
cca gaa ttc ata atc cca act ctc aac ctt aat gat ttt caa gtt cct	8330
Pro Glu Phe Ile Ile Pro Thr Leu Asn Leu Asn Asp Phe Gln Val Pro	
2720 2725 2730	
gac ctt cac ata cca gaa ttc cag ctt ccc cac atc tca cac aca att	8378
Asp Leu His Ile Pro Glu Phe Gln Leu Pro His Ile Ser His Thr Ile	
2735 2740 2745 2750	
gaa gta cct act ttt ggc aag cta tac agt att ctg aaa atc caa tct	8426
Glu Val Pro Thr Phe Gly Lys Leu Tyr Ser Ile Leu Lys Ile Gln Ser	
2755 2760 2765	
cct ctt ttc aca tta gat gca aat gct gac ata ggg aat gga acc acc	8474
Pro Leu Phe Thr Leu Asp Ala Asn Ala Asp Ile Gly Asn Gly Thr Thr	

2770	2775	2780	
tca gca aac gaa gca ggt atc gca gct tcc atc act gcc aaa gga gag			8522
Ser Ala Asn Glu Ala Gly Ile Ala Ala Ser Ile Thr Ala Lys Gly Glu			
2785	2790	2795	
tcc aaa tta gaa gtt ctc aat ttt gat ttt caa gca aat gca caa ctc			8570
Ser Lys Leu Glu Val Leu Asn Phe Asp Phe Gln Ala Asn Ala Gln Leu			
2800	2805	2810	
tca aac cct aag att aat ccg ctg gct ctg aag gag tca gtg aag ttc			8618
Ser Asn Pro Lys Ile Asn Pro Leu Ala Leu Lys Glu Ser Val Lys Phe			
2815	2820	2825	2830
tcc agc aag tac ctg aga acg gag cat ggg agt gaa atg ctg ttt ttt			8666
Ser Ser Lys Tyr Leu Arg Thr Glu His Gly Ser Glu Met Leu Phe Phe			
2835	2840	2845	
gga aat gct att gag gga aaa tca aac aca gtg gca agt tta cac aca			8714
Gly Asn Ala Ile Glu Gly Lys Ser Asn Thr Val Ala Ser Leu His Thr			
2850	2855	2860	
gaa aaa aat aca ctg gag ctt agt aat gga gtg att gtc aag ata aac			8762
Glu Lys Asn Thr Leu Glu Leu Ser Asn Gly Val Ile Val Lys Ile Asn			
2865	2870	2875	
aat cag ctt acc ctg gat agc aac act aaa tac ttc cac aaa ttg aac			8810
Asn Gln Leu Thr Leu Asp Ser Asn Thr Lys Tyr Phe His Lys Leu Asn			
2880	2885	2890	
atc ccc aaa ctg gac ttc tct agt cag gct gac ctg cgc aac gag atc			8858
Ile Pro Lys Leu Asp Phe Ser Ser Gln Ala Asp Leu Arg Asn Glu Ile			
2895	2900	2905	2910
aag aca ctg ttg aaa gct ggc cac ata gca tgg act tct tct gga aaa			8906
Lys Thr Leu Leu Lys Ala Gly His Ile Ala Trp Thr Ser Ser Gly Lys			
2915	2920	2925	
ggg tca tgg aaa tgg gcc tgc ccc aga ttc tca gat gag gga aca cat			8954
Gly Ser Trp Lys Trp Ala Cys Pro Arg Phe Ser Asp Glu Gly Thr His			
2930	2935	2940	
gaa tca caa att agt ttc acc ata gaa gga ccc ctc act tcc ttt gga			9002
Glu Ser Gln Ile Ser Phe Thr Ile Glu Gly Pro Leu Thr Ser Phe Gly			
2945	2950	2955	
ctg tcc aat aag atc aat agc aaa cac cta aga gta aac caa aac ttg			9050
Leu Ser Asn Lys Ile Asn Ser Lys His Leu Arg Val Asn Gln Asn Leu			
2960	2965	2970	
gtt tat gaa tct ggc tcc ctc aac ttt tct aaa ctt gaa att caa tca			9098
Val Tyr Glu Ser Gly Ser Leu Asn Phe Ser Lys Leu Glu Ile Gln Ser			
2975	2980	2985	2990
caa gtc gat tcc cag cat gtg ggc cac agt gtt cta act gct aaa ggc			9146
Gln Val Asp Ser Gln His Val Gly His Ser Val Leu Thr Ala Lys Gly			
2995	3000	3005	
atg gca ctg ttt gga gaa ggg aag gca gag ttt act ggg agg cat gat			9194
Met Ala Leu Phe Gly Glu Gly Lys Ala Glu Phe Thr Gly Arg His Asp			
3010	3015	3020	
gct cat tta aat gga aag gtt att gga act ttg aaa aat tct ctt ttc			9242

Ala His Leu Asn Gly Lys Val Ile Gly Thr Leu Lys Asn Ser Leu Phe	
3025 3030 3035	
ttt tca gcc cag cca ttt gag atc acg gca tcc aca aac aat gaa ggg	9290
Phe Ser Ala Gln Pro Phe Glu Ile Thr Ala Ser Thr Asn Asn Glu Gly	
3040 3045 3050	
aat ttg aaa gtt cgt ttt cca tta agg tta aca ggg aag ata gac ttc	9338
Asn Leu Lys Val Arg Phe Pro Leu Arg Leu Thr Gly Lys Ile Asp Phe	
3055 3060 3065 3070	
ctg aat aac tat gca ctg ttt ctg agt ccc agt gcc cag caa gca agt	9386
Leu Asn Asn Tyr Ala Leu Phe Leu Ser Pro Ser Ala Gln Gln Ala Ser	
3075 3080 3085	
tgg caa gta agt gct agg ttc aat cag tat aag tac aac caa aat ttc	9434
Trp Gln Val Ser Ala Arg Phe Asn Gln Tyr Lys Tyr Asn Gln Asn Phe	
3090 3095 3100	
tct gct gga aac aac gag aac att atg gag gcc cat gta gga ata aat	9482
Ser Ala Gly Asn Asn Glu Asn Ile Met Glu Ala His Val Gly Ile Asn	
3105 3110 3115	
gga gaa gca aat ctg gat ttc tta aac att cct tta aca att cct gaa	9530
Gly Glu Ala Asn Leu Asp Phe Leu Asn Ile Pro Leu Thr Ile Pro Glu	
3120 3125 3130	
atg cgt cta cct tac aca ata atc aca act cct cca ctg aaa gat ttc	9578
Met Arg Leu Pro Tyr Thr Ile Ile Thr Thr Pro Pro Leu Lys Asp Phe	
3135 3140 3145 3150	
tct cta tgg gaa aaa aca ggc ttg aag gaa ttc ttg aaa acg aca aag	9626
Ser Leu Trp Glu Lys Thr Gly Leu Lys Glu Phe Leu Lys Thr Thr Lys	
3155 3160 3165	
caa tca ttt gat tta agt gta aaa gct cag tat aag aaa aac aaa cac	9674
Gln Ser Phe Asp Leu Ser Val Lys Ala Gln Tyr Lys Lys Asn Lys His	
3170 3175 3180	
agg cat tcc atc aca aat cct ttg gct gtg ctt tgt gag ttt atc agt	9722
Arg His Ser Ile Thr Asn Pro Leu Ala Val Leu Cys Glu Phe Ile Ser	
3185 3190 3195	
cag agc atc aaa tcc ttt gac agg cat ttt gaa aaa aac aga aac aat	9770
Gln Ser Ile Lys Ser Phe Asp Arg His Phe Glu Lys Asn Arg Asn Asn	
3200 3205 3210	
gca tta gat ttt gtc acc aaa tcc tat aat gaa aca aaa att aag ttt	9818
Ala Leu Asp Phe Val Thr Lys Ser Tyr Asn Glu Thr Lys Ile Lys Phe	
3215 3220 3225 3230	
gat aag tac aaa gct gaa aaa tct cac gac gag ctc ccc agg acc ttt	9866
Asp Lys Tyr Lys Ala Glu Lys Ser His Asp Glu Leu Pro Arg Thr Phe	
3235 3240 3245	
caa att cct gga tac act gtt cca gtt gtc aat gtt gaa gtg tct cca	9914
Gln Ile Pro Gly Tyr Thr Val Pro Val Val Asn Val Glu Val Ser Pro	
3250 3255 3260	
ttc acc ata gag atg tcg gca ttc ggc tat gtg ttc cca aaa gca gtc	9962
Phe Thr Ile Glu Met Ser Ala Phe Gly Tyr Val Phe Pro Lys Ala Val	

3265	3270	3275	
agc atg cct agt ttc tcc atc cta ggt tct gac gtc cgt gtg cct tca Ser Met Pro Ser Phe Ser Ile Leu Gly Ser Asp Val Arg Val Pro Ser 3280 3285 3290			10010
tac aca tta atc ctg cca tca tta gag ctg cca gtc ctt cat gtc cct Tyr Thr Leu Ile Leu Pro Ser Leu Glu Leu Pro Val Leu His Val Pro 3295 3300 3305 3310			10058
aga aat ctc aag ctt tct ctt cca cat ttc aag gaa ttg tgt acc ata Arg Asn Leu Lys Leu Ser Leu Pro His Phe Lys Glu Leu Cys Thr Ile 3315 3320 3325			10106
agc cat att ttt att cct gcc atg ggc aat att acc tat gat ttc tcc Ser His Ile Phe Ile Pro Ala Met Gly Asn Ile Thr Tyr Asp Phe Ser 3330 3335 3340			10154
ttt aaa tca agt gtc atc aca ctg aat acc aat gct gaa ctt ttt aac Phe Lys Ser Ser Val Ile Thr Leu Asn Thr Asn Ala Glu Leu Phe Asn 3345 3350 3355			10202
cag tca gat att gtt gct cat ctc ctt tct tca tct tca tct gtc att Gln Ser Asp Ile Val Ala His Leu Leu Ser Ser Ser Ser Ser Val Ile 3360 3365 3370			10250
gat gca ctg cag tac aaa tta gag ggc acc aca aga ttg aca aga aaa Asp Ala Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys 3375 3380 3385 3390			10298
agg gga ttg aag tta gcc aca gct ctg tct ctg agc aac aaa ttt gtg Arg Gly Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val 3395 3400 3405			10346
gag ggt agt cat aac agt act gtg agc tta acc acg aaa aat atg gaa Glu Gly Ser His Asn Ser Thr Val Ser Leu Thr Thr Lys Asn Met Glu 3410 3415 3420			10394
gtg tca gtg gca aaa acc aca aaa gcc gaa att cca att ttg aga atg Val Ser Val Ala Lys Thr Thr Lys Ala Glu Ile Pro Ile Leu Arg Met 3425 3430 3435			10442
aat ttc aag caa gaa ctt aat gga aat acc aag tca aaa cct act gtc Asn Phe Lys Gln Glu Leu Asn Gly Asn Thr Lys Ser Lys Pro Thr Val 3440 3445 3450			10490
tct tcc tcc atg gaa ttt aag tat gat ttc aat tct tca atg ctg tac Ser Ser Ser Met Glu Phe Lys Tyr Asp Phe Asn Ser Ser Met Leu Tyr 3455 3460 3465 3470			10538
tct acc gct aaa gga gca gtt gac cac aag ctt agc ttg gaa agc ctc Ser Thr Ala Lys Gly Ala Val Asp His Lys Leu Ser Leu Glu Ser Leu 3475 3480 3485			10586
acc tct tac ttt tcc att gag tca tct acc aaa gga gat gtc aag ggt Thr Ser Tyr Phe Ser Ile Glu Ser Ser Thr Lys Gly Asp Val Lys Gly 3490 3495 3500			10634
tcg gtt ctt tct cgg gaa tat tca gga act att gct agt gag gcc aac Ser Val Leu Ser Arg Glu Tyr Ser Gly Thr Ile Ala Ser Glu Ala Asn 3505 3510 3515			10682
act tac ttg aat tcc aag agc aca cgg tct tca gtg aag ctg cag ggc			10730

Thr Tyr Leu Asn Ser Lys Ser Thr Arg Ser Ser Val Lys Leu Gln Gly	
3520 3525 3530	
act tcc aaa att gat gat atc tgg aac ctt gaa gta aaa gaa aat ttt	10778
Thr Ser Lys Ile Asp Asp Ile Trp Asn Leu Glu Val Lys Glu Asn Phe	
3535 3540 3545 3550	
gct gga gaa gcc aca ctc caa cgc ata tat tcc ctc tgg gag cac agt	10826
Ala Gly Glu Ala Thr Leu Gln Arg Ile Tyr Ser Leu Trp Glu His Ser	
3555 3560 3565	
acg aaa aac cac tta cag cta gag ggc ctc ttt ttc acc aac gga gaa	10874
Thr Lys Asn His Leu Gln Leu Glu Gly Leu Phe Phe Thr Asn Gly Glu	
3570 3575 3580	
cat aca agc aaa gcc acc ctg gaa ctc tct cca tgg caa atg tca gct	10922
His Thr Ser Lys Ala Thr Leu Glu Leu Ser Pro Trp Gln Met Ser Ala	
3585 3590 3595	
ctt gtt cag gtc cat gca agt cag ccc agt tcc ttc cat gat ttc cct	10970
Leu Val Gln Val His Ala Ser Gln Pro Ser Ser Phe His Asp Phe Pro	
3600 3605 3610	
gac ctt ggc cag gaa gtg gcc ctg aat gct aac act aag aac cag aag	11018
Asp Leu Gly Gln Glu Val Ala Leu Asn Ala Asn Thr Lys Asn Gln Lys	
3615 3620 3625 3630	
atc aga tgg aaa aat gaa gtc cgg att cat tct ggg tct ttc cag agc	11066
Ile Arg Trp Lys Asn Glu Val Arg Ile His Ser Gly Ser Phe Gln Ser	
3635 3640 3645	
cag gtc gag ctt tcc aat gac caa gaa aag gca cac ctt gac att gca	11114
Gln Val Glu Leu Ser Asn Asp Gln Glu Lys Ala His Leu Asp Ile Ala	
3650 3655 3660	
gga tcc tta gaa gga cac cta agg ttc ctc aaa aat atc atc cta cca	11162
Gly Ser Leu Glu Gly His Leu Arg Phe Leu Lys Asn Ile Ile Leu Pro	
3665 3670 3675	
gtc tat gac aag agc tta tgg gat ttc cta aag ctg gat gta acc acc	11210
Val Tyr Asp Lys Ser Leu Trp Asp Phe Leu Lys Leu Asp Val Thr Thr	
3680 3685 3690	
agc att ggt agg aga cag cat ctt cgt gtt tca act gcc ttt gtg tac	11258
Ser Ile Gly Arg Arg Gln His Leu Arg Val Ser Thr Ala Phe Val Tyr	
3695 3700 3705 3710	
acc aaa aac ccc aat ggc tat tca ttc tcc atc cct gta aaa gtt ttg	11306
Thr Lys Asn Pro Asn Gly Tyr Ser Phe Ser Ile Pro Val Lys Val Leu	
3715 3720 3725	
gct gat aaa ttc att act cct ggg ctg aaa cta aat gat cta aat tca	11354
Ala Asp Lys Phe Ile Thr Pro Gly Leu Lys Leu Asn Asp Leu Asn Ser	
3730 3735 3740	
gtt ctt gtc atg cct acg ttc cat gtc cca ttt aca gat ctt cag gtt	11402
Val Leu Val Met Pro Thr Phe His Val Pro Phe Thr Asp Leu Gln Val	
3745 3750 3755	

cca tcg tgc aaa ctt gac ttc aga gaa ata caa atc tat aag aag ctg	11450
Pro Ser Cys Lys Leu Asp Phe Arg Glu Ile Gln Ile Tyr Lys Lys Leu	
3760 3765 3770	
aga act tca tca ttt gcc ctc aac cta cca aca ctc ccc gag gta aaa	11498
Arg Thr Ser Ser Phe Ala Leu Asn Leu Pro Thr Leu Pro Glu Val Lys	
3775 3780 3785 3790	
ttc cct gaa gtt gat gtg tta aca aaa tat tct caa cca gaa gac tcc	11546
Phe Pro Glu Val Asp Val Leu Thr Lys Tyr Ser Gln Pro Glu Asp Ser	
3795 3800 3805	
ttg att ccc ttt ttt gag ata acc gtg cct gaa tct cag tta act gtg	11594
Leu Ile Pro Phe Phe Glu Ile Thr Val Pro Glu Ser Gln Leu Thr Val	
3810 3815 3820	
tcc cag ttc acg ctt cca aaa agt gtt tca gat ggc att gct gct ttg	11642
Ser Gln Phe Thr Leu Pro Lys Ser Val Ser Asp Gly Ile Ala Ala Leu	
3825 3830 3835	
gat cta aat gca gta gcc aac aag atc gca gac ttt gag ttg ccc acc	11690
Asp Leu Asn Ala Val Ala Asn Lys Ile Ala Asp Phe Glu Leu Pro Thr	
3840 3845 3850	
atc atc gtg cct gag cag acc att gag att ccc tcc att aag ttc tct	11738
Ile Ile Val Pro Glu Gln Thr Ile Glu Ile Pro Ser Ile Lys Phe Ser	
3855 3860 3865 3870	
gta cct gct gga att gtc att cct tcc ttt caa gca ctg act gca cgc	11786
Val Pro Ala Gly Ile Val Ile Pro Ser Phe Gln Ala Leu Thr Ala Arg	
3875 3880 3885	
ttt gag gta gac tct ccc gtg tat aat gcc act tgg agt gcc agt ttg	11834
Phe Glu Val Asp Ser Pro Val Tyr Asn Ala Thr Trp Ser Ala Ser Leu	
3890 3895 3900	
aaa aac aaa gca gat tat gtt gaa aca gtc ctg gat tcc aca tgc agc	11882
Lys Asn Lys Ala Asp Tyr Val Glu Thr Val Leu Asp Ser Thr Cys Ser	
3905 3910 3915	
tca acc gta cag ttc cta gaa tat gaa cta aat gtt ttg gga aca cac	11930
Ser Thr Val Gln Phe Leu Glu Tyr Glu Leu Asn Val Leu Gly Thr His	
3920 3925 3930	
aaa atc gaa gat ggt acg tta gcc tct aag act aaa gga aca ctt gca	11978
Lys Ile Glu Asp Gly Thr Leu Ala Ser Lys Thr Lys Gly Thr Leu Ala	
3935 3940 3945 3950	
cac cgt gac ttc agt gca gaa tat gaa gaa gat ggc aaa ttt gaa gga	12026
His Arg Asp Phe Ser Ala Glu Tyr Glu Glu Asp Gly Lys Phe Glu Gly	
3955 3960 3965	
ctt cag gaa tgg gaa gga aaa gcg cac ctc aat atc aaa agc cca gcg	12074
Leu Gln Glu Trp Glu Gly Lys Ala His Leu Asn Ile Lys Ser Pro Ala	
3970 3975 3980	
ttc acc gat ctc cat ctg cgc tac cag aaa gac aag aaa ggc atc tcc	12122
Phe Thr Asp Leu His Leu Arg Tyr Gln Lys Asp Lys Lys Gly Ile Ser	
3985 3990 3995	
acc tca gca gcc tcc cca gcc gta ggc acc gtg ggc atg gat atg gat	12170
Thr Ser Ala Ala Ser Pro Ala Val Gly Thr Val Gly Met Asp Met Asp	

4000	4005	4010	
gaa gat gac gac ttt tct aaa tgg aac ttc tac tac agc cct cag tcc			12218
Glu Asp Asp Asp Phe Ser Lys Trp Asn Phe Tyr Tyr Ser Pro Gln Ser			
4015	4020	4025	4030
tct cca gat aaa aaa ctc acc ata ttc aaa act gag ttg agg gtc cgg			12266
Ser Pro Asp Lys Lys Leu Thr Ile Phe Lys Thr Glu Leu Arg Val Arg			
4035	4040		4045
gaa tct gat gag gaa act cag atc aaa gtt aat tgg gaa gaa gag gca			12314
Glu Ser Asp Glu Glu Thr Gln Ile Lys Val Asn Trp Glu Glu Glu Ala			
4050	4055		4060
gct tct ggc ttg cta acc tct ctg aaa gac aac gtg ccc aag gcc aca			12362
Ala Ser Gly Leu Leu Thr Ser Leu Lys Asp Asn Val Pro Lys Ala Thr			
4065	4070		4075
ggg gtc ctt tat gat tat gtc aac aag tac cac tgg gaa cac aca ggg			12410
Gly Val Leu Tyr Asp Tyr Val Asn Lys Tyr His Trp Glu His Thr Gly			
4080	4085		4090
ctc acc ctg aga gaa gtg tct tca aag ctg aga aga aat ctg cag aac			12458
Leu Thr Leu Arg Glu Val Ser Ser Lys Leu Arg Arg Asn Leu Gln Asn			
4095	4100	4105	4110
aat gct gag tgg gtt tat caa ggg gcc att agg caa att gat gat atc			12506
Asn Ala Glu Trp Val Tyr Gln Gly Ala Ile Arg Gln Ile Asp Asp Ile			
4115	4120		4125
gac gtg agg ttc cag aaa gca gcc agt ggc acc act ggg acc tac caa			12554
Asp Val Arg Phe Gln Lys Ala Ala Ser Gly Thr Thr Gly Thr Tyr Gln			
4130	4135		4140
gag tgg aag gac aag gcc cag aat ctg tac cag gaa ctg ttg act cag			12602
Glu Trp Lys Asp Lys Ala Gln Asn Leu Tyr Gln Glu Leu Leu Thr Gln			
4145	4150		4155
gaa ggc caa gcc agt ttc cag gga ctc aag gat aac gtg ttt gat ggc			12650
Glu Gly Gln Ala Ser Phe Gln Gly Leu Lys Asp Asn Val Phe Asp Gly			
4160	4165		4170
ttg gta cga gtt act caa aaa ttc cat atg aaa gtc aag cat ctg att			12698
Leu Val Arg Val Thr Gln Lys Phe His Met Lys Val Lys His Leu Ile			
4175	4180	4185	4190
gac tca ctc att gat ttt ctg aac ttc ccc aga ttc cag ttt ccg ggg			12746
Asp Ser Leu Ile Asp Phe Leu Asn Phe Pro Arg Phe Gln Phe Pro Gly			
4195	4200		4205
aaa cct ggg ata tac act agg gag gaa ctt tgc act atg ttc ata agg			12794
Lys Pro Gly Ile Tyr Thr Arg Glu Glu Leu Cys Thr Met Phe Ile Arg			
4210	4215		4220
gag gta ggg acg gta ctg tcc cag gta tat tcg aaa gtc cat aat ggt			12842
Glu Val Gly Thr Val Leu Ser Gln Val Tyr Ser Lys Val His Asn Gly			
4225	4230		4235
tca gaa ata ctg ttt tcc tat ttc caa gac cta gtg att aca ctt cct			12890
Ser Glu Ile Leu Phe Ser Tyr Phe Gln Asp Leu Val Ile Thr Leu Pro			
4240	4245		4250
ttc gag tta agg aaa cat aaa cta ata gat gta atc tcg atg tat agg			12938

-19-

4495	4500	4505	4510	
gaa aaa ttt att gct gaa tcc aaa aga ttg att gac ctg tcc att caa				13706
Glu Lys Phe Ile Ala Glu Ser Lys Arg Leu Ile Asp Leu Ser Ile Gln				
	4515	4520	4525	
aac tac cac aca ttt ctg ata tac atc acg gag tta ctg aaa aag ctg				13754
Asn Tyr His Thr Phe Leu Ile Tyr Ile Thr Glu Leu Leu Lys Lys Leu				
	4530	4535	4540	
caa tca acc aca gtc atg aac ccc tac atg aag ctt gct cca gga gaa				13802
Gln Ser Thr Thr Val Met Asn Pro Tyr Met Lys Leu Ala Pro Gly Glu				
	4545	4550	4555	
ctt act atc atc ctc taa ttttttaaaa gaaatcttca tttattcttc				13850
Leu Thr Ile Ile Leu *				
	4560			
ttttccaatt gaactttcac atagcacaga aaaaattcaa actgcctata ttgataaaac				13910
catacagtga gccagccttg cagtaggcag tagactataa gcagaagcac atatgaactg				13970
gacctgcacc aaagctggca ccagggtctg gaagggtctct gaactcagaa ggatggcatt				14030
ttttgcaagt taaagaaaat caggatctga gttattttgc taaacttggg ggaggaggaa				14090
caaataaatg gagtctttat tgtgtatcat a				14121
<210> 4				
<211> 21				
<212> DNA				
<213> Artificial Sequence				
<220>				
<223> PCR Primer				
<400> 4				
tgctaaaggc acatatggcc t				21
<210> 5				
<211> 23				
<212> DNA				
<213> Artificial Sequence				
<220>				
<223> PCR Primer				
<400> 5				
ctcaggttgg actctccatt gag				23
<210> 6				
<211> 28				
<212> DNA				
<213> Artificial Sequence				
<220>				
<223> PCR Probe				
<400> 6				
cttgtcagag ggatcctaac actggccg				28
<210> 7				
<211> 19				

<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 7
gaaggtgaag gtcggagtc 19

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 8
gaagatggtg atgggatttc 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 9
caagcttccc gttctcagcc 20

<210> 10
<211> 2354
<212> DNA
<213> Mus musculus

<400> 10
gaattccaac ttcttcacct ctcacatata attgaaatac ctgcttttgg caaactgcat 60
agcatcctta agatccaatc ttctctcttt atattagatg ctaatgcaa catacagaat 120
gtaacaactt cagggaaaca agcagagatt gtggcttctg tcactgctaa aggagagtcc 180
caatttgaag ctctcaattt tgattttcaa gcacaagctc aattcctgga gttaaactcct 240
catctccag ttctgaagga atccatgaac ttctccagta agcatgtgag aatggagcat 300
gagggtgaga tagtatttga tggaaaggcc attgagggga aatcagacac agtcgcaagt 360
ttacacacag agaaaaatga agtagagttt aataatggta tgactgtcaa agtaaacaat 420
cagctcacc ttgacagtca cacaaagta ttccacaagt tgagtgttcc taggctggac 480
ttctccagta aggcttctct taataatgaa atcaagacac tattagaagc tggacatgtg 540
gcattgacat cttcaggga agggcatgg aactgggcct gtcccaactt ctcgatgaa 600
ggcatacatt cgtcccaa at tagctttact gtggatgggc ccattgcttt tggtagacta 660
tccaataaca taaatggcaa aacttacgg gtcacccaaa aactgactta tgaatctggc 720
ttctcaact attctaagtt tgaagttgag tcaaaagttg aatctcagca cgtgggctcc 780

agcattctaa cagccaatgg tcgggcactg ctcaaggacg caaaggcaga aatgactggt 840
gagcacaatg ccaacttaaa tggaaaagtt attggaactt tgaaaaattc tctcttcttt 900
tcagcacaac catttgagat tactgcatcc acaaataatg aaggaaattt gaaagtgggt 960
tttcactaa agctgactgg gaaaatagac ttctgaata actatgcatt gtttctgagt 1020
ccccgtgccc aacaagcaag ctggcaagcg agtaccagat tcaatcagta caaatacaat 1080
caaaactttt ctgctataaa caatgaacac aacatagaag ccagtatagg aatgaatgga 1140
gatgccaaac tggatttctt aaacatacct ttaacaattc ctgaaattaa cttgccttac 1200
acggagttca aaactccctt actgaaggat ttctccatat gggaagaaac aggcttgaaa 1260
gaatttttga agacaacaaa gcaatcattt gatttgagtg taaaggctca atataaaaag 1320
aacagtgaca agcattccat tgttgcctt ctgggtatgt tttatgaatt tattctcaac 1380
aatgtcaatt cgtgggacag aaaatttgag aaagtcagaa acaatgcttt acattttctt 1440
accacctcct ataatgaagc aaaaattaag gttgataagt acaaaactga aaattccctt 1500
aatcagccct ctgggacctt tcaaaatcat ggctacacta tcccagttgt caacattgaa 1560
gtatctccat ttgctgtaga gacactggct tccaggcatg tgatccccac agcaataagc 1620
acccaagtg tcacaatccc tggctcctaac atcatggtgc cttcatacaa gttagtgtg 1680
ccacccttg agttgccagt ttccatggt cctgggaatc tattcaagtt tttcctocca 1740
gatttcaagg gattcaacac tattgacaat atttatattc cagccatggg caactttacc 1800
tatgactttt cttttaaatc aagtgtcatc acactgaata ccaatgctgg actttataac 1860
caatcagata tcgttgccca ttctctttct tctcttcat ttgtcactga cgccctgcag 1920
tacaaattag agggaacatc acgtctgatg cgaaaaaggg gattgaaact agccacagct 1980
gtctctctaa ctaacaaatt tgtaaagggc agtcatgaca gcaccattag tttaaccaag 2040
aaaaacatgg aagcatcagt gagaacaact gccaacctcc atgctcccat attctcaatg 2100
aacttcaagc aggaacttaa tggaaatacc aagtcaaac ccactgtttc atcatccatt 2160
gaactaaact atgacttcaa ttctcaaag ctgcactota ctgcaacagg aggcattgat 2220
cacaagttca gcttagaaag tctcacttcc tacttttcca ttgagtcatt caccaaagga 2280
aatatcaaga gttccttctt ttctcaggaa tattcaggaa gtgttgccaa tgaagccaat 2340
gtatatctga attc 2354

<210> 11

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 11

cgtgggctcc agcattcta

19

<210> 12

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 12

agtcatttct gcctttgcgt c

21

<210> 13

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 13

ccaatggtcg ggcactgctc aa

22

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 14

ggcaaattca acggcacagt

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 15

gggtctcgct cctggaagat

20

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 16

aaggccgaga atgggaagct tgtcatc

27

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 17

ccgcaggtcc cggtgggaat

20

<210> 18

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 18

accgagaagg gcactcagcc

20

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 19

gcctcggcct cgcgccctg

20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 20

tccatcgcca gctgcggtg

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 21

cagcgccagc agcgccagca

20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22

gcccgcagc agcagcagca

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23

cttgaatcag cagtcccagg

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24

cttcagcaag gctttgccct

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25

tttctgttgc cacattgccc

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26

ggaagaggtg ttgctccttg

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27

tgtgctacca tccatactt

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28

tcaaattgcga ggcccatctt

20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 29
ggacacctca atcagctgtg 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 30
tcagggccac caggtagggtg 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 31
gtaatcttca tccccagtg 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 32
tgctccatgg tttggcccat 20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 33
gcagccagtc gcttatctcc 20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 34
gtatagccaa agtggtccac 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 35
cccaggagct ggaggtcatg 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 36
ttgagccctt cctgatgacc 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 37
atctggaccc cactcctagc 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 38
cagacccgac tcgtggaaga 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 39
gccctcagta gattcatcat 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 40
gccatgccac cctcttgaa 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 41
aaccacgtg ccggaagtc 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 42
actcccagat gccttctgaa 20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 43
atgtggtaac gagccgaag 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 44
ggcgtagaga cccatcacat 20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 45
gtgttaggat ccctctgaca 20

<210> 46
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 46
cccagtgata gctctgtgag 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 47
atttcagcat atgagcccat 20

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 48
ccctgaacct tagcaacagt 20

<210> 49
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 49
gctgaagcca gcccagcgat 20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 50
acagctgccc agtatgttct 20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 51
cccaataaga tttataacaa 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 52
tggcctacca gagacaggta 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 53
tcatacgttt agcccaatct 20

<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 54
gcatgggtccc aaggatggtc 20

<210> 55
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 55
agtgatggaa gctgcgatac 20

<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 56
atgagcatca tgcctcccag 20

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 57
gaacacatag ccgaatgccg 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 58
gtgggtgccct ctaatttgta 20

<210> 59
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 59
cccagaaaag aaccgaaccc 20

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 60
tgccctgcag cttcactgaa 20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 61
gaaatcccat aagctcttgt 20

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 62
agaagctgcc tcttcttccc 20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63

tcaggggtgag ccctgtgtgt

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 64

ctaattggccc cttgataaac

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65

acgttatcct tgagtcctg

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66

tatatcccag gtttccccgg

20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67

acctgggaca gtaccgtccc

20

<210> 68

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68

ctgcctactg caaggctggc

20

<210> 69

<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 69
agagaccttc cgagccctgg 20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 70
atgatacaca ataaagactc 20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 71
attgtatgtg agaggtgagg 20

<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 72
gaggagattg gatcttaagg 20

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 73
cttcaaattg ggactctcct 20

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 74
tccaggaatt gagcttggtgc 20

<210> 75
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 75
ttcaggactg gaggatgagg 20

<210> 76
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 76
tctcaccctc atgtccatt 20

<210> 77
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 77
tgactgtcaa gggtagctg 20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 78
gtccagccta ggaacactca 20

<210> 79
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 79
atgtcaatgc cacatgtcca 20

<210> 80
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 80
ttcatccgag aagttgggac 20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 81
atttgggacg aatgtatgcc 20

<210> 82
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 82
agttgaggaa gccagattca 20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 83
ttcccagtca gctttagtgg 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 84
agcttgcttg ttgygcacgg 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 85
cctatactgg cttctatggt 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 86
tgaactccgt gtaaggcaag

<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 87
gagaaatcct tcagtaaggg

<210> 88
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 88
caatggaatg cttgtcactg

<210> 89
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 89
gcttcattat aggaggtggt

<210> 90
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 90
acaactggga tagtgtagcc

<210> 91
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 91
gttaggacca gggattgtga

<210> 92
<211> 20

20

20

20

20

20

20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 92
accatggaaa actggcaact 20

<210> 93
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 93
tgggaggaaa aacttgaata 20

<210> 94
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 94
tgggcaacga tatctgattg 20

<210> 95
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 95
ctgcagggcg tcagtgacaa 20

<210> 96
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 96
gcatcagacg tgatgttccc 20

<210> 97
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 97
cttggttaaa ctaatggtgc 20

<210> 98
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 98
atgggagcat ggaggttggc 20

<210> 99
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 99
aatggatgat gaaacagtgg 20

<210> 100
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 100
atcaatgcct cctgttgacg 20

<210> 101
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 101
ggaagtgaga ctttctaagc 20

<210> 102
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 102
aggaaggaac tcttgatatt 20

<210> 103
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 103
attggcttca ttggcaacac 20

<210> 104
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 104
aggtagaggaa gttggaattc 20

<210> 105
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 105
ttgttccctg aagttgttac 20

<210> 106
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 106
gttcatggat tccttcagga 20

<210> 107
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 107
atgctccatt ctcacatgct 20

<210> 108
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 108
tgcgactgtg tctgatttcc 20

<210> 109
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 109
gtccctgaag atgtcaatgc 20

<210> 110
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 110
aggcccagtt ccatgaccct 20

<210> 111
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 111
ggagcccacg tgctgagatt 20

<210> 112
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 112
cgtccttgag cagtgccga 20

<210> 113
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 113
cccatatgga gaaatccttc 20

<210> 114
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 114
catgcctgga agccagtgtc 20

<210> 115
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 115
gtggtgaatc ccttgaaatc 20

<210> 116
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 116
ggtaaagttg cccatggctg 20

<210> 117
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 117
gttataaagt ccagcattgg 20

<210> 118
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 118
catcagacgt gatgttcctt 20

<210> 119
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 119
tggctagttt caatcccctt 20

<210> 120
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 120
ctgtcatgac tgccctttac 20

<210> 121
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 121
gcttgaagtt cattgagaat 20

<210> 122
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 122
ttcctgagaa aggaaggaac 20

<210> 123
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 123
tcagatatac attggcttca 20

<210> 124
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 124
ttcctcttcg gccctggcgc 20

<210> 125
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 125
ctccactgga actctcagcc 20

<210> 126
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 126
cctccagctc aaccttgag 20

<210> 127
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 127
gggttgaagc catacacctc 20

<210> 128
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 128
ccagctgag ctcatacctg 20

<210> 129
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 129
ccctcttgat gttcaggatg 20

<210> 130
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 130
gagcagtttc catacacggt 20

<210> 131
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 131
cccttctcg tcttgacggt 20

<210> 132
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 132
ttgaagcgat cacactgccc 20

<210> 133
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 133
gcctttgatg agagcaagtg 20

<210> 134
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 134
tcctcttagc gtccagtgtg 20

<210> 135
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 135
cctctcagct cagtaaccag 20

<210> 136
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 136
gcactgaggc tgtccacact 20

<210> 137
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 137
cgctgatccc tcgccatgtt 20

<210> 138
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 138
gttgaccgcg tggctcagcg 20

<210> 139
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 139
gcagctcctg ggtccctgta 20

<210> 140
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 140
cccatggtag aatttgaca 20

<210> 141
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 141
aatctcgatg aggtcagctg 20

<210> 142
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 142
gacaccatca ggaacttgac 20

<210> 143
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 143
gtcctctccc caagatgcgg 20

<210> 144
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 144
ggcaccatc agaagcagct 20

<210> 145
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 145
agtccggaat gatgatgcc 20

<210> 146
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 146
ctgagcagct tgactggtct 20

<210> 147
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 147
cccggtcagc ggatagtagg 20

<210> 148
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 148
tgtcacaact taggtggccc 20

<210> 149
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 149
gtctggcaat cccatgttct 20

<210> 150
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 150
cccacagact tgaagtggag 20

<210> 151
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 151
gaactgcccc tcaatcttga 20

<210> 152
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 152
cccagagagg ccaagctctg 20

<210> 153
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 153
tgtgttccct gaagcggcca 20

<210> 154
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 154
accagaatc atggcctgat 20

<210> 155
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 155
ggtgcctgtc tgctcagctg 20

<210> 156
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 156
atgtgaaact tgtctctccc 20

<210> 157
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 157
tatgctcgca gttgagatag 20

<210> 158
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 158
ttgaatccag gatgcagtag 20

<210> 159
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 159
gagtctctga gtcacctcac 20

<210> 160
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 160
gatagaatat tgctctgcaa 20

<210> 161
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 151
cccttgctct accaatgctt 20

<210> 162
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 162
tccattccct atgtcagcat 20

<210> 163
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 163
gactccttca gagccagcgg 20

<210> 164
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 164
cccatgctcc gttctcaggt 20

<210> 165
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 165
cgcaggtcag cctgactaga 20

<210> 166
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 166
cagttagaac actgtggccc 20

<210> 167
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 167
cagtgtgatg acacttgatt 20

<210> 168
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 168
ctgtggctaa cttcaatccc 20

<210> 169
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 169
cagtactgtt atgactaccc 20

<210> 170
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 170
cactgaagac cgtgtgctct 20

<210> 171
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 171
tcgtactgtg ctcccagagg 20

<210> 172
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 172
aagaggccct ctagctgtaa 20

<210> 173
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 173
aagaccaga atgaatccgg 20

<210> 174
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 174
gtctacctca aagcgtgcag 20

<210> 175
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 175
tagaggctaa cgtaccatct 20

<210> 176
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 176
ccatatccat gccacggtg 20

<210> 177
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 177
agtttcctca tcagattccc 20

<210> 178
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 178
cccagtggtg cttgttgaca 20

<210> 179
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 179
cccagtggtg ccactggctg 20

<210> 180
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 180
gtcaacagtt cctggtagag 20

<210> 181
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 181
ccctagtgtg tatcccaggt 20

<210> 182
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 182
ctgaagatta cgtagcacct 20

<210> 183
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 183
gtccagccaa ctatacttgg 20

<210> 184
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 184
cctggagcaa gcttcagtga 20

<210> 185
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 185
tggacagacc aggtgacat 20

<210> 186
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 186
atgtgtactt ccggaggtgc 20

<210> 187
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 187
tcttcaggat gaagctgcag 20

<210> 188
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 188
tcagcaaggc tttgccctca 20

<210> 189
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 189
ctgcttcct tctggaatgg 20

<210> 190
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 190
tgccacattg cccttcctcg 20

<210> 191
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 191
gctgatcaga gttgacaagg 20

<210> 192
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 192
tactgacagg actggctgct 20

<210> 193
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 193
gatggcttct gccacatgct 20

<210> 194
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 194
gatgtggatt tggtgctctc 20

<210> 195
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 195
tgactgcttc atcactgagg 20

<210> 196
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 196
ggtaggtgac cacatctatc 20

<210> 197
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 197
tcgcagctgc tgtgctgagg 20

<210> 198
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 198
ttccaatgac ccgcagaatc 20

<210> 199
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 199
gatcatcagt gatggctttg 20

<210> 200
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 200
agcctggatg gcagctttct 20

<210> 201
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 201
gtctgaagaa gaacctcctg

20

<210> 202
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 202
tatctgcctg tgaaggactc

20

<210> 203
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 203
ctgagttcaa gatattggca

20

<210> 204
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 204
cttccaagcc aatctcgatg

20

<210> 205
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 205
tgcaactgta atccagctcc

20

<210> 206
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 206
ccagttcagc ctgcatgttg

20

<210> 207
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 207
gtagagacca aatgtaatgt 20

<210> 208
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 208
cgttgagta agcgctgag 20

<210> 209
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 209
cagctctaatt ctggtgtccc 20

<210> 210
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 210
ctgtcctctc tctggagctc 20

<210> 211
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 211
caaggtcata ctctgccgat 20

<210> 212
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 212
gtatggaaat aacacccttg 20

<210> 213
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 213
taagctgtag cagatgagtc 20

<210> 214
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 214
tagatctctg gaggatttgc 20

<210> 215
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 215
gtctagaaca cccaggagag 20

<210> 216
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 216
accacagagt cagccttcat 20

<210> 217
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 217
aagcagacat ctgtggtccc 20

<210> 218
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 218
ctctccattg agccggccag 20

<210> 219
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 219
cctgatattc agaacgcagc 20

<210> 220
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 220
cagtgcctaa gatgtcagca 20

<210> 221
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 221
agcaccagga gactacactt 20

<210> 222
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 222
cccatccaga ctgaattttg 20

<210> 223
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 223
ggttctagcc gtagttttccc 20

<210> 224
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 224
aggttaccag ccacatgcag 20

<210> 225
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 225
atgtgcatcg atggtcattg 20

<210> 226
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 226
ccagagagcg agtttcccat 20

<210> 227
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 227
ctagacacga gatgatgact 20

<210> 228
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 228
tccaagtcct ggctgtattc 20

<210> 229
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 229
cgtccagtaa gctccacgcc 20

<210> 230
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 230
tcaacggcat ctctcatctc 20

<210> 231
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 231
tgatagtgt catcaagact 20

<210> 232
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 232
gattctgatt tggtaacttag 20

<210> 233
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 233
ctctcgatta actcatggac 20

<210> 234
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 234
atacactgca actgtggcct 20

<210> 235
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 235
gcaagagtcc accaatcaga 20

<210> 236
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 236
agagcctgaa gactgacttc 20

<210> 237
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 237
tccctcatct gagaatctgg 20

<210> 238
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 238
cagtgcata atgacagatg 20

<210> 239
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 239
ccgaaccctt gacatctcct 20

<210> 240
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 240
gcctcactag caatagttcc 20

<210> 241
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 241
gacatttgcc atggagagag 20

<210> 242
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 242
ctgtctccta ccaatgctgg 20

<210> 243
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 243
tctgcactga agtcacggtg 20

<210> 244
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 244
tcccggaccc tcaactcagt 20

<210> 245
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 245
gcaggtccag ttcatatgtg 20

<210> 246
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 246
gccatccttc tgagttcaga 20

<210> 247
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 247
gcctcagtct gcttcgcacc 20

<210> 248
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 248
ccccgcaggt ccggtggga 20

<210> 249
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 249
cagccccgca ggtcccgggtg 20

<210> 250
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 250
caaccgagaa gggcactcag 20

<210> 251
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 251
cctcagcggc agcaaccgag 20

<210> 252
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 252
tcctcagcgg cagcaaccga 20

<210> 253
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 253
ctcctcagcg gcagcaaccg 20

<210> 254
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 254
ggctcctcag cggcagcaac 20

<210> 255
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 255
ggcgggctcc tcagcggcag 20

<210> 256
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 256
ggtccatcgc cagctgcggt 20

<210> 257
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 257
ggcgggtcca tcgccagctg 20

<210> 258
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 258
tagaggatga tagtaagttc 20

<210> 259
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 259
aaatgaagat ttctttttaa 20

<210> 260
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 260
tatgtgaaag ttcaattgga 20

<210> 261
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 261
atataggcag ttggaatttt 20

<210> 262
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 262
gctcactgta tggttttatc 20

<210> 263
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 263
ggctcactgt atggttttat 20

<210> 264
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 264
ggctggctca ctgtatggtt 20

<210> 265
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 265
aggctggctc actgtatggt 20

<210> 266
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 266
aaggctggct cactgtatgg 20

<210> 267
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 267
ctactgcaag gctggctcac 20

<210> 268
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 268
actgcctact gcaaggctgg 20

<210> 269
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 269
tgcttatagt ctactgccta 20

<210> 270
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 270

ttctgcttat agtctactgc

20

<210> 271

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 271

tttgggtgcag gtccagttca

20

<210> 272

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 272

cagctttgggt gcaggtccag

20

<210> 273

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 273

gccagctttg gtgcaggtcc

20

<210> 274

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 274

tggtgccagc tttgggtgcag

20

<210> 275

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 275

gccctgggtgc cagctttggt

20

<210> 276

<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 276
gagttcagag accttccgag 20

<210> 277
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 277
aaatgccatc cttctgagtt 20

<210> 278
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 278
aaaaatgcca tccttctgag 20

<210> 279
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 279
aaaataactc agatcctgat 20

<210> 280
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 280
agcaaaataa ctcagatcct 20

<210> 281
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 281
agtttagcaa aataactcag 20

<210> 282
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 282
tcccccaagt ttagcaaaat 20

<210> 283
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 283
ttctctctcc cccaagttta 20

<210> 284
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 284
agaactccatt tatttgttcc 20

<210> 285
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 285
cttctgcttg agttacaaac 20

<210> 286
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 286
accttctgct tgagttacaa 20

<210> 287
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 287
gcaccttctg cttgagttac 20

<210> 288
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 288
tcgcaccttc tgcttgagtt 20

<210> 289
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 289
cttcgcacct tctgcttgag 20

<210> 290
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 290
tgcttcgcac cttctgcttg 20

<210> 291
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 291
tctgcttcgc accttctgct 20

<210> 292
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 292
agtctgcttc gcaccttctg 20

<210> 293
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 293
tcagtctgct tcgcaccttc 20

<210> 294
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 294
cctcagtctg cttcgcacct 20

<210> 295
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 295
agcctcagtc tgcttcgcac 20

<210> 296
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 296
gtagcctcag tctgcttcgc 20

<210> 297
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 297
tggtagcctc agtctgcttc 20

<210> 298
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 298
catggtagcc tcagtctgct 20

<210> 299
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 299
gtcatggtag cctcagtcctg 20

<210> 300
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 300
atgtcatggg agcttcagtc 20

<210> 301
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 301
gaatgtcatg gtagcctcag 20

<210> 302
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 302
ttgaatgtca tggtagcctc 20

<210> 303
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 303
atttgaatgt catggtagcc 20

<210> 304
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 304
atatttgaat gtcaggtag 20

<210> 305
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 305
cagccacatg cagcttcagg 20

<210> 306
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 306
accagccaca tgcagcttca 20

<210> 307
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 307
ttaccagcca catgcagctt 20

<210> 308
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 308
ggttaccagc cacatgcagc 20

<210> 309
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 309
taggttacca gccacatgca 20

<210> 310
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 310
tttaggttac cagccacatg

20

<210> 311
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 311
cttttaggtt accagccaca

20

<210> 312
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 312
tccttttagg ttaccagcca

20

<210> 313
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 313
gctcctttta gggtaccagc

20

<210> 314
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 314
aggctccttt taggttacca

20

<210> 315
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 315
gtaggctcct ttttaggttac

20

<210> 316
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 316
tggtaggctc ctttttaggtt

20

<210> 317
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 317
tttggtaggc tccttttagg

20

<210> 318
<211> 13993
<212> DNA
<213> H. sapiens

<220>
<221> CDS
<222> (1).. (13692)

<400> 318
atg gac ccg ccg agg ccc gcg ctg ctg gcg ctg ctg gcg ctg cct gcg 48
Met Asp Pro Pro Arg Pro Ala Leu Leu Ala Leu Leu Ala Leu Pro Ala
1 5 10 15

ctg ctg ctg ctg ctg ctg gcg ggc gcc agg gcc gaa gag gaa atg ctg 96
Leu Leu Leu Leu Leu Leu Ala Gly Ala Arg Ala Glu Glu Glu Met Leu
20 25 30

gaa aat gtc agc ctg gtc tgt cca aaa gat gcg acc cga ttc aag cac 144
Glu Asn Val Ser Leu Val Cys Pro Lys Asp Ala Thr Arg Phe Lys His
35 40 45

ctc cgg aag tac aca tac aac tat gag gct gag agt tcc agt gga gtc 192
Leu Arg Lys Tyr Thr Tyr Asn Tyr Glu Ala Glu Ser Ser Ser Gly Val
50 55 60

cct ggg act gct gat tca aga agt gcc acc agg atc aac tgc aag gtt 240
Pro Gly Thr Ala Asp Ser Arg Ser Ala Thr Arg Ile Asn Cys Lys Val
65 70 75 80

gag ctg gag gtt ccc cag ctc tgc agc ttc atc ctg aag acc agc cag 288
Glu Leu Glu Val Pro Gln Leu Cys Ser Phe Ile Leu Lys Thr Ser Gln
85 90 95

tgc acc ctg aaa gag gtg tat ggc ttc aac cct gag ggc aaa gcc ttg 336
Cys Thr Leu Lys Glu Val Tyr Gly Phe Asn Pro Glu Gly Lys Ala Leu
100 105 110

ctg aag aaa acc aag aac tct gag gag ttt gct gca gcc atg tcc agg 384
Leu Lys Lys Thr Lys Asn Ser Glu Glu Phe Ala Ala Ala Met Ser Arg
115 120 125

tat gag ctc aag ctg gcc att cca gaa ggg aag cag gtt ttc ctt tac 432
Tyr Glu Leu Lys Leu Ala Ile Pro Glu Gly Lys Gln Val Phe Leu Tyr
130 135 140

ccg gag aaa gat gaa cct act tac atc ctg aac atc aag agg ggc atc	480
Pro Glu Lys Asp Glu Pro Thr Tyr Ile Leu Asn Ile Lys Arg Gly Ile	
145 150 155 160	
att tct gcc ctc ctg gtt ccc cca gag aca gaa gaa gcc aag caa gtg	528
Ile Ser Ala Leu Leu Val Pro Pro Glu Thr Glu Glu Ala Lys Gln Val	
165 170 175	
ttg ttt ctg gat acc gtg tat gga aac tgc tcc act cac ttt acc gtc	576
Leu Phe Leu Asp Thr Val Tyr Gly Asn Cys Ser Thr His Phe Thr Val	
180 185 190	
aag acg agg aag ggc aat gtg gca aca gaa ata tcc act gaa aga gac	624
Lys Thr Arg Lys Gly Asn Val Ala Thr Glu Ile Ser Thr Glu Arg Asp	
195 200 205	
ctg ggg cag tgt gat cgc ttc aag ccc atc cgc aca ggc atc agc cca	672
Leu Gly Gln Cys Asp Arg Phe Lys Pro Ile Arg Thr Gly Ile Ser Pro	
210 215 220	
ctt gct ctc atc aaa ggc atg acc cgc ccc ttg tca act ctg atc agc	720
Leu Ala Leu Ile Lys Gly Met Thr Arg Pro Leu Ser Thr Leu Ile Ser	
225 230 235 240	
agc agc cag tcc tgt cag tac aca ctg gac gct aag agg aag cat gtg	768
Ser Ser Gln Ser Cys Gln Tyr Thr Leu Asp Ala Lys Arg Lys His Val	
245 250 255	
gca gaa gcc atc tgc aag gag caa cac ctc ttc ctg cct ttc tcc tac	816
Ala Glu Ala Ile Cys Lys Glu Gln His Leu Phe Leu Pro Phe Ser Tyr	
260 265 270	
aag aat aag tat ggg atg gta gca caa gtg aca cag act ttg aaa ctt	864
Lys Asn Lys Tyr Gly Met Val Ala Gln Val Thr Gln Thr Leu Lys Leu	
275 280 285	
gaa gac aca cca aag atc aac agc cgc ttc ttt ggt gaa ggt act aag	912
Glu Asp Thr Pro Lys Ile Asn Ser Arg Phe Phe Gly Glu Gly Thr Lys	
290 295 300	
aag atg ggc ctc gca ttt gag agc acc aaa tcc aca tca cct cca aag	960
Lys Met Gly Leu Ala Phe Glu Ser Thr Lys Ser Thr Ser Pro Pro Lys	
305 310 315 320	
cag gcc gaa gct gtt ttg aag act ctc cag gaa ctg aaa aaa cta acc	1008
Gln Ala Glu Ala Val Leu Lys Thr Leu Gln Glu Leu Lys Lys Leu Thr	
325 330 335	
atc tct gag caa aat atc cag aga gct aat ctc ttc aat aag ctg gtt	1056
Ile Ser Glu Gln Asn Ile Gln Arg Ala Asn Leu Phe Asn Lys Leu Val	
340 345 350	
act gag ctg aga ggc ctc agt gat gaa gca gtc aca tct ctc ttg cca	1104
Thr Glu Leu Arg Gly Leu Ser Asp Glu Ala Val Thr Ser Leu Leu Pro	
355 360 365	
cag ctg att gag gtg tcc agc ccc atc act tta caa gcc ttg gtt cag	1152
Gln Leu Ile Glu Val Ser Ser Pro Ile Thr Leu Gln Ala Leu Val Gln	
370 375 380	
tgt gga cag cct cag tgc tcc act cac atc ctc cag tgg ctg aaa cgt	1200

-78-

aaa tct gtt tct ctt cca tca ctt gac cca gcc tca gcc aaa ata gaa Lys Ser Val Ser Leu Pro Ser Leu Asp Pro Ala Ser Ala Lys Ile Glu 645 650 655	1968
ggg aat ctt ata ttt gat cca aat aac tac ctt cct aaa gaa agc atg Gly Asn Leu Ile Phe Asp Pro Asn Asn Tyr Leu Pro Lys Glu Ser Met 660 665 670	2016
ctg aaa act acc ctc act gcc ttt gga ttt gct tca gct gac ctc atc Leu Lys Thr Thr Leu Thr Ala Phe Gly Phe Ala Ser Ala Asp Leu Ile 675 680 685	2064
gag att ggc ttg gaa gga aaa ggc ttt gag cca aca ttg gag gct cct Glu Ile Gly Leu Glu Gly Lys Gly Phe Glu Pro Thr Leu Glu Ala Pro 690 695 700	2112
ttt ggg aag caa gga ttt ttc cca gac agt gtc aac aaa gct ttg tac Phe Gly Lys Gln Gly Phe Phe Pro Asp Ser Val Asn Lys Ala Leu Tyr 705 710 715 720	2160
tgg gtt aat ggt caa gtt cct gat ggt gtc tct aag gtc tta gtg gac Trp Val Asn Gly Gln Val Pro Asp Gly Val Ser Lys Val Leu Val Asp 725 730 735	2208
cac ttt ggc tat acc aaa gat gat aaa cat gag cag gat atg gta aat His Phe Gly Tyr Thr Lys Asp Asp Lys His Glu Gln Asp Met Val Asn 740 745 750	2256
gga ata atg ctc agt gtt gag aag ctg att aaa gat ttg aaa tcc aaa Gly Ile Met Leu Ser Val Glu Lys Leu Ile Lys Asp Leu Lys Ser Lys 755 760 765	2304
gaa gtc ccg gaa gcc aga gcc tac ctc cgc atc ttg gga gag gag ctt Glu Val Pro Glu Ala Arg Ala Tyr Leu Arg Ile Leu Gly Glu Glu Leu 770 775 780	2352
ggt ttt gcc agt ctc cat gac ctc cga ctc ctg gga aag ctg ctt ctg Gly Phe Ala Ser Leu His Asp Leu Arg Leu Leu Gly Lys Leu Leu Leu 785 790 795 800	2400
atg ggt gcc cgc act ctg cag ggg atc ccc cag atg att gga gag gtc Met Gly Ala Arg Thr Leu Gln Gly Ile Pro Gln Met Ile Gly Glu Val 805 810 815	2448
atc agg aag ggc tca aag aat gac ttt ttt ctt cac tac atc ttc atg Ile Arg Lys Gly Ser Lys Asn Asp Phe Phe Leu His Tyr Ile Phe Met 820 825 830	2496
gag aat gcc ttt gaa ctc ccc act gga gct gga tta cag ttg caa ata Glu Asn Ala Phe Glu Leu Pro Thr Gly Ala Gly Leu Gln Leu Gln Ile 835 840 845	2544
tct tca tct gga gtc att gct ccc gga gcc aag gct gga gta aaa ctg Ser Ser Ser Gly Val Ile Ala Pro Gly Ala Lys Ala Gly Val Lys Leu 850 855 860	2592
gaa gta gcc aac atg cag gct gaa ctg gtg gca aaa ccc tcc gtg tct Glu Val Ala Asn Met Gln Ala Glu Leu Val Ala Lys Pro Ser Val Ser 865 870 875 880	2640
gtg gag ttt gtg aca aat atg ggc atc atc att ccg gac ttc gct agg	2688

Val Glu Phe Val Thr Asn Met Gly Ile Ile Ile Pro Asp Phe Ala Arg	885	890	895	
agt ggg gtc cag atg aac acc aac ttc ttc cac gag tcg ggt ctg gag				2736
Ser Gly Val Gln Met Asn Thr Asn Phe Phe His Glu Ser Gly Leu Glu	900	905	910	
gct cat gtt gcc cta aaa gct ggg aag ctg aag ttt atc att cct tcc				2784
Ala His Val Ala Leu Lys Ala Gly Lys Leu Lys Phe Ile Ile Pro Ser	915	920	925	
cca aag aga cca gtc aag ctg ctc agt gga ggc aac aca tta cat ttg				2832
Pro Lys Arg Pro Val Lys Leu Ser Gly Gly Asn Thr Leu His Leu	930	935	940	
gtc tct acc acc aaa acg gag gtc atc cca cct ctc att gag aac agg				2880
Val Ser Thr Thr Lys Thr Glu Val Ile Pro Pro Leu Ile Glu Asn Arg	945	950	955	960
cag tcc tgg tca gtt tgc aag caa gtc ttt cct ggc ctg aat tac tgc				2928
Gln Ser Trp Ser Val Cys Lys Gln Val Phe Pro Gly Leu Asn Tyr Cys	965	970		975
acc tca ggc gct tac tcc aac gcc agc tcc aca gac tcc gcc tcc tac				2976
Thr Ser Gly Ala Tyr Ser Asn Ala Ser Ser Thr Asp Ser Ala Ser Tyr	980	985		990
tat ccg ctg acc ggg gac acc aga tta gag ctg gaa ctg agg cct acc				3024
Tyr Pro Leu Thr Gly Asp Thr Arg Leu Glu Leu Glu Leu Arg Pro Thr	995	1000		1005
gga gag att gag cag tat tct gtc agc gca acc tat gag ctc cag aga				3072
Gly Glu Ile Glu Gln Tyr Ser Val Ser Ala Thr Tyr Glu Leu Gln Arg	1010	1015		1020
gag gac aga gcc ttg gtg gat acc ctg aag ttt gta act caa gca gaa				3120
Glu Asp Arg Ala Leu Val Asp Thr Leu Lys Phe Val Thr Gln Ala Glu	1025	1030	1035	1040
ggc gcg aag cag act gag gct acc atg aca ttc aaa tat aat cgg cag				3168
Gly Ala Lys Gln Thr Glu Ala Thr Met Thr Phe Lys Tyr Asn Arg Gln	1045	1050		1055
agt atg acc ttg tcc agt gaa gtc caa att ccg gat ttt gat gtt gac				3216
Ser Met Thr Leu Ser Ser Glu Val Gln Ile Pro Asp Phe Asp Val Asp	1060	1065		1070
ctc gga aca atc ctc aga gtt aat gat gaa tct act gag ggc aaa acg				3264
Leu Gly Thr Ile Leu Arg Val Asn Asp Glu Ser Thr Glu Gly Lys Thr	1075	1080		1085
tct tac aga ctc acc ctg gac att cag aac aag aaa att act gag gtc				3312
Ser Tyr Arg Leu Thr Leu Asp Ile Gln Asn Lys Lys Ile Thr Glu Val	1090	1095		1100
gcc ctc atg ggc cac cta agt tgt gac aca aag gaa gaa aga aaa atc				3360
Ala Leu Met Gly His Leu Ser Cys Asp Thr Lys Glu Glu Arg Lys Ile	1105	1110	1115	1120
aag ggt gtt att tcc ata ccc cgt ttg caa gca gaa gcc aga agt gag				3408
Lys Gly Val Ile Ser Ile Pro Arg Leu Gln Ala Glu Ala Arg Ser Glu	1125	1130		1135

atc ctc gcc cac tgg tgc cct gcc aaa ctg ctt ctc caa atg gac tca Ile Leu Ala His Trp Ser Pro Ala Lys Leu Leu Leu Gln Met Asp Ser 1140 1145 1150	3456
tct gct aca gct tat ggc tcc aca gtt tcc aag agg gtg gca tgg cat Ser Ala Thr Ala Tyr Gly Ser Thr Val Ser Lys Arg Val Ala Trp His 1155 1160 1165	3504
tat gat gaa gag aag att gaa ttt gaa tgg aac aca ggc acc aat gta Tyr Asp Glu Glu Lys Ile Glu Phe Glu Trp Asn Thr Gly Thr Asn Val 1170 1175 1180	3552
gat acc aaa aaa atg act tcc aat ttc cct gtg gat ctc tcc gat tat Asp Thr Lys Lys Met Thr Ser Asn Phe Pro Val Asp Leu Ser Asp Tyr 1185 1190 1195 1200	3600
cct aag agc ttg cat atg tat gct aat aga ctc ctg gat cac aga gtc Pro Lys Ser Leu His Met Tyr Ala Asn Arg Leu Leu Asp His Arg Val 1205 1210 1215	3648
cct caa aca gac atg act ttc cgg cac gtg ggt tcc aaa tta ata gtt Pro Gln Thr Asp Met Thr Phe Arg His Val Gly Ser Lys Leu Ile Val 1220 1225 1230	3696
gca atg agc tca tgg ctt cag aag gca tct ggg agt ctt cct tat acc Ala Met Ser Ser Trp Leu Gln Lys Ala Ser Gly Ser Leu Pro Tyr Thr 1235 1240 1245	3744
cag act ttg caa gac cac ctc aat agc ctg aag gag ttc aac ctc cag Gln Thr Leu Gln Asp His Leu Asn Ser Leu Lys Glu Phe Asn Leu Gln 1250 1255 1260	3792
aac atg gga ttg cca gac tcc cac atc cca gaa aac ctc ttc tta aaa Asn Met Gly Leu Pro Asp Ser His Ile Pro Glu Asn Leu Phe Leu Lys 1265 1270 1275 1280	3840
agc gat ggc cgc gtc aaa tat acc ttg aac aag aac agt ttg aaa att Ser Asp Gly Arg Val Lys Tyr Thr Leu Asn Lys Asn Ser Leu Lys Ile 1285 1290 1295	3888
gag att cct ttg cct ttt ggt ggc aaa tcc tcc aga gat cta aag atg Glu Ile Pro Leu Pro Phe Gly Gly Lys Ser Ser Arg Asp Leu Lys Met 1300 1305 1310	3936
tta gag act gtt agg aca cca gcc ctc cac ttc aag tct gtg gga ttc Leu Glu Thr Val Arg Thr Pro Ala Leu His Phe Lys Ser Val Gly Phe 1315 1320 1325	3984
cat ctg cca tct cga gag ttc caa gtc cct act ttt acc att ccc aag His Leu Pro Ser Arg Glu Phe Gln Val Pro Thr Phe Thr Ile Pro Lys 1330 1335 1340	4032
ttg tat caa ctg caa gtg cct ctc ctg ggt gtt cta gac ctc tcc acg Leu Tyr Gln Leu Gln Val Pro Leu Leu Gly Val Leu Asp Leu Ser Thr 1345 1350 1355 1360	4080
aat gtc tac agc aac ttg tac aac tgg tcc gcc tcc tac agt ggt ggc Asn Val Tyr Ser Asn Leu Tyr Asn Trp Ser Ala Ser Tyr Ser Gly Gly 1365 1370 1375	4128
aac acc agc aca gac cat ttc agc ctt cgg gct cgt tac cac atg aag	4176

Asn Thr Ser Thr Asp His Phe Ser Leu Arg Ala Arg Tyr His Met Lys	
1380	1385 1390
gct gac tct gtg gtt gac ctg ctt tcc tac aat gtg caa gga tct gga	4224
Ala Asp Ser Val Val Asp Leu Ser Tyr Asn Val Gln Gly Ser Gly	
1395	1400 1405
gaa aca aca tat gac cac aag aat acg ttc aca cta tca tgt gat ggg	4272
Glu Thr Thr Tyr Asp His Lys Asn Thr Phe Thr Leu Ser Cys Asp Gly	
1410	1415 1420
tct cta cgc cac aaa ttt cta gat tgg aat atc aaa ttc agt cat gta	4320
Ser Leu Arg His Lys Phe Leu Asp Ser Asn Ile Lys Phe Ser His Val	
1425	1430 1435 1440
gaa aaa ctt gga aac aac cca gtc tca aaa ggt tta cta ata ttc gat	4368
Glu Lys Leu Gly Asn Asn Pro Val Ser Lys Gly Leu Leu Ile Phe Asp	
1445	1450 1455
gca tct agt tcc tgg gga cca cag atg tct gct tca gtt cat ttg gac	4416
Ala Ser Ser Ser Trp Gly Pro Gln Met Ser Ala Ser Val His Leu Asp	
1460	1465 1470
tcc aaa aag aaa cag cat ttg ttt gtc aaa gaa gtc aag att gat ggg	4464
Ser Lys Lys Lys Gln His Leu Phe Val Lys Glu Val Lys Ile Asp Gly	
1475	1480 1485
cag ttc aga gtc tct tgg ttc tat gct aaa ggc aca tat ggc ctg tct	4512
Gln Phe Arg Val Ser Ser Phe Tyr Ala Lys Gly Thr Tyr Gly Leu Ser	
1490	1495 1500
tgt cag agg gat cct aac act ggc cgg ctc aat gga gag tcc aac ctg	4560
Cys Gln Arg Asp Pro Asn Thr Gly Arg Leu Asn Gly Glu Ser Asn Leu	
1505	1510 1515 1520
agg ttt aac tcc tcc tac ctc caa ggc acc aac cag ata aca gga aga	4608
Arg Phe Asn Ser Ser Tyr Leu Gln Gly Thr Asn Gln Ile Thr Gly Arg	
1525	1530 1535
tat gaa gat gga acc ctc tcc ctc acc tcc acc tct gat ctg caa agt	4656
Tyr Glu Asp Gly Thr Leu Ser Leu Thr Ser Thr Ser Asp Leu Gln Ser	
1540	1545 1550
ggc atc att aaa aat act gct tcc cta aag tat gag aac tac gag ctg	4704
Gly Ile Ile Lys Asn Thr Ala Ser Leu Lys Tyr Glu Asn Tyr Glu Leu	
1555	1560 1565
act tta aaa tct gac acc aat ggg aag tat aag aac ttt gcc act tct	4752
Thr Leu Lys Ser Asp Thr Asn Gly Lys Tyr Lys Asn Phe Ala Thr Ser	
1570	1575 1580
aac aag atg gat atg acc ttc tct aag caa aat gca ctg ctg cgt tct	4800
Asn Lys Met Asp Met Thr Phe Ser Lys Gln Asn Ala Leu Leu Arg Ser	
1585	1590 1595 1600
gaa tat cag gct gat tac gag tca ttg agg ttc ttc agc ctg ctt tct	4848
Glu Tyr Gln Ala Asp Tyr Glu Ser Leu Arg Phe Phe Ser Leu Leu Ser	
1605	1610 1615
gga tca cta aat tcc cat ggt ctt gag tta aat gct gac atc tta ggc	4896
Gly Ser Leu Asn Ser His Gly Leu Glu Leu Asn Ala Asp Ile Leu Gly	

1620	1625	1630	
act gac aaa att aat agt ggt gct cac aag gcg aca cta agg att ggc			4944
Thr Asp Lys Ile Asn Ser Gly Ala His Lys Ala Thr Leu Arg Ile Gly			
1635	1640	1645	
caa gat gga ata tct acc agt gca acg acc aac ttg aag tgt agt ctc			4992
Gln Asp Gly Ile Ser Thr Ser Ala Thr Thr Asn Leu Lys Cys Ser Leu			
1650	1655	1660	
ctg gtg ctg gag aat gag ctg aat gca gag ctt ggc ctc tct ggg gca			5040
Leu Val Leu Glu Asn Gly Leu Asn Ala Glu Leu Gly Leu Ser Gly Ala			
1665	1670	1675	1680
tct atg aaa tta aca aca aat ggc cgc ttc agg gaa cac aat gca aaa			5088
Ser Met Lys Leu Thr Thr Asn Gly Arg Phe Arg Glu His Asn Ala Lys			
1685	1690	1695	
ttc agt ctg gat ggg aaa gcc gcc ctc aca gag cta tca ctg gga agt			5136
Phe Ser Leu Asp Gly Lys Ala Ala Leu Thr Glu Leu Ser Leu Gly Ser			
1700	1705	1710	
gct tat cag gcc atg att ctg ggt gtc gac agc aaa aac att ttc aac			5184
Ala Tyr Gln Ala Met Ile Leu Gly Val Asp Ser Lys Asn Ile Phe Asn			
1715	1720	1725	
ttc aag gtc agt caa gaa gga ctt aag ctc tca aat gac atg atg ggc			5232
Phe Lys Val Ser Gln Glu Gly Leu Lys Leu Ser Asn Asp Met Met Gly			
1730	1735	1740	
tca tat gct gaa atg aaa ttt gac cac aca aac agt ctg aac att gca			5280
Ser Tyr Ala Glu Met Lys Phe Asp His Thr Asn Ser Leu Asn Ile Ala			
1745	1750	1755	1760
ggc tta tca ctg gac ttc tct tca aaa ctt gac aac att tac agc tct			5328
Gly Leu Ser Leu Asp Phe Ser Ser Lys Leu Asp Asn Ile Tyr Ser Ser			
1765	1770	1775	
gac aag ttt tat aag caa act gtt aat tta cag cta cag ccc tat tct			5376
Asp Lys Phe Tyr Lys Gln Thr Val Asn Leu Gln Leu Gln Pro Tyr Ser			
1780	1785	1790	
ctg gta act act tta aac agt gac ctg aaa tac aat gct ctg gat ctc			5424
Leu Val Thr Thr Leu Asn Ser Asp Leu Lys Tyr Asn Ala Leu Asp Leu			
1795	1800	1805	
acc aac aat ggg aaa cta cgg cta gaa ccc ctg aag ctg cat gtg gct			5472
Thr Asn Asn Gly Lys Leu Arg Leu Glu Pro Leu Lys Leu His Val Ala			
1810	1815	1820	
ggt aac cta aaa gga gcc tac caa aat aat gaa ata aaa cac atc tat			5520
Gly Asn Leu Lys Gly Ala Tyr Gln Asn Asn Glu Ile Lys His Ile Tyr			
1825	1830	1835	1840
gcc atc tct tct gct gcc tta tca gca agc tat aaa gca gac act gtt			5568
Ala Ile Ser Ser Ala Ala Leu Ser Ala Ser Tyr Lys Ala Asp Thr Val			
1845	1850	1855	
gct aag gtt cag ggt gtg gag ttt agc cat ggg ctc aac aca gac atc			5616
Ala Lys Val Gln Gly Val Glu Phe Ser His Gly Leu Asn Thr Asp Ile			
1860	1865	1870	
gct ggg ctg gct tca gcc att gac atg agc aca aac tat aat tca gac			5664

Ala Gly Leu Ala Ser Ala Ile Asp Met Ser Thr Asn Tyr Asn Ser Asp	
1875	1880 1885
tca ctg cat ttc agc aat gtc ttc cgt tct gta atg gcc cgc ttt acc	5712
Ser Leu His Phe Ser Asn Val Phe Arg Ser Val Met Ala Pro Phe Thr	
1890	1895 1900
atg acc atc gat gca cat aca aat ggc aat ggg aaa ctc gct ctc tgg	5760
Met Thr Ile Asp Ala His Thr Asn Gly Asn Gly Lys Leu Ala Leu Trp	
1905	1910 1915 1920
gga gaa cat act ggg cag ctg tat agc aaa ttc ctg ttg aaa gca gaa	5808
Gly Glu His Thr Gly Gln Leu Tyr Ser Lys Phe Leu Leu Lys Ala Glu	
	1925 1930 1935
cct ctg gca ttt act ttc tct cat gat tac aaa ggc tcc aca agt cat	5856
Pro Leu Ala Phe Thr Phe Ser His Asp Tyr Lys Gly Ser Thr Ser His	
	1940 1945 1950
cat ctc gtg tct agg aaa agc atc agt gca gct ctt gaa cac aaa gtc	5904
His Leu Val Ser Arg Lys Ser Ile Ser Ala Ala Leu Glu His Lys Val	
	1955 1960 1965
agt gcc ctg ctt act cca gct gag cag aca ggc acc tgg aaa ctc aag	5952
Ser Ala Leu Leu Thr Pro Ala Glu Gln Thr Gly Thr Trp Lys Leu Lys	
	1970 1975 1980
acc caa ttt aac aac aat gaa tac agc cag gac ttg gat gct tac aac	6000
Thr Gln Phe Asn Asn Asn Glu Tyr Ser Gln Asp Leu Asp Ala Tyr Asn	
	1985 1990 1995 2000
act aaa gat aaa att ggc gtg gag ctt act gga cga act ctg gct gac	6048
Thr Lys Asp Lys Ile Gly Val Glu Leu Thr Gly Arg Thr Leu Ala Asp	
	2005 2010 2015
cta act cta cta gac tcc cca att aaa gtg cca ctt tta ctc agt gag	6096
Leu Thr Leu Leu Asp Ser Pro Ile Lys Val Pro Leu Leu Leu Ser Glu	
	2020 2025 2030
ccc atc aat atc aat gat gct tta gag atg aga gat gcc gtt gag aag	6144
Pro Ile Asn Ile Asn Asp Ala Leu Glu Met Arg Asp Ala Val Glu Lys	
	2035 2040 2045
ccc caa gaa ttt aca att gtt gct ttt gta aag tat gat aaa aac caa	6192
Pro Gln Glu Phe Thr Ile Val Ala Phe Val Lys Tyr Asp Lys Asn Gln	
	2050 2055 2060
gat gtt cac tcc att aac ctc cca ttt ttt gag acc ttg caa gaa tat	6240
Asp Val His Ser Ile Asn Leu Pro Phe Phe Glu Thr Leu Gln Glu Tyr	
	2065 2070 2075 2080
ttt gag agg aat cga caa acc att ata gtt gta ctg gaa aac gta cag	6288
Phe Glu Arg Asn Arg Gln Thr Ile Ile Val Val Leu Glu Asn Val Gln	
	2085 2090 2095
aga aac ctg aag cac atc aat att gat caa ttt gta aga aaa tac aga	6336
Arg Asn Leu Lys His Ile Asn Ile Asp Gln Phe Val Arg Lys Tyr Arg	
	2100 2105 2110
gca gcc ctg gga aaa ctc cca cag caa gct aat gat tat ctg aat tca	6384
Ala Ala Leu Gly Lys Leu Pro Gln Gln Ala Asn Asp Tyr Leu Asn Ser	

2115	2120	2125	
ttc aat tgg gag aga caa gtt tca cat gcc aag gag aaa ctg act gct			6432
Phe Asn Trp Glu Arg Gln Val Ser His Ala Lys Glu Lys Leu Thr Ala			
2130	2135	2140	
ctc aca aaa aag tat aga att aca gaa aat gat ata caa att gca tta			6480
Leu Thr Lys Lys Tyr Arg Ile Thr Glu Asn Asp Ile Gln Ile Ala Leu			
2145	2150	2155	2160
gat gat gcc aaa atc aac ttt aat gaa aaa cta tct caa ctg cag aca			6528
Asp Asp Ala Lys Ile Asn Phe Asn Glu Lys Leu Ser Gln Leu Gln Thr			
2165	2170	2175	
tat atg ata caa ttt gat cag tat att aaa gat agt tat gat tta cat			6576
Tyr Met Ile Gln Phe Asp Gln Tyr Ile Lys Asp Ser Tyr Asp Leu His			
2180	2185	2190	
gat ttg aaa ata gct att gct aat att att gat gaa atc att gaa aaa			6624
Asp Leu Lys Ile Ala Ile Ala Asn Ile Ile Asp Glu Ile Ile Glu Lys			
2195	2200	2205	
tta aaa agt ctt gat gag cac tat cat acc cgt gta aat tta gta aaa			6672
Leu Lys Ser Leu Asp Glu His Tyr His Thr Arg Val Asn Leu Val Lys			
2210	2215	2220	
aca atc cat gat cta cat ttg ttt att gaa aat att gat ttt aac aaa			6720
Thr Ile His Asp Leu His Leu Phe Ile Glu Asn Ile Asp Phe Asn Lys			
2225	2230	2235	2240
agt gga agt agt act gca tcc tgg att caa aat gtg gat act aag tac			6768
Ser Gly Ser Ser Thr Ala Ser Trp Ile Gln Asn Val Asp Thr Lys Tyr			
2245	2250	2255	
caa atc aga atc cag ata caa gaa aaa ctg cag cag ctt aag aga cac			6816
Gln Ile Arg Ile Gln Ile Gln Glu Lys Leu Gln Gln Leu Lys Arg His			
2260	2265	2270	
ata cag aat ata gac atc cag cac cta gct gga aag tta aaa caa cac			6864
Ile Gln Asn Ile Asp Ile Gln His Leu Ala Gly Lys Leu Lys Gln His			
2275	2280	2285	
att gag gct att gat gtt aga gtg ctt tta gat caa ttg gga act aca			6912
Ile Glu Ala Ile Asp Val Arg Val Leu Leu Asp Gln Leu Gly Thr Thr			
2290	2295	2300	
att tca ttt gaa aga ata aat gat gtt ctt gag cat gtc aaa cac ttt			6960
Ile Ser Phe Glu Arg Ile Asn Asp Val Leu Glu His Val Lys His Phe			
2305	2310	2315	2320
gtt ata aat ctt att ggg gat ttt gaa gta gct gag aaa atc aat gcc			7008
Val Ile Asn Leu Ile Gly Asp Phe Glu Val Ala Glu Lys Ile Asn Ala			
2325	2330	2335	
ttc aga gcc aaa gtc cat gag tta atc gag agg tat gaa gta gac caa			7056
Phe Arg Ala Lys Val His Glu Leu Ile Glu Arg Tyr Glu Val Asp Gln			
2340	2345	2350	
caa atc cag gtt tta atg gat aaa tta gta gag ttg gcc cac caa tac			7104
Gln Ile Gln Val Leu Met Asp Lys Leu Val Glu Leu Ala His Gln Tyr			
2355	2360	2365	
aag ttg aag gag act att cag aag cta agc aat gtc cta caa caa gtt			7152

Lys Leu Lys Glu Thr Ile Gln Lys Leu Ser Asn Val Leu Gln Gln Val	
2370 2375 2380	
aag ata aaa gat tac ttt gag aaa ttg gtt gga ttt att gat gat gct	7200
Lys Ile Lys Asp Tyr Phe Glu Lys Leu Val Gly Phe Ile Asp Asp Ala	
2385 2390 2395 2400	
gtc aag aag ctt aat gaa tta tct ttt aaa aca ttc att gaa gat gtt	7248
Val Lys Lys Leu Asn Glu Leu Ser Phe Lys Thr Phe Ile Glu Asp Val	
2405 2410 2415	
aac aaa ttc ctt gac atg ttg ata aag aaa tta aag tca ttt gat tac	7296
Asn Lys Phe Leu Asp Met Leu Ile Lys Lys Leu Lys Ser Phe Asp Tyr	
2420 2425 2430	
cac cag ttt gta gat gaa acc aat gac aaa atc cgt gag gtg act cag	7344
His Gln Phe Val Asp Glu Thr Asn Asp Lys Ile Arg Glu Val Thr Gln	
2435 2440 2445	
aga ctc aat ggt gaa att cag gct ctg gaa cta cca caa aaa gct gaa	7392
Arg Leu Asn Gly Glu Ile Gln Ala Leu Glu Leu Pro Gln Lys Ala Glu	
2450 2455 2460	
gca tta aaa ctg ttt tta gag gaa acc aag gcc aca gtt gca gtg tat	7440
Ala Leu Lys Leu Phe Leu Glu Glu Thr Lys Ala Thr Val Ala Val Tyr	
2465 2470 2475 2480	
ctg gaa agc cta cag gac acc aaa ata acc tta atc atc aat tgg tta	7488
Leu Glu Ser Leu Gln Asp Thr Lys Ile Thr Leu Ile Ile Asn Trp Leu	
2485 2490 2495	
cag gag gct tta agt tca gca tct ttg gct cac atg aag gcc aaa ttc	7536
Gln Glu Ala Leu Ser Ser Ala Ser Leu Ala His Met Lys Ala Lys Phe	
2500 2505 2510	
cga gag act cta gaa gat aca cga gac cga atg tat caa atg gac att	7584
Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr Gln Met Asp Ile	
2515 2520 2525	
cag cag gaa ctt caa cga tac ctg tct ctg gta ggc cag gtt tat agc	7632
Gln Gln Glu Leu Gln Arg Tyr Leu Ser Leu Val Gly Gln Val Tyr Ser	
2530 2535 2540	
aca ctt gtc acc tac att tct gat tgg tgg act ctt gct gct aag aac	7680
Thr Leu Val Thr Tyr Ile Ser Asp Trp Trp Thr Leu Ala Ala Lys Asn	
2545 2550 2555 2560	
ctt act gac ttt gca gag caa tat tct atc caa gat tgg gct aaa cgt	7728
Leu Thr Asp Phe Ala Glu Gln Tyr Ser Ile Gln Asp Trp Ala Lys Arg	
2565 2570 2575	
atg aaa gca ttg gta gag caa ggg ttc act gtt cct gaa atc aag acc	7776
Met Lys Ala Leu Val Glu Gln Gly Phe Thr Val Pro Glu Ile Lys Thr	
2580 2585 2590	
atc ctt ggg acc atg cct gcc ttt gaa gtc agt ctt cag gct ctt cag	7824
Ile Leu Gly Thr Met Pro Ala Phe Glu Val Ser Leu Gln Ala Leu Gln	
2595 2600 2605	
aaa gct acc ttc cag aca cct gat ttt ata gtc ccc cta aca gat ttg	7872
Lys Ala Thr Phe Gln Thr Pro Asp Phe Ile Val Pro Leu Thr Asp Leu	

2610	2615	2620	
agg att cca tca gtt	cag ata aac ttc aaa	gac tta aaa aat ata aaa	7920
Arg Ile Pro Ser Val	Gln Ile Asn Phe Lys	Asp Leu Lys Asn Ile Lys	
2625	2630	2635 2640	
atc cca tcc agg ttt	tcc aca cca gaa ttt	acc atc ctt aac acc ttc	7968
Ile Pro Ser Arg Phe	Ser Thr Pro Glu Phe	Thr Ile Leu Asn Thr Phe	
2645	2650	2655	
cac att cct tcc ttt	aca att gac ttt gta	gaa atg aaa gta aag atc	8016
His Ile Pro Ser Phe	Thr Ile Asp Phe Val	Glu Met Lys Val Lys Ile	
2660	2665	2670	
atc aga acc att gac	cag atg ctg aac agt	gag ctg cag tgg ccc gtt	8064
Ile Arg Thr Ile Asp	Gln Met Leu Asn Ser	Glu Leu Gln Trp Pro Val	
2675	2680	2685	
cca gat ata tat ctc	agg gat ctg aag gtg	gag gac att cct cta gcg	8112
Pro Asp Ile Tyr Leu	Arg Asp Leu Lys Val	Glu Asp Ile Pro Leu Ala	
2690	2695	2700	
aga atc acc ctg cca	gac ttc cgt tta cca	gaa atc gca att cca gaa	8160
Arg Ile Thr Leu Pro	Asp Phe Arg Leu Pro	Glu Ile Ala Ile Pro Glu	
2705	2710	2715 2720	
ttc ata atc cca act	ctc aac ctt aat gat	ttt caa gtt cct gac ctt	8208
Phe Ile Ile Pro Thr	Leu Asn Leu Asn Asp	Phe Gln Val Pro Asp Leu	
2725	2730	2735	
cac ata cca gaa ttc	cag ctt ccc cac atc	tca cac aca att gaa gta	8256
His Ile Pro Glu Phe	Gln Leu Pro His Ile	Ser His Thr Ile Glu Val	
2740	2745	2750	
cct act ttt ggc aag	cta tac agt att ctg	aaa atc caa tct cct ctt	8304
Pro Thr Phe Gly Lys	Leu Tyr Ser Ile Leu	Lys Ile Gln Ser Pro Leu	
2755	2760	2765	
ttc aca tta gat gca	aat gct gac ata ggg	aat gga acc acc tca gca	8352
Phe Thr Leu Asp Ala	Asn Ala Asp Ile Gly	Asn Gly Thr Thr Ser Ala	
2770	2775	2780	
aac gaa gca ggt atc	gca gct tcc atc act	gcc aaa gga gag tcc aaa	8400
Asn Glu Ala Gly Ile	Ala Ala Ser Ile Thr	Ala Lys Gly Glu Ser Lys	
2785	2790	2795 2800	
tta gaa gtt ctc aat	ttt gat ttt caa gca	aat gca caa ctc tca aac	8448
Leu Glu Val Leu Asn	Phe Asp Phe Gln Ala	Asn Ala Gln Leu Ser Asn	
2805	2810	2815	
cct aag att aat ccg	ctg gct ctg aag gag	tca gtg aag ttc tcc agc	8496
Pro Lys Ile Asn Pro	Leu Ala Leu Lys Glu	Ser Val Lys Phe Ser Ser	
2820	2825	2830	
aag tac ctg aga acg	gag cat ggg agt gaa	atg ctg ttt ttt gga aat	8544
Lys Tyr Leu Arg Thr	Glu His Gly Ser Glu	Met Leu Phe Phe Gly Asn	
2835	2840	2845	
gct att gag gga aaa	tca aac aca gtg gca	agt tta cac aca gaa aaa	8592
Ala Ile Glu Gly Lys	Ser Asn Thr Val Ala	Ser Leu His Thr Glu Lys	
2850	2855	2860	
aat aca ctg gag ctt	agt aat gga gtg att	gtc aag ata aac aat cag	8640

-88-

3105	3110	3115	3120	
gca aat ctg gat ttc tta aac att cct tta aca att cct gaa atg cgt				9408
Ala Asn Leu Asp Phe Leu Asn Ile Pro Leu Thr Ile Pro Glu Met Arg				
	3125	3130	3135	
cta cct tac aca ata atc aca act cct cca ctg aaa gat ttc tct cta				9456
Leu Pro Tyr Thr Ile Ile Thr Thr Pro Pro Leu Lys Asp Phe Ser Leu				
	3140	3145	3150	
tgg gaa aaa aca ggc ttg aag gaa ttc ttg aaa acg aca aag caa tca				9504
Trp Glu Lys Thr Gly Leu Lys Glu Phe Leu Lys Thr Thr Lys Gln Ser				
	3155	3160	3165	
ttt gat tta agt gta aaa gct cag tat aag aaa aac aaa cac agg cat				9552
Phe Asp Leu Ser Val Lys Ala Gln Tyr Lys Lys Asn Lys His Arg His				
	3170	3175	3180	
tcc atc aca aat cct ttg gct gtg ctt tgt gag ttt atc agt cag agc				9600
Ser Ile Thr Asn Pro Leu Ala Val Leu Cys Glu Phe Ile Ser Gln Ser				
	3185	3190	3195	3200
atc aaa tcc ttt gac agg cat ttt gaa aaa aac aga aac aat gca tta				9648
Ile Lys Ser Phe Asp Arg His Phe Glu Lys Asn Arg Asn Asn Ala Leu				
	3205	3210	3215	
gat ttt gtc acc aaa tcc tat aat gaa aca aaa att aag ttt gat aag				9696
Asp Phe Val Thr Lys Ser Tyr Asn Glu Thr Lys Ile Lys Phe Asp Lys				
	3220	3225	3230	
tac aaa gct gaa aaa tct cac gac gag ctc ccc agg acc ttt caa att				9744
Tyr Lys Ala Glu Lys Ser His Asp Glu Leu Pro Arg Thr Phe Gln Ile				
	3235	3240	3245	
cct gga tac act gtt cca gtt gtc aat gtt gaa gtg tct cca ttc acc				9792
Pro Gly Tyr Thr Val Pro Val Val Asn Val Glu Val Ser Pro Phe Thr				
	3250	3255	3260	
ata gag atg tcg gca ttc ggc tat gtg ttc cca aaa gca gtc agc atg				9840
Ile Glu Met Ser Ala Phe Gly Tyr Val Phe Pro Lys Ala Val Ser Met				
	3265	3270	3275	3280
cct agt ttc tcc atc ata ggt tct gac gtc cgt gtg cct tca tac aca				9888
Pro Ser Phe Ser Ile Ile Gly Ser Asp Val Arg Val Pro Ser Tyr Thr				
	3285	3290	3295	
tta atc ctg cca tca tta gag ctg cca gtc ctt cat gtc cct aga aat				9936
Leu Ile Leu Pro Ser Leu Glu Leu Pro Val Leu His Val Pro Arg Asn				
	3300	3305	3310	
ctc aag ctt tct ctt cca gat ttc aag gaa ttg tgt acc ata agc cat				9984
Leu Lys Leu Ser Leu Pro Asp Phe Lys Glu Leu Cys Thr Ile Ser His				
	3315	3320	3325	
att ttt att cct gcc atg ggc aat att acc tat gat ttc tcc ttt aaa				10032
Ile Phe Ile Pro Ala Met Gly Asn Ile Thr Tyr Asp Phe Ser Phe Lys				
	3330	3335	3340	
tca agt gtc atc aca ctg aat acc aat gct gaa ctt ttt aac cag tca				10080
Ser Ser Val Ile Thr Leu Asn Thr Asn Ala Glu Leu Phe Asn Gln Ser				
	3345	3350	3355	3360

gat att gtt gct cat ctc ctt tct tca tct tca tct gtc att gat gca	10128
Asp Ile Val Ala His Leu Leu Ser Ser Ser Ser Val Ile Asp Ala	
3365 3370 3375	
ctg cag tac aaa tta gag ggc acc aca aga ttg aca aga aaa agg gga	10176
Leu Gln Tyr Lys Leu Glu Gly Thr Thr Arg Leu Thr Arg Lys Arg Gly	
3380 3385 3390	
ttg aag tta gcc aca gct ctg tct ctg agc aac aaa ttt gtg gag ggt	10224
Leu Lys Leu Ala Thr Ala Leu Ser Leu Ser Asn Lys Phe Val Glu Gly	
3395 3400 3405	
agt cat aac agt act gtg agc tta acc acg aaa aat atg gaa gtg tca	10272
Ser His Asn Ser Thr Val Ser Leu Thr Thr Lys Asn Met Glu Val Ser	
3410 3415 3420	
gtg gca aaa acc aca aaa ccg gaa att cca att ttg aga atg aat ttc	10320
Val Ala Lys Thr Thr Lys Pro Glu Ile Pro Ile Leu Arg Met Asn Phe	
3425 3430 3435 3440	
aag caa gaa ctt aat gga aat acc aag tca aaa cct act gtc tct tcc	10368
Lys Gln Glu Leu Asn Gly Asn Thr Lys Ser Lys Pro Thr Val Ser Ser	
3445 3450 3455	
tcc atg gaa ttt aag tat gat ttc aat tct tca atg ctg tac tct acc	10416
Ser Met Glu Phe Lys Tyr Asp Phe Asn Ser Ser Met Leu Tyr Ser Thr	
3460 3465 3470	
gct aaa gga gca gtt gac cac aag ctt agc ttg gaa agc ctc acc tct	10464
Ala Lys Gly Ala Val Asp His Lys Leu Ser Leu Glu Ser Leu Thr Ser	
3475 3480 3485	
tac ttt tcc att gag tca tct acc aaa gga gat gtc aag ggt tgg gtt	10512
Tyr Phe Ser Ile Glu Ser Ser Thr Lys Gly Asp Val Lys Gly Ser Val	
3490 3495 3500	
ctt tct cgg gaa tat tca gga act att gct agt gag gcc aac act tac	10560
Leu Ser Arg Glu Tyr Ser Gly Thr Ile Ala Ser Glu Ala Asn Thr Tyr	
3505 3510 3515 3520	
ttg aat tcc aag agc aca cgg tct tca gtg aag ctg cag ggc act tcc	10608
Leu Asn Ser Lys Ser Thr Arg Ser Ser Val Lys Leu Gln Gly Thr Ser	
3525 3530 3535	
aaa att gat gat atc tgg aac ctt gaa gta aaa gaa aat ttt gct gga	10656
Lys Ile Asp Asp Ile Trp Asn Leu Glu Val Lys Glu Asn Phe Ala Gly	
3540 3545 3550	
gaa gcc aca ctc caa cgc ata tat tcc ctc tgg gag cac agt acg aaa	10704
Glu Ala Thr Leu Gln Arg Ile Tyr Ser Leu Trp Glu His Ser Thr Lys	
3555 3560 3565	
aac cac tta cag cta gag ggc ctc ttt ttc acc aac gga gaa cat aca	10752
Asn His Leu Gln Leu Glu Gly Leu Phe Phe Thr Asn Gly Glu His Thr	
3570 3575 3580	
agc aaa gcc acc ctg gaa ctc tct cca tgg caa atg tca gct ctt gtt	10800
Ser Lys Ala Thr Leu Glu Leu Ser Pro Trp Gln Met Ser Ala Leu Val	
3585 3590 3595 3600	
cag gtc cat gca agt cag ccc agt tcc ttc cat gat ttc cct gac ctt	10848
Gln Val His Ala Ser Gln Pro Ser Ser Phe His Asp Phe Pro Asp Leu	

3605	3610	3615	
ggc cag gaa gtg gcc ctg aat gct aac act aag aac cag aag atc aga Gly Gln Glu Val Ala Leu Asn Ala Asn Thr Lys Asn Gln Lys Ile Arg 3620 3625 3630			10896
tgg aaa aat gaa gtc cgg att cat tct ggg tct ttc cag agc cag gtc Trp Lys Asn Glu Val Arg Ile His Ser Gly Ser Phe Gln Ser Gln Val 3635 3640 3645			10944
gag ctt tcc aat gac caa gaa aag gca cac ctt gac att gca gga tcc Glu Leu Ser Asn Asp Gln Glu Lys Ala His Leu Asp Ile Ala Gly Ser 3650 3655 3660			10992
tta gaa gga cac cta agg ttc ctc aaa aat atc atc cta cca gtc tat Leu Glu Gly His Leu Arg Phe Leu Lys Asn Ile Ile Leu Pro Val Tyr 3665 3670 3675 3680			11040
gac aag agc tta tgg gat ttc cta aag ctg gat gtc acc acc agc att Asp Lys Ser Leu Trp Asp Phe Leu Lys Leu Asp Val Thr Thr Ser Ile 3685 3690 3695			11088
ggt agg aga cag cat ctt cgt gtt tca act gcc ttt gtg tac acc aaa Gly Arg Arg Gln His Leu Arg Val Ser Thr Ala Phe Val Tyr Thr Lys 3700 3705 3710			11136
aac ccc aat ggc tat tca ttc tcc atc cct gta aaa gtt ttg gct gat Asn Pro Asn Gly Tyr Ser Phe Ser Ile Pro Val Lys Val Leu Ala Asp 3715 3720 3725			11184
aaa ttc att att cct ggg ctg aaa cta aat gat cta aat tca gtt ctt Lys Phe Ile Ile Pro Gly Leu Lys Leu Asn Asp Leu Asn Ser Val Leu 3730 3735 3740			11232
gtc atg cct acg ttc cat gtc cca ttt aca gat ctt cag gtt cca tgc Val Met Pro Thr Phe His Val Pro Phe Thr Asp Leu Gln Val Pro Ser 3745 3750 3755 3760			11280
tgc aaa ctt gac ttc aga gaa ata caa atc tat aag aag ctg aga act Cys Lys Leu Asp Phe Arg Glu Ile Gln Ile Tyr Lys Lys Leu Arg Thr 3765 3770 3775			11328
tca tca ttt gcc ctc acc cta cca aca ctc ccc gag gta aaa ttc cct Ser Ser Phe Ala Leu Thr Leu Pro Thr Leu Pro Glu Val Lys Phe Pro 3780 3785 3790			11376
gaa gtt gat gtg tta aca aaa tat tct caa cca gaa gac tcc ttg att Glu Val Asp Val Leu Thr Lys Tyr Ser Gln Pro Glu Asp Ser Leu Ile 3795 3800 3805			11424
ccc ttt ttt gag ata acc gtg cct gaa tct cag tta act gtg tcc cag Pro Phe Phe Glu Ile Thr Val Pro Glu Ser Gln Leu Thr Val Ser Gln 3810 3815 3820			11472
ttc acg ctt cca aaa agt gtt tca gat ggc att gct gct ttg gat cta Phe Thr Leu Pro Lys Ser Val Ser Asp Gly Ile Ala Ala Leu Asp Leu 3825 3830 3835 3840			11520
aat gca gta gcc aac aag atc gca gac ttt gag ttg ccc acc atc atc Asn Ala Val Ala Asn Lys Ile Ala Asp Phe Glu Leu Pro Thr Ile Ile 3845 3850 3855			11568

gtg cct gag cag acc att gag att ccc tcc att aag ttc tct gta cct Val Pro Glu Gln Thr Ile Glu Ile Pro Ser Ile Lys Phe Ser Val Pro 3860 3865 3870	11616
gct gga att gtc att cct tcc ttt caa gca ctg act gca cgc ttt gag Ala Gly Ile Val Ile Pro Ser Phe Gln Ala Leu Thr Ala Arg Phe Glu 3875 3880 3885	11664
gta gac tct ccc gtg tat aat gcc act tgg agt gcc agt ttg aaa aac Val Asp Ser Pro Val Tyr Asn Ala Thr Trp Ser Ala Ser Leu Lys Asn 3890 3895 3900	11712
aaa gca gat tat gtt gaa aca gtc ctg gat tcc aca tgc agc tca acc Lys Ala Asp Tyr Val Glu Thr Val Leu Asp Ser Thr Cys Ser Ser Thr 3905 3910 3915 3920	11760
gta cag ttc cta gaa tat gaa cta aat gtt ttg gga aca cac aaa atc Val Gln Phe Leu Glu Tyr Glu Leu Asn Val Leu Gly Thr His Lys Ile 3925 3930 3935	11808
gaa gat ggt acg tta gcc tct aag act aaa gga aca ctt gca cac cgt Glu Asp Gly Thr Leu Ala Ser Lys Thr Lys Gly Thr Leu Ala His Arg 3940 3945 3950	11856
gac ttc agt gca gaa tat gaa gaa gat ggc aaa tat gaa gga ctt cag Asp Phe Ser Ala Glu Tyr Glu Glu Asp Gly Lys Tyr Glu Gly Leu Gln 3955 3960 3965	11904
gaa tgg gaa gga aaa gcg cac ctc aat atc aaa agc cca gcg ttc acc Glu Trp Glu Gly Lys Ala His Leu Asn Ile Lys Ser Pro Ala Phe Thr 3970 3975 3980	11952
gat ctc cat ctg cgc tac cag aaa gac aag aaa ggc atc tcc acc tca Asp Leu His Leu Arg Tyr Gln Lys Asp Lys Lys Gly Ile Ser Thr Ser 3985 3990 3995 4000	12000
gca gcc tcc cca gcc gta ggc acc gtg ggc atg gat atg gat gaa gat Ala Ala Ser Pro Ala Val Gly Thr Val Gly Met Asp Met Asp Glu Asp 4005 4010 4015	12048
gac gac ttt tct aaa tgg aac ttc tac tac agc cct cag tcc tct cca Asp Asp Phe Ser Lys Trp Asn Phe Tyr Tyr Ser Pro Gln Ser Ser Pro 4020 4025 4030	12096
gat aaa aaa ctc acc ata ttc aaa act gag ttg agg gtc cgg gaa tct Asp Lys Lys Leu Thr Ile Phe Lys Thr Glu Leu Arg Val Arg Glu Ser 4035 4040 4045	12144
gat gag gaa act cag atc aaa gtt aat tgg gaa gaa gag gca gct tct Asp Glu Glu Thr Gln Ile Lys Val Asn Trp Glu Glu Glu Ala Ala Ser 4050 4055 4060	12192
ggc ttg cta acc tct ctg aaa gac aac gtg ccc aag gcc aca ggg gtc Gly Leu Leu Thr Ser Leu Lys Asp Asn Val Pro Lys Ala Thr Gly Val 4065 4070 4075 4080	12240
ctt tat gat tat gtc aac aag tac cac tgg gaa cac aca ggg ctc acc Leu Tyr Asp Tyr Val Asn Lys Tyr His Trp Glu His Thr Gly Leu Thr 4085 4090 4095	12288
ctg aga gaa gtg tct tca aag ctg aga aga aat ctg cag aac aat gct Leu Arg Glu Val Ser Ser Lys Leu Arg Arg Asn Leu Gln Asn Asn Ala	12336

4100	4105	4110	
gag tgg gtt tat caa ggg gcc att agg caa att gat gat atc gac gtg Glu Trp Val Tyr Gln Gly Ala Ile Arg Gln Ile Asp Asp Ile Asp Val 4115 4120 4125			12384
agg ttc cag aaa gca gcc agt ggc acc act ggg acc tac caa gag tgg Arg Phe Gln Lys Ala Ala Ser Gly Thr Thr Gly Thr Tyr Gln Glu Trp 4130 4135 4140			12432
aag gac aag gcc cag aat ctg tac cag gaa ctg ttg act cag gaa ggc Lys Asp Lys Ala Gln Asn Leu Tyr Gln Glu Leu Leu Thr Gln Glu Gly 4145 4150 4155 4160			12480
caa gcc agt ttc cag gga ctc aag gat aac gtg ttt gat ggc ttg gta Gln Ala Ser Phe Gln Gly Leu Lys Asp Asn Val Phe Asp Gly Leu Val 4165 4170 4175			12528
cga gtt act caa aaa ttc cat atg aaa gtc aag aag ctg att gac tca Arg Val Thr Gln Lys Phe His Met Lys Val Lys Lys Leu Ile Asp Ser 4180 4185 4190			12576
ctc att gat ttt ctg aac ttc ccc aga ttc cag ttt ccg ggg aaa cct Leu Ile Asp Phe Leu Asn Phe Pro Arg Phe Gln Phe Pro Gly Lys Pro 4195 4200 4205			12624
ggg ata tac act agg gag gaa ctt tgc act atg ttc atg agg gag gta Gly Ile Tyr Thr Arg Glu Glu Leu Cys Thr Met Phe Met Arg Glu Val 4210 4215 4220			12672
ggg acg gta ctg tcc cag gta tat tgc aaa gtc cat aat ggt tca gaa Gly Thr Val Leu Ser Gln Val Tyr Ser Lys Val His Asn Gly Ser Glu 4225 4230 4235 4240			12720
ata ctg ttt tcc tat ttc caa gac cta gtg att aca ctt cct ttc gag Ile Leu Phe Ser Tyr Phe Gln Asp Leu Val Ile Thr Leu Pro Phe Glu 4245 4250 4255			12768
tta agg aaa cat aaa cta ata gat gta atc tgc atg tat agg gaa ctg Leu Arg Lys His Lys Leu Ile Asp Val Ile Ser Met Tyr Arg Glu Leu 4260 4265 4270			12816
ttg aaa gat tta tca aaa gaa gcc caa gag gta ttt aaa gcc att cag Leu Lys Asp Leu Ser Lys Glu Ala Gln Glu Val Phe Lys Ala Ile Gln 4275 4280 4285			12864
tct ctc aag acc aca gag gtg cta cgt aat ctt cag gac ctt tta caa Ser Leu Lys Thr Thr Glu Val Leu Arg Asn Leu Gln Asp Leu Leu Gln 4290 4295 4300			12912
ttc att ttc caa cta ata gaa gat aac att aaa cag ctg aaa gag atg Phe Ile Phe Gln Leu Ile Glu Asp Asn Ile Lys Gln Leu Lys Glu Met 4305 4310 4315 4320			12960
aaa ttt act tat ctt att aat tat atc caa gat gag atc aac aca atc Lys Phe Thr Tyr Leu Ile Asn Tyr Ile Gln Asp Glu Ile Asn Thr Ile 4325 4330 4335			13008
ttc aat gat tat atc cca tat gtt ttt aaa ttg ttg aaa gaa aac cta Phe Asn Asp Tyr Ile Pro Tyr Val Phe Lys Leu Leu Lys Glu Asn Leu 4340 4345 4350			13056

tgc ctt aat ctt cat aag ttc aat gaa ttt att caa aac gag ctt cag 13104
 Cys Leu Asn Leu His Lys Phe Asn Glu Phe Ile Gln Asn Glu Leu Gln
 4355 4360 4365

gaa gct tct caa gag tta cag cag atc cat caa tac att atg gcc ctt 13152
 Glu Ala Ser Gln Glu Leu Gln Gln Ile His Gln Tyr Ile Met Ala Leu
 4370 4375 4380

cgt gaa gaa tat ttt gat cca agt ata gtt ggc tgg aca gtg aaa tat 13200
 Arg Glu Glu Tyr Phe Asp Pro Ser Ile Val Gly Trp Thr Val Lys Tyr
 4385 4390 4395 4400

tat gaa ctt gaa gaa aag ata gtc agt ctg atc aag aac ctg tta gtt 13248
 Tyr Glu Leu Glu Glu Lys Ile Val Ser Leu Ile Lys Asn Leu Leu Val
 4405 4410 4415

gct ctt aag gac ttc cat tct gaa tat att gtc agt gcc tct aac ttt 13296
 Ala Leu Lys Asp Phe His Ser Glu Tyr Ile Val Ser Ala Ser Asn Phe
 4420 4425 4430

act tcc caa ctc tca agt caa gtt gag caa ttt ctg cac aga aat att 13344
 Thr Ser Gln Leu Ser Ser Gln Val Glu Gln Phe Leu His Arg Asn Ile
 4435 4440 4445

cag gaa tat ctt agc atc ctt acc gat cca gat gga aaa ggg aaa gag 13392
 Gln Glu Tyr Leu Ser Ile Leu Thr Asp Pro Asp Gly Lys Gly Lys Glu
 4450 4455 4460

aag att gca gag ctt tct gcc act gct cag gaa ata att aaa agc cag 13440
 Lys Ile Ala Glu Leu Ser Ala Thr Ala Gln Glu Ile Ile Lys Ser Gln
 4465 4470 4475 4480

gcc att gcg acg aag aaa ata att tct gat tac cac cag cag ttt aga 13488
 Ala Ile Ala Thr Lys Lys Ile Ile Ser Asp Tyr His Gln Gln Phe Arg
 4485 4490 4495

tat aaa ctg caa gat ttt tca gac caa ctc tct gat tac tat gaa aaa 13536
 Tyr Lys Leu Gln Asp Phe Ser Asp Gln Leu Ser Asp Tyr Tyr Glu Lys
 4500 4505 4510

ttt att gct gaa tcc aaa aga ttg att gac ctg tcc att caa aac tac 13584
 Phe Ile Ala Glu Ser Lys Arg Leu Ile Asp Leu Ser Ile Gln Asn Tyr
 4515 4520 4525

cac aca ttt ctg ata tac atc acg gag tta ctg aaa aag ctg caa tca 13632
 His Thr Phe Leu Ile Tyr Ile Thr Glu Leu Leu Lys Lys Leu Gln Ser
 4530 4535 4540

acc aca gtc atg aac ccc tac atg aag ctt gct cca gga gaa ctt act 13680
 Thr Thr Val Met Asn Pro Tyr Met Lys Leu Ala Pro Gly Glu Leu Thr
 4545 4550 4555 4560

atc atc ctc taa tttttttaa agaaatcttc atttattctt cttttccaat 13732
 Ile Ile Leu *

tgaactttca catagcacag aaaaaattca aactgcctat attgataaaa ccatacagtg 13792

agccagcctt gcagtaggca gtagactata agcagaagca catatgaact ggacctgcac 13852

caaagctggc accagggctc ggaaggctc tgaactcaga aggatggcat tttttgcaag 13912

ttaaagaaaa tcaggatctg agttattttg ctaaacttgg gggaggagga acaaataaat 13972

ggagtcttta ttgtgtatca t

13993

<210> 319

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 319

gcctcagtct gcttcgcgcc

20

<210> 320

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 320

gctcactgtt cagcatctgg

20

<210> 321

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 321

tgagaatctg ggcgaggccc

20

<210> 322

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 322

gtccttcata ttgcatct

20

<210> 323

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 323

cctccctcat gaacatagtg

20

<210> 324

<211> 20

<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 324
gacgtcagaa cctatgatgg 20

<210> 325
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 325
tgagtgagtc aatcagcttc 20

<210> 326
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 326
gccttctgct tgagttacaa 20

<210> 327
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 327
gcgccttctg cttgagttac 20

<210> 328
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 328
tcgcgccttc tgcttgagtt 20

<210> 329
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 329
cttcgcgcct tctgcttgag 20

<210> 330
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 330
agtcctgcttc gcgccttctg 20

<210> 331
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 331
tcagtcctgct tcgcgccttc 20

<210> 332
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 332
cctcagtcctg cttcgcgcct 20

<210> 333
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 333
agcctcagtc tgcttcgcgc 20

<210> 334
<211> 43445
<212> DNA
<213> H. sapiens

<400> 334
accaagacag cgctcaggac tggttctcct cgtggctccc aattcagtc aggagaagca 60
gagattttgt ccccatggtg ggtcatctga agaaggcacc cctggtcagg gcaggcttct 120
cagaccctga ggcgctggcc atggccccac tgagacacag gaagggccgc gccagagcac 180
tgaagacgct tggggaaggg aaccacctg ggaccagcc cctggtggct gcggctgcat 240
cccagggtggg cccctcccc gaggtctctc aaggctcaaa gagaagccag ttagaaaaag 300
caaacaggtc aggcccgga ggcgcctttt ggaccttttg caatcctggc gctcttgag 360
cctgggcttc ctataaatgg ggtgcgggag ccggccgcgc attcccaccg ggacctgcgg 420
ggctgagtcg ccttctcggg tgctgcgct gaggagcccg ccagccagc cagggccgcg 480

aggcgcgagc cagggccgag cccaggagcc gccccaccgc agctggcgat ggacccgcgc 540
 agggccgcgc tgctggcgct gctggcgctg cctgcgctgc tgctgctgct gctggcgggc 600
 gccagggccg gtgagtgccg ggcgctctg cgggcgcaga gggagcggga gggagccggc 660
 ggcacgaggt tggccgggjc agcctgggccc taggcragag ggagggcagc cacagggccc 720
 agggcgagtg gggggattgg accagctggc gggccctgca ggctcaggat ggggggcgcg 780
 ggatggaggg gctgaggagg gggctctcgg agcctgcctc cctcctgaaa ggtgaaacct 840
 gtgcgggtgg tccccctgtc gggccctagc acccgctggg aagacgtggg aagctcacag 900
 atttctttct cctgtcttac agaagaggaa atgctggaaa atgtcagcct ggtctgtcca 960
 agtaaggcat ctgcgcatgg ggcgtggaag ggcgcaccag cccgtgcact ctctacacc 1020
 cgggtccctg agggcctccc actctacagg gctgagatgg catcggtgtg tgccttgctc 1080
 tgacccaggg aagcaagttc cctgagcctc tgccacacc caagggatgc caactctctt 1140
 ctacctggcc ttctgttctg tccaaaagt tcagcctggg ggcgggggag ggaagggtt 1200
 gtctctccgc tggcctgtgc acactttgaa gaaacatcac tgtcctgttt atcagtact 1260
 agtcattgat tcgaagcatg tgagggtgag gaaatactga ctttaacctt tgtgaagaaa 1320
 tcgaacctcc acccccttcc tatttacctg acccctgggg gttaaaggaa ctggcctcca 1380
 agcgcgaccc tgtgtgctgg agccgcgggg cggaattctg atggggcagc accgccatct 1440
 agtggcgcgc tgtcatcact gcagctggac tcaggaccca gatgttcttt ttcttcaatt 1500
 gttcagaaaa ttctctctca ctacagtggg aacctccaga aattcttttc taggagtttg 1560
 ttaagttagt tacgcttaat gcttaatgaa ctttgcctta agtatttggg agtcttagag 1620
 tcacggaatt acggcggtgt caagctaaaa aagcattaga gatagtacta tttgcgtaat 1680
 gttgtcatct cttaatttgc cagagggctc ctcatgcaga ttttctgagc cccattactt 1740
 gacacttgct actcccttcc ctgtgcctca gatgagatat tcaagacatg ccagccaatt 1800
 taaacattag cctcagcaaa aacataatgg agaagtcaaa tctataaagg aaaattaag 1860
 ataaagtcaa ttaaaaaata atttgagttg aattaccatt ttaattctc tatgccactg 1920
 cccctctctg ccagaaattg gctgtccttg ggagagctat ttctgctatg tggctgacgt 1980
 atttctcccc acgttagaag atgcgacccg attcaagcac ctccggaagt acacatacaa 2040
 ctatgagget gagagttcca gtggagtccc tgggactgct gattcaagaa gtgccaccag 2100
 gatcaactgc aaggtatgga ggatgcaggc aggagggacc tagagccac agctttcccc 2160
 cagccctggt ccagcggggc cccaacacgc gaccttcccg gagggtgtgt actgagcaaa 2220
 cgcagaacat ccagaactg ttgtaatctg atcaaagcac tgggactttg cctctgtttg 2280
 taagtcagcc acattgctga gatgtggtct gccccacca aatttcgcaa gtcagaagta 2340
 ttttcccggt aacttcccag atgcaatagg aatccatgat ctgattagc agcagtgtgg 2400

gtctgtagat ttcagcgtga gagaggccca gtaggtgagc tatgggaggc aggcaactcg 2460
 gaatcgcaact gtgaaatgca gtttttataa tttaagtcaa acagaatctg ttgctgaaaa 2520
 atgaatggaa agaagaaaaa aatataaaca tacagtttgt tctaaaataa aactttgctt 2580
 attattgaga ctgggtgtac tcatgttaca tacatgtgga gcagatctac aggctgctat 2640
 tgggggtttgg gtggggaaga gaagtcaagc tgagcagtc a cttttttta gagagtaccg 2700
 tagctcttgt atgtgctgtc caatatggta gacatgagcc acattgggct atttaaattgg 2760
 aatgaaatta aaaattcata ttctgtgtca cattagctgc atttcaactg ctcaacagcc 2820
 accctggcta ctggctccca tattgaacag cacacatgta caacatttct ataaagttat 2880
 ttgaatagtg ctggataata agtaggaatc cgttgaaact ccagctatat gcaaagctct 2940
 aaataggccc taatagatat aaccagtttt ttgggtgaca ttaaggagac atttgctgtg 3000
 gaaacgaagg atggccctct tctgtcttct tgttttctt cttcacttct actcctagtc 3060
 tgcagcgctt ctatttaacc acagctcttt ataattaaag tgagtaactt tagaaccaat 3120
 aaaaggacat cctccttccc atgcctaggg gcaacttaaa gaaatgtgtt acccgaggag 3180
 gggaaaacgt cagcaatagg actaagtcta ggttggtgca cagagaacct aggaggcatg 3240
 ttgataaggc atgtggtgtt gagggcagg cagtgggtgt cccagcacca ttccctttgg 3300
 tgctctgatt agagattaag ccctgggctt caggggccc cttctattct tgatagacaa 3360
 cctcaatgct ctgctacct gaattctcag gttgagctgg aggttcccc gctctgcagc 3420
 ttcatcctga agaccagcca gtgcacctg aaagaggtgt atggttcaa ccctgagggc 3480
 aaagccttgc tgaagaaaac caagaactct gaggagtgtg ctgcagccat gtccaggtaa 3540
 gtcattgtgt acatgagcac acgcatgtgt gtgtgtccgc tgaggatga acttgtgtgt 3600
 ttgcaccagg caaggatgtg actgtaagta ttgtattcc gtatccatcg tggatcaggg 3660
 aattactgag ttttcacaat catcaaaag agagaagcat tagttaacct tccctagtta 3720
 ggttcttcta attatcattt tcatgtgtt ctaaaaatct catgctttaa acttcttgag 3780
 attataaaac tgagatgctt tgtttaaaca agtgaattct tatttaaaga actagtcaag 3840
 actagtgtt ggtggtcttt ggtgtgggg cccagaggca ctggctgtg tggccggcac 3900
 atggcggggc agggctctgt caccgcagg cagaggagca ccaaggcttc ggtggctccc 3960
 cctcctaggc tggcattcag ccactgcacg ctgatcggcc actgcagctg catctctgct 4020
 gactggtcag ggcccatgtc gcaccattg taaatatttt caacatcacc cctgctcat 4080
 cctcaatcac agttttagg gtccataggtg tgtatgaata caggcaggat agagttgtta 4140
 acttggtagc atcagaaaac tctgtctgta ttagtctgtt ttcattgtgc tgataaagac 4200
 atacctgaga ctgggcaatt tacaaaagaa aggtttattg gactcacagt tccacgtggc 4260
 tggggagggtc tcacaatcat ggcggaaggg gagggacagc aagtcacatc ttatgtatg 4320

ggtggctggc aaagagagct tgtgcagaga aactcctgtt tttagaacca tcagatctcc 4380
cgacacccat ctgcaatcac gagaacagca cgggaaagac ctgcccccat gattcaatca 4440
cctccccccg ggtccctccc acaacacgtg ggaattatga gagctacgag acgaaatttg 4500
ggtggggagc cagagccaaa ccatatcacc atccttgccc atttttcagt tttgctaaac 4560
attagattca gatgccagtc ctttcttgcc aaaataggct gtgaggcttc tttctttcct 4620
atgctttatt ttctccaaga cttaactgta tatgagggag aggggatgg tggcaggagg 4680
aaagagtggc ttattttttg gtccttggc ttctccaaat acagaagaga ctctgttct 4740
tgaaaaggag ggctttccat gtttgcctc tcatgacttt aactgtcttt tttaaaaatt 4800
gacatacaat aattatacat atttattgag aacatagtga tattttgata catgtaatgt 4860
atggtgatca gatcagagta attagcatac ccatcatctc aaacatttat catctcttcg 4920
tggtgggaac tttctgagag agtgtaggct gtgggagata agtccgtcac cttttccttc 4980
tgatgtaacc agagtggctg cagccaggtc ctccagaaact cagagagtac ccagtgggaa 5040
atccctaaga ccaagtcag catgggcttc agccatggcc tgacaccata caaaagaatg 5100
actgtccaac aagtgtatga aaataagctc caattcactg gtagtcaaga aatgcgaatt 5160
aatgtaacaa caagatattt atctgtttt acccatcata ctgcaaaact ggaaaacagt 5220
gatagcacct gttgctggca ggccagtga gaaaagtgct ctgtcctgag ctgctgggtg 5280
aaagagagc catcaggcaa tatctactgt aatttaaaat acttaatacc ctttgacaca 5340
gataatttag tttttgggac tctagcccat gaaaataaaa gcagtaatgt gtgaagatag 5400
gcacataagg atgtttgtt ttgtattgtt tgtgtggtt aaaaaaaatc cagaaagaga 5460
gagggcaaat gccatcaaat ggggcaatgt gtgaataaat tatatttagc catggaatgg 5520
aatgttctgc atgcagcttt taaaaaaatc tgtagagct gtaccaagtg actcagaagg 5580
atttttgtga agtataatta agtgagaaaa acaagataaa agtatgcata atacaatgcc 5640
acttgtataa aacaaacaat ggcaaaatct ttgtatgact ctgtttgcac tcacccatgt 5700
ttacagagga ttgtatgagt gtgcagaaac aaatggaac accactoggg tgtccgtatg 5760
gggaggatgg gcaaagagac tgatatgggt ggagaacaga gcagggctgg atgagccaag 5820
caaaaaaagt taaaacacag ctggacctgg tggtcatgc ctgtagtccc agcactttgg 5880
gaggccgagg agggagaatc acctgaggtc aggagtttga gaccagcctg gccaacatgg 5940
tgaaactgt ctctactaaa aatacaaaaa ttagctgggt gtgatggcac atgccagtag 6000
tctagctac tccggaggct gaggcaggag aatcacttga tcccaggagg tggaggttgc 6060
agtgaagtga ggttgcgcca ttgcactcca gcccgggcga ccgagcgaga ctccatttca 6120
aaaaaagaaa aagaaaaaag aaaaaaagaa aaaaaaagaa tcacaaaaac ttatgtatat 6180
gtgcatactt ttttgaaaat gtatgtctat gtgtagctat attctatatt taaaaataaa 6240

tgatgtcaga agaacaattg gttaaaaaaa tatgagaaaa gaaacttcag tgccaccag 6300
cttacttcca gcaagttgta atggagaagg acatttccgt gaccatctc tctctgggac 6360
aggtatgagc tcaagctggc cattccagaa gggaagcagg ttttccctta ccgggagaaa 6420
gatgaacctt cttacatctt gaacatcaag aggggcatca tttctgcctt cctgggtccc 6480
ccagagacag aagaagccaa gcaagtgttg tttctggtga ggatttagaa agctgatagc 6540
agtggccctt gaaactcctt ttcattgtgt agagaccagt cctaccatat acaaagcaga 6600
tctactgagtc agctccatga ctagttacat aggaagccct ggattggcgt gaaatactgg 6660
tgccccgaggt tctctctgcc ccttaggctc actgacagat catcccaagc aggcttatca 6720
ggttgggtct aattttaaaa cagtcattga ggagtcctgg ccaccccacc cctgcttttg 6780
tttgatgctt cactgtgtt tgctgggtta tgggtgtacac agtaaatcct gtgtgtattt 6840
taaacaccaa aaataatggg atctgttgct ggtctctttt acgaatttca ggtttcactg 6900
tgagacagaa ttcatttcac ctcagtcca tgagcacttt tgtgtgttct aatttctcta 6960
cgacaccata atgggagaag acaccgatgc aacctgcgga ggcctttctg cagaccacc 7020
tttaactggt tttctctctc ccaacttggg ctggccaggc actagcaaga ccacactctg 7080
cataggaaga aaaagaaagt cctcccaaa gctagattcc ttctgctttt tctttcacga 7140
tccccaccc atccctcca agtacccaag gatgttgccc gtgttgaata catgtgggtg 7200
cacttcttc ctcctagga taccgtgtat ggaaactgct ccactcactt taccgtcaag 7260
acgaggaagg gcaatgtggc aacagaaata tccactgaaa gagacctggg gcagtgtgat 7320
cgcttcaagc ccatccgcac aggcctcagc ccaattgctc tcatcaaagg catggtaagt 7380
cccattgtag cactgtcgtg cacagcaagg agcatcctct tattaatata attccagaac 7440
ttttgagcta gtgggcacct ttgaggacag cctgccctgg ctgtttttta tacagactag 7500
agataggacc ctgagcaggc acgggaaggt ctgccaggc ttcacggcct gggatcagtt 7560
gagccaaggc ttgagtcagg ctcctccctc ccagcccaga gctctgtctt tctctctgtc 7620
cttctgtcac tggcaccaaa ctgcctctaa tctcatcact tgagagtaat gactactcac 7680
ctctgagaag gttccgggga tggatgtagg gcagcaaac caccttctgt tcttttctgc 7740
acaaggactc cttgtgccag ctccaagcct ctggccttg aagaagtccc aagacctgtg 7800
ttctccctct ctcctcctc ccatgaagtg gactgactta gactgtcca gcttcttctc 7860
cttccacccc cagtaccacc ctgaccaaac atggcccccac tgccaccggc ctggagcacc 7920
ctctctctc tgttaactgg ggccatggag caccatatta cctgagcctg cctgaccct 7980
gcaacatctt cctgatatg agccccagcc tgtctcagtg aacatgaata acttgggcaa 8040
tcactgtcat gctgggcgct gttcctggtc attgtcctta ggggtgaaaa caggagctct 8100
gatgaccatg agtgccacag tcagaagagg ataatgcaat ggcttagggg tcttttctga 8160

gcatctgctg tttgctcaac cccactctgg gcagcaccaa ggaagggaca gtggcagatg 8220
 aaccatggac cttccctca g gatgcttc agtctaagtc aggagccagg tcaataaagt 8280
 atacgtggta tactcaataa ggtgataagc tgaacagtgc agacaagaag tccctgggcct 8340
 gaccaggaag gagaaagaat tattcatgta gctcagcggg caacatttca tgggaagatgt 8400
 ggagcaggaa cccaaaaaat gcaaagaata tgtaaatgaa agagacatgt aagaatgggc 8460
 ttttgggcaa agaaaagtta ctgagcaggt gtgtgagggg ctatgtggtg ggatgggcat 8520
 gtggaggata caaagtttag acattgtcca gtgaggggtg aaaaagagga gtctacagct 8580
 tgactcagct ttggggatgc cgacttggtg cccccctgg tctaaatgtc aagtaccag 8640
 ttatcttctt tctctgagtt tatctagtgg tacaggactc ctgctccctt ctacctgaa 8700
 ggtaaatgct tttaacagaa gatacagga ctgatcaaaa tgctcgtctc caatctcttt 8760
 catagacccg ccccttgtca actctgatca gcagcagcca gtctgtcag tacacactgg 8820
 acgctaagag gaagcatgtg gcagaagcca tctgcaagga gcaacacctc ttctgcctt 8880
 tctctacaa gtaggtcatg tgatgcaccc ctgattgtc atttaatggg tcagtgtgaa 8940
 ctgaacactt ctcaagtgt ctgttcagg caaacctgtg cctgggaggy aggaatggag 9000
 agggataaaa tgccgcccc cctgtcccc ctttttaagc gaacaggcca ttggcagaa 9060
 aagtcctagg catgcaaaac aatccaagac caacaaaga tatctaagac ccattcttta 9120
 agggctgtag atccagaaaa cctgaggatc actgcagggc acctgggtta gaaaaggttt 9180
 catggaagat ttgggatact gactggaac ttgtgtatcc aaatccactt tgaaaactga 9240
 taatcaatga atatatattg agtaactgcc atattcttgg ctctatgttg tggagatac 9300
 gaaagaattt tgagacattg cactagtcc tacctctggc cactccagac tagtggagag 9360
 tataaggcac gcatgtcttt ttgatgggag gataactagc gtgaccagga agaggtggat 9420
 gttattcatt cagggccaac aatggctgga tttacccatg ctttgaaaga tgggcaggac 9480
 ttgggtagat gcagagacag ggaaaacctt caacatggaa agaatagtat gttctggcca 9540
 tccgtgacat ggtgtgcttc cttgggtacc aggaataagt atgggatggg agcacaagtg 9600
 acacagactt tgaaacttga agacacacca aagatcaaca gccgcttctt tgggaaggt 9660
 aagagtttct gtccacatag ttgctggaaa atctactcaa gatgtgccta tcatggctta 9720
 gccacttgct gagccctggt aaatgtctgc tgactaacia gtgatacaga cactggtggt 9780
 ctggctacct ctagtgaag agcaaactca tttcatgatg tcaagttgca atggcataaa 9840
 ggaaaagaag ttcccaaagc tacttaggca tttgtaaata gaaaactgga atcctaagtt 9900
 taacatgaca tatttgatag aactgacatc accatcctg tgataagatc cagagctgtc 9960
 ccagacgagg tggaccaagt gggagagaac cttcagagtc tggccagata gtaacctcag 10020
 gagtcagtct ttagaggtag aaggaactct aacaatctca agtccaacct ttaccagta 10080

ttgtattgta tttatatctg tccaaattcc ttcttgtaga ttacctcatt gtcctttttg 10140
ctcatagcaa cctgtgatgt caggtggtag agatgtgatt ttatacctat tctacagagg 10200
agacagtga acagagagggc ttagagtttg atgtagtcaa ggccgcagaa tattagaggg 10260
gggaaaataa gtgccagggt gtaactaag ccaggactat tctcattaca ccacatttcc 10320
atgatgactt ttacctctct tcttggcata ggtcacagta ggtggtggag aggatacaaa 10380
agtgtctccc ctccccacaa gctgctggta gacccaatta gaagaaatgg tgataagcac 10440
ccatgtgcct ggtcccagtt gtaaccatgt caacagtagc acctcctcac caattatttc 10500
aagctaaggg taacctgatg atagactcag acaagtctgg attccacttt agctctacct 10560
cttagaccct gagagctctt gggaaacctt agttgctcat ctctgggtca cacttctca 10620
tctctgggtc tcatctcttt gtctcatctc tgggactcag agctgagatc cagggatgag 10680
caatttacat ggcccaasaa ctctgtgggt ctccagaagca gggctgaatt tatcattaaa 10740
ttgaacaata atgccacccc acagggatag gatgatgagt cagtgaaac aagtcaatca 10800
cctatggcag agccagatct agcaggcatt gaatacagga tagtttcttt ccttttccc 10860
ctgtgctgat actccacaat ttccagcttc cagtagacaa agatatggtt gagatgaaga 10920
aagctagagt tcttttgaca ctttccatct tccaggtaact aagaagatgg gctctgcatt 10980
tgagagcacc aaatccacat cacctccaaa gcaggccgaa gctgttttga agactctcca 11040
gggaactgaa aaactaacca tctctgagca aaatatccag agagctaato tcttcaataa 11100
gctggttact gagctgagag gctcagtgta tgaagcagtc acatctctct tgcacagct 11160
gattgaggtg tccaggtatc taatggttac agctcaactt tttataaaac tgatggtaac 11220
tgactgaact ttcaaactt ggccaaatgg agaactcag ggaccatttg gatataatc 11280
cagttaatca attagtcaat cagttcatga ttgctggata gagaactatc agctgctgcg 11340
ctgagttcca tgaaacacac acgcgcatac tgtgttcaag gcagctatgt atttgtgtgt 11400
taaaacagaa ggagaatagt tcccacattt tgatgggtaa cttttaattc ctaggctctat 11460
tgcaggtgct ctccagaagc ttataggctg gtggagagag aactcagacg aaaaatataa 11520
tatgatttct ctaccttca aggcactggc tttaagtgt atgaaggtga gagaagggac 11580
tgaggccagg aatgagaccc agctaagtgt ggccaggcat attctgtgtg ctggccaaag 11640
gactgtgata acagtcttct tgttgctaca gatccacagt cccctcttgg aacttttctc 11700
gattgggctt cttctgtggg taatattcct aaggaaagca tcatggttct gagctccaag 11760
ttgggttttg aagttagatt tgaatagtga atgaggtgat taagggtctt cctggcagag 11820
gacacaccat gagcaatatt ttatgtgcc tgaaggtggt ctgtataact ttatccatgt 11880
ctttcttctc agcccatca ctttacaagc cttgggttcag tgtggacagc ctcaagtgtc 11940
cactcacatc ctccagtggc tgaaacgtgt gcatgccaac ccccttctga tagatgtggt 12000

cacctacctg gtggccctga tccccgagcc ctcagcacag cagctgcgag agatcttcaa 12060
catggcgagg gatcagcgca gccgagccac cttgtatgcg ctgagccacg cgggtcaacaa 12120
gtgagtttcc aactgtatt tctctctcta ggagcagagg aacatcttgc acctctgtgc 12180
atctctgtat taaaactgaa cccctccttc cactttcaaa ctctgctcct tactcttgtg 12240
ttttttcttg atcatttttg gggtaatgac ttgaaataag aaatcagcaa acacaaattg 12300
aatttttaaa aatattttct ctacattata ttataaaagt tttgaacat agcaaagttg 12360
acagaatttc acagggaaaa cccctagaaa accagctatc tcctactatt taagtgttat 12420
tatatttgct ttatcacata tacatccatc cattaattca tcttattttc tgaagcattt 12480
caaagtaaat tgcaaacatc aacacacttt cccctaagta ttacagcttg catattatta 12540
acttcagttc aatattagtt agcagttttt tctctgaat tttttgttt gtttgttttg 12600
ttttttttg ttgttgttgt ttttttgaga tgggtctcaat gtgtcaccga ggctggagtg 12660
cagtgatgca gtcacggctc actgaagcct caaatctctg ggctgaagtg atcctccac 12720
ctcagcctcc tgagtagctg ggaccacagg tgcattgtac catgccctgg ctaatttttg 12780
tattcttggt agatacaggg tttcaccatg ttgctcaggc tagcaggttt ttcttttgat 12840
gaaatttttt ggctttttct tttttacatt tttatataaa tttatgtgga acaagtgtaa 12900
ttttgttaca tgaatagatt gtgcagtagt taagtccaggg ctttcagggt atccatcacc 12950
cagacaacat atagtgtacc cactaagtaa tttctacca tccatctccc tccacttcca 13020
cagcttctga gtctcaattg tctatcattc cacacattat gtcttgtgt gcacattatt 13080
tccatccac ttataaatga caacacgcaa ttttgtctt tctgtgactg tctgtttca 13140
cttaagacaa tgacctccag ttccatccat gttgctgcaa atgacatgat tctattctt 13200
ttatggccga atagtatttt attgctata catttcacat ttttaatcca atcgtccatt 13260
gatagacact taggttgatt ccatgtcttt gctattgtga atagtgtgt gataaacata 13320
tggtgagcagg ttctcttggt atataatgat ttcttttctt ttaggtatat acccagtaat 13380
gggattgttg gatttatttg tagttctatt tttagttctt tgagaaatct ctgtattgtt 13440
ttccatagtg gttgtactta ttacaatcc catcaacagt gattaactgt ttctttttct 13500
ctgtatctct accaacaact gttatttttt gtcttttgaa taatggccct cctgactctt 13560
gtaagatgtt atctcattgt ggttttaatt tacattctct taatgattag taatgltatg 13620
cattttttca tatgctatt gccatttgta tgtcttcttt tgaaaaaat gtctattcat 13680
gtcttttgcc tactttttta tgggattatt tgggggattt ttttgttgag ttgtttgaat 13740
tgcttgata ttccgatat tagtacccca ttggatgaat agtttgcaa tttttctcc 13800
cattctgcag gttaccacc tgttgattat ttgttttact gtgcagaaac tttttacttt 13860
aattaagttc tatttgtcta tttttgttt ttgtgtctt tgccttgag gtcttattca 13920

cgatttttt gtctaggcca atgtccagag aagttttccc taggttttct tcttgcat 13980
ttatagtctc aggtcttata ttttaagtctt tgatccatct tgagttgatt tttttatatg 14040
gtgacagata ggagtccagt tttattcttc tgcataatggc aatccatctt tcccagcacc 14100
acttattgaa aagggtgtcc tttccctagt gtatgttttt gtcaattttg tcaaagatcc 14160
gttgactgta agtatgtgac tttatttctg gggttcagtat tctgttccat tgatctatgt 14220
gtctattttt atgccagtac catgctgttt agattactat agccttggtg tataatctga 14280
agtcaggtaa tgtgatgcct ccagctatgt tctttttgct taaaattgct tcagctattc 14340
aggctctttt tggattccat atgaatttta taattatttt ttctaattca caagtttggg 14400
ttttaagaca aacctaaactg gggttaccaa gtccctgactc tcttctctta tctgtagct 14460
atcataagac aaacctaca gggaccagg agctgctgga cattgctaata taccgatgg 14520
aacagattca agatgaactgc actggggatg aagattacac ctatttgatt ctgggggtaa 14580
tctcagctctt ttatatgaca tacatcattt cagaagcact tttcctggac accttttact 14640
tccctctctt gcacctgat gggttcttgt ttcttttctt caatgcaggt cattggaaat 14700
atgggcaaaa ccatggagca gttaactcca gaactcaagt ctccaatcct gaaatgtgtc 14760
caaagtacaa agccatcact gatgatccag aaagctgcca tccaggctct gcggaaaatg 14820
gagcctaaag acaaggtaaa gtccacaaga agaggtctga aagtgaagat ttattaacaa 14880
ggatttggaa ggtactaggg gaatgagact ctgatttca tctactgact ttattctgt 14940
gtttctttcc tttccttctt tcttcttctt ctcttctctt ccttctctctt ctcttctctt 15000
tcttcttctt ctcttctctt togagatgga atctcactct attgcccagg ctggagtga 15060
gtggcatgat ctgggtcac tgcaacttct gcctcctggg ttcaagcaat tctctctgct 15120
tcagcctcct gagtaactgg gattacaggc atgtgacatt acaccagct aatttttgta 15180
ttttttagta gagatggagt tttgccatgt tggccaggct ggtcttgagc tctgacctc 15240
aggtgatccg cctgcctcag ccttgcaaag tgetgggatt acaggcgtga gccactgcac 15300
ctggcctcta ctgttttcta attgcaaatt tcaacaagcc tattgacttg actgcctagc 15360
agtatgtgac gtgagagaaa tacttgactt tgetgctatg tcaacatgca gaacgtgaga 15420
tgtttttget tctaccgct cacctaccag attgaccatc cctctcatca tggaaaaaca 15480
tgcttaattt tcccccaata agcttaggct aggatagcca acttggcccc ctcttaggtg 15540
caaagactcc agaactttgg aaactaccct atttattagc cccaaactct tactacctc 15600
tctcatcttt atcctcacat taaaataact tacgttaaaa caacttgatt ttcacttagt 15660
gggtgatctc caaacaatc acaacttggc cataatttat gtgttttaat ggaattgaat 15720
tcaacaggca ttccacaggc tttttctggg aaccttact tgatagtgtc ctaggaaaca 15780
ctggcaagaa gattcaatac cagcatttga agaacgatta cagagaaatt agacctgtgc 15840

ttaagaaaga gctagcagac aatgccagt tttgccaggc atgttctgtg ttctgaccac 15900
aggacagtga taaccatctc ctcttttgac tgcaggacca ggaggttctt cttcagactt 15960
tccttgatga tgcttctcgc ggagataagc gactggctgc ctatcttatg ttgatgagga 16020
gtccttcaca ggcagatatt aacaaaattg tccaaattct accatgggaa cagaatgagc 16080
aagtgaagaa ctttgtggct tcccatattg ccaatatctt gaactcagaa gaattggata 16140
tccaagagta agtaagagct attcaccoca tataccactg agggccctga gctggaattc 16200
caaccctagg ttttggcata gccactgtct gcccttgctt ctgaaacaaa cacttgtgca 16260
aatgtgtagc agatctagac ccaaagactt agggtaaatg aaatcaagac attttggtag 16320
tgattggaaa tccatattta cttgggggtgc aagagtcaaa ggataataac atgggtgtgtc 16380
agctcaaaat atactttctc ttatctagtc tgaaaaagtt agtgaaagaa gctctgaaag 16440
aatctcaact tccaactgtc atggacttca gaaaattctc tcggaactat caactctaca 16500
aatctgttct tcttccatca cttgaccag cctcagccaa aatagaaggg aatcttata 16560
ttgatocaaa taactacctt cctaaagaaa gcatgctgaa aactaccctc actgcctttg 16620
gatttgcttc agctgacctc atcgaggtaa gtgtgaagag tttgaggttc tctagcccat 16680
tttgtacagc atcataaaca gagagtcctt gggagccagg agctaccagc aggaaaacta 16740
agaaccacca ggcacttctt accatgatct tgaggcttct ttcttttctt ccttccccgc 16800
cttctctctt ccccgctagg ggtcacctga agcatgactt cttaacatta atagaaatgc 16860
aggcctggcg aggtggctca ctctgtaat ccagcactt tgggaggccg aggcgggtgg 16920
atcatgaggt caggatatcg acaccatctt ggctaacacg gtgaaagccc atctctacta 16980
aaaaracaaa aaattagccg ggcgtgggtg caggcacctg tagtcccagc tacttgggag 17040
gatgaggcag gagaatggcg tgaaccacagc aggtgagct tgcagtgagc cgagagattg 17100
cgccactgcg ctccagcctg ggcgacagag caagactcca tctcaaaaaa aaaaaaaaaa 17160
aaaaaaaaattg aaatycaaat gtctcgtctt taagtcccaa agccaaggaa gcatatgtgc 17220
tgcttagtca gatctgcttc aaatctcaaa tcaactccaa ctctgaatcc tttgttgaat 17280
tatttgcctt atctgaacct tagctgcctc ttctagaaaa aagcaagtaa taaggtcaag 17340
attctagtga gattttaata aagcagctcc tgtgaaatgc taaggccagc tctggcctg 17400
tggtattcaa atacttgttt agataaatgg acatcaagag tggggactac taggctggca 17460
tacaacaaag aaacctgatg ccattttctt gtctgatttt ctttctcaga ttggcttggga 17520
aggaaaaggc tttgagccaa cattggaagc tctttttggg aagcaaggat ttttccaga 17580
cagtgtcaac aaagctttgt actgggttaa tggtaagtt cctgatggtg tctctaaggt 17640
cttagtggac cactttggct ataccaaaga tgataaacat gagcaggtgt gtatttgtga 17700
agtatcttct taaggaaagc tttgggtctc aatgcaaaaa caattctttt ctaagcatgg 17760

aagtcctcaa aatactatct aactgaaggg ataactatgg tttttatcaa ccagacctgc 17820
tggggtaagg gccagtatcc tctgcagtta aagatctcct gaattcagtg tgcccagaaa 17880
ccagactcac aataagtact ctaggataac aagagtatga actctgggct ggggtgtggtg 17940
gttcatgcct gtaatcccag cactttggga ggccaagggtg ggcagatcac aaggtcagga 18000
atttgagacc agcctggcca acatactgaa accccgtctc tactaaaaat acaaaaaaac 18060
tagctgggca tggtagtggg tgctgtaat cctagctact cgggaggctg agacaggaga 18120
attgcttgaa cccgggaggt ggaggttgca gtgagccgag atcacgccgt tacactccag 18180
cccgggtgac agtgtgagac tgtatcttaa aaaaaaaaaa agtatgaact ctgggcatag 18240
atttaattct aacttccttg tcttgaagct gtgcgcactt ggggaagttg gttgatatta 18300
tgtgtatctg tttctgtctg tatccagac tactaaraac agtccaaac tcacaaggtt 18360
atttaaagac aatgaaataa ggcactctaa atgccaagca cagtgcctga tgctggcatt 18420
ggttgttcaa taagcagaca ctattacgag ttctaaatta atattttcat tattattaac 18480
tgctgtcttt ggctctcact cccatcagtg cactagcaaa tgagaccaa cttccacttt 18540
gaagctagca atgagcccc atttaaggag ggaaataggt tgtatgatct ggagcttatt 18600
cttgaatttt ttgctaccca aagtgtggtc tggtcagaaa tacagcttct catgctccac 18660
ccacaatcta ctgaatcaga agcgcatitt agcaagacct catgtgactt gtatgcacat 18720
tcaactttgc agagcaaggg agtaatttac ccttcaggc tcaactgtga gcacgagctc 18780
catctttctaa tttctgacc cccacttgag gcgaggatc tttgatctgc tttgagtctg 18840
tcagtttcac attttttttt tcccaatgcc tgggcatcca tctctgagal tcttctctc 18900
tctgagaaga acttgtctag gatcaagtg ttttcaaact tctgggtgaat ttatataaca 18960
gctacatttt cttaagaaac accttgtagt cttcactggc caaagaagag aaggctaagc 19020
agggaaacggg tgggggatag aggatcttct aatcttgagg atcctggcat actggagaat 19080
agggaccctt cctctcatcc caccacatct tactatgtct acagattttt taattaagaa 19140
tagcttttagg agtgccacta tccctgacaa gaccttagtt ctttaatctc tgcttagagg 19200
aattagcctg gacttcagtg tctccctggt cctcacctgg agcatttttt aggcccatcc 19260
tggtgtcatc agacaggtcc cacattggga actgaaaggt gtttgacatt gctgacatct 19320
cactggccat tttattacta aactctcagg atatggtaaa tgggaataatg ctcagtgttg 19380
agaagctgat taaagatttg aaatccaaag aagtcocgga agccagagcc tacctccgca 19440
tcttgggaga ggagcttggg ttgcccagtc tccatgaact ccagctcctg ggaaagctgc 19500
ttctgatggg tgcccgact ctgcagggga tccccagat ggtaagtac caggccccac 19560
tgggggccca tgagaccaga cgttggtttt tttttagatc gccagactc cttacgatc 19620
ccagctgcac aagcccgaag agatgcttgt actttcttca gagatggagg tttgccttga 19680

atttcactga agatgactct tggatcacat ggaaatgtta acatttagaa attaagctat 19740
tcataatgtt agctgtatct ttaagagcat taatttattc atctggaaaa caatgttcgg 19800
tataccttcc tctacctttg ctgaaggtcc ttttattttt atttttattt ttttaatttt 19860
ttgagatgga gtcttgctcc caggtctggag tgcagtgata caatctcgcc tcaactgcaac 19920
tctgccttcc gggttcaagg aattctcttg cctcagcctc ccaagtagct gggactgtgg 19980
acgtgcacca gcatgcccgg ctaatttgtg tatctttagt agagacaagg ctgttgacaa 20040
ccatgtcagg ctgggtttcga actcctgacc tcaagtgatc ctccagcctg ggccctccac 20100
agtgtcggaa taacaggtgt gagccactgc acctgacctg aaggctcttt taagattgaa 20160
atgatacaat gattataaaa gaaagtattt ggcaaacctat aattcactat ctaaatatgc 20220
tataattttt attattaatt cataaaagga aatatataaa cgtactccta tggcttgatt 20280
aaaaaatgt tgactttaag aaaacaggtc tcaagctatt ttattgaaat attatttaa 20340
aaataaaacc caatgcaaat tgatatgtac atcatctcaa taggcctttg gtttcaaaaa 20400
attgatttta tcataatata ataatttca agtacacctt cacttacagt cagactccag 20460
aacaccagaa ttaagccatg gcataatga tacttaaagt ccataaagct ctgaggccca 20520
gcaatattct taagagcctt ctgagtcac ttgaaaatga catgatctct atctagtga 20580
attttttata tcttgattca ctgaacagg taaaacatg agtttgatct ttatttatca 20640
aaetantcag ctcatcaaaa taigtatgtc ctccctttcc agataaagag gaattactct 20700
ccaatgtatg ggaggttgta attaacaaaa ccgactttta aaagacttac ttttatttgc 20760
tctcccttgt tgggtctaca gatcggagag gtcatcagga agggctcaaa gaatgacttt 20820
ttttctcact acatcttcat ggagaatgcc tttgactcc ccactggagc tggattacag 20880
ttgcaaatat ctccatctgg agtcattgct cccggagcca aggcctggagt aaaactggaa 20940
gtagccaacg taagattctg tttgcctttt gatttcttag gtattactt tcttccaggg 21000
tgcatctctt gttaaaacat atttaaaaat gtgttccac ttcaagacaa aatgcttcat 21060
cattgtaac acctcattat ttttttatga aaaacttcaa gcttccacca gaatgcacta 21120
cctcactagc tccagtagtg gtatggccat aagacaagaa ctcagttctc tcaacaaatg 21180
agtattccta tcatcttttt aatctgggtt tgcctcacgt taactcaggt gctttctagt 21240
tctgggtagt atactccaac tctagagaac tgagaactcg ctctccttct tccaaacaaa 21300
tcccagtaat gtttccaaag gtctyagtta tccaggaaat ctttgcccg aggtgagaaa 21360
gggtgggtga tctgactgac aggggactga agtatttaat gaatctgaat aggttgtttt 21420
ctgacttata gatgcaggct gaactgggtg caaaacctc cgtgtctgtg gagtttgtga 21480
caaatatggg catcatcatt ccggacttcg ctaggagtgg ggtccagatg aacaccaact 21540
tcttccacga gtcgggtctg gaggtcatg ttgcctaaa agctgggaag ctgaagttta 21600

tcattccttc cccaaagaga ccagtcgaagc tgctcagtgaggaggtaattc ttccagccaa 21660
 gtctgcctag ccagtttgaa agagagaaca gagaatgtac ctgcagaatt ttgccaggct 21720
 aaacagttga ttgagatcat tcaggtcctg aggaagcagg agaggagtag aaaggaaaga 21780
 ttccgggtta cctattttaa ttctagccta gacttactac ataactacat aattaccttt 21840
 cttctacttt tcacatttta ctaaaactgtc ctttatcttt ctgctttgag acttattaag 21900
 acctactgct taattagttt ttattaagtt gtgatttttt gttatctatt tgttttgaga 21960
 atgaagaaac aatagctctg gagagatcat ctttggaaaa ttaatatttt ccccccaaa 22020
 aaatacctaa gaacatattg atttgaggta gctaggtagg taaagcatga aactcctaac 22080
 ctctgataa tgggaatacag cctcttttgg agagttccat ttttaagtggc acctcaaac 22140
 attgatttgc cttagttttc atattttaga cacattcatg tgttcattca aaaataatat 22200
 ttaattggcc agccacgggtg gttcatgcct gtaatcctag cactttggga gcccagggtg 22260
 gatggatcgc ttgagccctg gtgtttggat accagcctgg gcaacatggc azaaccccat 22320
 ctctacaaaa aaaattaaat aaataacaaa attagccagt cgtgggtggca catgcctgta 22380
 gctccagcta ctcagaaggc tgagatggga ggatcaactg agcccaagag ttcaagcctt 22440
 cagtgaacca tgcctgcacc actgcactcc agcctgggag acagagcaag atcctgtctc 22500
 acaaaaaaca aaaaatagta tattttaactg cctaatatat accacgtatg ttgagtgaga 22560
 cacacaggt ccttgacctt tgaacgutta ctttttataa gggagacaca caattaagca 22620
 agcagtaatc atagagtaag ggctaagtta tagaaagtat tagagtacca tgaaatttta 22680
 tatcatgtag cctgtgctag tcagggaatg cattctgaag caagtgtact tgacctgata 22740
 actgaggact gtgtcagagt catttaggca aaggagaaag gagtgagtgt tccaggcaaa 22800
 aggaaaagca tgtaatggcc tgaaggtaaa ggaatatggt tcaaggaact ggaagaagtg 22860
 cagaatggta aggggctcag agatgatggg gagaggtagg caggggagag agcatgccca 22920
 gctgcgaaag ccatcctaag gagtttgac tcttttgaag gcacaggagt tgaaaagggg 22980
 agcagaaata agataggggt gatgttttag aagaaatact ctgactctag tgtggaagat 23040
 gggtgagaag gaggcacagc tggacacgaa gagaccattg gacatctctt acgatcctat 23100
 gtggctaaga gctgataatg gcctgcagtg gagaaaagcc aggtatagaa aggagtgagc 23160
 agattctaca actttctaag aggcagaatc ataagtactg ggtgattaac tgggtatggg 23220
 gacaaggcaa aagaaagaag aaaagaggaa ggaggcgccc ttcattttta taagaactac 23280
 agtgggagag cttctggttt caaggaaagt gacaaattca gttttggatg tgctgtattt 23340
 gatgtctcc tatgaaacaa ccagttttaga aatctagctg tcaaatagac ctatggatct 23400
 gagcccagta aagaggcttg ggctccacat atggatttgg gaatcattag tatacagagg 23460
 ttgttgtgggt taaacagcaa ctggtataga gtgagacatg agagatgagg acagaaatat 23520

ggagaagaca aacatataaa ggaagaaggg gaataaccag caatgagtta gaagaagtga 23580
ccagagaagc agaaggagaa ccaaagccat aaaagggtcac agaagccaaa gagcagccac 23640
aggggagatc accccatggg taggcgaaag ctggcattag gactccagca catcagcaaa 23700
gcttgggtctt gtggcacccc caacttggag aaacaatact tggaggaaaa tgtgctatctt 23760
caaagaaagc atccttagaa aaaaccaggc caatgttgaa ctttcttaca tgtactaagt 23820
ttttaagtac acacttggaa ggaaggtgcc atcatctctt cagatgtgag aggctccagc 23880
gtcttagtct ggtcatgagt gcgcaactct atggaaggct tctgggaggt caaggaagat 23940
gaaacctaaa tatgccatt ggatgtagga gcaaggaggg cattagagac attgatgaaa 24000
gcattttcag gagatggagt gagcagtcag agcacattgg gaggaagtag agactgcaaa 24060
ggcagacaac tcttgatggg gaggaagatg agaaagcaag aaaagaaaga aaggagcata 24120
ggggaggggc acaggggaag agacttgagc gtgcttaatg cagggtggaag gaagcaggta 24180
gagagttaga gatttcatat gaaagagaca gtttctcttg ccttgcatg taggaaggaa 24240
ggggcacact gaagttcagc cccagtgatc agctatttaa catctctgag cctctgcttc 24300
tgtaaaatga gaaccataag cctactgttg tggggattac aggtaacaga tggaaagaac 24360
tcagccagaa gcttcayagt cactctcatg gcttgtcatg ttgatgttct ttctaataatt 24420
atttgtttct cagtaaatta aatagttaga gatadgtgtg gactgagga agacaggagg 24480
ataagggggg atttgcaccc tgagaatttg tgatgtccat ttgattcat gacttggcaa 24540
taactcaggt attttgttc ttaccagca acacattaca tttggtctct accacaaaaa 24600
cggaggtgat cccacctctc attgagaaca ggcagtccg gtcagtttgc aagcaagtct 24660
ttctggcct gaattactgc acctcaggcg cttactccaa cgcagctcc acagactccg 24720
cctectacta tccgtgacc ggggacacca ggtagagat gctcagtgc tgaccagca 24780
ttttctcacc ttccacatca tggccacct gcatggcaca ggaaaaata ctctgtgttg 24840
taagacctg tcactagcct tctgggttg caccatcttt gggatattta agcagggtcc 24900
tctggccaac acattgggtg tcacctttg cttccttgtg catgggatgg gatcacagca 24960
cagatcccaa tttgctcta attcagtgtc catgtttctg agcctccaga cccatcgcta 25020
tgagcttctt ggagcccacc aatgtgcttg aagccttcac cgtacttagg tggctccctg 25080
tcttcagccc ccaagttcca gtgctgttc tcagctttgc tgaaacaacc agccaactcc 25140
tgctctgctt gtccaaagtc ttgggaatcc tgggtgtctgc ccttgcttg ggttcttgta 25200
ggactgaggg atcaaaaaga tcatcttagt taagggcaag agacaatgtt aaaataagga 25260
ccatattttt gttgcatttg aggctgaatt gttttgggaa cataatcacc atccttgaaa 25320
gctctaacar tatgcactgt cttcattgta atgtctttag attagagctg gaactgaggc 25380
ctacaggaga gattgagcag tattctgtca gcgcaacctc tgagctccag agagaggaca 25440

gagccttggg ggataccctg aagtttgtaa ctcaagcaga aggtgagtat tcaaaacaca 25500
gctgcctcat ctctgctcgc agtctcaggt tcagaattca tgaggagaag acatgtaatt 25560
taacctatctt aacaaatagg ttaactgagt acccactaag cggcaggcct attctaagac 25620
ctgggttaac tgagtaccca ataagcggca ggcctattct aagacctggg gctagaacag 25680
tgaacaatgg agtctctgcc ttcattggaag ttacagtga caaccacaaga agttaatat 25740
tggaatatca gataagtact gaggaggaaa acagagcgta gactgggtcta tggagggcta 25800
ggagtaggag ggaggaagaa gggcagggaa agcagtgcat ttggaataat aagggaagt 25860
ctccctggta aagtgagcat aaggagacct atcagaaata agaggagaag ccgtgtggta 25920
agactgttaa caggcagagg gaccagcaag tgcaaaggcc ctgaggctga cacactacta 25980
ccatgtttca aggaaaggaa ggaagacagt atggctggag caaaaagacc agggagaaaa 26040
gaggtagaag atgaggacag agagatatgg agaggtgaag gaaggataat ctcataggcc 26100
atggtaagaa ctttggcttt ttctatgaat taaacgaaag ccattgggga gtctcatga 26160
tttgatttat gtttatgttg agaaaagact atgggcagac aagggcagag aaactaatat 26220
gtaggttatc acaataatcc aggcaggaat cagtgttgtt ttggatcagg gcaatggcag 26280
aagagatatg agaaggggat ggattctggc catattttga agattaggct gacaagattt 26340
gctgatacag tggatgttga gtgtaagagg aaaaggggaa tgaagacaaa cctaagggtt 26400
ttggcccggg caactgaaaa atggaacttc cttttattga gatggaaagg gctactggag 26460
gagcaggttt tagggaatgg gagaaattta ggtgttcact ttggaaaaaa aattatatag 26520
ggatagcgag gagcaggttt tagggaatgg ggcacattta ggtgttcact ttggaaaaat 26580
ttttatatag ggetagcata tcacagaatt aaactaggaa gaaaatceca tgatagaaag 26640
cactggagga gcagggcacg ctggggaaat agtgtttggg aaacattgtt ttacgaagga 26700
tataaatgg accagcctat ggattgaagg acgcccggga atcttgttac aaagaaaggg 26760
ggagttgggg agatggagcc cagggcaagg gcagcaagga accaggacag gcattctggg 26820
tagaaagtaa tatagagatg tcgtgtcttc ctggcccaga agggctgcga gcctttgctg 26880
ttccacaaac aagctaagtg ctccccattt cagggccttt gcattcctga cctctgccc 26940
ggaatgtgct cctcccagaa ctacagcgtg ctccaacctc ttttcattct ggtctctgcc 27000
cacatgtgcc cttatcagag agaatttctc tgaccacca gtagaaata acattctctc 27060
tatccctttc ttttatcctt gtatccagtt ttactcttct tcataacatt cattaccatc 27120
tgacatgagc aagttacttg tttattgcct gtacacctcc cccactagaa ggttaagcccc 27180
atgaaagcaa ggattcccca gtaccaagag cagtgccag cacacaatag gtcataaca 27240
ggcaatccat aaagacttgc atacatgaac acaactgagt ttaaaattat cagtaaatga 27300
gaccatttaa aaaattttta tgagaaaaaa aaaattcagt aaaatcctga actgtgtttt 27360

tgtttaagca cattgattcc ttggagtttc tctacctttt cctctctttc cttccaaaac 27420
 atagcttctt tttttattta tttatttatt tgtttgttta tttatttatt tttttattta 27480
 tttatttttt gagatggagt ctgctctttt tgcccagggt gcagtgcagt ggtgccatct 27540
 cggctcactg caagccccgc ctcccgggtt catgccatcc tctgcctca gcctctgag 27600
 tagctgggac tacaggcacc caccaacgcg cccggctaatt tttttgtatt tttagtagag 27660
 acgggggttc accatgttag ccagaatggt cttgatctcc tgacctcatg atctgccccg 27720
 cttggcctcc caaagtgctg ggattacagg tgtgagccac cgcacccggc caaaaacata 27780
 gcttcttacc acacatctct tgattctctt atacactcgt ccaggtgcga agcagactga 27840
 ggctaccatg acattcaaatt ataatcggca gagtatgacc ttgtccagtg aagtccaaat 27900
 tccggatttt gatgttgacc tcggaacaat cctcagagtt aatgatgaat ctactgaggg 27960
 caaaacgtct tacagactca ccctggacat tcagaacaag aadattactg aggtcgccct 28020
 catgggccac ctaaggtaaa gaaggccgag ggtcatctga cctgcactgc aggcctgggt 28080
 ggttcttttt attattcttc ttccacttca tacctgacca agccatgttc tcccctagtc 28140
 tacaatcaga gtggcagaga gagccctcaa caattttttt tttttttgag atggagtctc 28200
 actctgtcac caggctggag tgcagtggca caatctcggc tcaactgcaac ctccgcctcc 28260
 cgagttcaag tgattctctt gcttaagcct cccaaggagc tggaaactata ggtgcacgcc 28320
 accacaccca gctaattttt atatttttag tagagacagg gtttcaccat attgaccagg 28380
 atgggtctga tctctgacc tcgtgatcca cctgccttgg cctcccaaag tgcagggttt 28440
 acagggtgaa gccactgcac cggccaagc tctcaacatt ttaacctctt gcgcattgtc 28500
 agttggattt tctaccatt tatcaggcac ttactattca tgtatcaagc acagtgcctg 28560
 gtgctttaaa gaaattatct cggctctcac aataaactgc gaggtcactg tgagttttcc 28620
 tgtttcatgg ataaggaaat ggtagctcag aggggttaaa tcatttggtc aaaatcacag 28680
 agctagtaaa tagcagagca ggattcaaac agttttcaaa aaacttctct ttctctaaa 28740
 cctgtttgca aagtccttaa tttgtgctga atgttggtt tagaagttga tgagtttgat 28800
 ctgtggctgt ttctctgaac catccttgta tctggttttg atcaccacaa atggaacttc 28860
 tgtttaatcc tgcatatctc cattgaaagg acaaaatcat tggtgccaac tgattttctt 28920
 taccatagtt gtgacacaaa ggaagaaaga aaaatcaagg gtgttatttc cataccccgt 28980
 ttgcaagcag aagccagaag tgagatcttc gccactggt cgcctgcaa actgcttctc 29040
 caaatggact catctgctac agcttatggc tccacagttt ccaagagggt ggcattggcat 29100
 tatgglatgt gtctcttccc ctgtgtgagc acttccaaag taatgcaggt gttgagacct 29160
 gtggttacag gctgaactag taccattcac aactatttcc tacgtatttt cagatgaaga 29220
 gaagattgaa tttgaatgga acacaggcac caatgtagat accaaaaaaa tgacttccaa 29280

tttcctgtg gatctctccg attatcctaa gagcttgcac atgtatgcta atagactcct 29340
ggatcacaga gtccctcaaa cagacatgac tttccggcac gtgggttcca aattaatagt 29400
tgtaagtatg agtctgccag tcaataaata catggatata agtgctaatt acatcctcaa 29460
clctgagcta ggtgcaggaa ggtttccaaa gatgtataag gcatgcttcc ttccccccag 29520
ggaattcttg gggagaaaaa aaaactttca caagtgtgta gtlaccagcgt tacacaaagc 29580
tgaatgtgat acatatcaaa gagatgctac taagtagaac agttctttgc ctagtgggtat 29640
caaaggaagc ttcaggacac cagctaggag gctgactatg ttagacattc cttttataaa 29700
tatggacagt gatcagtgc tggcaacgaa gattcataat tttctgttat ttatttttaa 29760
ctttcagtgc attgtccagc ttaataatta acttgtcaaa tcggtatttt tgcctaattgt 29820
tcattgctct ttgaggctca tccaagccca ttaccttaaa aatctcctgt cat.tttgtag 29880
gcaatgagct catggcttca gaaggcatct gggagtcttc cttataccca gactttgcaa 29940
gaccacctca atagcctgaa ggagttcaac ctccagaaca tgggattgcc agacttcac 30000
atccagaaa acctcttctt aaaaaggtaa aagaagaaag cagcaaggct tcttgaacca 30060
tgcaaagtaa atgaaagatt ttacatagca tgatttagac atttttttaa attttttaaag 30120
gaaataattt aagcatttta aggagattaa taactatagc acaaacactg tggcatcttt 30180
gcattagtaa acatgagaac accaaccctg tcaggaagaa tctaagaaag tcattagagg 30240
attctgttac tttcaccta agatatttta ttcagtacaa cctgttataa gcaaattctc 30300
cctctgactg tgaagaattc agaattgcta gaggcgttat tgactacagg cttgctgtta 30360
agctagagag agtcagaaca gccattgagc actaaatgga ggcagcattc tgagaaaata 30420
ctttaacca ggcttactga ctccatacc tatgttcttt ccacaaatca agttgtctca 30480
attcagttta gcaaatttgt atcaagtatc ccctatgtgc aaaatgctag actaggtaca 30540
gtgagaagat agaaactggg taaggatatag ccttttcttt caagaagata ccatggagac 30600
atcaacaaat gagaaataat taattatata agcaaaatta tgacatgctc tttgagaaag 30660
gtgcaaggga ctatgtaact gtaagaatga gacaaattgg ctatgactta ggtgggatgg 30720
taatgataag gagtggccct tagaagagct ttgtcaggat ttgagtgttt gacagggtga 30780
ggtaaaagca aaggggtcca ggcattaggag tagcaciaag aaaagtgcag agtggctttg 30840
ggaatggggc aagtacaata ttgttgtgaa ggtcagaggc agagaacttt gaatgactga 30900
tgtctgactg tggggatgtt atctttgttg ttcatttcag cgatggccgg gtcaaata 30960
ccttgaacaa gaacagtttg aaaattgaga ttcctttgcc ttttgggtggc aaatcctcca 31020
gagatctaaa gatgttagag actgtragga caccagccct ccacttcaag tctgtgggat 31080
tccatctgcc atctcgagag ttccaagtcc ctacttttac cattccaag ttgtatcaac 31140
tgcaagtgcc tctcctgggt gttctagacc tctccacgaa tgtctacagc aacttgtaca 31200

actggtccgc ctctacagt ggtggcaaca ccagcacaga ccatttcage cttcgggctc 31260
gttaccacat gaaggctgac tctgtggttg acctgctttc ctacaatgtg caagggtgagc 31320
tatgctcagg taaaggggtgc accgggctag ttcattggcag gctctaagag gagagcctcc 31380
tccagggagg aaaggacttt ggctttctag cagataatct tccttgctac ttggaagtct 31440
tttattttat tcaacaaata gaaatattta ttaaaccatat cactgtgatt aaatattcta 31500
gtaggcagta acagaaagta gacagataag ccagcaatta taattcagtg tgagaggtgc 31560
tatgataaag tgtagtatat aagtataagg tagagtggaa gcactcaaca aggaaccta 31620
aacaaagcct gtggtggtca ggcaaggctt cctggaggaa tgctttttgc tatcagattt 31680
tatctttgca ttacagatgg aggagtctat tgcacaattg gccagaaaa atggggcttt 31740
attattgaaa gactttcaac atagagattg ctctggaaat gtactgctta atttaaccaa 31800
tgtcttttca tttttatgtt aggatctgga gaaacaacat atgaccacaa gaatacgttc 31860
acactatcat atgatgggtc tctacgccac aaatttctag attcgaatat caaattcagt 31920
catgtagaaa aacttgga aaaccagtc tcaaaagggt tactaatatt cgatgcattc 31980
agttcctggg gaccacagat gtctgcttca gttcatttgg actccaaaaa gaaacagcat 32040
ttgtttgtca aagaagtcaa gattgatggg cagttcagag tctcttcgtt ctatgctaaa 32100
ggcacatatg gctgtcttg tcagagggat cctaacactg gccggctcaa tggagagtcc 32160
aacctgaggt ttaactctc ctacctccaa ggcaccaacc agataacagy aagatatgae 32220
gatggaaccc tctccctcac ctccacctct gatctgcaaa gtggcatcat taaaaatact 32280
gcttccttaa agtatgagaa ctacgagctg actttaaat ctgacaccaa tgggaagtat 32340
aagaactttg ccacttctaa caagatggat atgacctct ctaagcaaaa tgcactgctg 32400
cgttctgaat atcaggctga ttacgagtea ttgaggttct tcagcctgct ttctggatca 32460
ctaaattccc atggtcttga gttaaatgct gacatcttag gcactgacaa aattaatagt 32520
ggtgctcaca aggcgacact aaggattggc caagatggaa tatctaccag tgcaacgacc 32580
aacttgaagt gtagtctcct ggtgctggag aatgagctga atgcagagct tggcctctct 32640
ggggcatcta tgaaattaac aacaaatggc cgcttcaggg aacacaatgc aaaattcagt 32700
ctggatggga aagccgcct cacagagcta tcaactggga gtgcttatca ggccatgatt 32760
ctgggtgtcg acagcaaaaa cattttcaac ttcaaggtea gtcaagaagg acttaagctc 32820
tcaaatgaca tgatgggctc atatgctgaa atgaaatttg accacacaaa cagtctgaac 32880
attgcaggct tatcactgga cttctcttca aaacttgaca acatttacag ctctgacaag 32940
ttttataagc aaactgttaa ttacagcta cagccctatt ctctggtaac tactttaaac 33000
agtgaacctga aatacaatgc tctggatctc accaacaatg ggaaactacg gctagaaccc 33060
ctgaagctgc atgtggctgg taacctaaaa ggagcctacc aaaataatga aataaacac 33120

atctatgcc a tctcttctgc tgccttatca gcaagctata aagcagacac tgttgctaag 33180
 gttcaggggtg tggagtttag ccateggctc aacacagaca tcgctgggct ggcttcagcc 33240
 attgacatga gcacaaacta taattcagac tcaactgcatt tcagcaatgt cttccgttct 33300
 gtaatggccc cgtttaccat gaccatcgat gcacatacaa atggcaatgg gaaactcgct 33360
 ctctggggag aacatactgg gcagctgtat agcaaattcc tgttgaaagc agaacctctg 33420
 gcatttactt tctctcatga ttacaaaggc tccacaagtc atcatctcgt gtctaggaaa 33480
 agcatcagtg cagctcttga acacaaagtc agtgccctgc ttactccagc tgagcagaca 33540
 ggcacctgga aactcaagac ccaatttaac aacaatgaat acagccagga cttggatgct 33600
 tacaacacta aagataaaat tggcgtggag cttactggac gaactctggc tgacctaaact 33660
 ctactagact cccaattaa agtgccactt ttactcagtg agcccatcaa tatcattgat 33720
 gcttttagaga tgagagatgc cgttgagaag cccaagaat ttacaattgt tgcttttgta 33780
 aagtatgata aaaaccaaga tgttcaactc attaacctcc cattttttga gaccttgcaa 33840
 gaatattttg agaggaatcg acaaaccatt atagttgtac tggaaaacgt acagagaaac 33900
 ctgaagcaca tcaatattga tcaatttgta agaaaatata gagcagccct gggaaaactc 33960
 ccacagcaag ctaatgatta tctgaattca ttcaattggg agagacaagt ttcacatgcc 34020
 aaggagaaac tgactgctct cacaaaaaag tatagaatta cagaaaatga tatacaaatt 34080
 gcattagatg atgccaaaat caactttaat gaaaaactat ctcaactgca gacatatatg 34140
 atacaatttg atcagtatat taaagatagt tatgatttac atgatttgaa aatagctatt 34200
 gctaataatta ttgatgaaat cattgaaaaa ttaaaaagtc ttgatgagca ctatcatatc 34260
 cgtgtaaatt tagtaaaaac aatccatgat ctacatttgt ttattgaaaa tattgatttt 34320
 aacaaaagtg gaagtagtac tgcacctcgg attcaaaatg tggatactaa gtaccaaactc 34380
 agaatccaga tacaagaaaa actgcagcag cttaagagac acatacagaa tatagacatc 34440
 cagcacctag ctggaaagtt aaaacaacac attgaggcta ttgatgtag agtgctttta 34500
 gatcaattgg gaactacaat ttcatttgaa agaataaag acattcttga gcatgtcaaa 34560
 cactttgtta taaatcttat tggggatttt gaagtagctg agaaaatcaa tgccctcaga 34620
 gccaaagtcc atgagttaat cgagaggtat gaagtagacc aacaaatcca ggttttaatg 34680
 gataaattag tagagttggc ccaccaatac aagttgaagg agactattca gaagctaagc 34740
 aatgtcctac aacaagttaa gataaaagat tactttgaga aattggttgg atttattgat 34800
 gatgctgtca agaagcttaa tgaattatct tttaaaacat tcattgaaga tgtaacaaa 34860
 ttccctgaca tgttgataaa gaaattaaag tcatttgatt accaccagtt tglagatgaa 34920
 accaatgaca aaatccgtga ggtgactcag agactcaatg gtgaaattca ggctctggaa 34980
 ctaccacaaa aagctgaagc attaaaactg tttttagagg aaaccaaggc cacagttgca 35040

gtgtatctgg aaagcctaca ggacacccaaa ataaccttaa tcatcaattg gttacaggag 35100
 gctttaagtt cagcatcttt ggtcacatg aaggccaaat tccgagagac cctagaagat 35160
 acacgagacc gaatgtatca aatggacatt cagcaggaac ttcaacgata cctgtctctg 35220
 gtaggcagg tttatagcac acttgtcacc tacatttctg attggtggac tcttgctgct 35280
 aagaacctta ctgactttgc agagcaatat tctatccaag attgggctaa acgtatgaaa 35340
 gcattggtag agcaaggggt cactgttctt gaaatcaaga ccatccttgg gaccatgcct 35400
 gcctttgaag tcagtcttca ggetcttcag aaagctacct tccagacacc tgattttata 35460
 gtccccctaa cagatttgag gattccatca gttcagataa acttcaaaga cttaaaaaat 35520
 ataaaaatcc catccagggt ttccacacca gaatttacca tcttaaacac ctccacatt 35580
 ccttccttta caattgactt tgtagaaatg aaagtaaaga tcatcagaac cattgaccag 35640
 atgctgaaca gtgagctgca gtggcccggt ccagatatat atctcagggg tctgaagggtg 35700
 gaggacattc ctctagcgag aatcacctg ccagacttcc gtttaccaga aatcgcaatt 35760
 ccagaattca taatcccaac tctcaacctt aatgattttc aagtctctga ccttcacata 35820
 ccagaattcc agcttcccc cactccacac acaattgaag tacctacttt tggcaagcta 35880
 tacagtattc tgaaaatcca atctctctt ttcacattag atgcaaatgc tgacataggg 35940
 aatggaacca cctcagcaaa cgaagcaggt atcgagctt ccatcactgc caaaggagag 36000
 tccaaattag aagttctcaa ttttgatttt caagcaaatg cacaactctc aaaccttaag 36060
 attaatccgc tggctctgaa ggagtcagtg aagtctcca gcaagtacct gagaacggag 36120
 catgggagtg aaatgctgtt ttttgaaaat gctattgagg gaaaatcaaa cacagtggca 36180
 agtttacaca cagaaaaaaa tacactggag cttagtaatg gagtgattgt caagataaac 36240
 aatcagctta ccctggatag caacactaaa tacttcaca aattgaacat ccccaaactg 36300
 gacttctcta gtcaggctga cctgcgcaac gagatcaaga cactgttgaa agctggccac 36360
 atagcatgga cttcttctgg aaaaggggtc tggaaatggg cctgccccag attctcagat 36420
 gagggaacac atgaatcaca aattagtttc acvatagaag gacccctcac ttcctttgga 36480
 ctgtccaata agatcaatag caaacaccta agagtaaacc aaaacttggg ttatgaatct 36540
 ggctccctca acttttctaa acttgaaatt caatcacaag tcgattccca gcatgtgggc 36600
 cacagtgttc taactgctaa aggcattggc ctgtttggag aaggggaaggc agagtttact 36660
 gggaggcatg atgctcattt aatggaaaag gttattggaa ctttgaaaaa ttctcttttc 36720
 ttttcagccc agccatttga gatcacggca tccacaaaca atgaagggaa tttgaaagt 36780
 cgttttccat taagggttaac aggggaagata gacttctga ataactatgc actgtttctg 36840
 agtcccatg cccagcaagc aagttggcaa gtaagtgcta ggttcaatca gtataagtac 36900
 aacaaaaatt tctctgctgg aaacaacgag aacattatgg aggcccatgt aggaataaat 36960

ggagaagcaa atctggattt cttaaacatt cctttaacaa ttcctgaaat gcgtctacct 37020
 tacacaataa tcacaactcc tccactgaaa gatttctctc tatgggaaaa aacaggcttg 37080
 aaggaattct tgaaaacgac aaagcaatca ttgtatttaa gtgtaaaagc tcagtataag 37140
 aaaaacaaac acaggcattc catcacaat cctttggctg tgctttgtga gtttatcagt 37200
 cagagcatca aatcctttga caggcatttt gaaaaaaca gaaacaatgc attagatttt 37260
 gtcaccaaatt cctataatga aacaaaaatt aagtttgata agtacaaagc tgaaaaatct 37320
 cagcagcagc tccccaggac ctttcaaatt cctggataca ctgttccagt tgtcaatggt 37380
 gaagtgtctc cattcaccat agagatgtcg gcattcggct atgtgttccc aaaagcagtc 37440
 agcatgccta gtttctccat cctaggttct gacgtccgtg tgccttcata cacattaatc 37500
 ctgccatcat tagagctgcc agtccttcat gtccctagaa atctcaagct ttctcttcca 37560
 gatttcaagg aattgtgtac cataagccat atttttattc ctgccatggg caatattacc 37620
 tatgatttct cctttaaatc aagtgtcatc acctgaata ccaatgctga actttttaac 37680
 cagtcagata ttgttgcctc tctcctttct tcctcttcat ctgtcattga tgcactgcag 37740
 taaaaattag agggcaccac aagattgaca agaaaaaggg gattgaagtt agccacagct 37800
 ctgtctctga gcaacaaatt tgtggagggt agtcataaca gtactgtgag ctttaaccacg 37860
 aaaaatatgg aagtgtcagt ggcaacaacc acaaaagccc aaatlccaat ttgagaatg 37920
 aatttcaagc aagaacttaa tggaaatacc aagtcaaac ctactgtctc ttctccatg 37980
 gaatttaagt atgatttcaa ttcttcaatg ctgtactcta ccgctaaagg agcagttgac 38040
 cacaagctta gcttggaag cctcacctct tacttttcca ttgagtcac taccaaagga 38100
 gatgtcaagg gttcggttct ttctcgggaa tattcaggaa ctattgctag tgaggccaac 38160
 acttacttga attccaagag cacacggtct tcagtgaagc tgcagggcac ttccaaat 38220
 gatgatctc ggaaccttga agtaaaagaa aattttgctg gagaagccac actccaacgc 38280
 atatattccc tctgggagca cagtacgaaa aaccacttac agctagaggg cctctttttc 38340
 accaacggag aacatacaag caaagccacc ctggaactct ctccatggca aatgtcagct 38400
 cttgttcagg tccatgcaag tcagcccagt tcttccatg atttccctga ccttggccag 38460
 gaagtggccc tgaatgctaa cactaagaac cagaagatca gatggaaaaa tgaagtccgg 38520
 attcattctg ggtctttcca gagccaggtc gagctttcca atgaccaaga aaaggcacac 38580
 cttgacattg caggatcctt agaaggacac ctaaggttcc tcaaaaatat catcctacca 38640
 gtctatgaca agagcttatg ggatttcta aagctggatg taaccaaccag cattggtagg 38700
 agacagcatc ttcgtgtttc aactgccttt gtgtacacca aaaaccccaa tggctattca 38760
 ttctccatcc ctgtaaaagt ttggctgat aaattcatta ttctgggct gaaactaaat 38820
 gatctaaatt cagttcttgt catgcctacg ttccatgtcc catttacaga tcttcaggtt 38880

ccacgtgca aacttgactt cagagaaata caaatctata agaagctgag aacttcatca 38940
 tttgccctca acctaccaac actccccgag gtaaaatlcc ctgaagttga tgtgttaaca 39000
 aaatattctc aaccagaaga ctcccttgatt cccttttttg agataaccgt gcctgaatct 39060
 cagttaactg tgtcccagtt cacgcttcca aaaagtgttt cagatggcat tgctgctttg 39120
 gatctaaatg cagtagccaa caagatcgca gactttgagt tgcccaccat catcgtgcct 39180
 gagragacca ttgagattcc ctccattaag ttctctgtac ctgctggaat tgtcattcct 39240
 tcctttcaag cactgactgc acgctttgag gtagactctc ccgtgtataa tgccacttgg 39300
 agtgccagtt tgaaaaacaa agcagattat gttgaaacag tcctggattc cacatgcagc 39360
 tcaaccgtac agttcctaga atatgaacta aatggtaaga aatatcctgc ctccctcctc 39420
 agatactgta tattttcaat gagagttatg agtaaaataat tatgtattta gttgtgagta 39480
 gatgtacaat tactcaatgt cacaaaattt taagtaagaa aagagatata tgtataccct 39540
 acacgtaaaa accaaactgt agaaaatcta gtgtcattca agacaaacag atttaaagaa 39600
 aatggatttt tctgtaatta ttttaggact aacaatgtct tttactatt tattttaaaa 39660
 taagtgtgag ctgtacattg catattttta acacaagtga aatatctggg taggatagaa 39720
 ttctcccagt ttccacaatg aaaacatcaa cgtcctactg ttatgaatct aataaatac 39780
 aaaatctctc ctatacagtt ttgggaacac acaaaatcga agatggtagc ttagcctcta 39840
 agactaaagg aacatttgca caccgtgact tcagtgcaga atatgaagaa gatggcaaat 39900
 atgaaggact tcagtatgga gcttttattg aattgaaacc ttataccttt tgaaaactca 39960
 ttgtgatttt ctccatctcc atacccttt cgtgatagct catctgtttt tctgctttca 40020
 gggaatggga aggaaaagcg cacctcaata tcaaaagccc agcgttcacc gatctccatc 40080
 tgcgtacca gaaagacaag aaaggcatct ccacctcagc agcctcccca gccgtaggca 40140
 ccgtgggcat ggatatggat gaagatgacg actttttctaa atgggaactc tactacagcc 40200
 ctccagtaaa taccaccta tgagtgcac gcccccaaga gcgagtggag aattggggca 40260
 gatacattta attcaggacc aaatattcag agatteccca aactaggtga aagacaggcg 40320
 gtaagcaact tcttctctga ggaaatattc tctagaaagt attacaatga gtccttgatt 40380
 gatttttaatg tttagatgca cacatgacat cccatcagca ctattattta ttaattctgg 40440
 gcaaattccag gaagatgagg gttatacctc atcatctaaa tcataggcaa gctcagccat 40500
 aggcagggta tatttttcag agaggactgg tttctgtagt atttaaaact ttaaaattct 40560
 tccccacaat agaattgcta gatgagatac atcaaatcc tctcatgtca ttacaagct 40620
 ctgccagggc caaatcaagg gtgacattac cagaggagaa gaccaaacat ggttctatga 40680
 ctgttactaa aagtttgtca tgggcttgga gaatgcgtac tgatgttggg attctgggtc 40740
 tetgcagggt gggctccaac ttgccttttt tgctatttct tcttttcta tctgtcattt 40800

cctgactctt cttctctctc ctcttctttc tcttcccc actcctcttc cagttttcag 40860
tcctaggaag gctttaatth taagtytcac aatgtaaag acaaacagca agcgtttttg 40920
ttaaactcctt tctggggcat gtgataaaga gaaattaaca acagtagact tatttaacca 40980
taaaacaaac acatgaactg acatatgaaa gataaatccc tticagtata tgaaagattc 41040
tctgatcttt atttttaact gctaataaag ttttagtgta ctatattgtg taattggagt 41100
aattgaaaac atgttattht tttttttctc tctgtttagt cctctccaga taaaaaactc 41160
accatattca aaactgagtt gagggccgg gaatctgatg aggaaactca gatcaaagtt 41220
aattgggaag aagaggcagc ttctggcttg ctaacctctc tgaaagacaa cgtgcccaag 41280
gccacagggg tcctttatga ttatgtcaac aagtaccact gggaacacac agggctcacc 41340
ctgagagaag tgtcttcaa gctgagaaga aatctgcaga acaatgctga gtgggtttat 41400
caaggggcca ttaggcaaat tgatgatatc gacgtgaggt tccagaaagc agccagtggc 41460
accactggga cctaccaaga gtggaaggac aaggccaga atctgtacca ggaactgttg 41520
actcaggaag gccaaagccag ttccaggga ctcaaggata acgtgtttga tggcttggtg 41580
cgagttactc aagaattcca tatgaaagtc aagcatctga ttgactcact cattgattht 41640
ctgaaacttc ccagattcca gtttccgggg aaacctggga tatacactag ggaggaactt 41700
tgcactatgt tcataaggga ggtagggacg gtactgtccc aggtatatth gaaagtcct 41760
aatggttcag aaatactgtt tcttattht caagacctag tgattacact tcttttcag 41820
ttaaggaaac ataaactaat agatgtaatc tcgatgtata gggaactgtt gaaagattta 41880
tcaaaagaag cccaagaggt atttaaagcc attcagctc tcaagaccac agagggtgct 41940
cgtaatcttc aggaccttht acaattcatt ttccaactaa tagaagataa cattaaacag 42000
ctgaaagaga tgaaatttac ttatcttatt aattatatcc aagatgagat caacacaatc 42060
ttcagtgatt atatcccata tgtttttaaa ttgttgaaag aaaacctatg ccttaatctt 42120
cataagttca atgaatttat tcaaaacgag cttcaggaag cttctcaaga gttacagcag 42180
atccatcaat acattatggc ccttcgtgaa gaatattht atccaagtat agttggctgg 42240
acagtgaat attatgaact tgaagaaaag atagtcagtc tgatcaagaa cctgttagtt 42300
gctcttaagg acttccattc tgaatatatt gtcagtgcct ctaactttac ttcccaactc 42360
tcaagtcaag ttgagcaatt tctgcacaga aatattcagg aatatcttag catccttacc 42420
gatccagatg gaaaagggaa agagaagatt gcagagcttt ctgccactgc tcaggaaata 42480
attaaaagcc aggcattgc gacgaagaaa ataatttctg attaccacca gcagtttaga 42540
tataaactgc aagatttht agaccaactc tctgattact atgaaaaatt tattgctgaa 42600
tccaaaagat tgattgacct gtccattcaa aactaccaca cttttctgat atacatcacg 42660
gagttactga aaaagctgca atcaaccaca gtcatgaacc cctacatgaa gcttgctcca 42720

ggagaactta ctatcatcct ctaatttttt aaaagaaatc ttcatttatt cttcttttcc 42780
 aattgaactt tcacatagca cagaaaaaat tcaaactgcc tatattgata aaaccataca 42840
 gtgagccagc cttgcagtag gcagtagact ataagcagaa gcacatatga actggacctg 42900
 caccaaagct ggcaccaggg ctcggaaggt ctctgaactc agaaggatgg ctttttttgc 42960
 aagthaaaga aaatcaggat ctgagttatt ttgctaaact tgggggagga ggaacaaata 43020
 aatggagtct ttattgtgta tcataccact gaatgtggct cttttgtatt gaaagacagt 43080
 gaaacgaggg cattgataaa atgttctggc acagcaaac ctctagaaca catagtgtga 43140
 ttttaagtaac agaataaaaa tggaaacgga gaaattatgg agggaaatat tttgcaaaaa 43200
 tatttaaaaa gatgaggtaa ttgtgttttt ataattaaat attttataat taaaatattt 43260
 ataattaaaa tatttataat taaatatttt ataattaaaa tatttataat taaatatttt 43320
 ataattaaag tatttataat taaatatttt ataattaaaa tatttataat taaatatttt 43380
 ataattaaaa tatttataat taaatatttt ataattaaaa tatttataat taaatatttt 43440
 ataatt 43445

<210> 335

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 335

tctgtaagac aggagaaaga

20

<210> 336

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 336

atttcctctt ctgtaagaca

20

<210> 337

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 337

gatgccttac ttggacagac

20

<210> 338

<211> 20

<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 338
agaaatagct ctccaagga 20

<210> 339
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 339
gtcgcatctt ctaacgtggg 20

<210> 340
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 340
tcctccatac cttgcagttg 20

<210> 341
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 341
tggctcatgt ctaccatatt 20

<210> 342
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 342
cagttgaaat gcagctaattg 20

<210> 343
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 343
tgcagactag gaggtaaagt 20

<210> 344
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 344
aggaggatgt ccttttattg

20

<210> 345
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 345
atcagagcac caaagygaat

20

<210> 346
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 346
ccagctcaac ctgagaattc

20

<210> 347
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 347
catgacttac ctggacatgy

20

<210> 348
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 348
cctcagcgga cacacacaca

20

<210> 349
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 349
gtcacatccg tgctggtgc

20

<210> 350
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 350
cagtgcctct gggacccac 20

<210> 351
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 351
agctgcagtg gccgatcagc 20

<210> 352
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 352
gacctcccca gccacgtgga 20

<210> 353
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 353
tctgatcacc atacattaca 20

<210> 354
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 354
atttcccact gggactactc 20

<210> 355
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 355
ggctgaagcc catgctgact

20

<210> 356
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 356
gttggacagt cattcttttg

20

<210> 357
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 357
cacttggttg acagtcattc

20

<210> 358
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 358
atttttaaatt acagtagata

20

<210> 359
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 359
ctgttctcca cccatattcag

20

<210> 360
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 360
gagctcatatc ctgtcccaga

20

<210> 361
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 361
ttcaagggcc actgctatca

20

<210> 362
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 362
ccagtatttc acgccaatcc

20

<210> 363
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 363
ggcaggagga acctcgggca

20

<210> 364
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 364
ttttaaaatt agaccaaac

20

<210> 365
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 365
tgactgtttt aaaattagac

20

<210> 366
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 366
cccagcaaac acaggtgaag

20

<210> 367
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 367
gagtggtgggc ttgctagtgc 20

<210> 368
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 368
ctatgcagag tgtggtcttg 20

<210> 369
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 369
agaagatgca accacatgta 20

<210> 370
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 370
acacggtatc ctatggagga 20

<210> 371
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 371
tgggacttac catgcctttg 20

<210> 372
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 372
ggttttgctg ccctacatcc 20

<210> 373
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 373
acaaggagtc cttgtgcaga 20

<210> 374
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 374
atgttcactg agacaggctg 20

<210> 375
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 375
gaaggccat ggttcacatg 20

<210> 376
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 376
attagactgg aagcatcctg 20

<210> 377
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 377
gagattggag acgagcattt 20

<210> 378
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 378
catgacctac ttgtaggaga

20

<210> 379
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 379
tggatttgga tacacaagtt

20

<210> 380
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 380
actcaatata tattcattga

20

<210> 381
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 381
caaggaagca caccatgtca

20

<210> 382
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 382
atacttattc ctggtaacca

20

<210> 383
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 383
ggtagccaga acaccagtgt

20

<210> 384
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 384
actagaggta gccagaacac 20

<210> 385
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 385
accacctgac atcacaggtt 20

<210> 386
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 386
tactgtgacc tatgccagga 20

<210> 387
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 387
ggaggtgcta ctgttgacat 20

<210> 388
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 388
tccagacttg tctgagtcta 20

<210> 389
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 389
tctaagaggt agagctaaag 20

<210> 390
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 390
ccagagatga gcaacttagg 20

<210> 391
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 391
ggccatgtaa attgctcatc 20

<210> 392
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 392
aaagaaacta tctgtattc 20

<210> 393
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 393
ttcttagtac ctggaagatg 20

<210> 394
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 394
cattagatac ctggacacct 20

<210> 395
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 395
gtttcatgga actcagcgca 20

<210> 396
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 396
ctggagagca cctgcaatag

20

<210> 397
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 397
tgaagggtag agaaatcata

20

<210> 398
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 398
ggaaactcac ttgttgacg

20

<210> 399
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 399
aggtgcaaga tgctcctctg

20

<210> 400
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 400
tgcaagagg tgcaagatgt

20

<210> 401
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 401
cacaagagta aggagcagag 20

<210> 402
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 402
gatggatggt gagaaattac 20

<210> 403
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 403
tagacaattg agactcagaa 20

<210> 404
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 404
atgtgcacac aaggacatag 20

<210> 405
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 405
acatacaaatt ggcaataggc 20

<210> 406
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 406
taggcaaagg acatgaatag 20

<210> 407
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 407
ttatgatagc tacagaataa 20

<210> 408
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 408
ctgagattac ccgcagaatc 20

<210> 409
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 409
gatgtatgtc atataaaaga 20

<210> 410
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 410
tttccaatga cctgcattga 20

<210> 411
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 411
agggatggtc aatctggtag 20

<210> 412
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 412
ggctaataaaa tagggtagtt 20

<210> 413
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 413
tcctagagca ctatcaagta 20

<210> 414
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 414
cctcctgggc ctgcagtcaa 20

<210> 415
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 415
catttgacaca agtgtttgtt 20

<210> 416
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 416
ctgacacacc atgttattat 20

<210> 417
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 417
ctttttcaga ctagataaga 20

<210> 418
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 418
tcacacttac ctcgatgagg 20

<210> 419
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 419
aagaaaatgg catcaggttt

20

<210> 420
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 420
ccaagccaat ctgagaaaga

20

<210> 421
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 421
aaatacacac ctgctcargt

20

<210> 422
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 422
cttcacaaat acacacctgc

20

<210> 423
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 423
agtggaagtt tggcttcatt

20

<210> 424
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 424
ttgctagctt caaagtggaa 20

<210> 425
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 425
tcaagaataa gctccagatc 20

<210> 426
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 426
gcatacaagt cacatgaggt 20

<210> 427
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 427
tacaaggtgt ttcttaagaa 20

<210> 428
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 428
atgcagccag gatgggccta 20

<210> 429
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 429
ttaccatata ctgagagttt 20

<210> 430
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 430
gcaaaggtag aggaaggat 20

<210> 431
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 431
aaggaccttc agcaaagga 20

<210> 432
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 432
cataggagta catttatata 20

<210> 433
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 433
attatgataa aatcaatttt 20

<210> 434
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 434
agaaatttca ctagatagat 20

<210> 435
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 435
agcatatttt gatgagctga 20

<210> 436
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 436
gaaaggaagg actagcatat 20

<210> 437
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 437
cctctccaat ctgtagaccc 20

<210> 438
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 438
ctggataact cagacctttg 20

<210> 439
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 439
agtcagaaaa caacctattc 20

<210> 440
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 440
cagcctgcat ctataagtca 20

<210> 441
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 441
aaagaattac cctccactga 20

<210> 442
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 442
tctttcaaac tggctaggca

20

<210> 443
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 443
gcctggcaaa attctgcagg

20

<210> 444
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 444
ctacctcaaa tcaatatgtt

20

<210> 445
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 445
tgctttacct acctagctac

20

<210> 446
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 446
accttggtgtg tctcactcaa

20

<210> 447
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 447
atgcattccc tgactagcac 20

<210> 448
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 448
catctctgag ccccttacca 20

<210> 449
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 449
gctgggcatg cctctctccc 20

<210> 450
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 450
gctttcgcag ctgggcatgc 20

<210> 451
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 451
actcctttct atacctggct 20

<210> 452
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 452
attctgcctc ttagaaagtt 20

<210> 453
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 453
ccaagcctct ttactgggct 20

<210> 454
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 454
cactcatgac cagactaaga 20

<210> 455
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 455
acctcccaga agccttccat 20

<210> 456
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 456
ttcatatgaa atctcctact 20

<210> 457
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 457
tattttaattt actgagaaac 20

<210> 458
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 458
taatgtgttg ctggtgaaga 20

<210> 459
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 459
catctctaac ctggtgtccc 20

<210> 460
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 460
gtgccatgct aggtggccat 20

<210> 461
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 461
agcaaattgg gatctgtgct 20

<210> 462
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 462
tctggaggct cagaaacatg 20

<210> 463
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 463
tgaagacagg gagccaccta 20

<210> 464
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 464
aggattccca agactttgga 20

<210> 465
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 465
cagctctaata ctaaagacat

<210> 466
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 466
gaatactcac cttctgcttg

<210> 467
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 467
atctctctgt cctcatcttc

<210> 468
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 468
ccaactcccc ctttctttgt

<210> 469
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 469
tctgggccag gaagacacga

<210> 470
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

20

20

20

20

20

<400> 470
tatttgtgtgc tgggcactgc 20

<210> 471
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 471
tgcttcgcac ctggacgagt 20

<210> 472
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 472
ccttcctttac cttagggtggc 20

<210> 473
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 473
gctctctctg ccactctgat 20

<210> 474
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 474
aacttctaaa gccaacattc 20

<210> 475
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 475
tgtgtcacaa ctatggtaaa 20

<210> 476
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 476

agacacatac cataatgcca

20

<210> 477

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 477

ttctcttcac ctgaaaatac

20

<210> 478

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 478

tgaggatgta attagcactt

20

<210> 479

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 479

agctcattgc ctacaaaatg

20

<210> 480

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 480

gttctcatgt ttactaatgc

20

<210> 481

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 481

gaattgagac aacttgattt

20

<210> 482

<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 482
ccggccatcg ctgaaatgaa 20

<210> 483
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 483
catagctcac cttgcacatt 20

<210> 484
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 484
cggtgcacccc ttacctgag 20

<210> 485
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 485
tctccagatc ctaacataaa 20

<210> 486
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 486
ttgaatgaca ctagattttc 20

<210> 487
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 487
aaaatccatt ttctttaag 20

<210> 488
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 488
cagctcacac ttatttttaa

20

<210> 489
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 489
gttcccaaaa ctgtatagga

20

<210> 490
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 490
agctccatac tgaagtcctt

20

<210> 491
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 491
caattcaata aaagctccat

20

<210> 492
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 492
gttttcaaaa ggtataaggt

20

<210> 493
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 493
ttccattcc ctgaaagcag 20

<210> 494
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 494
tggtatttac ctgagggctg 20

<210> 495
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 495
ataaataata gtgctgatgg 20

<210> 496
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 496
ctatggctga gcttgccat 20

<210> 497
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 497
ctctctgaaa aatataccct 20

<210> 498
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 498
ttgatgtatc tcatctagca 20

<210> 499
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 499

tagaaccatg ttggtcttc

20.

<210> 500

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 500

tttctcttta tcacatgccc

20

<210> 501

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 501

tatagtacac taaaacttca

20

<210> 502

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 502

ctggagagga ctaaacagag

20

<210> 503

<211> 568

<212> DNA

<213> H. sapiens

<220>

<221> misc_feature

<222> 44, 99, 156, 468

<223> n = A,T,C or G

<400> 503

ccaaaagatt gattgactgt ccattcaaag ctacacgcaa tttntgatat acatcacgta 60

gttactgaaa aagctgcaat caacacagtt catggaccnc taccatgaag cttgctccag 120

gagaacttct atcattcctc taatttttta aaaganatct tcattttattc ttcttttcca 180

attgaacttt cacatagcac agaaaaaatt caaactgcct atattgataa aaccatacag 240

tgagccagcc ttgcagtagg cagtagacta taagcagaag cacatatgaa ctggacctgc 300

accaaagctg gcaccagggc tcggaaggtc tctgaactca gaaggatggc attttttgca 360

agttaaagaa aatcaggatc tgagttatctt tgctaaactt gggggaggag gaacaaataa 420
atggagtctt tattgtgtat cataccactg aatgtggctc atttgtanta aaagacagtg 480
aaacgagggc attgataaaa tgttctggca cagcaaaacc tctagaacac atagtgtgat 540
ttaagtaaca gaataaaaaat ggaaacgg 568

<210> 504
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 504
acattttatc aatgccctcg 20

<210> 505
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 505
gccagaacat tttatcaatg 20

<210> 506
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 506
agaggttttg ctgtgccaga 20

<210> 507
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 507
ctagaggttt tgctgtgcca 20

<210> 508
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 508
tctagaggtt ttgctgtgcc 20

<210> 509
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 509
aatcacacta tgtgttctag

20

<210> 510
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 510
aaatcacact atgtgttcta

20

<210> 511
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 511
taaatacacac tatgtgttct

20

<210> 512
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 512
cttaaatacac actatgtgtt

20

<210> 513
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 513
tattctgtta cttaaatacac

20

<210> 514
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 514
tggtagcctc agtctgcttc

20

<210> 515
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 515
agtctgcttc gcgccttctg

20

<210> 516
<211> 20
<212> DNA
<213> H. sapiens

<400> 516
gcgccagggc cgaagaggaa

20

<210> 517
<211> 20
<212> DNA
<213> H. sapiens

<400> 517
caggtatgag ctcaagctgg

20

<210> 518
<211> 20
<212> DNA
<213> H. sapiens

<400> 518
catcctgaac atcaagaggc

20

<210> 519
<211> 20
<212> DNA
<213> H. sapiens

<400> 519
gggcagtgtg atcgcttcaa

20

<210> 520
<211> 20
<212> DNA
<213> H. sapiens

<400> 520
cacttgctct catcaaaggc

20

<210> 521
<211> 20
<212> DNA
<213> H. sapiens

<400> 521
cacactggac gctaagagga

20

<210> 522

<211> 20
<212> DNA
<213> H. sapiens

<400> 522
cgctgagcca cgcggtcaac

20

<210> 523
<211> 20
<212> DNA
<213> H. sapiens

<400> 523
tgtccaaatt ctaccatggg

20

<210> 524
<211> 20
<212> DNA
<213> H. sapiens

<400> 524
cagctgacct catcgagatt

20

<210> 525
<211> 20
<212> DNA
<213> H. sapiens

<400> 525
gtcaagttcc tgatggtgtc

20

<210> 526
<211> 20
<212> DNA
<213> H. sapiens

<400> 526
agctgcttct gatgggtgcc

20

<210> 527
<211> 20
<212> DNA
<213> H. sapiens

<400> 527
gggcatcatc attccggact

20

<210> 528
<211> 20
<212> DNA
<213> H. sapiens

<400> 528
cctactatcc gctgaccggg

20

<210> 529
<211> 20
<212> DNA
<213> H. sapiens

<400> 529
gggccaccta agttgtgaca

20

<210> 530
<211> 20
<212> DNA
<213> H. sapiens

<400> 530
agaacatggg attgccagac

20

<210> 531
<211> 20
<212> DNA
<213> H. sapiens

<400> 531
ctccacttca agtctgtggg

20

<210> 532
<211> 20
<212> DNA
<213> H. sapiens

<400> 532
cagagcttgg cctctctggg

20

<210> 533
<211> 20
<212> DNA
<213> H. sapiens

<400> 533
tgcccgcttc agggaaacaca

20

<210> 534
<211> 20
<212> DNA
<213> H. sapiens

<400> 534
cagctgagca gacaggcacc

20

<210> 535
<211> 20
<212> DNA
<213> H. sapiens

<400> 535
gggagagaca agtttcacat

20

<210> 536
<211> 20
<212> DNA
<213> H. sapiens

<400> 536
gtactgcata ctggattcaa

20

<210> 537
<211> 20
<212> DNA
<213> H. sapiens

<400> 537
gtgaggtgac tcagagactc

20

<210> 538
<211> 20
<212> DNA
<213> H. sapiens

<400> 538
ttgcagagca atattctatc 20

<210> 539
<211> 20
<212> DNA
<213> H. sapiens

<400> 539
aagcattggt agagcaaggg 20

<210> 540
<211> 20
<212> DNA
<213> H. sapiens

<400> 540
ccgctggctc tgaaggagtc 20

<210> 541
<211> 20
<212> DNA
<213> H. sapiens

<400> 541
tctagtcagg ctgacctgcg 20

<210> 542
<211> 20
<212> DNA
<213> H. sapiens

<400> 542
gggccacagt gttctaactg 20

<210> 543
<211> 20
<212> DNA
<213> H. sapiens

<400> 543
aatcaagtgt catcacactg 20

<210> 544
<211> 20
<212> DNA
<213> H. sapiens

<400> 544
gggtagtcac aacagtactg 20

<210> 545
<211> 20
<212> DNA
<213> H. sapiens

<400> 545
agagcacacg gtcttcagtg 20

<210> 546
<211> 20
<212> DNA
<213> H. sapiens

<400> 546
ttacagctag agggcctctt

20

<210> 547
<211> 20
<212> DNA
<213> H. sapiens

<400> 547
cacctgtgggc atggatatgg

20

<210> 548
<211> 20
<212> DNA
<213> H. sapiens

<400> 548
gggaatctga tgaggaaact

20

<210> 549
<211> 20
<212> DNA
<213> H. sapiens

<400> 549
tgtcaacaag taccactggg

20

<210> 550
<211> 20
<212> DNA
<213> H. sapiens

<400> 550
acctgggata tacactaggg

20

<210> 551
<211> 20
<212> DNA
<213> H. sapiens

<400> 551
ccaagtatag ttggctggac

20

<210> 552
<211> 20
<212> DNA
<213> H. sapiens

<400> 552
tacatgaagc ttgctccagg

20

<210> 553
<211> 20
<212> DNA
<213> H. sapiens

<400> 553
atgtcagcct ggtctgtcca

20

<210> 554
<211> 20
<212> DNA
<213> H. sapiens

<400> 554
gcacctccgg aagtacacat

20

<210> 555
<211> 20
<212> DNA
<213> H. sapiens

<400> 555
ctgcagcttc atcctgaaga

20

<210> 556
<211> 20
<212> DNA
<213> H. sapiens

<400> 556
tgagggcaaa gacctgctga

20

<210> 557
<211> 20
<212> DNA
<213> H. sapiens

<400> 557
ccattccaga agggaagcag

20

<210> 558
<211> 20
<212> DNA
<213> H. sapiens

<400> 558
cgaggaaggg caatgtggca

20

<210> 559
<211> 20
<212> DNA
<213> H. sapiens

<400> 559
ccttgtcaac tctgatcagc

20

<210> 560
<211> 20
<212> DNA
<213> H. sapiens

<400> 560
agcagccagt cctgtcagta

20

<210> 561
<211> 20
<212> DNA
<213> H. sapiens

<400> 561
agcatgtggc agaagccatc

20

<210> 562
<211> 20
<212> DNA
<213> H. sapiens

<400> 562
gagagcacca aatccacatc 20

<210> 563
<211> 20
<212> DNA
<213> H. sapiens

<400> 563
cctcagtgat gaagcagtc 20

<210> 564
<211> 20
<212> DNA
<213> H. sapiens

<400> 564
gatagatgtg gtcacctacc. 20

<210> 565
<211> 20
<212> DNA
<213> H. sapiens

<400> 565
cctcagcaca gcagctgcga 20

<210> 566
<211> 20
<212> DNA
<213> H. sapiens

<400> 566
gattctgcgg gtcattggaa 20

<210> 567
<211> 20
<212> DNA
<213> H. sapiens

<400> 567
caaagccatc actgatgatc 20

<210> 568
<211> 20
<212> DNA
<213> H. sapiens

<400> 568
agaaagctgc catccaggct 20

<210> 569
<211> 20
<212> DNA
<213> H. sapiens

<400> 569
caggaggttc ttcttcagac 20

<210> 570
<211> 20
<212> DNA
<213> H. sapiens

<400> 570
gagtccttca caggcagata 20

<210> 571
<211> 20
<212> DNA
<213> H. sapiens

<400> 571
tgccaatata ttgaactcag 20

<210> 572
<211> 20
<212> DNA
<213> H. sapiens

<400> 572
catcgagatt ggcttggaag 20

<210> 573
<211> 20
<212> DNA
<213> H. sapiens

<400> 573
ggagctggat tacagttgca 20

<210> 574
<211> 20
<212> DNA
<213> H. sapiens

<400> 574
caacatgcag gctgaactgg 20

<210> 575
<211> 20
<212> DNA
<213> H. sapiens

<400> 575
acattacatt tggctctctac 20

<210> 576
<211> 20
<212> DNA
<213> H. sapiens

<400> 576
ctcaggcgct tactccaacg 20

<210> 577
<211> 20
<212> DNA
<213> H. sapiens

<400> 577
gggacaccag attagagctg 20

<210> 578
<211> 20
<212> DNA
<213> H. sapiens

<400> 578
gagctocaga gagaggacag

20

<210> 579
<211> 20
<212> DNA
<213> H. sapiens

<400> 579
atcggcagag tatgaccttg

20

<210> 580
<211> 20
<212> DNA
<213> H. sapiens

<400> 580
caagggtggt atttcatac

20

<210> 581
<211> 20
<212> DNA
<213> H. sapiens

<400> 581
gactcatctg ctacagctta

20

<210> 582
<211> 20
<212> DNA
<213> H. sapiens

<400> 582
gcaaattcctc cagagatcta

20

<210> 583
<211> 20
<212> DNA
<213> H. sapiens

<400> 583
ctctcctggg tgttctagac

20

<210> 584
<211> 20
<212> DNA
<213> H. sapiens

<400> 584
atgaaggctg actctgtggt

20

<210> 585
<211> 20
<212> DNA
<213> H. sapiens

<400> 585
gggaccacag atgtctgctt

20

<210> 586
<211> 20
<212> DNA
<213> H. sapiens

<400> 586
ctggccggct caatggagag 20

<210> 587
<211> 20
<212> DNA
<213> H. sapiens

<400> 587
gctgcgttct gaatatcagg 20

<210> 588
<211> 20
<212> DNA
<213> H. sapiens

<400> 588
tgctgacatc ttaggcactg 20

<210> 589
<211> 20
<212> DNA
<213> H. sapiens

<400> 589
aagtgtagtc tcctgggtgct 20

<210> 590
<211> 20
<212> DNA
<213> H. sapiens

<400> 590
caaaattcag tctggatggg 20

<210> 591
<211> 20
<212> DNA
<213> H. sapiens

<400> 591
gggaaactac ggctagaacc 20

<210> 592
<211> 20
<212> DNA
<213> H. sapiens

<400> 592
ctgcatgtgg ctggtaacct 20

<210> 593
<211> 20
<212> DNA
<213> H. sapiens

<400> 593
ccatgacct cgatgcacat 20

<210> 594
<211> 20
<212> DNA
<213> H. sapiens

<400> 594
atgggaaact cgctctctgg

20

<210> 595
<211> 20
<212> DNA
<213> H. sapiens

<400> 595
agtcacatc tcgtgtctag

20

<210> 596
<211> 20
<212> DNA
<213> H. sapiens

<400> 596
gaatacagcc aggacttgga

20

<210> 597
<211> 20
<212> DNA
<213> H. sapiens

<400> 597
ggcgtggagc ttactggacg

20

<210> 598
<211> 20
<212> DNA
<213> H. sapiens

<400> 598
gagatgagag atgccgttga

20

<210> 599
<211> 20
<212> DNA
<213> H. sapiens

<400> 599
agtcttgatg agcactatca

20

<210> 600
<211> 20
<212> DNA
<213> H. sapiens

<400> 600
ctaagtacca aatcagaatc

20

<210> 601
<211> 20
<212> DNA
<213> H. sapiens

<400> 601
gtccatgagt taatcgagag

20

<210> 602
<211> 20
<212> DNA
<213> H. sapiens

<400> 602
aggccacagt tgcagtgtat 20

<210> 603
<211> 20
<212> DNA
<213> H. sapiens

<400> 603
tctgattggg ggactcttgc 20

<210> 604
<211> 20
<212> DNA
<213> H. sapiens

<400> 604
gaagtcagtc ttcaggctct 20

<210> 605
<211> 20
<212> DNA
<213> H. sapiens

<400> 605
ccagattctc agatgaggga 20

<210> 606
<211> 20
<212> DNA
<213> H. sapiens

<400> 606
catctgtcat tgatgcactg 20

<210> 607
<211> 20
<212> DNA
<213> H. sapiens

<400> 607
aggagatgtc aagggttcgg 20

<210> 608
<211> 20
<212> DNA
<213> H. sapiens

<400> 608
ggaactattg ctagtgaggc 20

<210> 609
<211> 20
<212> DNA
<213> H. sapiens

<400> 609
ctctctccat ggcaaagtgc 20

<210> 610
<211> 20
<212> DNA
<213> H. sapiens

<400> 610
caccgtgact tcagtgcaga 20

<210> 611
<211> 20
<212> DNA
<213> H. sapiens

<400> 611
actgagttga ggggccggga 20

<210> 612
<211> 20
<212> DNA
<213> H. sapiens

<400> 612
cacatatgaa ctggacctgc 20

<210> 613
<211> 20
<212> DNA
<213> H. sapiens

<400> 613
tctgaactca gaaggatggc 20

<210> 614
<211> 20
<212> DNA
<213> H. sapiens

<400> 614
gggtgcgaagc agactgaggc 20

<210> 615
<211> 20
<212> DNA
<213> H. sapiens

<400> 615
tcccaccggg acctgcgggg 20

<210> 616
<211> 20
<212> DNA
<213> H. sapiens

<400> 616
caccgggacc tgcggggctg 20

<210> 617
<211> 20
<212> DNA
<213> H. sapiens

<400> 617
ctgagtgcc ttctcggttg 20

<210> 618
<211> 20
<212> DNA
<213> H. sapiens

<400> 618
ctcggttgct gccgctgagg 20

<210> 619
<211> 20
<212> DNA
<213> H. sapiens

<400> 619
tcggttgctg ccgctgagga 20

<210> 620
<211> 20
<212> DNA
<213> H. sapiens

<400> 620
cggttgctgc cgctgaggag 20

<210> 621
<211> 20
<212> DNA
<213> H. sapiens

<400> 621
gttgctgccg ctgaggagcc 20

<210> 622
<211> 20
<212> DNA
<213> H. sapiens

<400> 622
ctgccgctga ggagcccgcc 20

<210> 623
<211> 20
<212> DNA
<213> H. sapiens

<400> 623
accgcagctg gcgatggacc 20

<210> 624
<211> 20
<212> DNA
<213> H. sapiens

<400> 624
cagctggcga tggacccgcc 20

<210> 625
<211> 20
<212> DNA
<213> H. sapiens

<400> 625
gaacttacta tcacctcta 20

<210> 626
<211> 20
<212> DNA
<213> H. sapiens

<400> 626
tccaattgaa ctttcacata
20

<210> 627
<211> 20
<212> DNA
<213> H. sapiens

<400> 627
aaaattcaaa ctgcctatat
20

<210> 628
<211> 20
<212> DNA
<213> H. sapiens

<400> 628
gataaaacca tacagtgagc
20

<210> 629
<211> 20
<212> DNA
<213> H. sapiens

<400> 629
ataaaaaccat acagtgagcc
20

<210> 630
<211> 20
<212> DNA
<213> H. sapiens

<400> 630
aaccatacag tgagccagcc
20

<210> 631
<211> 20
<212> DNA
<213> H. sapiens

<400> 631
accatacagt gagccagcct
20

<210> 632
<211> 20
<212> DNA
<213> H. sapiens

<400> 632
ccatacagtg agccagcctt
20

<210> 633
<211> 20
<212> DNA
<213> H. sapiens

<400> 633
gtgagccagc cttgcagtag
20

<210> 634
<211> 20
<212> DNA
<213> H. sapiens

<400> 634
ccagccttgc agtaggcagt 20

<210> 635
<211> 20
<212> DNA
<213> H. sapiens

<400> 635
taggcagtag actataagca 20

<210> 636
<211> 20
<212> DNA
<213> H. sapiens

<400> 636
gcagtagact ataagcagaa 20

<210> 637
<211> 20
<212> DNA
<213> H. sapiens

<400> 637
tgaactggac ctgcaccaaaa 20

<210> 638
<211> 20
<212> DNA
<213> H. sapiens

<400> 638
ctggacctgc accaaaagctg 20

<210> 639
<211> 20
<212> DNA
<213> H. sapiens

<400> 639
ggacctgcac caaagctggc 20

<210> 640
<211> 20
<212> DNA
<213> H. sapiens

<400> 640
ctgcacaaaa gctggcacca 20

<210> 641
<211> 20
<212> DNA
<213> H. sapiens

<400> 641
accaaagctg gcaccagggc 20

<210> 642
<211> 20
<212> DNA
<213> H. sapiens

<400> 642
ctcgggaaggt ctctgaactc

20

<210> 643
<211> 20
<212> DNA
<213> H. sapiens

<400> 643
aactcagaag gatggcattt

20

<210> 644
<211> 20
<212> DNA
<213> H. sapiens

<400> 644
ctcagaagga tggcattttt

20

<210> 645
<211> 20
<212> DNA
<213> H. sapiens

<400> 645
atcaggatct gagttatttt

20

<210> 646
<211> 20
<212> DNA
<213> H. sapiens

<400> 646
aggatctgag ttatttttgct

20

<210> 647
<211> 20
<212> DNA
<213> H. sapiens

<400> 647
ctgagttatt ttgctaaact

20

<210> 648
<211> 20
<212> DNA
<213> H. sapiens

<400> 648
attttgctaa acttggggga

20

<210> 649
<211> 20
<212> DNA
<213> H. sapiens

<400> 649
taaacttggg ggaggaggaa

20

<210> 650
<211> 20
<212> DNA
<213> H. sapiens

<400> 650
ggaacaaata aatggagtct

20

<210> 651
<211> 20
<212> DNA
<213> H. sapiens

<400> 651
gtttgtaact caagcagaag

20

<210> 652
<211> 20
<212> DNA
<213> H. sapiens

<400> 652
ttgtaactca agcagaaggt

20

<210> 653
<211> 20
<212> DNA
<213> H. sapiens

<400> 653
gtaactcaag cagaaggtgc

20

<210> 654
<211> 20
<212> DNA
<213> H. sapiens

<400> 654
aactcaagca gaaggtgcga

20

<210> 655
<211> 20
<212> DNA
<213> H. sapiens

<400> 655
ctcaagcaga aggtgcgaag

20

<210> 656
<211> 20
<212> DNA
<213> H. sapiens

<400> 656
caagcagaag gtgcgaagca

20

<210> 657
<211> 20
<212> DNA
<213> H. sapiens

<400> 657
agcagaaggt gcgaagcaga

20

<210> 658
<211> 20
<212> DNA
<213> H. sapiens

<400> 658
cagaaggtgc gaagcagact

20

<210> 659
<211> 20
<212> DNA
<213> H. sapiens

<400> 659
gaaggtgcga agcagactga

20

<210> 660
<211> 20
<212> DNA
<213> H. sapiens

<400> 660
aggtgcgaag cagactgagg

20

<210> 661
<211> 20
<212> DNA
<213> H. sapiens

<400> 661
gtgcgaagca gactgaggct

20

<210> 662
<211> 20
<212> DNA
<213> H. sapiens

<400> 662
gcgaagcaga ctgaggctac

20

<210> 663
<211> 20
<212> DNA
<213> H. sapiens

<400> 663
gaagcagact gaggctacca

20

<210> 664
<211> 20
<212> DNA
<213> H. sapiens

<400> 664
agcagactga ggctaccatg

20

<210> 665
<211> 20
<212> DNA
<213> H. sapiens

<400> 665
cagactgagg ctaccatgac

20

<210> 666
<211> 20
<212> DNA
<213> H. sapiens

<400> 666
gactgaggct accatgacat 20

<210> 667
<211> 20
<212> DNA
<213> H. sapiens

<400> 667
ctgaggctac catgacattc 20

<210> 668
<211> 20
<212> DNA
<213> H. sapiens

<400> 668
gaggctacca tgacattcaa 20

<210> 669
<211> 20
<212> DNA
<213> H. sapiens

<400> 669
ggctaccatg acattcaa 20

<210> 670
<211> 20
<212> DNA
<213> H. sapiens

<400> 670
ctaccatgac attcaaatat 20

<210> 671
<211> 20
<212> DNA
<213> H. sapiens

<400> 671
cctgaagctg catgtggctg 20

<210> 672
<211> 20
<212> DNA
<213> H. sapiens

<400> 672
tgaagctgca tgtggctggt 20

<210> 673
<211> 20
<212> DNA
<213> H. sapiens

<400> 673
aagcty catg tggctggtaa 20

<210> 674
<211> 20
<212> DNA
<213> H. sapiens

<400> 674
gctgcatgtg gctggtaacc

20

<210> 675
<211> 20
<212> DNA
<213> H. sapiens

<400> 675
tgcatgtggc tggtaaccta

20

<210> 676
<211> 20
<212> DNA
<213> H. sapiens

<400> 676
catgtggctg gtaacctaaa

20

<210> 677
<211> 20
<212> DNA
<213> H. sapiens

<400> 677
tgtggctggt aacctaataag

20

<210> 678
<211> 20
<212> DNA
<213> H. sapiens

<400> 678
tggctggtaa cctaaaagga

20

<210> 679
<211> 20
<212> DNA
<213> H. sapiens

<400> 679
gctggttaacc taaaaggagc

20

<210> 680
<211> 20
<212> DNA
<213> H. sapiens

<400> 680
tggtaaccta aaaggagcct

20

<210> 681
<211> 20
<212> DNA
<213> H. sapiens

<400> 681
gtaacctaaa aggagcctac

20

<210> 682
<211> 20
<212> DNA
<213> H. sapiens

<400> 682
aacctaaaag gagcctacca 20

<210> 683
<211> 20
<212> DNA
<213> H. sapiens

<400> 683
cctaaaagga gcctaccaaa 20

<210> 684
<211> 20
<212> DNA
<213> H. sapiens

<400> 684
ggcgcgaagc agactgaggc 20

<210> 685
<211> 20
<212> DNA
<213> H. sapiens

<400> 685
cactatgttc atgagggagg 20

<210> 686
<211> 20
<212> DNA
<213> H. sapiens

<400> 686
ccatcatagg ttctgacgtc 20

<210> 687
<211> 20
<212> DNA
<213> H. sapiens

<400> 687
gaagctgatt gactcactca 20

<210> 688
<211> 20
<212> DNA
<213> H. sapiens

<400> 688
ttgtaactca agcagaaggc 20

<210> 689
<211> 20
<212> DNA
<213> H. sapiens

<400> 689
gtaactcaag cagaaggcgc 20

<210> 690
<211> 20
<212> DNA
<213> H. sapiens

<400> 690
aactcaagca gaaggcgcga

20

<210> 691
<211> 20
<212> DNA
<213> H. sapiens

<400> 691
ctcaagcaga aggcgcgaag

20

<210> 692
<211> 20
<212> DNA
<213> H. sapiens

<400> 692
cagaaggcgc gaagcagact

20

<210> 693
<211> 20
<212> DNA
<213> H. sapiens

<400> 693
gaaggcgcga agcagactga

20

<210> 694
<211> 20
<212> DNA
<213> H. sapiens

<400> 694
aggcgcgaag cagactgagg

20

<210> 695
<211> 20
<212> DNA
<213> H. sapiens

<400> 695
gcgcgaagca gactgaggct

20

<210> 696
<211> 20
<212> DNA
<213> H. sapiens

<400> 696
gaagcagact gaggctacca

20

<210> 697
<211> 20
<212> DNA
<213> H. sapiens

<400> 697
cagaaggcgc gaagcagact

20

<210> 698
<211> 20
<212> DNA
<213> H. sapiens

<400> 698
tctttctcct gtcttacaga 20

<210> 699
<211> 20
<212> DNA
<213> H. sapiens

<400> 699
cccacgttag aagatgcgac 20

<210> 700
<211> 20
<212> DNA
<213> H. sapiens

<400> 700
aatatggttag acatgagcca 20

<210> 701
<211> 20
<212> DNA
<213> H. sapiens

<400> 701
cattagctgc atttcaactg 20

<210> 702
<211> 20
<212> DNA
<213> H. sapiens

<400> 702
actttcactc ctagtctgca 20

<210> 703
<211> 20
<212> DNA
<213> H. sapiens

<400> 703
ccatgtccag gtaagtcattg 20

<210> 704
<211> 20
<212> DNA
<213> H. sapiens

<400> 704
gcaccaggca cggatgtgac 20

<210> 705
<211> 20
<212> DNA
<213> H. sapiens

<400> 705
gtgggggtccc agaggcactg 20

<210> 706
<211> 20
<212> DNA
<213> H. sapiens

<400> 706
gctgatcggc cactgcagct 20

<210> 707
<211> 20
<212> DNA
<213> H. sapiens

<400> 707
tccacgtggc tggggaggtc 20

<210> 708
<211> 20
<212> DNA
<213> H. sapiens

<400> 708
tgtaatgtat ggtgatcaga 20

<210> 709
<211> 20
<212> DNA
<213> H. sapiens

<400> 709
gagagtaccc agtgggaaat 20

<210> 710
<211> 20
<212> DNA
<213> H. sapiens

<400> 710
agtcagcatg ggcttcagcc 20

<210> 711
<211> 20
<212> DNA
<213> H. sapiens

<400> 711
caaaagaatg actgtccaac 20

<210> 712
<211> 20
<212> DNA
<213> H. sapiens

<400> 712
gaatgactgt ccaacaagtg 20

<210> 713
<211> 20
<212> DNA
<213> H. sapiens

<400> 713
tatctactgt aatttaaaat 20

<210> 714
<211> 20
<212> DNA
<213> H. sapiens

<400> 714
ctgatatggg tggagaacag

20

<210> 715
<211> 20
<212> DNA
<213> H. sapiens

<400> 715
tctgggacag gtatgagctc

20

<210> 716
<211> 20
<212> DNA
<213> H. sapiens

<400> 716
tgatagcagt ggcccttgaa

20

<210> 717
<211> 20
<212> DNA
<213> H. sapiens

<400> 717
ggattggcgt gaaatactgg

20

<210> 718
<211> 20
<212> DNA
<213> H. sapiens

<400> 718
tgcccgaggt tcctcctgcc

20

<210> 719
<211> 20
<212> DNA
<213> H. sapiens

<400> 719
gcactagcaa gaccacactc

20

<210> 720
<211> 20
<212> DNA
<213> H. sapiens

<400> 720
caagaccaca ctctgcatag

20

<210> 721
<211> 20
<212> DNA
<213> H. sapiens

<400> 721
tcctccatag gataccgtgt

20

<210> 722
<211> 20
<212> DNA
<213> H. sapiens

<400> 722
ggatgtaggg cagcaaaacc 20

<210> 723
<211> 20
<212> DNA
<213> H. sapiens

<400> 723
tctgcacaag gactccttgt 20

<210> 724
<211> 20
<212> DNA
<213> H. sapiens

<400> 724
cagcctgtct cagtgaacat 20

<210> 725
<211> 20
<212> DNA
<213> H. sapiens

<400> 725
caggatgctt ccagtctaata 20

<210> 726
<211> 20
<212> DNA
<213> H. sapiens

<400> 726
aaatgctcgt ctccaatctc 20

<210> 727
<211> 20
<212> DNA
<213> H. sapiens

<400> 727
aacttgtgta tccaaatcca 20

<210> 728
<211> 20
<212> DNA
<213> H. sapiens

<400> 728
tgacatgggtg tgcttccttg 20

<210> 729
<211> 20
<212> DNA
<213> H. sapiens

<400> 729
acactgggtgt tctggctacc 20

<210> 730
<211> 20
<212> DNA
<213> H. sapiens

<400> 730
gtgttctggc tacctctagt 20

<210> 731
<211> 20
<212> DNA
<213> H. sapiens

<400> 731
tcctggcata ggtcacagta 20

<210> 732
<211> 20
<212> DNA
<213> H. sapiens

<400> 732
atgtcaacag tagcacctcc 20

<210> 733
<211> 20
<212> DNA
<213> H. sapiens

<400> 733
tagactcaga caagtctgga 20

<210> 734
<211> 20
<212> DNA
<213> H. sapiens

<400> 734
cctaagttgc tcatctctgg 20

<210> 735
<211> 20
<212> DNA
<213> H. sapiens

<400> 735
tgcgctgagt tccatgaaac 20

<210> 736
<211> 20
<212> DNA
<213> H. sapiens

<400> 736
ctattgcagg tgctctccag 20

<210> 737
<211> 20
<212> DNA
<213> H. sapiens

<400> 737
cagaggaaca tcttgcacct 20

<210> 738
<211> 20
<212> DNA
<213> H. sapiens

<400> 738
ctctgctcct tactcttgtg

20

<210> 739
<211> 20
<212> DNA
<213> H. sapiens

<400> 739
gtaatttctc accatccatc

20

<210> 740
<211> 20
<212> DNA
<213> H. sapiens

<400> 740
ttctgagtct caattgtcta

20

<210> 741
<211> 20
<212> DNA
<213> H. sapiens

<400> 741
ctatgtcctt gtgtgcacat

20

<210> 742
<211> 20
<212> DNA
<213> H. sapiens

<400> 742
gcctattgcc atttgatatg

20

<210> 743
<211> 20
<212> DNA
<213> H. sapiens

<400> 743
ctattcatgt cctttgccta

20

<210> 744
<211> 20
<212> DNA
<213> H. sapiens

<400> 744
gattctgcgg gtaatctcag

20

<210> 745
<211> 20
<212> DNA
<213> H. sapiens

<400> 745
tcaatgcagg tcattggaaa

20

<210> 746
<211> 20
<212> DNA
<213> H. sapiens

<400> 746
ctaccagatt gaccatccct

20

<210> 747
<211> 20
<212> DNA
<213> H. sapiens

<400> 747
tacttgatag tgctctagga

20

<210> 748
<211> 20
<212> DNA
<213> H. sapiens

<400> 748
ttgactgcag gaccaggagg

20

<210> 749
<211> 20
<212> DNA
<213> H. sapiens

<400> 749
aacaaacact tgtgcaaattg

20

<210> 750
<211> 20
<212> DNA
<213> H. sapiens

<400> 750
aatgagacca aacttccact

20

<210> 751
<211> 20
<212> DNA
<213> H. sapiens

<400> 751
ttccactttg aagctagcaa

20

<210> 752
<211> 20
<212> DNA
<213> H. sapiens

<400> 752
gatctggagc ttattcttga

20

<210> 753
<211> 20
<212> DNA
<213> H. sapiens

<400> 753
acctcatgtg acttgatatgc

20

<210> 754
<211> 20
<212> DNA
<213> H. sapiens

<400> 754
ttcttaagaa acaccttgta 20

<210> 755
<211> 20
<212> DNA
<213> H. sapiens

<400> 755
taggcccatc ctggctgcat 20

<210> 756
<211> 20
<212> DNA
<213> H. sapiens

<400> 756
aaactctcag gatatggtaa 20

<210> 757
<211> 20
<212> DNA
<213> H. sapiens

<400> 757
ataccttcct ctaccttrgc 20

<210> 758
<211> 20
<212> DNA
<213> H. sapiens

<400> 758
tacctttgct gaaggctcctt 20

<210> 759
<211> 20
<212> DNA
<213> H. sapiens

<400> 759
atctatctag tgaaatttct 20

<210> 760
<211> 20
<212> DNA
<213> H. sapiens

<400> 760
tcagctcatc aaaatatgct 20

<210> 761
<211> 20
<212> DNA
<213> H. sapiens

<400> 761
atatgctagt ccttcctttc 20

<210> 762
<211> 20
<212> DNA
<213> H. sapiens

<400> 762
caaaggtctg agttatccag

20

<210> 763
<211> 20
<212> DNA
<213> H. sapiens

<400> 763
tgacttatag atgcaggctg

20

<210> 764
<211> 20
<212> DNA
<213> H. sapiens

<400> 764
tcagtggagy gtaattcttt

20

<210> 765
<211> 20
<212> DNA
<213> H. sapiens

<400> 765
tgcctagcca gtttgaaaga

20

<210> 766
<211> 20
<212> DNA
<213> H. sapiens

<400> 766
cctgcagaat tttgccaggc

20

<210> 767
<211> 20
<212> DNA
<213> H. sapiens

<400> 767
gtagctaggt aggtaaagca

20

<210> 768
<211> 20
<212> DNA
<213> H. sapiens

<400> 768
ttgagtgaga cacacaaggt

20

<210> 769
<211> 20
<212> DNA
<213> H. sapiens

<400> 769
gtgctagtca gggaatgcat

20

<210> 770
<211> 20
<212> DNA
<213> H. sapiens

<400> 770
ggggagagag catgcccagc 20

<210> 771
<211> 20
<212> DNA
<213> H. sapiens

<400> 771
gcatgcccag ctgcgaaagc 20

<210> 772
<211> 20
<212> DNA
<213> H. sapiens

<400> 772
agccagggtat agaaaggagt 20

<210> 773
<211> 20
<212> DNA
<213> H. sapiens

<400> 773
aactttctaa gaggcagaat 20

<210> 774
<211> 20
<212> DNA
<213> H. sapiens

<400> 774
tcttagtctg gtcattgagt 20

<210> 775
<211> 20
<212> DNA
<213> H. sapiens

<400> 775
agtaggagat ttcattatgaa 20

<210> 776
<211> 20
<212> DNA
<213> H. sapiens

<400> 776
tcttcaccag caacacatta 20

<210> 777
<211> 20
<212> DNA
<213> H. sapiens

<400> 777
atggccacct agcatggcac 20

<210> 778
<211> 20
<212> DNA
<213> H. sapiens

<400> 778
catgtttctg agcctccaga

20

<210> 779
<211> 20
<212> DNA
<213> H. sapiens

<400> 779
taggtggctc cctgtcttca

20

<210> 780
<211> 20
<212> DNA
<213> H. sapiens

<400> 780
tccaaagtct tgggaatcct

20

<210> 781
<211> 20
<212> DNA
<213> H. sapiens

<400> 781
acaaagaaag ggggagttgg

20

<210> 782
<211> 20
<212> DNA
<213> H. sapiens

<400> 782
tcgtgtcttc ctggcccaga

20

<210> 783
<211> 20
<212> DNA
<213> H. sapiens

<400> 783
gcagtgccca gcacacaata

20

<210> 784
<211> 20
<212> DNA
<213> H. sapiens

<400> 784
actcgtccag gtgcgaagca

20

<210> 785
<211> 20
<212> DNA
<213> H. sapiens

<400> 785
gccacctaag gttaaagaagg

20

<210> 786
<211> 20
<212> DNA
<213> H. sapiens

<400> 786
atcagagtgg cagagagagc 20

<210> 787
<211> 20
<212> DNA
<213> H. sapiens

<400> 787
tttaccatag ttgtgacaca 20

<210> 788
<211> 20
<212> DNA
<213> H. sapiens

<400> 788
catTTTgtag gcaatgagct. 20

<210> 789
<211> 20
<212> DNA
<213> H. sapiens

<400> 789
gcattagtaa acatgagaac 20

<210> 790
<211> 20
<212> DNA
<213> H. sapiens

<400> 790
ttcatttcag cgatggccgg 20

<210> 791
<211> 20
<212> DNA
<213> H. sapiens

<400> 791
gaaaatctag tgtcattcaa 20

<210> 792
<211> 20
<212> DNA
<213> H. sapiens

<400> 792
tcctatacag ttttgggaac 20

<210> 793
<211> 20
<212> DNA
<213> H. sapiens

<400> 793
aaggacttca gtatggagct 20

<210> 794
<211> 20
<212> DNA
<213> H. sapiens

<400> 794
atggagcttt tattgaattg

20

<210> 795
<211> 20
<212> DNA
<213> H. sapiens

<400> 795
ccatcagcac tattatttat

20

<210> 796
<211> 20
<212> DNA
<213> H. sapiens

<400> 796
ataggcaagc tcagccatag

20

<210> 797
<211> 20
<212> DNA
<213> H. sapiens

<400> 797
tgctagatga gatacatcaa

20

<210> 798
<211> 20
<212> DNA
<213> H. sapiens

<400> 798
gaagaccaaa catggttcta

20

<210> 799
<211> 20
<212> DNA
<213> H. sapiens

<400> 799
ctctgttttag tctctccag

20

<210> 800
<211> 20
<212> DNA
<213> H. sapiens

<400> 800
cattgataaa atgttctggc

20

<210> 801
<211> 20
<212> DNA
<213> H. sapiens

<400> 801
tctggcacag caaaacctct

20

<210> 802
<211> 20
<212> DNA
<213> H. sapiens

<400> 802
tggcacagca aaacctctag

20

<210> 803
<211> 20
<212> DNA
<213> H. sapiens

<400> 803
tagaacacat agtgtgattt

20

<210> 804
<211> 20
<212> DNA
<213> H. sapiens

<400> 804
aacacatagt gtgatttaag

20

<210> 805
<211> 20
<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 805
ctttccgttg gacccctggg

20

<210> 806
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 806
tcccgcctgt gacatgcatt

20

<210> 807
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 807
ttctacctcg cgcgatttac

20

<210> 808
<211> 432
<212> DNA
<213> O. cuniculus

<400> 808
 gatcttacct tctccaagca aaatgcattg ctacgtgctg agtatcaggc tgattacaag 60
 tcactgaggt tcttcaccct gctttctggg ttgttgaata cccatgggtct tgaattaaat 120
 gctgacatct tgggcactga caaaatgaat actgctgctc acaaggcaac tctaagaatt 180
 ggccaaaatg gagtatctac cagtgcaca accagcttga ggtacagtcc cctgatgctg 240
 gagaatgagc tgaacgcaga gcttgccctt tctggggcat ctatgaaatt agcaacaaat 300
 ggccgcttca aggaacacaa tgcaaaattc agcctagatg ggaaagctac cctcacagag 360
 ttatccctgg gaagcgctta ccaggccatg attctgggtg ctgacagcaa gaacattttc 420
 aacttcaaga tc 432

<210> 809
 <211> 660
 <212> DNA
 <213> O. cuniculus

<400> 809
 ctgggaaaac tcccacagca agttaatgat tatctgagta cattcaattg ggagagacaa 60
 gtttccagtg ccaaggagaa actaactact ttcacaaaaa attataaaat tacagagaat 120
 gatatacaaa ctgcattgga taatgccaaa atcaacttaa atgaaaaact gtctcaactt 180
 cagacatatg tgatataatt tgatcagtat attaaagata attttgatct acatgatttt 240
 aaaatagcta tagctagtat tatagatcaa atcatggaaa aattaaaaat tcttgatgaa 300
 cgttatcata tccgtgcaca ttttaattaaa tcaatccara atttatattt gtttattgaa 360
 gctattgatt ttaacaaaaat tggaagtagt actgcattct ggattcaaaa tgtggatacc 420
 aagtatcaag tcagaatctg gatacaagaa atattgcaac agtttaagac acagattcag 480
 aatacaaaaca tcccatacct ggctgaaaaa ctgaaacaac agattgaggc tattgatgtc 540
 agagtgcctt tagatcaatt gagaactaca attccatttc gtataataaa ggacattatt 600
 gaacatttca aatactttgt tataaatatt attgaaaatt ttgaagtaat tgacaaaatc 660

<210> 810
 <211> 543
 <212> DNA
 <213> O. cuniculus

<220>
 <221> misc_feature
 <222> (45)
 <223> n = a, c, g, or t

<220>
 <221> misc_feature
 <222> (118)
 <223> n = a, c, g, or t

<220>

<221> misc_feature
 <222> (148)
 <223> n = a, c, g, or t

<220>
 <221> misc_feature
 <222> (173)
 <223> n = a, c, g, or t

<220>
 <221> misc_feature
 <222> (180)
 <223> n = a, c, g, or t

<400> 810
 cagaacatcg gagacaacgc attggatttt ctactaaat cttanaatga agcaaaaatt 60
 aagtttgata agtacaaagt tgaaaaatcg ctcaacaggg tccccaggac ctttcagmct 120
 cctggatata ttattccaat tttcaatntt gaagtatctc cactcacaat agnagacgtn 180
 agcattcagt catgtgatcc caaaatcaat aagcaccccc aatgtcarca tcctggattc 240
 aagcttctat gtgccttcat atacattggc tctgccatcc ctagagctgc cagtcttcca 300
 tgtccccagg aatctactca aggtctctct tccagatttc aaggaattga aaaccattaa 360
 caatatthtt attccagcca tgggcaacat tacctatgaa ttttccttca aatcaacgat 420
 cattacactg aataccaatg ctggacttta taaccaatca gacattgttg cccatattct 480
 ttcttctctt tcatctgtca ttgatgcact acagtacaaa ttagagggca cgttcaagtt 540
 tga 343

<210> 811
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 811
 aagcaccccc aatgtcacc 19

<210> 812
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 812
 gggatggcag agccaatgta 20

<210> 813
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Probe

<400> 813

tcctggattc aagcttctat gtgccttca

29

<210> 814

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 814

tgcttggaga aggtaagatc

20

<210> 815

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 815

gcgttgtctc cgatgttctg

20

<210> 816

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 816

taatcattaa cttgctgtgg

20

<210> 817

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 817

tcagcacgta gcaatgcatt

20

<210> 818

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 818
gcctgatact cagcacgtag

20

<210> 819
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 819
caattgaatg tactcagata

20

<210> 820
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 820
acctcagtga cttgtaatca

20

<210> 821
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 821
cactggaaac ttgtctctcc

20

<210> 822
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 822
agtagttagt ttctccttgg

20

<210> 823
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 823
tcagtgccca agatgtcagc

20

<210> 824
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 824
attggaataa tgtatccagg 20

<210> 825
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 825
ttggcattat ccaatgcagt 20

<210> 826
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 826
gttgccttgt gagcagcagt 20

<210> 827
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 827
attgtgagtg gagatacttc 20

<210> 828
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 828
catatgtctg aagttgagac 20

<210> 829
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 829

gtagatactc cattttggcc

20

<210> 830

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 830

ggatcacatg actgaatgct

20

<210> 831

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 831

tcaagctggt tgttgcactg

20

<210> 832

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 832

ggactgtacc tcaagctggt

20

<210> 833

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 833

gctcattctc cagcatcagg

20

<210> 834

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 834

ttgatctata atactagcta

20

<210> 835

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 835

atggaagact ggcagctcta

20

<210> 836

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 836

ttgtgttcct tgaagcggcc

20

<210> 837

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 837

tgtgcacgga tatgataacg

20

<210> 838

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 838

gaccttgagt agattcctgg

20

<210> 839

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 839
gaaatctgga agagagacct

<210> 840
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

20

<400> 840
gtagctttcc catctaggct

<210> 841
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

20

<400> 841
gataactctg tgagggtagc

<210> 842
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

20

<400> 842
atgttgccca tggctggaat

<210> 843
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

20

<400> 843
aagatgcagt actacttcca

<210> 844
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

20

<400> 844
gcaccagaa tcatggcctg

20

<210> 845
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 845
cttgatactt ggtatccaca

20

<210> 846
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 846
cagtgtaatg atcgttgatt

20

<210> 847
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 847
taaagtccag cattgggtatt

20

<210> 848
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 848
caacaatgtc tgattgggta

20

<210> 849
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 849
gaagaggaag aaaggatatg

20

<210> 850
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 850

tgacagatga agaggaagaa

20

<210> 851

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 851

ttgtactgta gtgcatcaat

20

<210> 852

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 852

gcctcaatct gttgtttcag

20

<210> 853

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 853

acttgagcgt gccctctaata

20

<210> 854

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 854

gaaatggaat tgtagttctc

20

<210> 855

<211> 479

<212> DNA

<213> M. fascicularis

<220>

<221> misc_feature

<222> (7)

<223> n = A,T,C or G

<220>

<221> misc_feature
 <222> (469)..(474)
 <223> n = A,T,C or G

<221> misc_feature
 <222> (476)..(479)
 <223> n = A,T,C or G

<400> 855
 tgcgtcnaga ctccgcccc tactatccgc tgaccgggga caccagatta gagctggaac 60
 tgaggcctac aggagaagtt gagcagtatt ctgtcagtgc aacctatgag ctccagagag 120
 aggacagagc cttggtggac accctgaagt ttgtaactca agcagaaggt gtaaagcaga 180
 ctgaggctac catgacattc aaatataatc ggcagagtat gaccttgtcc agtgaagtcc 240
 aaattccgga ttttgagggt gaccttggaa caatctcag agttaatgat gaatctactg 300
 agggcagaaa gtcttacaga ctccacctgg acattcagaa ccagaaaatt actgagggtca 360
 cctcatggg ccacctaaagt tgyacacaa aggaagaagg aaaaatcaaa ggtgttatti 420
 ccgtaccccg tttgcaagca gaagccagaa gtgagatcct cgccacann nnnnannnn 479

<210> 856
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense Oligonucleotide

<400> 856
 gtcctcaac atctgaatgc 20

<210> 857
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense Oligonucleotide

<400> 857
 ctgctagcct ctggatttga 20

<210> 858
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Antisense Oligonucleotide

<400> 858
 ccttcctga aggttcctcc 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/15493

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04

US CL : 536/23.1, 24.3, 24.31, 24/33, 24.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 24.3, 24.31, 24/33, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/12789 A2 (CHAN et al.) 22 February 2001 (22.02.2001), page 2, lines 15-27.	1-7

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 October 2003 (16.10.2003)

Date of mailing of the international search report

22 OCT 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Janet L. Epps-Ford, Ph.D.

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/15493

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 8-93
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US03/15493

Continuation of B. FIELDS SEARCHED Item 3:

CAplus, Medline, Biosis, USPAT, EPO, USPG-Pub, JPO, Derwent

search terms:

apolipoprotein B, apoB, antisense, aptamer, triplex, oligonucleotide, ribozyme, peptide nucleic acid